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Abstract
Normal cellular homeostasis is established and maintained by the positive and negative
regulatory activities of many genes. When these genes are mutated to forms that can contribute to
tumorigenesis, either by dominant, gain of function mutations in positive regulators or recessive, loss
of function mutations in negative regulators, they are termed oncogenes or tumour suppressor genes,
respectively. Identified human tumour suppressor genes, though still relatively few in number, are
found to be active in many different cellular processes. I have studied two such genes, the WT1 and
pJ6 genes, which in their wild type forms are known to contribute to development of the urogenital
system and the mesothelium (WTI) and to control of the cell cycle (pi6).
WT1 was identified as a gene repeatedly disrupted in Wilms' tumour, a common paediatric
renal malignancy. This study is one of many which sought to confirm and understand some of the
roles of WTI in both normal development and tumorigenesis. Mutation analysis of WTI in samples
from patients with sporadic, bilateral and syndrome-associated Wilms' tumour has produced a pattern
of results consistent with the findings of other groups. No mutations were detected in the sporadic and
bilateral tumours, however exonic point mutations were detected in 7 out of 9 syndrome-associated
Wilms' tumour samples that were analysed in detail. Studies examining parental WTI status, genomic
imprinting and allele loss distal to the WTI locus are detailed for the syndrome-associated Wilms'
tumour samples. Additionally, analysis of WTI in samples from patients with testicular tumours or
malignant mesothelioma did not identify any mutations believed to be significant in tumorigenesis.
pl6 was identified not only as a cell cycle regulator, but also as a gene repeatedly deleted in
tumour cell lines. Previous studies showed that tumours of various types, including primary malignant
mesothelioma, often contain deletions spanning the pl6 locus. In this study detailed deletion analysis
is presented for pl6 and the adjacent related gene, pl5, in Wilms' tumour and malignant
mesothelioma samples. Both primary tumours and tumour cell lines were analysed. Deletions of pi6
were not detected in Wilms' tumour and derived tumour cell lines. Deletions of pi6 were however
detected in all malignant mesothelioma cell lines analysed, and in the majority of these (14 out of 15)
the deletions extended to the pi5 locus. Analysis of p!6 and pi5 in primary malignant mesothelioma
samples did not identify deletions of either gene.
The contribution, resulting effects and complementary nature of WTI and pl6 mutations in
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1.1 Contribution of tumour suppressor genes to tumorigenesis
1.1.1 Mode of action
Normal cellular homeostasis is established and maintained by the positive and negative
regulatory actions of many genes. Collectively these genes can encode many different types of
product, for example functional RNA molecules, cell surface and cytoplasmic proteins, and nuclear
proteins that include transcription factors. This variety of products suggests that when any one (or
more) of these genes is disrupted a wide spectrum of cellular processes may be affected, perhaps
causing a breakdown of normal homeostasis. This in turn can result in aberrant cell growth and
division, a feature which is the hallmark of all forms of tumorigenesis, including development of both
benign and malignant tumours. When genes are mutated to forms that can contribute to tumorigenesis,
either by dominant, gain of function mutations in positive regulators or recessive, loss of function
mutations in negative regulators, they are termed oncogenes or tumour suppressor genes, respectively.
In comparison to identified human oncogenes, identified human tumour suppressor genes are
still relatively few in number. The cellular processes by which the latter contribute to normal
development (when wild type) and tumorigenesis, although not fully understood, are known to be
varied (reviewed by Bryant 1993). Detection of loss of function mutations can be used to identify
candidate tumour suppressor genes. Techniques to detect such mutations include: functional analysis
of growth suppression by transfection of whole or partial chromosomes, or specific genes, into
tumorigenic cells; analysis of homozygous loss of markers using cytogenetic or molecular methods;
analysis of loss of heterozygosity (LOH) to reveal acquisition of homozygosity for an original
mutation; and positional cloning of genes and subsequent mutation analysis (reviewed by Ponder
1988, Sager 1989). Before these techniques came into use, a statistical study of a paediatric tumour,
retinoblastoma, by Knudson (1971) introduced a model detailing the requirement for two mutational
events for tumorigenesis in this type of early onset malignancy. This concept was later extended to
indicate that these events represent functional loss of both copies of one gene, that is, the action of a
tumour suppressor gene. This type of statistical study is now applied to distinct paediatric tumour
types to investigate the possible involvement of tumour suppressor genes and, similarly, the model is
applied to genes that are candidate tumour suppressors. This model is most commonly referred to as
the two hit model for tumorigenesis.
1.1.2 The two hit model for tumorigenesis
As mentioned in 1.1.1, the two hit model for tumorigenesis resulted from a statistical study of a
paediatric malignancy, retinoblastoma (Knudson 1971). Application of this model to distinct
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paediatric malignancies is reported, for example for Wilms' tumour (see 1.2), however the data
detailed in the original study remains the most comprehensive reported. The major aspects of this data
are as follows. Retinoblastoma is a malignancy of the eye which can present as a unilateral, bilateral
or familial tumour. The majority of unilateral retinoblastoma are predicted to be sporadic, whereas all
bilateral retinoblastoma are predicted to be hereditary. Moreover, for individuals with the latter form
or with familial retinoblastoma, 50% of offspring develop a similar tumour, indicating the involvement
of an autosomal dominant gene. A further difference is that the proportion of the total number of
retinoblastoma and the mean age at presentation is lower for bilateral and familial tumours than for
unilateral tumours; approximately 40% of retinoblastoma are bilateral or familial and present at a
mean age of 15 months, as compared to a mean age of 32 months for unilateral tumours.
To account for these differences it was proposed that development of retinoblastoma requires
two mutational events, the pattern of which alters for hereditary and sporadic tumours. More
specifically, individuals with hereditary tumours suffer a first mutational event, or hit, constitutionally,
thereby affecting every cell, and a second hit somatically and affecting a retinal cell, whereas
individuals with sporadic tumours suffer both hits somatically and affecting the same retinal cell
(Figure 1.1.1). As the incidence of two somatic hits affecting the same cell is low it will, on average,
take longer to generate this form of double hit, hence explaining the later mean age at presentation for
unilateral retinoblastoma.
The fact that the first and second hits affect the two copies of a single gene was subsequently
reported by Comings (1973), and for retinoblastoma chromosome loss studies, involving cytogenetic
analysis and assaying the activity of a closely linked marker, highlighted the involvement of a locus
within the region chromosome 13q 14 (Knudson et al. 1976, Benedict et al. 1983). This in turn
facilitated the positional cloning from this region of the actual retinoblastoma gene, RBI, (Friend et al.
1986, Lee et al. 1987) and numerous reports of mutation analysis of this gene have identified a pattern
of mutations that are consistent with the two hit model for tumorigenesis (reviewed by Cowell and
Hogg 1992). The product of this gene is a nuclear protein, RB1, which, by suppressing the activity of
the E2F group of transcription factors, performs a critical role as a negative regulator of the cell cycle
(reviewed by Weinberg 1995).
Furthermore, although the rate of transmission of bilateral and familial retinoblastoma indicated
involvement of an autosomal dominant gene, the requirement for loss of both functional copies of RBI
for tumorigenesis indicates that, at the cellular level, this gene is actually recessive. This apparent
ambiguity can be explained by the fact that the first hit, although simply causing predisposition for
tumorigenesis, can appear to be dominant when present constitutionally as a second hit, functionally
























Figure 1.1.1 The two hit model for tumorigenesis. On the left of the figure the pattern of mutations
predicted for hereditary tumours is illustrated; the first hit is present constitutionally and
the second hit present somatically. On the right of the figure the pattern predicted for
sporadic tumours is illustrated; both the first and second hits present somatically, and
within the same cell.
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1.1.3 Paediatric and adult tumours
The involvement of mutations in only one or very few critical genes is predicted for paediatric
tumours, such as retinoblastoma, to a greater extent than for adult tumours. One reason for this
difference may be that the progenitor cells of paediatric tumours have had less time than adult cells to
accumulate many mutations, and are therefore less likely to display a multigene and multistep series of
mutations. The proportion of adult tumours which display complexities such as the latter rather than
relatively few mutations is not known.
In this study the involvement of tumour suppressor genes in paediatric and adult tumours has
been investigated; analysis is focused on the paediatric renal malignancy, Wilms' tumour, and the
predominantly adult tumour, malignant mesothelioma, and on two specific genes, the WT1 and pl6
genes, which in their wild type forms contribute to distinct cellular processes. A detailed description
of each of these tumour types and genes, and the reasons for their selection, is presented in the
following sections.
1.2 Wilms' tumour
1.2.1 Histopathology of the kidney and of Wilms' tumour (WT)
1.2.1.1 Structure and function of the kidney
In humans the two kidneys are abdominal visceral organs, located laterally, one on either side
of the vertebral column. They differ from most of the other abdominal organs as they lie out with the
peritoneal cavity, adjacent to the dorsal wall of the abdomen. This retroperitoneal position is
vulnerable to forces of impact and the kidneys are therefore embedded in adipose tissue for protection.
Each kidney is directly enveloped by a renal capsule and is composed of three major segments; the
outer renal cortex, the central renal medulla and the inner renal pelvis (Figure 1.2.1a) (van dc Graaff
1995). The cortex and the medulla are comprised of nephrons, of which there are approximately one
million in a mature human kidney (Lawler 1991). The nephron is the functional unit of the kidney and
has a specific orientation within it (Figure 1.2.1b). The glomerulus, glomerular capsule (Bowman's
capsule), proximal convoluted tubule and distal convoluted tubule structures of the nephron lie within
the renal cortex, whereas the descending and ascending tubules of the nephron loop (loop of Henle) lie
within the renal medulla. The distal end (relative to the glomerulus) is fused to a collecting duct,
which extends through the renal cortex and renal medulla to the renal pelvis, where it opens to permit

























Figure 1.1.2 Structure of the human kidney and nephron, a) gross structure of the kidney
illustrating the three major segments of this tissue; the renal cortex, medulla and pelvis,
b) the nephron, which comprises a glomerulus and a proximal and distal convoluted
tubule within the renal cortex, and a nephron loop within the renal medulla. Both
drawings reproduced from van de Graaff (1995).
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The functions of the kidney are to remove waste products from the blood and to maintain the
fluid, electrolyte and acid-base levels of the body. Waste products are removed by ultrafiltration.
Arterial blood is pumped in to the capillary network of the glomerulus and the resulting filtrate
removed by the glomerular capsule to the nephron tubules. Waste products contained in the filtrate
pass from here to the collecting system which transports them, via the ureter, to the urinary bladder for
storage and subsequent voiding from the body. Components of the filtrate that are to be retained, such
as salts, water, amino acids and glucose, are actively reabsorbed in to the blood from the proximal
convoluted tubule and ascending limb of the nephron loop (van de Graaff 1995).
1.2.1.2 Development of the kidney
The mammalian kidney develops from intraembryonic mesoderm in three consecutive and
overlapping stages; the pronephric, mesonephric and metanephric stages. In humans formation of
pronephric structures commences during the fourth week of embryogenesis. Pronephric ducts form
within the nephrogenic ridge region of the intermediate mesoderm and extend in a caudal direction to
open in to the cloaca. Rudimentary kidney structures, pronephroi, join the pronephric ducts. In
humans pronephroi are non-functional and they degenerate by the sixth week of embryogenesis. Their
apparently unnecessary formation is considered an evolutionary remnant. The pronephric ducts do not
degenerate but persist to the following stage, when mesonephroi form. These intermediate kidney
structures form caudal to the pronephroi and each consists of a mesonephric tubule fused to the
persistent duct, now termed the mesonephric or Wolffian duct. The free end of the mesonephric tubule
forms a simple glomerular capsule and this surrounds a primitive glomerulus. Unlike the pronephroi,
the mesonephroi are functional (Moore and Persaud 1993).
The progressively caudal nature of nephrogenesis is maintained in the final stage, the
metanephric stage. Metanephroi commence development during the fifth week of embryogenesis and
form from two distinct domains of mesoderm. The first of these is the mesonephric duct, which, at its
most caudal end, develops an outgrowth, the primitive ureteric bud. This extends in a cranial direction
to the second mesodermal domain, the metanephric mesenchyme which, in common with the
pronephric duct, derives from the nephrogenic ridge region of the intermediate mesoderm. Reciprocal
inductive interactions between these two mesodermal structures result in dichotomous branching of the
ureteric bud and condensation of the metanephric mesenchyme at the tip of each branch. Successive
branching of the ureteric bud forms the renal pelvis and the network of renal collecting ducts.
Simultaneously, the condensed mesenchyme, termed metanephric blastema, proliferates and
differentiates to form immature epithelial renal vesicles which, in turn, form comma- and S- shaped
bodies, and glomeruloid bodies (Figure 1.2.2). These structures are the precursors of the more
complex epithelial tubules and glomerular capsule of the mature nephron. In contrast to the
proliferative nature of metanephric blastema, many cells within the uncondensed mesenchyme are







Figure 1.2.2 Development of the metanephros. a) reciprocal induction of the ureteric bud (U) and
metanephric mesenchyme (M). b) condensation of mesenchyme forms metanephric
blastema (B) c) differentiation of the latter forms renal vesicles (RV) d) these elongate
and differentiate further to form comma- and S-shaped bodies (C/S) and podocytes (P)
e) elongation and differentiation continues, with formation of glomeruloid bodies (GB)
f) the mature nephron is formed, with a glomerulus (G) and a proximal and distal
convoluted tubule (PT and DT).
critical for normal development of this tissue (Chandler et al. 1994, Koseki et al. 1992 [rat study]).
During weeks five to nine of embryogenesis a sufficient number of mature nephrons are formed to
permit the metanephroi to replace the mesonephroi as the functioning kidneys. The metanephroi
continue to mature and form the permanent kidneys, which, by the end of the foetal period, contain the
full complement of nephrons. Functional maturation of these nephrons is achieved postnatally (Moore
and Persaud 1993).
The vascular and mesangial cells of the glomerulus differ from the other components of the
nephron as they do not derive from the nephrogenic ridge region of the intermediate mesoderm but
from the cardiogenic region of the lateral mesoderm (Moore and Persaud 1993). Mature glomeruli are
composed of a network of capillaries that are intimately associated with two types of specialised cells,
mesangial cells and podocytes, both of which are critical for the correct functioning of the glomerulus
(Figure 1.2.3). Mesangial cells are interspersed within the capillary network and secrete mesangial
matrix. By varying the volume of matrix these cells are thought to assist in regulating the pressure
within the glomerulus (Lawler 1991). Podocytes are part of the glomerular capsule. This structure has
an outer, parietal layer and an inner, visceral layer, between which is the glomerular space. The
podocytes are the epithelial cells of the visceral layer, which forms a sheath over the glomerulus.
These cells have numerous cytoplasmic foot processes, termed pedicels, which interdigitate to
surround individual capillaries. Slits are present between adjacent pedicels and filtrate has to pass
through these to enter the glomerular space. Podocytes are therefore thought to assist in regulating the
flow of filtrate and, like mesangial cells, perhaps also the pressure within the glomerulus (van de
Graaff 1995).
1.2.1.3 Contribution to gonadal development
Although redundant as excretory organs by the end of the embryonic period (week nine), the
mesonephric structures have by this stage contributed to the developing gonadal system. This
association between the renal and gonadal systems is not only temporal but also spatial. Gonads
develop from the gonadal ridge, a mesodermal region of thickened mesenchyme and mesothelium,
which forms during the fifth week of embryogenesis. The gonadal ridge is positioned adjacent to the
mesonephroi and is therefore contiguous with the nephrogenic ridge. Both ridges are often
collectively termed the urogenital ridge. The initial development of the gonadal ridge is indifferent
between the sexes. Cells from degenerating mesonephric structures migrate to the latter and associate
with the mesothelial component (germinal epithelium), permitting formation of tubules, the primary
sex cords, within the mesenchyme (Buehr et al. 1993). During the sixth week of embryogenesis a
second cell type migrates to the gonadal ridge, primordial germ cells. These cells, which derive from
endoderm, are destined for the primary sex cords. It is a further week until the gonad is



















Figure 1.2.3 Structure of the glomerulus. The arrangement and gross structure of the cell types that
comprise a glomerulus is illustrated. These specialised cell types include podocytes and
mesangial cells, which are intimately associated with the capillary network. Drawing
reproduced from Netter (1979).
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If the gonad is male, development of the Mullerian duct is inhibited and the adjacent
mesonephric structures are incorporated in to the developing testis and the associated genital tissues,
most obviously the Wolffian duct forms the epididymis, vas deferens and seminal vesicle (Figure
1.2.4). Of vital importance at this stage are the male-specific somatic cells within the testis, of which
there are two types, Sertoli cells and Leydig cells. Sertoli cells derive from and are present within the
primary sex cords. These cells are the support cells of the spermatocytes/spermatids and they secrete
Mullerian-inhibiting substance (MIS), which blocks development of the Mullerian duct. Leydig cells
are thought to derive from mesonephric tubule epithelium and are present in the interstitium of the
testis (Buehr et al. 1993). The main function of these cells is to produce and secrete testosterone,
which is necessary for maintenance of the Wolffian duct derived structures of the genital system
(Moore and Persaud 1993).
If the gonad is female, the opposite pattern to that seen in males is observed. Firstly,
development of the Mullerian duct is not inhibited, as there are no Sertoli cells, and it forms the
fallopian tubes, uterus and upper vagina. Secondly, the adjacent mesonephric structures are not
incorporated into the ovary or the associated genital tissues (Figure 1.2.4). Some non-functional
remnants of mesonephric tubules may persist in the ovary but, in general, these and the Wolffian duct
degenerate because there are no testosterone secreting Leydig cells to maintain them. Female-specific
somatic cells within the ovary include granulosa cells, which are thought to derive from the primary
sex cords. These cells are the support cells of the oocyte and therefore their function, and origin, is
similar to that of the male-specific Sertoli cells. It is evident though that by this stage of development
the renal and gonadal systems are far more independent of each other in females than in males (Moore
and Persaud 1993).
1.2.1.4 Structure of WT
WT is human nephroblastoma, a malignant embryonal tumour of the kidney. Embryonal
tumours develop postnatally but contain structures normally present only during embryogenesis. Such
tumours can therefore contain structures appropriate for the tissue of origin but wholly inappropriate
for the developmental stage of that tissue, a feature which illustrates clearly the extent to which normal
development and tumorigenesis are interrelated. The embryonal precursors in nephrogenesis comprise
metanephric blastema and the immature epithelial structures which differentiate from it; renal vesicles,
comma- and S-shaped bodies, and glomeruloid bodies. It is these normally transitory structures that
present in WT. The cells of origin in this tumour are thought to be abnormally persistent nephrogenic
cells, perhaps metanephric blastema. These nephrogenic stem cells may lie dormant during early
postnatal life until stimulated to proliferate. Their arrest at the embryonal stage in tumorigenesis is
thought to result from an inability to respond correctly to signals for differentiation and maturation



















































































Figure 1.2.4 Mesonephric contribution to gonadal development, a) the indifferent gonad. The
mesonephric (Wolffian) duct and tubules contribute to the sex cords, b) c) and d) if the
gonad is male the Wolffian duct persists and mesonephric structures contribute to the
efferent ducts and ductules, epididymis, vas deferens and seminal vesicle components of
the testis, e) f) and g) if the gonad is female the Wolffian duct degenerates. If
mesonephric structures persist they are present as only non-functional remnants within
the epoophoron, paroophoron and Gartner's cyst components of the ovary.
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In addition to metanephric blastema and immature epithelium, WT also contain mesenchyme
(stroma). This is not thought to be original uncondensed metanephric mesenchyme but rather is
thought to derive, in common with the epithelial component, from differentiation of metanephric
blastema (Pritchard-Jones and Fleming 1991). The majority of WT contain approximately equal
proportions of blastema, epithelium and stroma and are said to display triphasic or classic histology.
In WT that display a different histological pattern the proportions of each of these elements can vary,
and any one of these can predominate. Furthermore, a minority of WT contain elements of heterotopic
cells, such as mesodermally derived smooth and striated muscle cells, chondrocytes and adipocytes,
and occasionally neuroblasts and ganglia (Sotelo-Avila 1990). These inappropriate cell types are
thought to derive from aberrant differentiation of the nephrogenic stem cells along non renal pathways.
This implies that these cells can be pluripotent, a feature masked during normal development when
only nephrogenic signals are responded to. Only when normal development is disrupted in WT are
other differentiation pathways realised.
1.2.2 Epidemiology
1.2.2.1 Incidence
The first comprehensive description of human nephroblastoma was published in 1899 by Max
Wilms (reference not consulted), after whom the tumour is named. Approximately 1 per 10 000
children develop WT, making it one of the most common paediatric solid tumours and the most
common paediatric renal malignancy. The majority of WT develop in the first decade of life, with a
median age at presentation of 3 years for males and 3 years, 6 months for females (Breslow et al.
1988). The reason for the difference between the sexes is not clear. Only rarely does this tumour
present in adults or at extrarenal sites, with less than 200 and 34 cases, respectively, reported world¬
wide (Mehta et al. 1991). It has been suggested that these rare forms of WT develop from remnants of
mesonephric structures that have failed to degenerate (Akhtar 1977, Aterman 1989). The existence of
congenital WT is debatable as many pathologists consider all congenital renal tumours, which are
extremely rare, to be the histologically distinct tumour, benign mesoblastic nephroma (reviewed by
Olsen 1984).
The incidence of WT is uniform for all but one of the parameters studied, geographical
location; with figures approximately 40% lower than and 30% higher than average in Japan and the
Scandinavian countries, respectively (Breslow and Langholz 1983). This variation may be an effect of
the different gene pools of these populations.
1.2.2.2 Unilateral, bilateral and familial WT
The majority of WT are sporadic and unilateral (Knudson and Strong 1972, Breslow and
Beckwith 1982) but between 5% and 10% are bilateral (Coppes et al. 1989). Individuals with the
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latter form present at a median age that is lower by 1 year, that is at 2 years and 2 years, 6 months for
males and females, respectively, in comparison to the majority (Breslow et al. 1988). The statistical
study of retinoblastoma that produced the classic two hit model for tumorigenesis (Knudson 1971) (see
1.1.2) has similarly been applied to WT (Knudson and Strong 1972). Many aspects of WT aetiology
are found to differ from the classic model (see below), however the earlier presentation of bilateral
tumours does correlate. Similarly to the extended model for retinoblastoma, individuals with bilateral
WT are predicted to have a constitutional first hit affecting a predisposition gene and a somatic second
hit affecting the remaining copy of this gene. Individuals with sporadic, unilateral WT will most often
have suffered both hits somatically and therefore these tumours present at a later age, again concordant
with retinoblastoma statistics. These data therefore provided evidence for involvement of a tumour
suppressor gene in WT development. In contrast to the retinoblastoma statistics however, the
predicted frequency of bilateral WT is approximately four times that of the observed frequency, and a
further discrepancy is evident when familial WT is considered; only approximately 1% of WT present
in this form. It is however important to note that, as described by Knudson (1993), comparisons
between retinoblastoma and WT may not always be appropriate as the former is known to be a
monogenic disorder whereas the complete genetic basis of the latter remains unknown. Nonetheless,
the paucity of inherited WT (bilateral and familial) does indicate that, in general, the genetic factors
involved in development of this tumour are either non-transmissible or are deleterious to development
soon after transmission. In agreement with this proposal, from a total of 270 offspring of unilateral
WT individuals (a proportion of whom will have constitutional mutations), only one child developed a
similar tumour (reviewed by Pritchard-Jones and Hastie 1990). Moreover, the observation that the
incidence of genital abnormalities in WT individuals is higher than average (see 1.2.2.3) suggested
that the fertility of these individuals is compromised, implicating non-transmission of a predisposing
mutation (van Heyningen 1990).
1.2.2.3 Associated developmental abnormalities
Approximately 8% of WT individuals have associated developmental abnormalities (Clericuzio
1993), the most common of which are aniridia (iris hypoplasia), genitourinary (GU) abnormalities and
hemihypertrophy (asymmetrical overgrowth). The range of GU abnormalities observed includes those
most frequently affecting the genital system; hypospadias (misplaced urethral orifice, usually of the
penis) and cryptorchidism (undescended testes), which together constitute 75% of WT associated GU
abnormalities (Breslow et al. 1988), and those most frequently affecting the urinary system; horseshoe
kidney (fusion of the superior or, more commonly, inferior poles), duplex kidney and bifid ureters
(division of one or both ureters).
The frequency of these abnormalities is considerably higher than average in WT individuals;
0.8% (children with WT) versus 0.001% (children without WT) for aniridia, similarly 1.8% versus
0.9% for hypospadias, 2.8% versus 1.4% for cryptorchidism and 2.5% versus 0.003% for
hemihypertrophy (Clericuzio 1993). These figures indicated that common genetic defects may
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contribute to development of both WT and the associated abnormalities. Subsequent studies have
identified such defects, these are described in 1.2.4.
1.2.2.4 Prognosis
Prognosis for WT is, in general, good, with overall survival rates currently approaching 90%.
This figure can however vary greatly, depending on the stage and histology of the tumour. Individuals
with stage I or II tumours (least aggressive) with favourable histology have a two year survival rate of
97%. This rate decreases for stage III, IV and V tumours (most aggressive, metastases) and those of
unfavourable, anaplastic histology. The two year survival rate for these tumours can be as low as 52%
(D'Angio et al. 1989). These rates are however improving as a result of continued advances made in
surgical and post operative regimes. Furthermore, deaths among individuals with syndrome-associated
WT (see 1.2.4) are more frequently attributable to the associated abnormalities than to the tumour and
therefore overall prognosis for these individuals can be poor.
1.2.3 Precursor lesions
Nephrogenic rests are foci of nephrogenic cells which persist in the kidney postnatally but have
only a weak propensity for malignancy. They are classified into two major categories, intralobar
nephrogenic rests (ILNR) and perilobar nephrogenic rests (PLNR). Both ILNR and PLNR derive
from metanephric blastema but each has a distinct histology and is not classified solely on lobar
position. ILNR are predominantly stromal and frequently contain structures from the early stages of
ncphrogenesis. In addition they can also develop heterotopic elements. In contrast, PLNR are
predominantly blastcmal and epithelial, frequently contain structures from the later stages of
nephrogenesis and rarely develop heterotopic elements. ILNR and PLNR can solely or jointly
associate with metanephric blastema and other cell types derived from it to form nephroblastomatous
lesions, often termed nephroblastomatosis. Extrapolation of infant autopsy data indicates the presence
of PLNR-type lesions in approximately 1% of the general population (Beckwith et al. 1990). As the
incidence of WT in the paediatric population is approximately one hundredth of this figure, it would
appear that the majority of these lesions are benign and that only a minority may progress to
malignancy. Evidence that progression to malignancy does occur was reported by Beckwith et al.
(1990), with the observation that approximately 40% of kidneys with unilateral WT and virtually
100% with bilateral WT contain nephrogenic rests. Additionally, tumour histology matched that of the
associated nephrogenic rest. These data indicated that, in these cases, nephrogenic rests were
precursor lesions for WT, concordant with their befitting the description of WT stem cells.
Furthermore, a recent study has identified an association between nephrogenic rests and WT at the
molecular level (Park et al. 1993a). In this study specific mutations in the WT] gene (described in
detail in 1.3) were found to be not present in normal kidney, but present homozygously in an ILNR
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and associated WT, and heterozygously in a PLNR and associated WT, indicating that these tumours
were clonally derived from the rests.
1.2.4 Syndrome-associated WT
1.2.4.1 Common features
A minority of WT present as a component of specific clinical syndromes (reviewed by
Clericuzio 1993), the most prominent of which are listed in Table 1.2.1. Many of the abnormalities
that WT individuals are predisposed to, as described in 1.2.2.3, are also observed in these syndromes.
This feature, together with the degree of overlap between these syndromes, again suggests the
involvement of common or interacting genetic defects in the development of WT and associated
abnormalities. The WAGR, Denys-Drash and Beckwith-Wiedemann syndromes are described in more
detail below.
1.2.4.2 WAGR syndrome
WAGR is an acronym derived from the components of this syndrome, WT. aniridia, GU
abnormalities and mental retardation. An association between these phenotypes was first described by
Miller et al. (1964). Subsequent cytogenetic studies showed that these individuals have constitutional,
heterozygous interstitial deletions of chromosome lip 13 (Francke et al. 1979). The critical loci
deleted are described in 1.3.1. Not all WAGR syndrome individuals develop the full spectrum of
abnormalities, many have aniridia and WT in the absence of GU abnormalities and mental retardation.
Virtually all cases are sporadic, with only a single example of inherited 11 p 13 deletion reported
(Fantes et al. 1992). Both individuals in this report had partial spectrum WAGR syndrome, the
mother had aniridia and her son aniridia, WT and horseshoe kidney. Aniridia is fully penetrant in
WAGR syndrome as it is an autosomal dominant trait. In contrast, WT, and to a greater extent, GU
abnormalities and mental retardation, display moderate penetrance, suggesting that constitutional
heterozygous deletions of llpl3 are predisposing for the development of these traits but that
additional genetic factors are involved. WAGR-WT, which present at an incidence of approximately
30% (Coppes et al. 1994), are most frequently unilateral, can contain ILNR-type nephroblastomatous
lesions and are, accordingly, predominantly stromal (Beckwith et al. 1990). The predominance of this
type of lesion, containing relatively uncommitted metanephric blastema, may reflect the timing of the
effect that WAGR deletions have on development of these cells. Perhaps related to this, these tumours
have a lower median age at presentation in comparison to those not associated with ILNR (Breslow et
al. 1988). GU abnormalities and mental retardation also display variable expressivity. As with
sporadic unilateral and bilateral WT individuals, the most common forms of GU abnormality in
WAGR syndrome are hypospadias and cryptorchidism, and accordingly there is a paucity of GU
abnormalities in females with this syndrome in contrast to presentation in an estimated 80% of such
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Syndrome components references
WAGR syndrome WT, aniridia, GU abnormalities and mental retardation Miller et al. 1964
Denys-Drash syndrome WT, nephropathy and partial gonadal dysgenesis Denys et al. 1967,
Drash et al. 1970
Beckwith-Wiedemann
syndrome
WT or other embryonic tumours, gigantism,
organomegaly, hemihypertrophy, exomphalos Sotelo-Avila 1980
Perlman syndrome WT, nephroblastomatosis, gigantism, bilateral
nephromegaly, GU abnormalities
Perlman et al. 1975
Sotos syndrome WT and other tumours, cerebral gigantism,
developmental delay
Sotos et a I. 1964
Bloom syndrome WT and other tumours, growth failure, facial
telangiectasia, immunity defects
Cairney et al. 1987
Table 1.2.1 Clinical syndromes associated with WT
males. This increased sensitivity in males is perhaps a direct result of the greater association between
the developing renal and genital systems in this sex.
1.2.4.3 Denys-Drash syndrome (DDS)
DDS comprises WT, nephropathy and partial gonadal dysgenesis (PGD). An association
between these phcnotypes was first described by Denys et al. (1967) and Drash et al. (1970), after
whom the syndrome is named. Subsequent cytogenetic studies have failed to identify gross
chromosomal defects in virtually all DDS individuals investigated. Interestingly, the two exceptional
individuals identified (one XY individual and one XX female) both had constitutional heterozygous
deletions at chromosome 11 p 13 and a mixed WAGR syndrome and DDS phenotype (Jadresic et al.
1991, Baird et al. 1992b, Henry et al. 1993). This chromosomal and phenotypic overlap suggested a
common genetic basis, involving loci at 11 p 13, in the development of both syndromes (described in
1.3.6). In DDS the nephropathy appears to be fully penetrant, although this may result from
ascertainment bias, and is of a specific type, diffuse mesangial sclerosis (DMS) (Habib et al. 1985).
Histological studies of DMS have identified the mesangial cells, interspersed within the glomerular
capillary network, as frequently hypercellular and secreting excess matrix, which destroys the normal
structure and functioning of the glomeruli and the associated podocytes (Habib et al. 1985, Lawler
1991). In this syndrome WT and PGD are both highly penetrant, the incidence of the former is
approximately 90% (Coppes et al. 1994). Individuals presenting with only one of these features
together with DMS must therefore be considered as DDS patients and be closely monitored as they are
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at high risk for having or developing full spectrum DDS (Habib et al. 1985, Friedman and Finlay
1987. Jadresic et al. 1990, Melocoton et al. 1991). DDS-WT are similar to WAGR-WT in that they
are associated with ILNR, are consequently predominantly stromal (Beckwith et al. 1990) and have a
presentation age lower than the median value (Breslow et al. 1988). The GU abnormalities that
present in this syndrome are, in contrast to those in WAGR syndrome, severe. The abnormalities
observed, encompassed by the term PGD, range from streak gonad, where development of the gonadal
ridge is minimal, to XY pseudohermaphroditism, where the individual is phenotypically female.
Internal examination of these latter individuals, and of XX females, does however frequently reveal
abnormalities such as ovotestes and persistent Wolffian duct structures. Similar to the pattern in
WAGR syndrome, DDS-GU abnormalities are more prevalent in males, or XY individuals, than in
females. The severity of these abnormalities in both sexes, together with the high frequency of
paediatric death, often from end stage renal failure (ESRF), dictates that all cases of full spectrum
DDS arise sporadically.
1.2.4.4 Beckwith-Wiedemann syndrome (BWS)
BWS is an overgrowth syndrome, with both complete and incomplete forms described (Sotelo-
Avila 1980). In a proportion of affected individuals constitutional rearrangements that disrupt loci at
chromosome 11 p 15 have been identified (Grundy el al. 1991, Henry et al. 1991). These disruptions
always favour overrepresentation of the paternally derived alleles and indicated the involvement of
imprinted genes at this region (see 1.2.6). In addition to sporadic presentation, familial BWS is also
observed and is similarly associated with 11 p 15 (Koufos et al. 1989). BWS overgrowth can affect the
whole or part of one side of the body, causing hemihypertrophy, or specific organs and tissues such as
the tongue and umbilicus, causing macroglossia and exomphalos, respectively. Perhaps as an
extension of this general feature, the development of WT and other embryonal tumours is moderately
penetrant in this syndrome, the incidence of the former is approximately 5% (Coppes et al. 1994).
BWS-WT differ from WAGR-WT and DDS-WT in a number of features. Firstly, and most obviously,
loci at 11 pi5 rather than 11 p 13 are implicated in tumour predisposition. Secondly, when
nephroblastomatous lesions are present they are of PLNR-type and, accordingly, BWS-WT are
predominantly bastemal and epithelial (Beckwith et al. 1990). This suggests that the nature of the
constitutional defects in BWS affects metanephric blastema at a later stage of development, when it is
more committed. Thirdly, and perhaps a reflection of the previous feature, the median age at
presentation of these tumours is unremarkable (Breslow et al. 1988).
1.2.5 llpl3
The involvement of 11 p 13 loci in WT development was initially highlighted by the
constitutional heterozygous deletions of this region in WAGR syndrome individuals. Subsequent
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studies have showed that between approximately 30% and 40% of WT display LOH at lip, further
implicating this region (Schroeder et al. 1987, Williams et al. 1989, Pal et al. 1990). As one
consequence of LOH is loss of both functional copies of a gene, these studies also suggested a
requirement for such loss of at least one gene in this region. In WAGR-WT loci at 11 p 13 are
hemizygous and therefore only one additional event could, similar to LOH, cause loss of both
functional copies of genes in this region. These data provided strong evidence that the putative tumour
suppressor gene involved in WT development, suggested by Knudson's two hit model for
tumorigenesis, was allelic with the putative WT predisposition gene at 11 p 13. Interestingly, one study
has identified LOH at lip in normal tissues of WT individuals, indicating that this feature is
compatible with normal development (Chao et al. 1993).
LOH can be achieved by a number of mechanisms, most frequently identified are mitotic
recombination, loss and reduplication, and deletion. These events can constitute the first and/or
second hit, as can independent mutation of a locus. This last mechanism differs from the others in that
heterozygosity is retained. All of these mechanisms have been observed at 11 pi3 in WT (Figure
1.2.5). A further aspect of WT aetiology identified by these studies is that the lip alleles lost are
almost exclusively those derived maternally, highlighting the possibility that the putative WT
predisposition gene at 11 p 13 may be imprinted, that is expressed only from either the paternal or
maternal allele. A gene from 11 p 13 has been isolated and characterised and is recognised as the sole
WT predisposition gene within this region. This gene, the WT1 gene, is described in detail in 1.3.
1.2.6 llpl5 and imprinting
More detailed studies of LOH at lip identified that in approximately 50% of informative WT
with this feature loss does not involve the p 13 region but is confined to the most distal region, pi5.5
(Figure 1.2.5) (Mannens et al. 1988, Henry et al. 1989, Koufos et al. 1989, Reeve et al. 1989, Wadey
et al. 1990). Furthermore, these studies showed that, as at p 13, the alleles lost at the distal region are
almost exclusively those derived maternally. This again implicated the involvement of imprinting in
WT development and suggested that a second WT predisposition gene, speculatively named WT2, is
located at 11 p 15.5, concordant with the chromosomal rearrangements identified in BWS individuals.
It is not known if the WT and BWS putative genes at 11 p 15.5 are allelic. Genes in this region include
p57, a CDK inhibitor gene (Matsuoke et al. 1995) (see Table 1.5.1), HI9, a putative tumour
suppressor gene, and insulin-like growth factor 2 (IGF2). The latter two genes are known to be
imprinted in humans; H19 is exclusively maternally expressed (Zhang and Tycko 1992) and IGF2
exclusively paternally expressed (Ohlssen et al. 1993, Giannoukakis et al. 1993). Consequently, in
WT displaying LOH at pi5.5 expression of the negative regulator of growth, HI9, is virtually or
completely abolished (Steenman et al. 1994). In contrast, expression of the positive regulator of
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Figure 1.2.5 Mechanisms for functional loss of both copies of a chromosome 1 lp gene in WT
development. When LOH presents, the alleles lost are almost exclusively those derived
maternally, and loss can be confined to 1 lpl5. 1 - locus at 1 lpl3; 2 - locus at 11 p 15;
primed numbers indicate the maternally derived allele; * - hit.
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expression of H19 and IGF2 is also observed in WT that do not display LOH. In these tumours loss of
imprinting (LOI) results in biallelic expression of one or both of these genes (Rainier et al. 1993,
Ogawa et al. 1993a). More recent studies of this feature suggest that LOI of IGF2 is associated with
the down-regulation of H19 expression (Moulton et al. 1994, Steenman et al. 1994). These aberrant
expression patterns obviously contribute to growth promotion and the development of WT and BWS,
however the basis of cause and effect remains ambiguous. Perhaps causing further ambiguity, the
human homologue of the exclusively maternally expressed murine gene, Mash2 (Guillemot et al.
1995) may also map to this region. However, as this gene is not expressed in the developing renal
system, possible involvement of the human homologue in WT is not obvious.
1.2.7 Other loci
Chromosome 11 loci do not appear to be involved in development of virtually any familial and
in many other WT. It is not known whether there is just a single additional locus, WT3, or multiple
additional loci involved. The frequently observed non-random rearrangements of four specific
chromosomes, 1,7, 12 and 16, in WT supports the latter proposal. Chromosome 1 rearrangements
predominantly cause trisomy lq (Kaneko et al. 1983, Douglass et al. 1985, McDowell et al. 1989,
Golden et al. 1992), chromosome 7 rearrangements comprise trisomy 7q and LOH at 7p (Wang-Wuu
et al. 1990, Wilmore et al. 1994) and chromosome 12 rearrangements comprise trisomy 12 (Wang-
Wuu et al. 1990, Golden et al. 1992, Austruy et al. submitted). Chromosome 16 rearrangements cause
LOH at 16q (Kaneko et al. 1983, Coppes et al. 1992a, Maw et al. 1992, Grundy et al. 1994), and this
is observed in WT at a frequency second only to that for lip (Austruy et al. submitted). These data
indicate strongly that there is a WT predisposition gene in this region, however linkage studies have
shown that 16q is not associated with familial WT (Huff et al. 1992).
Breakpoints in chromosome 17p have also been reported in WT at a lower frequency (reviewed
by Slater and Mannens 1992). The p53 tumour suppressor gene maps to this region, at 17p 13 (Isobe
et al. 1986), and, as the most frequently mutated known gene in tumours, it was selected for more
detailed investigation. Intragenic p53 point mutations have been identified in a total of 17 out of 168
(10%) WT and it appears that these mutations correlate with tumour progression to anaplasia
(Bardeesy et al. 1994a, Malkin et al. 1994, Bardeesy et al. 1995). p53 remains the only gene other
than WT1 (described in 1.3) to be found to be specifically mutated in WT.
A number of genes that are known to be expressed during nephrogenesis, for example PAX2
and PAX8 (reviewed by Stuart and Gruss 1995) and RET (reviewed by van Heyningen 1994) may also
contribute to development of WT. It is however important to note that, although such genes may be
overexpressed in this tumour type, this feature may simply be a consequence rather than a cause of the
malignant state of specific cells within the kidney. Furthermore, subtractive hybridisation studies
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using normal kidney and WT material have isolated additional sequences, although none of these are
obvious candidates for involvement in WT (Austruy et al. 1993).
The apparent involvement of multiple loci, including those at lip, and the potential for
synergistic interactions between them may be one reason for the incomplete penetrance of WT.
1.3 The WT1 gene
1.3.1 Isolation and identification
As mentioned previously, partial and full spectrum WAGR syndrome individuals are
constitutionally deleted for loci at chromosome 11 p 13. These observations highlighted this region as a
target for containing genes for aniridia and WT predisposition. A distinct locus for each of these
putative genes was identified as a result of characterisation of a constitutional deletion present in an
individual with WT alone, and positioned the WT locus proximal to that for aniridia (Davis et al.
1988). The aniridia gene, AN2, also named PAX6, has been identified at the more distal locus (Ton et
al. 1991). The position and extent of the WT locus was confirmed by the discovery of a small
homozygous lip 13 somatic deletion in a sporadic WT (Lewis et al. 1988). This deletion covered
345kb and was proposed to encompass all or part of the putative WT gene. This positional cloning
approach led to the isolation of an 1 lp 13-specific complementary DNA (cDNA) clone, WT33 (Rose
et al. 1990). Preliminary characterisation of this clone demonstrated that it hybridises to RNA from
kidney, spleen and heart (baboon and mouse), and from WT and haematopoietic cell lines. As these
features are consistent with a gene involved in development of WT, WT33 was forwarded as the first
cloned candidate sequence representing the WT predisposition gene at 11 p 13 (Call et al. 1990). The
corresponding gene and was named WT1 (Haber et al. 1990). This gene was also isolated, using
chromosome jumping techniques, in an independent study (Gessler et al. 1990).
1.3.2 Expression pattern
1.3.2.1 In normal development
During human embryogenesis expression of WT1 messenger RNA (mRNA) is detected in
mesonephroi and metanephroi. In the latter structures expression is restricted to the metanephric
blastema and its epithelial derivatives; renal vesicles, and comma- and S-shaped bodies. As these
structures mature expression becomes confined to, and maximised in, the podocytes, the cells that
comprise the visceral layer of the glomerular capsule (Pritchard-Jones et al. 1990). These cells
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continue to express WT1 postnatally, however infant and adult levels are much reduced in comparison
to those observed during nephrogenesis (Pritchard-Jones et al. 1990, Haber et al. 1990).
A second site of expression during embryogenesis is the gonadal ridge and indifferent gonad,
where expression is observed in the mesothelium derived sex cords. As this tissue matures expression
is confined to the male-specific Sertoli cells and female-specific granulosa cells (Pritchard-Jones et al.
1990), the somatic supporting cells of spermatocytes/spermatids and oocytes, respectively. Similarly
to podocytes, postnatal expression is observed in Sertoli cells (Armstrong et al. 1992) and is predicted
for granulosa cells. Further sites of expression during embryogenesis are the mesothelium, spleen,
brain and spinal cord (Pritchard-Jones et al. 1990, Armstrong et al. 1992).
Similar expression patterns have been observed for the orthologue of WT1, Wtl, in mouse
(Buckler et al. 1991, Pelletier et al. 1991c, Armstrong et al. 1992) and rat (Sharma et al. 1992).
Furthermore, creation of Wtl homozygous mutant mice has shown that expression of this gene is
critical for murine development (Kriedberg et al. 1993). These mutant mice are non viable and have
bilateral renal agenesis, stemming from failure of the ureteric bud to develop, and are agonadal,
stemming from failure of the gonadal ridge to thicken. Additionally, the mesothelium fails to develop
correctly, causing partial diaphragmatic hernia and an incomplete pleura (see 1.4.1.2). Heart
abnormalities, perhaps another consequence of abnormal mesothelial development (of the
pericardium), are also observed and are thought to be the cause of death, which occurs in utero. It is
evident, therefore, that in these mutant mice all of the tissues that fail to develop or develop
abnormally are those which would normally express Wtl.
In addition to the above mRNA expression studies, in vitro translation and transfection studies
have shown that WT1 is expressed as an exclusively nuclear protein (Morris et al. 1991, Telerman et
al. 1992). These studies involved the use of polyclonal antisera and immunofluorescence analysis,
immunoprecipitation or confocal microscopy. Similar techniques have been used by Mundlos et al.
(1993), who confirmed this subcellular expression pattern and identified WT1 in vivo in podocytes,
presumptive granulosa cells, Sertoli cells, and in blastemal and derived epithelial cells in WT.
1.3.2.2 In WT
WT express WT1 at levels which are, in general, comparable to those observed in foetal kidney
(Haber et al. 1990, Pritchard-Jones et al. 1990). These high levels are attained because the cell types
which express WT1 during normal nephrogenesis; metanephric blastema, the derived immature
epithelium and the podocytes, are those that present in WT, where, even though malignant, they
continue to express this gene. Accordingly, WT with predominantly blastemal and/or epithelial
histology express far higher levels of this gene than those with triphasic or predominantly stromal
histology (Pritchard-Jones et al. 1990, Pritchard-Jones and Fleming 1991, Miwa et al. 1992b, Gerald
etal. 1992, Yeger et al. 1992).
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1.3.2.3 Imprinting
The WTJ locus may be imprinted in a subset of expressing tissues. Jinno et al. (1994) have
presented evidence for monoallelic expression in a proportion of placentae (5 out of 9 investigated)
and in foetal brain. When the parental origin of this expression could be determined (placentae only)
it was found to be maternal. The significance of this feature in placentae, which had not previously
been identified as an expressing tissue, is however uncertain as no other differences between these
samples were reported. In normal kidney and WT this locus has been found to be not imprinted (Little
et al. 1992a, Zhang and Tycko 1992).
1.3.3 Gene structure
WTl contains ten exons which span approximately 50kb in length. Each exon contains coding
sequence, exons 1 to 5 encode a proline (P) and glutamine (Q) rich region, exon 6 a linker region, and
exons 7 to 10 each encode a zinc finger (ZF) motif (Figure 1.3.1) (Call et al. 1990, Haber et al. 1991,
Gessler et al. 1992, Tadokoro et al. 1992b). Within the 3' untranslated region of exon 10 there is a
guanine and thymidine (GT)„ microsatellite sequence (Call et al. 1990). Transcription proceeds in a
centromere proximal to distal direction and, as a result of two independent alternative splices, four
mRNA isoforms of 2.944kb, 2.953kb, 2.995kb and 3.004kb are produced. Both alternative splices are
within the coding sequence and therefore the open reading frame alters in length accordingly, it has a
maximum length of 1.347kb.
Alternative splice I involves 51 bp and comprises exon 5, which encodes 17 amino acids (17aa)
within the P and Q rich region. Alternative splice II involves 9bp and utilises two splice donor sites at
the 3' end of exon 9. If the downstream site is used an additional three amino acids, lysine, threonine
and serine (KTS), are encoded within the linker region of ZF3 and ZF4 (Figure 1.3.1). The four
mRNA isoforms are designated A (-17aa -KTS, or -/-), B (+17aa -KTS, or +/-), C (-17aa +KTS, or
-/+) and D (+17aa +KTS, or +/+) and in normal kidney they are always present in a ratio of
approximately 1 A:2.5B:4C:8D (Habere?al. 1991).
The promoter of WTl is G and cytosine (C) rich, containing putative binding sites for the
transcription factor Spl (Hofmann et al. 1993). A putative enhancer element 3' of the gene has been
described (Fraizer et al. 1994).
1.3.4 Protein structure
The protein product of WTl, WTl, is between 49kD and 52kD in size (Morris et al. 1991,
Telerman et al. 1992) and contains between 429 and 449 amino acids, depending on protein isoform,
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Figure 1.3.1 Structure of the WT1 gene at the cDNA level. The relative size of each exon is
illustrated along the top of the figure. Solid boxes depict the two independent
alternative splices, I (17aa) and II (KTS). The four mRNA isoforms, designated A, B, C
and D, are illustrated below. For each, the coding sequence is represented by a
schematic illustration of the protein motifs predicted, a P/Q rich domain and four zinc
fingers (ZF1-ZF4). The dotted lines depict the untranslated sequence at the junctions of
the coding region.
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terminal P and Q rich region, a linker region and four ZF motifs at the C-terminal. Regions rich in
either P or Q residues have been identified in other proteins, such as the transcription factors CTF/NF-
I (P rich) and Spl (Q rich). In these proteins the P or Q residues are critical components of the
transregulatory domain (TD), which mediates activation or repression of transcription. The high
content of these specific residues within this domain is thought to create an environment that promotes
contact with other components of the transcription complex (reviewed by Mitchell and Tijan 1989). In
WT1 20% of the residues within the N terminal region are P or Q. By performing domain swap
experiments with the early growth response gene family member protein, EGR1 or the yeast
transcription factor GAL4, both transcriptional activators, Madden et al. (1991) and Madden et al.
(1993) identified this latter region of WT1 as a TD which repressed transcription. It is proposed that,
similar to CTF/NF-I and Spl, the high content of P and Q residues within the TD of WT1 permit
contact with other proteins. Studies to identify such proteins, using the yeast two hybrid system, are in
progress (R. Davies, personal communication). Moreover, comparison of the -17aa and +17aa WT1
isoforms has identified the latter as a stronger transcriptional repressor (Rupprecht et al. 1994, Wang
et al. 1995), a feature which is thought to be mediated by the higher serine (S) content of the latter
isoforms (5/17 residues encoded by alternative splice I are S) (Wang et al. 1995). S and threonine (T)
residues are substrates for phosphorylation, a mechanism used frequently to regulate transcription
(reviewed by Hunter and Karin 1992). This mechanism does not appear to be used to a great extent by
WT1 (Morris et al. 1991), however this does not of course diminish the potential significance of any
phosphorylation events that do occur. Furthermore, from DNA sequence analysis it is predicted that
the most extensive region of polyP in the TD is conserved in Wtl in mouse and rat but not in chick,
and also that +17aa isoforms are not present in the latter and in alligator (Kent et al. 1995). This study
therefore suggests that some aspects of TD function may be mammalian-specific.
A linker region, which is highly conserved, joins the TD and the four ZF motifs. Each of these
motifs contains between 28 and 30 amino acids and has the consensus sequence X3CX2.4CX12HX3.
4HX4, where X is any residue, C is cysteine and H is histidine (Berg 1988). The invariant C and H
residues co-ordinate a zinc atom and, as a result, a finger-like conformation is adopted (Figure 1.3.2a,
schematically illustrated in Figure 1.3.1). The ZFs are the most highly conserved part of WT1,
displaying 99% identity at the amino acid level in all vertebrates investigated (Kent et al. 1995). This
suggests that any alteration to their structure is not tolerated in normal development. ZFs are present
as tandem repeats in many proteins and the C2H2 type of WT1 are similar to those identified in the
transcription factors TFIIIA and Spl (reviewed by Evans and Hollenberg 1988). Furthermore, WT1
ZF2, 3 and 4 are 63% identical at the amino acid level to the three ZFs of EGR1 (also named Zif268
and Krox 24) (Sukhatme et al. 1988). The primary function of ZFs is formation of sequence-specific
deoxyribonucleic acid (DNA) binding domains. The EGR1 ZFs bind DNA at the consensus target
sequence 5' GCG GGG GCG 3' (Christy and Nathans 1989) and, in this protein, specific residues at
the fingertips have been identified as those that contact the target nucleotides (Pavletich and Pabo
1991). This last study also demonstrated that each ZF recognises three such nucleotides and these lie
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Figure 1.3.2 Conformation of zinc fingers motifs, a) schematic illustration of a zinc finger motif.
The arrows represent anti-parallel (1-sheet and the coil represents a-helix. The
former structure contains the invariant C residues and the latter structure the invariant H
residues. A zinc atom, co-ordinated by these residues, is depicted by an open circle.
The junction between the (3-sheet and a-helix forms the fingertip region. Drawing
adapted from Berg (1988). b) binding of three zinc fingers to target nucleotides within
the major groove. The residues that contact the target nucleotides are those at the
fingertip, depicted as a solid line between arrowhead ((3-sheet) and cylinder (a-helix).









within the major groove (Figure 1.3.2b). In in vitro experiments WT1 -KTS isoforms, the ZFs of
which are the most similar to those of EGR1, also bind this target sequence (Rauscher et al. 1990) and
other target sequences, not exclusively G and C in composition, to which the WT1 +KTS isoforms
bind (Bickmore et al. 1992). Recent studies have identified additional target sequences (Wang et al.
1993b, Rupprecht et al. 1994), including one to which WT1 binds with higher affinity (Nakagama et
al. 1995), suggesting this may be a true, in vivo target.
Two additional features of WT1 structure have been identified more recently. Firstly, two
putative leucine zipper like motifs, one discontinuous and one continuous, are encoded by exons 2, 3
and 4 (Madden et al. 1993). These motifs have been identified in other proteins, such as the
transcription factors Fos and Jun, and function as protein-protein interaction domains (reviewed by
Mitchell and Tijan 1989). If they are functional in WT1 they may permit homo- and/or
heterodimerisation. Secondly, Sharma et al. (1994) discovered that a leucine (L) or a P residue can be
present at codon position 281 (encoded by exon 6) as a result of ribonucleic (RNA) editing converting
• 1222 • 1222 * •nucleotide uracil (U) to C in a proportion of mRNA. The L form may be a stronger
transcriptional repressor than the P form, as demonstrated for rat WT1.
1.3.5 Protein function
The presence of a TD and a sequence specific DNA binding domain are hallmarks of
transcription factors and the structure of WT1 therefore includes it as a member of this class of
proteins. The previously mentioned domain swap experiments suggested that WT1 functions as a
transcriptional repressor, perhaps acting on genes encoding growth promoters. This feature has been
demonstrated using in vitro transcription assays, where WT1 -KTS isoforms bind to the promoters
and repress transcription of the EGR1 (Madden et al. 1991), IGF2 (Drummond et al. 1992), platelet
derived growth factor A chain, PDGF-A (Gashler et al. 1992, Wang et al. 1992), insulin-like growth
factor I receptor, IGF-IR (Werner et al. 1993), colony stimulating factor I, CSF-I (Harrington et al.
1993) and retinoic acid receptor a, RAR-al (Goodyer et al. 1995) genes. These gene promoters all
contain sequences similar to the 5' GCG GGG GCG 3' consensus target sequence of EGR1, however,
as this sequence is highly represented throughout the human genome, it is proposed to be present
within the promoters of many other genes. There is no direct evidence that these five selected genes
are true, in vivo targets of WT1, although IGF2 is clearly involved in WT and is a candidate for the
putative WT2 gene (see 1.2.5). Additionally, it must be remembered that +KTS isoforms may interact
with a completely different set of promoters. Recent studies have been focusing on what the true
target genes may be. The observation that heterotopic elements in WT are often muscle led to
experiments that indicate that myogenic genes are transcriptionally repressed by WT1 (Miyagawa et
al. 1994). Similarly, persistent expression of PAX2 in WT indicates that this gene may also be an in
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vivo target (Dressier and Douglass 1992, Eccles et al. 1992, Ryan et al. 1995). A third gene identified
as such a target is WT1 itself, resulting in negative autoregulation (Rupprecht et al. 1994).
Additionally, it is possible that WT1 may function not only as a repressor, but also as an
activator of transcription. A number of proteins are known to have such dual function (reviewed by
Foulkes and Sassone-Corsi 1992) and activator regions have been identified within the WT1 TD
(Wang et al. 1993a). This study also observed two distinct binding sites for WT1 in the promoter of
the PDGF-A gene and noted that unless both sites were occupied, WT1 functioned as an activator.
Furthermore, one study has indicated that WT1 binds p53 and switches to an activator when the latter
is functionally absent (Maheswaran et al. 1993).
A function of WT1 distinct from that as a transcription factor has been described by Larsson et
al. (1995). This study identified the -KTS and +KTS isoforms as partially having different subnuclear
localisation, the former associating with domains of transcription factors and the latter with the snRNP
components of RNA splicing complexes. Perhaps associated with this feature, it is interesting that, in
vitro, WT1 ZFs can also bind RNA (A. Ward, personal communication). An exclusive role for +KTS
isoforms in splicing is, however, unlikely because of the evidence supporting a role for them in
transcription.
Overall, the utilisation of alternative splicing, RNA editing and post-translational modifications
demonstrates that from one gene a considerable range of WT1 variants may be produced, and these
could each have a distinct function.
1.3.6 A role in developmental abnormalities and tumorigenesis?
The fact that WT and GU abnormalities often co-develop indicated that WT1 acts
pleiotropically on the kidney and gonad (van Heyningen et al. 1990). Elucidation of the expression
pattern of WT1 (and Wtl) corroborates this proposal and suggests that mutations in this gene may
contribute to developmental abnormalities and/or tumorigenesis in these tissues, and furthermore, may
elicit all of the components of DDS (Pritchard-Jones et al. 1990). Somatic mutations alone may be
sufficient for tumorigenesis, however constitutional mutations are predicted in individuals with
developmental abnormalities. The loss of one copy of this gene in WAGR syndrome individuals
highlighted the possibility that, at the constitutional level, having only 50% of normal levels of WT1
causes relatively mild GU abnormalities, such as hypospadias and cryptorchidism. In this situation
WT1 would be described as haploinsufficient. Additionally, if WT1 is allelic with the 11 pi3 tumour
suppressor gene then mutation analysis should reveal functional loss of the remaining copy of WT1 in
WAGR-WT and specific functional loss of both copies in other forms of WT. This feature was
suggested by the homozygous lip 13 deletion in the sporadic WT reported by Lewis et al. (1988),
however genes additional to WT1 may have been affected by this deletion. Furthermore, if WT1 is a
transcription factor, it is obvious that constitutional or early somatic alteration of this protein could
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disrupt the normal pattern of gene expression, perhaps resulting in aberrant growth and differentiation,
and hence developmental abnormalities or tumorigenesis.
1.3.7 Mutation analysis in WT
Intragenic WT1 mutations have been identified in a total of 24 sporadic unilateral and bilateral
WT, representing approximately 10% of WT analysed. These mutations are detailed in Table 1.3.1
and schematically illustrated in Figure 1.3.3. With the exception of exon 5 (alternative splice I), all
exons have had mutations identified within them and these can be deletions, insertions, missense or
nonsense mutations. The majority of the deletions and insertions are frameshift mutations, the
exceptions being one deletion that causes splicing out of exon 9 (Haber et al. 1990) and two deletions
that remove exon 10 sequences (Cowell et al. 1991, Algar et al. 1995). At the protein level, the
majority of intragenic mutations identified in these forms of WT are predicted to disrupt only the ZFs
(18 out 25 mutations, 72%) or the TD and ZFs (5 out of 25 mutations, 20%). Of the 'ZF only' class, all
but the four missense mutations would cause loss of at least one ZF and therefore, most likely, loss of
sequence-specific DNA binding. The ZF residues altered by the missense mutations are those critical
for zinc co-ordination or contact with target nucleotides and, similarly, these mutations are predicted
to also cause loss of or compromise sequence-specific DNA binding. Of the 'TD and ZF' class, only
residual N-terminal peptide structures are predicted, with no capacity to bind DNA directly or elicit
novel phenotypes. The remaining two intragenic mutations are both exon 2 missense mutations and
are therefore predicted to affect only the TD (Park et al. 1993a, Gessler et al. 1994). LOH constitutes
the second hit in approximately 50% of these WT, however in four tumours heterozygosity is retained
as the second hit was by independent mutation (Radice et al. 1993, Gessler et al. 1994, Varanasi et al.
1994). In seven WT a second hit was not identified (Little et al. 1992b, Park et al. 1993a, Gessler et
al. 1994, Varanasi et al. 1994), suggesting that independent mutation within WT1 is present but
undetected or that mutations affecting other loci are also involved, perhaps in concert with a single hit
at WT1. Alternatively, these single hits may have a dominant effect, rendering a second hit
unnecessary. In the sporadic unilateral WT described by Haber et al. (1990) LOH and a deletion
causing splicing out of exon 9 were detected, however a normal copy of WT] is also present,
suggesting that LOH constitutes the first and not the second hit. In vitro studies have shown that the
predicted mutant protein, named WT1-ZF3 or WTAR, has altered DNA binding (Rauscher et al. 1990,
Drummond et al. 1994) and suggest that this mutant has a dominant effect (Haber et al. 1992,
Maheswaran et al. 1993).
There is one report of constitutional, intragenic WT1 mutation contributing to familial WT not
associated with a clinical syndrome (Pelletier et al. 1991b). In this family the father, a WT survivor,
transmitted a frameshift deletion within exon 6 (Table 1.3.1) to his son, who was born with GU
abnormalities and developed WT. This mutation is predicted to produce a protein that lacks all four
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ZFs and therefore cannot bind DNA directly. The GU abnormalities present in WAGR syndrome
individuals, who are constitutionally hemizygous for WT1, are predicted to develop because of WT1
haploinsufficiency. As the GU abnormalities observed in this familial WT individual and in one of the
bilateral WT individuals (Pelletier et al. 1991b) are similar to those of WAGR syndrome individuals,
WTI mutations associated with the former individuals appear to be functionally analogous to the
hemizygous WTI mutations present in the latter, that is they cause haploinsufficiency. This indicated
that the critical aspect of mutations identified in bilateral and familial WT is complete loss of DNA
binding and, if present residual N-terminal peptide structures that are non-functional. A similar nature
is proposed for the majority of WTI mutations associated with unilateral WT, the exceptions being the
two 'TD only1 mutations which may contribute to tumorigenesis by a different mechanism (see below).
Furthermore, similar to WAGR syndrome individuals, not all constitutional intragenic WTI mutations
elicit GU abnormalities, as demonstrated by three of the unilateral WT individuals and two of the
bilateral WT individuals (Tadokoro et al. 1992a, Akasaki et al. 1993, Coppes et al. 1993a, Huff et al.
1991, Little et al. 1992b).
Second hit intragenic WTI mutations have been identified in 8 WAGR-WT, representing the
majority investigated. These mutations are detailed in Table 1.3.2 and schematically illustrated in
Figure 1.3.3. Similar to the mutations detailed above, those in WAGR-WT are positioned throughout
the gene and are of different types. Again, no mutations within exon 5 have been identified. All but
one of the mutations create premature stop codons, through frameshift or nonsense mutations. In these
cases loss of sequence-specific DNA binding is predicted, through disruption to either the ZFs only (5
out of 7 mutations), with the removal of at least two ZFs, or the TD and ZFs (2 out of 7 mutations),
again resulting in residual N-terminal peptide structures that are apparently non-functional. The one
exceptional mutation is an exon 3 missense mutation, predicted to affect the TD only (Park et al.
1993c). Functional studies suggest that this mutation, which encodes the change G201D, may results
in WTI switching from a repressor to an activator of transcription. It is possible that the two
additional 'TD only' mutations described above may also elicit this effect.
The residues that are predicted to be altered most frequently in the above forms of WT are
detailed in Table 1.3.3.
Forty two constitutional intragenic WTI mutations have been identified in DDS individuals
with or without WT, representing virtually all DDS samples analysed. These mutations are detailed in
Table 1.3.4 and schematically illustrated in Figure 1.3.3. The pattern of mutations in DDS differs
from that observed for the other forms of WT described above. In DDS exon 9 missense mutations
predominate and the residues that are predicted to be altered most frequently are detailed in Table
1.3.5. Similar mutations within exon 8 are also common. These mutations are predicted to alter ZF2
and ZF3 residues critical for zinc co-ordination or contact with target nucleotides. At the
constitutional level, if such alterations resulted in complete loss of DNA binding, a phenotype of
relatively mild GU abnormalities, such as those observed in WAGR syndrome individuals, would be
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Table 1.3.1 Intragenic WT1 mutations detected in unilateral, bilateral and familial WT.
u - unilateral; b - bilateral; fa - familial; m - male; f - female; nd - not determined;
som - somatic; con - constitutional; fs - frameshift; del - deletion; ins - insertion; non -
nonsense; mis - missense; dup - duplication; A - adenine; * - stop codon; + - present;
- - absent. The standard single letter code for amino acids is used and is explained in
full on page xii.
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+ Santos et al.
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u XYm/ aniridia, hypospadias, failure of
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exon 9, R390*
+ Gessler et al.
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u XYm/ unusual WAGR as 1 lp 13 del but





Table 1.3.2 Second hit intragenic WT1 mutations detected in WAGR-WT. u - unilateral; m -
male; f - female; nd - not determined; fs - frameshitft; del - deletion; dup - duplication;
non - nonsense; mis - missense; * - stop codon; + - present. The standard single letter
code for amino acids is used and is explained in full on page xii.
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Table 1.3.4 Constitutional intragenic WT1 mutations detected in DDS individuals.
u - unilateral; b - bilateral; + - present; - - absent; nd - not determined; ? - status
uncertain; m - male; f - female;nephrectomy performed; h - associated gonadal
tumour; c- bilateral ILNRs present; d- wild type and mutant sequence observed
(authors give contamination as reason);e - reported as biateral by Jadresic et al. 1991.
*
- stop codon. The standard single letter code for amino acids is used and is explained
in full on page xii. Two entries have some features in parentheses (Baird et al. 1992
and Clarkson et al. 1993). These entries refer to the same individual (LB and CAM 14
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Residue codon position CpG in codon frequency of alteration
R 362 + 5/33 (15%)
R 390 + 3/33 (9%)
Table 1.3.3 Residues predicted to be altered most frequently in unilateral, bilateral, familial
and WAGR WT. C to T transition mutations (and the reciprocal G to A) frequently
occur at CpG dinucleotides. Within these dinucleotides the C is prone to methylation,
creating 5-methyl cytosine (5-mC). This in turn is substrate for hydrolytic deamination,
converting 5-mC to T (Yang et al. 1995). +-present.
nephropathy, indicating that these missense mutations confer a different aberrant function on WT1. It
was initially proposed that these mutations elicited a dominant action, with the altered ZFs perhaps
binding to novel and inappropriate DNA target sequences, or a dominant negative action (Pelletier et
al. 1991a). Studies to which I contributed indicated that it is the latter mutational mechanism that is
involved in this syndrome. These experiments are described in detail in Chapter 5. Similar to the
other forms of WT, mutations within exon 5 have not been identified. In addition to missense
mutations predicted to affect the ZFs, other studies have identified deletion, insertion, nonsense and
splicing mutations which are predicted to create premature stop codons (Baird et al. 1992b, Ogawa et
al. 1993b, Schneider et al. 1993, Bardeesy et al. 1994b). The predicted consequences of these
mutations are discussed in Chapter 5. Unique to DDS are three reports of an identical mutation in
intron 9, which eliminates generation of the +KTS isoforms (Bruening et al. 1992, Konig et al. 1993,
Bardeesy et al. 1994b). The ratio of the four mRNA isoforms is highly conserved, even in WT not
associated with DDS investigated (Brenner et al. 1992). Alteration of the ratio of the isoforms is
therefore thought sufficient to elicit DDS. All of the above DDS WTI mutations are present
heterozygously at the constitutional level. When available for analysis, WT from DDS individuals
virtually always display LOH for the constitutional mutation. Additionally, one study has identified a
familial case of DDS, where a phenotypically normal male transmitted the classic DDS mutation
Residue codon position CpG in codon frequency of alteration
R 394 + 19/42 (45%)
D 396 + 5/42 (12%)
Table 1.3.5 Residues predicted to be altered most frequently in DDS individuals. + - present.
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encoding R394W, which he carried constitutionally, to his son, who developed DDS (Coppes et al.
1992b). Furthermore, this mutation was identified constitutionally in a female with sporadic, unilateral
WT alone (Akasaki et al. 1993).
These last two studies and that of inherited WT1 mutation reported by Pelletier et al. (1991b)
illustrate that identical WT1 mutations can elicit different phenotypes in different individuals,
indicating the involvement of additional factors, such as genetic background. Providing evidence that
genetic sex may influence the effect of WT1 mutations, Henry et al. (1993) describe identical 11 p 13
deletions in two related children, an XY individual who developed WAGR syndrome and DDS and an
XX female who developed only aniridia.
Finally, the many examples of functional loss of both copies of WT1 clearly demonstrate that
this gene is a tumour suppressor gene and is involved in different forms of WT. The different types of
WT1 mutation identified do not, however, correlate with specific histological types of WT.
1.3.8 Mutation analysis in other tumour types
WT1 mutations are implicated in myeloid leukaemias. The original cDNA clone, WT33, was
isolated from a pre-B cell leukaemia cell line library (Call et al. 1990) and encodes the change F365S
(Haber et al. 1990). This may represent a mutation rather than a polymorphism as the S residue
compromises DNA binding (Bickmore et al. 1992, Little et al. 1995). Expression in primary
leukaemias has been reported (Miwa et al. 1992a, Miyagi et al. 1993) and an exon 9 mutation,
encoding the change C385Y, has been identified in a leukaemia that developed in a WAGR syndrome
individual (Pritchard-Jones et al. 1994). More recently, a further five WT1 mutations, each of which
creates a premature stop codon, have been identified in this tumour type (King-Underwood,
submitted).
WT1 mutations may also contribute to gonadal tumours as a bilateral juvenile granulosa cell
tumour, a form of gonadoblastoma, co-developed with WT in a DDS individual carrying the classic
DDS mutation encoding the change R394W (Pelletier et al. 1991a).
Finally, the Ewings sarcoma gene, EWS, can interact with WT1. The former gene is predicted
to produce protein which, although of unknown function, has an N-terminus putative TD and a C-
terminus RNA binding domain (Delattre et al. 1992). Translocations that juxtapose the 5' sequence to
those encoding DNA binding domains are observed and are thought to create aberrant EWS protein
which, with a novel but functional C-terminus, may have oncogenic potential. In desmoplastic small
round cell tumour (DSRCT) translocations that create a EWS-WT1ZF2-4 hybrid gene and mRNA have
been identified (Ladanyi and Gerald 1994, Rauscher et al. 1994, Gerald et al. 1995).
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1.4 Human malignant mesothelioma
1.4.1 Histopathology of the mesothelium and of mesothelioma
1.4.1.1 Structure and function of the mesothelium
The mesothelium is an epithelial membrane which lines the three major serosal cavities of the
human body; the pleural, the pericardial and the peritoneal cavities. The pleural cavity houses the
lungs, the pericardial the heart, and the peritoneal many of the abdominal visceral organs.
Additionally, in males the mesothelium invests the testes (Jones 1987). Although a membrane of
single cell thickness, the mesothelium does have a double layered structure, with an inner, visceral
layer adhering to the tissues and an outer, parietal layer adhering to the wall of the serosal cavity. In
healthy individuals the two layers in both the pleural and the pericardial cavities (and in males, in the
testes also) are juxtaposed and hence the fluid filled space between them is obscured. In the peritoneal
cavity double folds, termed mesenteries, juxtapose the visceral and parietal peritoneum (van de Graaff
1995).
The functions of the mesothelium are threefold. Firstly, it secretes serous fluid to lubricate the
adjacent tissues, stopping friction between them and the appropriate cavity wall. Secondly, by surface
tension of serosal fluid, it allows both the lungs and the heart to expand and contract in unison with the
pleural and pericardial cavity walls, respectively. And thirdly, sections of the peritoneum form into
folds, termed the lesser and the greater omentum, which store fat and cushion the abdominal visceral
organs against forces of impact (van de Graaff 1995).
1.4.1.2 Development of the mesothelium
The mesothclium forms from intraembryonic mesoderm, a process which commences during
the third week of human cmbryogenesis, coincident with somite development. Numerous small
cavities, termed coelomic spaces, form within the lateral mesoderm. As mesenchymal cells migrate
towards the midline these spaces fuse to form a horseshoe shaped structure, the intraembryonic
coelom. This process divides the lateral mesoderm in to two layers, a dorsal layer of somatic
mesoderm and a ventral layer of splanchnic mesoderm; the former gives rise to the parietal
mesothelium and the latter to the visceral mesothelium. At this stage of development the mesothelium
is continuous within the intraembyonic coelom. During the fourth week of embryogenesis
compartmentalization of the intraembryonic coelom is initiated, forming the primitive pericardial and
peritoneal cavities, which are linked together by two pericardioperitoneal canals. It is a further three
weeks until the pleural cavity is fully developed from and separated from the pericardial cavity,
although separation of the pleural and peritoneal cavities is completed one week earlier (week six)
concurrent with formation of the diaphragm. At week seven of embryogenesis therefore, when the
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three cavities are fully distinct from each other, the mesothelium is similarly isolated as pleurae,
pericadium and peritoneum (Moore and Persaud 1993).
When initially formed from the somatic and splanchnic mesoderm, parietal and visceral
mesothelial cells are cuboidal. A basal lamina is then established, separating these cells from the
underlying mesenchyme, and, concurrently with the formation of intercellular junctions, the cuboidal
form is lost. The morphology of the mature parietal and visceral mesothelium is simple, squamous
epithelium (Thomas 1987).
1.4.1.3 Structure of mesothelioma
Mesothelioma is a highly malignant tumour which derives from and selectively spreads along
the mesothelium. This type of tumour tends not to infiltrate the adjacent tissues directly, a feature
which is clearly evident when looking at the most common site of human malignant mesothelioma
(MM), the pleurae, as the lungs are rarely seeded with malignant cells (Jones et al. 1987). Lung
function is, however, greatly affected as the tumour encapsulates and 'strangles' the tissue. Similarly,
in pericardial MM, heart tissue can be free of malignancy but heart function can be severely, and
sometimes fatally, impaired, because of the surrounding tumour mass. The tumour is grey-white in
appearance and forms an extremely hard and tenacious structure, varying in thickness from a few
millimetres to several centimetres. It is usual for the visceral and parietal layers to become fused when
malignant (Jones et al. 1987). Additionally, it is common for MM to spread to other cavities, such as
the contralateral pleural cavity or from the pleura to the pericardial cavity or , by direct spread across
the diaphragm, to the peritoneal cavity. Metastases of MM are also frequent (Jones et al. 1987, Suzuki
1980).
Histologically, the majority of MM are epithelial predominant tumours, containing aberrant
sheetlike, tubular and papillary structures. Many of these tumours also contain foci of mesenchyme, a
component which is itself predominant in approximately 7% of MM. Approximately 25% of tumours
contain much of both components, and are said to be biphasic or mixed in composition. Tumours of
this latter histological group often contain a third cell type, intermediate in form between the epithelial
and mesenchymal cells. The presence of such transitional cells reflects the inherent plasticity of
mesothelial cells, having the capability to either further differentiate (epithelial cells) or to de¬
differentiate (mesenchymal cells) (Suzuki 1980).
1.4.2 Epidemiology
1.4.2.1 Incidence
MM in humans was described first in 1870 by Wagner (reference not consulted), who used the
term endothelioma. Spontaneous MM is a rare tumour, with an incidence of approximately 1-2 cases
per million individuals per year (McDonald and McDonald 1986). This figure is most probably
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equivalent to all cases of MM up to the 1950's, however over the last forty five years the aetiology of
this malignancy has altered dramatically. In Britain there are currently approximately 1000 deaths per
year from MM, with only a maximum of one tenth of these deaths attributable to the spontaneous form
of the tumour. Indeed, projected figures forecast a continuation of the increasing frequency of MM
cases in Britain, culminating in a peak incidence of >3000 deaths per year by the year 2020 (Webb
1995).
1.4.2.2 Influence of asbestos
The reason why an ever increasing number of individuals are developing MM is because they,
unlike their immediate ancestors, have experienced mainly occupational exposure to mineral fibres, in
particular the highly carcinogenic fibre, asbestos. Shipbuilders, building industry workers, World War
1 and II gas mask assemblers and miners working asbestos quarries have been particularly affected by
unacceptable levels of asbestos exposure, although the dangers were not recognised until 1960, when
the first report of an association between asbestos and MM was published (Wagner et al. 1960).
Alarmingly, unacceptable levels of exposure have persisted within certain sectors of employees until
as recently as the early 1980's (Webb 1995). Indeed, this type of asbestos exposure, together with
domestic exposure which affects employees' families (Vianna and Polan 1978, Li et al. 1978), is now
thought to be responsible for approximately 85% of all cases of MM (Jones et al. 1987). Passive,
environmental exposure to asbestos may also be capable of inducing this tumour (Risberg et al. 1980).
Neither the length of exposure time nor the intensity of exposure to asbestos is correlated with the
duration of the latent period or the severity of the resulting tumour, however, a threshold level of
asbestos burden, required for induction of MM, may exist (Browne 1983a).
With the exception of the World War I and II workforces, the occupations associated with
asbestos exposure have always been those that employ many times more men than women. It is this
pattern of employment that causes MM to present predominantly in males. Also, asbestos induced
MM does not, in general, develop until later life, as there is an average period of latency of between
thirty to forty years after first exposure (Browne 1983a). This extended latent period accounts for the
forecast peak of deaths from MM by the year 2020.
Again because of the influence of asbestos exposure, the majority of MM are pleural
(approximately 57% of cases), and >90% of these are unilateral (Fishman 1988). Peritoneal MM are
next most common (approximately 40% of cases), with pericardial and testicular MM both observed
infrequently (Suzuki 1980).
1.4.2.3 Asbestos-independent cases
Approximately 15% of MM patients do not have a history of occupational or domestic
exposure to asbestos, and represent the constantly rare and 'basal' incidence of this tumour. A
minority of these patients may have unknowingly suffered environmental asbestos exposure, however
the majority do appear to have developed MM in an asbestos-independent manner.
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The term spontaneous MM was used earlier (1.4.2.1) to encompass all asbestos-independent
tumours. Two reports (Ilgren and Wagner 1991, Peterson et al. 1984) detail the subdivision of
asbestos-independent MM into eight separate categories, although many of these can be overlapping.
The categories are as follows, 1- spontaneous cases, particularly applicable to pericardial and testicular
MM where intercavity spread is not apparent; 2- cases with a latent period of <10 years; 3- childhood
cases, post-mortem studies confirm this form is not associated with asbestos (Browne 1983b); 4-
familial cases; 5- cases prior to 1900, when asbestos was not an industrial material; 6- mineralogically
negative, histologically positive cases; 7- cases involving non-asbestos fibrous agents, such as
fibreglass and 8- cases involving non-fibrous agents, such as radiation, chemicals and chronic
inflamation.
Neither report details the possible involvement of specific genetic defects in the development of
this form of MM (see 1.4.4.3), a component which may explain why these patients have a younger age
at presentation, by an average of over seven years, in comparison to asbestos induced MM patients
(Hirsch et al. 1982). A second contrasting feature is that this form of the tumour affects men and
women at an equal frequency (Law et al. 1983, Hirsch et al. 1982). The lack of a sex bias reflects the
lack of involvement of asbestos, and, consequently, the proportion of MM individuals that are female
is far higher for the asbestos-independent form than for the asbestos induced form of the tumour.
1.4.2.4 Prognosis
Prognosis for MM is poor for two main reasons; firstly, the tumour is unresponsive to both
radiotherapy and chemotherapy and secondly, it tends to be well established before any symptoms
manifest. Hence the median survival time post-presentation is only one year (Fishman 1988). When
patients with asbestos-independent MM are considered separately, survival time is extended by
between seven and twelve months (Law et al. 1983, Hirsch et al. 1982). Death usually results from
respiratory failure, bronchopneumonia or pericardial haemorrhage (Browne 1994). MM has not been
reported as a component of any clinical syndromes.
1.4.3 Precursor lesions
Pleural plaques are dense masses present on the pleural mesothelium. They are most often
multiple, bilateral and acellular, and are composed of collagen bundles that form white or yellow
thickenings on the parietal surface. Well defined margins keep plaques distinct from the adjacent and
underlying mesothelium, which does not display signs of reactive change. The presence of pleural
plaques is an indicator for previous exposure to asbestos, with immunological reactions apparently
causing collagen deposition around the inhaled fibres subsequent to their transportation to the parietal
pleurae. The mesothelial cells do not appear to be involved in these reactions and pleural plaques are
therefore thought of as submesothelial structures. Hence, although their presence has a feature in
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common with mesothelioma, that is, exposure to asbestos, the distinct nature of pleural plaques
abolishes their consideration as precursor lesions for this malignancy (Jones et al. 1987).
1.4.4 Genetic component
1.4.4.1 Asbestos induces gross genetic change
Features of both asbestos induced and asbestos-independent MM indicate the involvement of
genetic defects in the development of this tumour. Early studies highlighted numerical and structural
chromosome abnormalities observed when asbestos fibres were introduced into Chinese hamster ovary
cell cultures (Sincock and Seabright 1975) and human mesothelial cell cultures (Lechner et al. 1985).
More recently, experiments have observed that phagocytosed asbestos fibres have affinity for the
cellular matrix rather than for chromosomes (Ault et al. 1995). It is believed that if the fibres are
sufficiently long they extend into and interfere with the mitotic spindle, causing the types of gross
genetic change mentioned above.
1.4.4.2 Predisposition for asbestos insult?
The idea that genetic change may precede asbestos insult has also been examined. Browne
(1983a) proposed that mesothelial cells may be initiated for asbestos insult prior to exposure, and the
fibres then act solely as the promoter of tumorigenesis. The mechanism of initiation is not specified
but could represent genetic predisposition. The fact that many asbestos exposed individuals never
develop MM, even after a suitable latent period, also supports the idea that an individual's genetic
background can influence whether the mesothelium remains normal or adopts malignancy in response
to asbestos insult (Hammar et al. 1989). An extension of this proposal is that, subsequent to
promotion, initiated mesothelial cells may still have to accumulate additional genetic changes, such as
discrete mutations, before they can become fully transformed, a model comparable to the multigene
model proposed for colorectal tumorigenesis (Fearon and Vogelstein 1990). The length of time
required to accumulate the minimum amount of genetic change for MM tumourigenesis is perhaps the
factor which dictates the precise length of the extended latent period (Gabrielson et al. 1992).
Further evidence for genetic predisposition comes from five independent studies where
domestic exposure to asbestos, though apparent, is thought insufficient to explain all aspects of
particular cases. Firstly, Vianna and Polan (1978) showed that the parents of asbestos exposed
females have a higher incidence of cancer (though never MM) in comparison to control cohorts.
Secondly, Browne (1983a) showed that familial cases of MM occur, in general, as parent-child or
sibling-sibling associations, and rarely develop in genetically distinct partners. And finally, Li et al.
(1978), Risberg et al. (1980) and Hammar et al. (1989) detail families where some members are
believed to have experienced only background levels of asbestos exposure and yet have developed
MM, often of a histological type identical to that of their relative(s) with confirmed asbestos exposure.
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1.4.4.3 Can genetic defects act alone?
Cases of MM presenting after a latent period of <10 years and/or in childhood are known to
develop in an asbestos-independent manner (see 1.4.2.3). It is possible that, because of the rapid
progression and/or paediatric nature of these particular tumours, other environmental factors have also
not had sufficient time to contribute significantly to tumorigenesis. In these cases, therefore, genetic
defects may constitute both the initiator and the promoter of tumorigenesis. This mechanism may also
apply to other forms of spontaneous MM (see 1.4.2.3), such as the familial form. With respect to the
latter, the report by Hirsch et al. (1982) of asbestos-independent MM presenting in two siblings (both
in their fifth decade of life) further indicates that genetic defects alone may be sufficient for MM
tumorigenesis.
Certain genetic defects may contribute to other types of malignancy together with MM. Kane
et al. (1990) report an individual with asbestos-independent MM and familial granular cell
myoblastoma, who subsequently developed renal oncocytoma, malignant melanoma and
adenocarcinoma of the bladder. No form of genetic analysis is detailed, but it is possible that this
individual was genetically predisposed for tumorigenesis, similar to individuals with Li-Fraumeni
syndrome (Li et al. 1988), who have constitutional mutations affecting the p53 gene (Malkin et al.
1990).
1.4.4.4 Specific cytogenetic and genetic defects
To date, there are no known genetic defects which are unique, and therefore diagnostic, for
human MM. Numerous chromosomal abnormalities are however a consistent feature of this tumour
type and many are observed as non-random events. These comprise both genetic gain, affecting
chromosomes 5, 7, 11 and 12, and genetic loss, affecting chromosomes 1, 3, 6, 9 and 22. The majority
of MM samples analysed for specific genetic defects are found to contain more than one of these gains
and/or losses, further indicating a multigene mechanism for tumorigenesis, perhaps involving both
oncogenes and tumour suppressor genes. This type of model has been outlined for MM tumorigenesis
by Meloni et al. (1992).
The most frequently observed gain involves chromosome 7 and is confined to 7p (Tiainen et al.
1988, Tiainen et al. 1989, Hansteen et al. 1993). The PDGF-A gene maps to this region, at 7p21-p22
(Bonthron et al. 1988), and may be significant as the growth factor it encodes has been implicated in
the malignant transformation of mesothelial cells (Gerwin et al. 1987, Versnel et al. 1988). The
reasons for the gains of chromosomes 5 (Tiainen et al. 1989), 11 (Tiainen et al. 1988, Tiainen et al.
1989, Hansteen et al. 1993) and 12 (Tiainen et al. 1988, Tiainen et al. 1989) also remain unknown.
The most frequently observed loss is monosomy of chromosome 22 (Tiainen et al. 1988,
Tiainen et al. 1989, Flejter et al. 1989, Hansteen et al. 1993, Taguchi et al. 1993). The PDGF-B gene
(Dalla-Favera et al. 1982, Swan et al. 1982) and the neurofibromatosis tumour suppressor gene, NF2
(Rouleau et al. 1993, Trofatter et al. 1993), both map to this chromosome and may contribue to MM
tumorigenesis. PDGF-B is implicated through interaction with PDGF-A. The potential involvement
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of NF2 is more apparent, though based on a single study. This study identified deletions and nonsense
mutations affecting NF2 in 7 out of 17 (41%) MM samples, including one primary tumour (Sekido et
al. 1995). Relatively few mutations in only one other tumour suppressor gene, p53 (chromosome
17p 13), have been reported for MM, although these data are based exclusively on the analysis of
tumour cell lines (Cote et al. 1991, Metcalf et al. 1992).
Loss of chromosome 1 appears to be confined to lp (Gibas et al. 1986, Popescu et al. 1988,
Tiainen ef a/. 1988, Flejter et al. 1989, Tiainen et al. 1989, Hansteen et al. 1993, Taguchi et al. 1993),
of chromosome 3 to 3p (Gibas et al. 1986, Popescu et al. 1988, Flejter et al. 1989, Tiainen et al. 1989,
Hansteen et al. 1993, Taguchi et al. 1993, Lu et al. 1994, Zeiger et at. 1994) and of chromosome 6 to
6q (Gibas et al. 1986, Meloni et al. 1992, Taguchi et al. 1993).
For chromosome 9, loss is confined to the short arm (Tiainen et al. 1988, Tiainen et al. 1989,
Center et al. 1993, Hansteen et al. 1993) and, more specifically, to the region 9p21-22 (Cheng et al.
1993, Taguchi et al. 1993). Subsequent to the identification of the pl6 gene at 9p21 (Kamb et al.
1994a, Nobori et al. 1994), this locus has been studied extensively in relation to tumorigenesis (see
1.5).
1.5 The p!6 gene
1.5.1 Isolation and identification
The human multiple tumour suppressor gene, MTS1, was isolated from chromosome 9p21 by
positional cloning and presented as a candidate tumour suppressor gene by Kamb et al. (1994a). This
study employed detailed deletion analysis of an approximately 120kb region of 9p21 in cell lines
derived from twelve different tumour types, including melanoma, lung cancer, glioma and leukaemia.
Earlier studies had implicated this locus in malignant melanoma (Cannon-Albright et al. 1992,
Fountain et al. 1992), non-small cell lung carcinoma (Center et al. 1993, Olopade et al. 1993),
malignant glioma (Ichimura et al. 1994), leukaemia (Diaz et al. 1990, Einhorn et al. 1990) and, as
mentioned above, MM (Cheng et al. 1993, Taguchi et al. 1993). Of all the different tumour cell lines
analysed, only those derived from colon carcinoma and neuroblastoma failed to show repeated
homozygous deletion of MTS1 or the flanking region.
Within the putative exonic segments of MTS1 complete identity to a previously known cDNA
sequence was demonstrated. This latter sequence had been deduced from a protein isolated through its
ability to complex with cyclin dependent kinase 4 (CDK4), an enzyme critical in cell cycle regulation
(Serrano et al. 1993). The protein was termed pl6INK4 (inhibitor of kinase 4) and was recognised as
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the product encoded by MTS1. An independent study using similar techniques also isolated this gene
(Nobori et al. 1994). They named it CDK4I, as, again, the connection with pl6INK4 was recognised.
To date, there are five names for this gene; MTS1, CDK4I, CDKN2 (the official name), pl6,NK4
and, most simply and now most commonly, pl6. The protein is now also referred to most commonly
as p 16.
1.5.2 Expression pattern
As a cell cycle regulator p 16 may be a critical protein, and it is therefore feasible that it is
required by all cells for correct growth and division. This would necessitate ubiquitous expression of
p!6, making it, in this respect, comparable to the genes that encode some of the other CDK inhibitors.
One study has addressed this topic by analysing pl6 levels in nine distinct and non-tumorigenic human
cell types (Tarn et al. 1994). T lymphocytes were the only cell type found to lack pi6. The other
mesoderm derived cell types analysed, all of which expressed pi6, consisted of endothelial cells,
osteocytes, fibroblasts and smooth muscle cells. Additionally, transformed epithelial cells from breast
and kidney (EMBK cells) were found to contain high levels of p 16 (also reported by Aagaard et al.
1995).
Within the limits of a single cell cycle levels of p 16 vary, with a peak of expression observed
during the Gl-S transition phase (Tarn et al. 1994).
1.5.3 Gene structure
pl6 contains three exons which span approximately lOkb in length. Each exon contains coding
sequence, 66% (307bp out of 468bp) of which is contained in exon 2. Both exons 1 and 2 encode
ankyrin repeat motifs (Figure 1.5.1a). Transcription proceeds in the proximal to distal direction, as
described by Kamb et al. (1994a) and produces a mRNA of at least 966bp (see Appendix A, Part II).
No alternative splice variants have been identified. The structure of the promoter has not been
elucidated.
1.5.4 Protein structure
pi6, named because it is 16kD in size, contains 156 amino acids (Serrano et al. 1993, revised
by Hannon and Beach 1994). As mentioned above, the majority of the primary amino acid sequence
can be aligned as four contiguous repeats, each displaying homology to the consensus amino acid
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Figure 1.5.1 Structure of the pl6 gene at the cDNA level and of the predicted protein motifs, a)
the relative size of each exon is illustrated. The full extent of exon I is not known, but
this cDNA is predicted to contain the complete coding sequence. The latter is
represented by a schematic illustration of the protein motifs predicted, four ankyrin
(ANK) repeats. The dotted line depicts the 3' untranslated sequence, b) alignment of
the primary amino acid sequence of p 16 demonstrates the potential for formation of
ankyrin repeat motifs. Drawing adapted from Serrano et al. (1993). c) predicted
conformation of ankyrin repeat motifs, six repeats are present. Drawing reproduced
from Michaely and Bennett (1992).
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number of diverse proteins (reviewed by Michaely and Bennett 1992) and are thought to function
exclusively as protein-protein interaction domains (Figure 1.5.1c). No additional motifs have been
identified.
1.5.5 Protein function
As mentioned above, p 16 is a CDK inhibitor, originally isolated through its association with
CDK4 (Serrano et al. 1993). Subsequently, a CDK4-related molecule, CDK6, has also been identified
as a target for p 16 (Hannon and Beach 1994). It is believed that the four ankyrin repeats which
comprise pi6 mediate the association with both CDK4 and CDK6. pl6 targets these CDK molecules
at a specific stage of the cell cycle, the Gl-S transition phase, when maximum levels of pl6 are
observed. By inhibiting kinase activity at this stage, pi6 antagonises entry in to S phase and, in doing
so, stalls cell proliferation. The function of p 16 in the cell cycle is therefore that of a negative
regulator, blocking premature DNA synthesis and cell division.
1.5.6 A role in tumorigenesis?
The positive regulators of the cell cycle are the CDKs and their cyclin molecule partners, and
the negative regulators are, as mentioned above, the CDK inhibitors. These components interact with
each other in many different combinations, with the exact composition depending on the phase of the
cell cycle together with the nature of the substrate complex (reviewed by Morgan 1995). At a basic
level, the genes encoding CDK and cyclin molecules have the potential to be oncogenes and
conversely, those encoding CDK inhibitors have the potential to be tumour suppressor genes. There
are currently six identified CDK inhibitors (Table 1.5.1) and all of them have been put forward as
candidate tumour suppressors. Much of the work that is required to confirm or refute these proposals
is still preliminary, as these genes are only recently cloned. Additionally, it is believed that the
lumorigenic potential of many of the cell cycle regulators will be masked because of the considerable
number and complexity of cell cycle interactions, which may result in functional redundancy.
There are a number of reasons for pl6 remaining the strongest candidate, among the CDK
inhibitors, for being a true tumour suppressor. Firstly, as p 16 does not appear to be expressed in a
stringent, tissue specific pattern, many different types of tissue should be affected if the gene is
mutated. This aspect is reflected by the observed repeated disruption of the pl6 locus in tumours
derived from many different tissue types (see 1.5.1). Secondly, studies suggest that loss of p 16 may
substitute for loss of RBI, as mutations in the corresponding genes appear to be mutually exclusive (Li
et al. 1994, Otterson et al. 1994, Aagaard et al. 1995). Associated with this, RB1 may
50
CDK inhibitor gene locus expression targets J references
p 15 9p21 nd CDK4, CDK6 Kamb et al. 1994a,
Hannon and Beach
1994.
p 16 9p21 ub? CDK4, CDK6 Serrano et al. 1993,
Kamb et al. 1994a,
Noboriera/. 1994.
p 18 lp32 ts CDK4, CDK6 Guan ef al. 1994.
p2i 6p21 ub CDK2, CDK4, CDK6 Xiongefa/. 1993.
p27 12p 12- 3 ub CDK2, CDK4, CDK6 Ponce-Castaneda et j
al. 1995.
p57 11 p 15.5 ts CDK2, CDK3, CDK4 Lee et al. 1995,
Matsuoka et al.
1995.
Table 1.5.1 Features of the six identified CDK inhibitors, nd - not determined; ub - ubiquitous
and ts - tissue specific.
transcriptionally repress pi6 (Li et al. 1994). Thirdly, recent in vitro studies indicate that pi6,
together with p21, may contribute to myoblast differentiation by eliminating the inhibitory effect an
active specific CDK complex has on myogenesis (Skapek et al. 1995, reviewed by Marx 1995).
Mutations affecting pi6 may therefore disrupt normal differentiation pathways and hence contribute to
tumorigenesis.
1.5.7 Mutation analysis in MM
Only one study has identified pl6 mutations in MM samples (Cheng et al. 1994). The majority
of these mutations are homozygous deletions, present in 34 out of 40 (85%) cell lines and 5 (matched)
out of 23 (22%) primary tumours. None of these deletions were however demonstrated to be
intragenic and were classified in to two main categories; those affecting proximal loci and/or pl6 and
those affecting distal loci and/or pl6. In six of the homozygously deleted cell lines both the proximal
and distal markers flanking pi6 were retained, but as these markers are approximately 1Mb apart
genes additional to pi6 may be disrupted (see 1.5.10). One intragenic mutation was detected, an A to
G transition in intron 2. This mutation, identified in one cell line, is predicted to eliminate splicing in
of exon 2, and would consequently create a frameshift. At the protein level it is predicted that the
three most C-terminal ankyrin repeat motifs would be destroyed, most likely causing loss of binding to
CDK4 and CDK6. In four additional cell lines pl6 mRNA was present at much reduced levels,
perhaps implicating a further mutational mechanism.
Finally, approximately 60% of the samples in this study derived from individuals known to
have suffered asbestos exposure. A correlation between pl6 mutation and MM aetiology or histology
could not, however, be demonstrated.
1.5.8 Mutation analysis in other tumour types
Intragenic pl6 mutations have been identified in cell lines derived from head and neck tumours,
lung carcinoma and melanoma at frequencies of 11%, 14% and 33%, respectively (Zhang et al. 1994,
Okamoto et al. 1995, Ohta et al. 1994). One recent study has calculated an overall frequency of 18%
for this type of mutation in tumour cell lines (Liu et al. 1995). In this type of sample homozygous
deletions of pl6 are, in general, observed at a higher frequency, ranging from 27%, for melanoma cell
lines, to 40%, for breast carcinoma cell lines (Ohta et al. 1994, Xu et al. 1994). Inclusion of the
figures reported by Kamb et al. (1994a) and Nobori et al. (1994) extends this range from 25%, for
lung carcinoma and leukaemia cell lines, to 87%, for glioma cell lines. This apparent predominance of
homozygous deletions in comparison to point mutations may, however, result from experimental bias
and not reflect a preferred mutational mechanism of pi6.
In primary tumours only a minority have been found to contain intragenic pl6 point mutations.
For example, studies on melanoma and nasopharangeal carcinoma identified no such mutations in 30
and 42 tumours, respectively (Ohta et al. 1994, Sun et al. 1995), whereas only 3% of bladder
carcinoma and astrocytoma (Spruck et al. 1994, Ueki et al. 1994) and 9% of lung carcinoma
(Okamoto et al. 1995) were mutated in this way. Head and neck tumours and oesophogeal carcinoma
contain point mutations at a higher frequency, 16% and 52%, respectively (Zhang et al. 1994, Mori et
al. 1994), suggesting that pl6 may be more widely involved in tumorigenesis in these tissues.
Furthermore, in primary tumours, as in cell lines, homozygous deletions appear to be more
prevalent than point mutations. Lung carcinoma, bladder carcinoma, leukaemia, anaplastic
astrocytoma and glioblastoma have been found to contain homozygous deletions at frequencies of
18%,19%, 35%, 52% and 59%, respectively (Okamoto et al. 1995, Spruck et al. 1994, Otsuki et al.
1995, Walker et al. 1995). Additionally, xenograft studies have demonstrated that 40% of pancreatic
adenocarcinomas are homozygously deleted and 85% display LOH for pl6 (Caldas et al. 1994).
Again, these studies suggest that pl6 mutations do contribute to tumorigenesis. Further
evidence for this is provided by studies on familial melanoma. One of the putative familial melanoma
genes, MLM. has been mapped to 9p21 by linkage studies and, as previously mentioned, by LOH
studies (Cannon-Albright et al. 1992, Fountain et al. 1992). pi6 was considered a candidate for MLM
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and, in support of this, one study has detected constitutional pl6 point mutations in individuals from
13 out of 18 9p-linked families and in 92% of associated melanomas (Hussussian et al. 1994).
Somewhat in contrast however, Kamb et al. (1994b) identified similar mutations in only 2 out of 13
9p-linked families. It is not possible to decide from these data whether p!6 is MLM and mutations
remain undetected in some families or whether an additional gene at 9p21 is involved.
The intragenic deletions and insertions, splicing and nonsense mutations identified in pI6 are
most likely loss of function mutations. These mutations are predicted to cause disruption, including
loss, of the ankyrin repeat motifs in the protein and, therefore, perhaps affect binding to CDK4 and
CDK6. The effect that missense mutations have at the protein level is more difficult to predict,
especially as a proportion of these mutations have been shown to be polymorphic (Spruck et al. 1994,
Cairns et al. 1994, Ranade et al. 1995). Clearly, functional studies are required. Such studies have
been performed for missense mutations identified in some of the 9p-linked melanoma families and
demonstrate that inhibition of CDK's is compromised (Ranade et al. 1995). Recently an additional
mutational mechanism has been implicated for pi6. Merlo et al. (1995) have demonstrated that
methylation of 5' sequences of pi6 blocked gene expression in primary lung carcinoma, head and neck
tumours and gliomas. Furthermore, in this latter tumour type and in associated cell lines amplification
of CDK4, rather than loss of pi6, has been detected (He et al. 1994). Similar observations have been
made for other tumour types (Maelandsmo et al. 1995), suggesting that correct stoichiometry between
inhibitor and target proteins is essential for normal cell cycle control.
1.5.9 Cell lines versus primary tumours
When the frequencies of homozygous deletions in tumour cell lines and primary tumours are
compared it is evident that, in general, the former far exceeds the latter. For example, 27% (cell line)
versus 0% (primary) for melanoma, similarly 33% versus 0% for head and neck tumours, 40% versus
0% for breast carcinoma, 32% versus 18% for lung carcinoma and 38% versus 19% for bladder
carcinoma (Ohta et al. 1994, Zhang et al. 1994, Xu et al. 1994, Okamoto et al. 1995, Spruck et al.
1994). These data suggest that loss of pi6 offers a growth advantage to tumour cells in vitro more
readily than to tumour cells in vivo. This in turn suggests that for tumours displaying LOH at 9p21 the
critical event involves a locus distinct from pl6. In support of this, from a total of 90 tumours with
LOH at 9p21 only 3 (3.3%) were identified as containing pi6 mutations (Cairns et al. 1994, Ueki et
al. 1994). Additionally, the proposal that there is at least one other gene at 9p21 involved in
tumorigenesis is also indicated by some 9p-linked melanoma families, as discussed in 1.5.8.
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1.5.10 pl5 and pl8
The pl5 gene maps approximately 25kb proximal and adjacent to pl6. Part of the genomic
sequence was identified by Kamb et al. (1994a) and was initially named MTS2. This partial sequence
displays 93% identity to MTS1 (pl6) and is structurally very similar to this gene, implicating the
occurrence of gene duplication and limited sequence divergence. Hannon and Beach (1994) isolated
the corresponding cDNA, 837bp in length, and the encoded protein, p 15, which contains 137 amino
acids. The overlapping sequences of p 15 and pl6 display 76% identity, however in the region which
forms the three most C-terminal ankyrin repeat motifs identity reaches 97%. The similarity of protein
structure is reflected at the functional level as p 15 is also an inhibitor of CDK4 and CDK6. However,
unlike pl6, pi5 expression is induced by transforming growth factor-P (TGF-P).
One other p 16-like protein, pi8, has also been isolated (Guan et al. 1994). Like p 15 and pi6,
pi8 is a CDK inhibitor, and targets CDK4 (weakly) and CDK6 (strongly). The primary amino acid
sequence of this protein displays moderate identity to p 15 and pl6 (less than 40% for each) but is most
similar to that of the Notch proteins. Initial studies suggest that the genomic structure of pl8 is similar
to that of pi5 and pl6, again implicating a common ancestral gene. p!8 is not, however, linked to pi5
and p!6\ it maps to chromosome lp32.
1.6 Do both genes contribute to both tumour types?
1.6.1 Association of urogenital and mesothelial tumours
1.6.1.1 Developmental association
As described previously, the kidney, gonad and mesothelium all derive from intraembryonic
mesoderm. More specifically, the kidney forms from intermediate and lateral mesoderm, whereas the
mesothelium forms from the latter only. Both the mesonephros and the mesothelium contribute to
gonadal development, hence this tissue also forms from intermediate and lateral mesoderm. A further
similarity between these tissues is that they all undergo a mesenchyme to epithelial cell type transition.
This pattern of regulated conversion during development is rare, and has been identified in only two
other tissues; trophectoderm in preimplantation embryos and endothelium (Ekblom 1989). The
capillary network of the glomerulus incorporates this last tissue type with the developing kidney. The
developmental origins of the kidney, gonad and mesothelium are therefore intimately associated,




So far I have discussed in detail the WT1 and pi 6 genes and the reasons why they are believed
to contribute to development of WT and human MM, respectively. These studies also reveal a number
of features, outlined and expanded below, supportive of the reciprocal arrangement, that is,
contribution of WT1 to MM and ofpI6 to WT. Indeed, a number of years prior to the identification of
these genes, evidence was gathering for a common genetic defect, predisposing for tumours of both the
urogenital system and the mesothelium. Antman et al. (1984), Anderson et al. (1985) and Austin et al.
(1986) describe a total of four individuals who each developed WT and MM. Further, Stock et al.
(1979) describe a case of MM developing subsequent to treatment for seminoma, which, despite the
influence of radiotherapy as emphasised by the authors, again provided early evidence for a genetic
link in these tumour types.
1.6.2 Involvement of WT1 in MM?
Analysis of the expression pattern of WT1 and the expression pattern and homozygous mutants
of Wtl indicated a requirement for this gene in development of the mesothelium (see 1.3.2).
Additionally, WT1 is expressed in a spatial and temporal pattern concordant with involvement in
regulating mesenchyme to epithelial cell type transitions, further implicating this gene in mesothelial
development. Evidence that constitutional WT1 mutations can disrupt development of the
mesothelium is presented by Devriendt et al. (1995), who describe an individual with a constitutional
WT1 missense mutation (Table 1.3.4), DDS (no WT, neonatal death) and an abnormal mesothelium in
the form of diaphragmatic hernia, a feature also observed in Wtl homozygous mutant mice. One study
has jointly analysed WT1 and the mesothelium from a tumorigenic perspective (Park et al. 1993b).
W77 mutation analysis was performed on 32 MM and 1 mesothelial lesion. The latter sample was the
only one in which a WT1 mutation was identified; a missense mutation in exon 6, which was found to
be not present constitutionally. Hence, although not contributing to MM tumorigenesis, this somatic
mutation may be a second example of WT1 mutation contributing to abnormal development of the
mesothelium.
1.6.3 Involvement ofpl6 in WT?
As previously stated the majority of sporadic unilateral, bilateral and familial WT, together
with a minority of syndrome-associated WT, do not appear to contain mutations in WT1 and are
therefore presumed to contain mutations which affect other critical genes. In addition to p53 and the
potential WT predisposition genes described earlier (1.2.6 and 1.2.7), pi6 was thought an excellent
candidate gene for involvement in this tumour, principally because the study by Kamb et al. (1994a)
55
highlighted mutations in this gene in many other tumour types and implicated it as having a
widespread role in tumorigenesis
1.7 Aims of this study
The aims of this study were to use mutation analysis techniques in the following ways: firstly to
characterise further the involvement of WTI in many forms of WT: sporadic unilateral, bilateral,
familial, WAGR- and DDS-WT. This analysis is important as, in concert with studies on gene
evolution, it can help elucidate the critical aspects of WTI structure and function. This, in turn, can
provide insight to the mechanisms underlying both normal and aberrant nephrogenesis and,
furthermore, development of other tissues known to express this gene. Secondly, the possible
involvement of WTI in tumorigenesis of one of these latter mentioned tissues, the mesothelium, was
investigated. The mesothelial tumour type studied was MM, for which a role for W77 is implicated
but not proven. Thirdly, the involvement of a second gene, pl6, in this latter tumour type was further
characterised. This analysis is important as high resolution studies of this candidate gene in MM are
lacking. Fourthly, and similarly, the possible involvement of pl6 in WT was investigated as, again,
this gene is a candidate for involvement in this tumour type but experimental evidence is lacking.
The accumulation and interpretation of data from two tumour suppressor genes, one well
characterised and one a recent discovery, and two tumour types is valuable as both common and
differing patterns of tumour suppressor gene action can be revealed, such as mutational mechanisms
























unilateral tumour, male WAGR patient with partial spectrum.
also known as NP11, unilateral tumour, female patient.
unilateral tumour, male patient.
unilateral tumour, male BWS patient.
also known as NP9, unilateral tumour.
also known as NP8, unilateral tumour.
unilateral tumour, sporadic, female patient.
unilateral tumour, male BWS patient.
unilateral tumour, sporadic, male patient.
unilateral tumour, sporadic, male patient.
unilateral tumour.
also known as 66.1 and STEBAK, bilateral tumour, female DDS patient,
also known as 30.1, unilateral tumour containing heterotopic ganglia, 'female' DDS
patient with accompanying cerebral atrophy, pyschomotor retardation, recurrent
bronchitis, dermatitis and low IgG.
also known as JGRD, bilateral tumour containing heterotopic muscle, male DDS patient
with accompanying horseshoe kidney, gross motor delay, craniosynostosis, and
prominent metopic suture.
also known as SATAY, unilateral tumour of multricentric origin and containing
heterotopic muscle, male DDS patient with accompanying developmental delay,
epilepsy and posterior scalp defect, contralateral kidney contains ILNR and heterotopic
muscle.
GAWA unilateral tumour.
JAHUM unilateral tumour, sporadic, male patient.
JOMEE unilateral tumour, sporadic, male patient.
KABEL unilateral tumour, sporadic, female patient.
KEARK unilateral tumour, sporadic, male patient.
KEDEV unilateral tumour, sporadic, female patient.
MIWAT unilateral tumour, sporadic, male patient.
MORGAN unilateral tumour, sporadic.
NAHAS unilateral tumour, male WAGR patient with full spectrum.
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NP58 bilateral tumour, from left kidney, contralateral tumour is NP57.
PACUR unilateral tumour, sporadic, male patient with accompanying epilepsy.
RUTPA unilateral tumour, sporadic, female patient.
ZAGRE unilateral tumour, sporadic, female patient.
68.1 unilateral tumour, accompanying congenital heart defect.
8RS unilateral tumour.
2.1.2 Matched normal kidney
Matched normal kidney samples obtained from some of the above WT patients and used for
study are as follows:
DDS2, DDS4, 68.1.
2.1.3 Cell cultures and cell lines from WT
Primary cell cultures (cc) and transformed cell lines (cl) derived from some of the above WT
(work of A. Seawright and V. van Heyningen) and used for study are as follows:
CRASI (cc), DAMBA (cc), JOMEE (cc), NAHAS (cc) and NAHAS (cl).
2.1.4 Lymphoblastoid cell lines (LCL) from WT patients and their parents
The laboratory code name of each WT patient or parent derived LCL (work of A. Seawright
and V. van Heyningen) studied and additional relevant details are as follows:
ALSTA see 2.1.1 for details.
ANRIA see 2.1.1 for details.
CAROL see 2.1.1 for details.
DAMBA see 2.1.1 for details.
DANLE see 2.1.1 for details.
DAVAT unilateral tumour, male patient, contralateral renal agenesis.
DYROG unilateral tumour in duplex kidney, male patient.
FAHAS father of NAHAS, see 2.1.1 for details.
FASTA father of ALSTA, see 2.1.1 for details.
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JAHUM see 2.1.1 for details.
JEDOY familial tumour, female patient with breast carcinoma in later life, daughter had WT.
JELON unilateral tumour, female BWS patient.
JOMEE see 2.1.1 for details.
KEARK see 2.1.1 for details.
KECUL unilateral tumour, male patient, contralateral kidney had duplex collecting system.
KEDEV see 2.1.1 for details.
LISWI familial tumour, sib died from WT.
MAHAS mother of NAHAS, see 2.1.1 for details.
MASOU bilateral tumour, female patient.
MASTA mother of ALSTA, see 2.1.1 for details.
MIWAT see 2.1.1 for details.
MORGAN unilateral tumour, sporadic.
NAHAS see 2.1.1 for details.
RUSSP bilateral tumour, male patient with accompanying hypertension.
RUTPA see 2.1.1 for details.
2.1.5 Peripheral blood and non-tumour DNA from DDS patients and their parents
The laboratory code name of each DDS patient or parent peripheral blood or non-tumour DNA
studied and additional relevant details are as follows:
DDS1 also known as HADO, 'female' DDS patient.
DDS IF father of DDS 1.
DDS lFe fetal elements from missed abortion of DDS 1M.
DDS 1M mother of DDS 1.
DDS2M also known as ABAK, mother of DDS2, see 2.1.1 for details.
DDS3 see 2.1.1 for details.
DDS3F also known as 30.2, father of DDS3, see 2.1.1 for details.
DDS3M also known as 30.3, mother of DDS3, see 2.1.1 for details.
DDS4 see 2.1.1 for details.
DDS5 also known as D1.1, male DDS patient with accompanying hypertension, extreme
oedema, respiratory infection and pneumonia.
DDS5F also known as D1.2, father of DDS5.
DDS5M also known as D1.3, mother of DDS5.
DDS6 also known as ZACEV, male DDS patient with accompanying hypertensive
encephalopathy and oedema.
60
DDS7 see 2.1.1 for details.
2.1.6 LCL from renal abnormality patients
The laboratory code name of each renal abnormality patient derived LCL (work of A.
Seawright and V. van Heyningen) studied and additional relevant details are as follows:
ANBLA male patient with retroperitoneal teratoma (possible WT), child has hemihypertrophy,
cousin died of childhood kidney tumour.
CORMU stillborn fetus of undetermined sex which had renal agenesis, mother and maternal
grandmother both had branchio-oto-renal (BOR) syndrome, latter also had a child with
bilateral renal agenesis (and one unaffected child).
CRAST female patient with unilateral renal agenesis, two children had bilateral renal agenesis,
mother has unilateral renal agenesis.
DABEL male patient with large multicystic kidneys and accompanying hypotonia, enlarged
cerebral ventricles, trigonocephaly and choroid cysts, half sister had similar
abnormalities and died of paediatric kidney tumour.
FEWAR fetus of undetermined sex with renal multicystic dysplasia.
JOHON male patient with unilateral renal agenesis, two children with bilateral renal cystic
dysplasia, cousin has child with renal multicystic dysplasia.
KIRHO female patient with renal mass (possible WT) and developmental delay, possible
Perlman syndrome.
REAKI female patient with two children (different fathers) with cystic kidneys.
RUFUL female patient with bifid ureter, child had renal agenesis.
2.1.7 Peripheral blood DNA from testicular tumour families
The laboratory code name of the peripheral blood DNA from each testicular tumour family
member studied and additional relevant details are as follows:
Family 1
MARBE son with right-sided intermediate teratoma and left-sided undescended testis, proband.





ALABO son with right-sided seminoma and undescended testis, proband.




JOGRI son with left-sided intermediate teratoma, seminoma and undescended testis, proband.
ANGRI son with left-sided intermediate teratoma.
Family 4
NIGUT son with right-sided undifferentiated teratoma and left-sided undescended testis,
proband.
PEGUT son with left-sided seminoma.
JAGUT father with bilateral sarcoma and hernia (unspecified).
MHGUT mother with breast carcinoma.
Family 5
JOPER son with bilateral intermediate teratoma and undescended testes, proband.
HEPER son with left-sided seminoma.
NANMO mother.
Family 6
DARSH son with right-sided teratoma and undescended testes, proband.
2.1.8 Human primary MM
The MM studied were asbestos induced unless otherwise stated. The laboratory code name
each of these tumour samples and additional relevant details are as follows:
DC peritoneal tumour, male teenage patient, asbestos independent, peripheral blood was
also available.
2125 wax embedded pleural tissue section, high tumour volume.
2125md microdissected tumour from 2125.
3775-1 wax embedded pleural tissue section, moderate to high tumour volume.
3775-11 wax embedded pleural tissue section, moderate to high tumour volume.




































2.1.9 Cell lines from human MM and mesothelium
The cell lines studied were kindly made available on a collaborative basis by T. Langerak
(Mero lines, TM2 and NM7) or as a gift from M. J. Garlepp (JU77 and Met5a). With the exception of
Mero-123, TM2, NM7 and Met5a, the cell lines have been described previously by Versnel et al.
(1989a), Versnel et al. (1989b), Manning et al. (1991) and Center et al. (1993), and the tumours of
origin are known to have been asbestos induced (Hagemeijer et al. 1990, Manning et al. 1991). A
summary of the basic features of each cell line is as follows:
Mero-14 MM, male patient, derived from pleural effusion, epithelial histology.
Mero-25 MM, male patient, derived from autopsy pleura, biphasic histology.
Mero-41 MM, male patient, derived from pleural effusion, epithelial histology.
Mero-48a MM, male patient, derived from autopsy pleura, biphasic histology.
Mero-48b MM, male patient (as above), derived from autopsy omentum, epithelial histology.
Mero-48c MM, male patient (as above), derived from autopsy liver, epithelial histology.
Mero-72 MM, male patient, derived from biopsy pleura, biphasic histology.
Mero-82 MM, female patient, derived from pleural effusion, mesenchymal histology.
Mero-83 MM, male patient, derived from pleural effusion, biphasic histology.
Mero-84 MM, male patient, derived from pleural effusion, epithelial histology.
Mero-95 MM, male patient, derived from pleural effusion, biphasic histology.
Mero-96 MM, male patient, derived from biopsy pleura, mesenchymal histology.
Mero-123 MM, male patient, derived from biopsy, mesenchymal histology.
JU77 MM, male patient, derived from pleural effusion, epithelial histology.
TM2 in vitro transformed, derived from NM7.
NM7 mesothelium, female patient.
Met5a SV40 transformed mesothelium.
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2.2 Nucleic acid extraction from human tissue
2.2.1 DNA extraction
Different DNA extraction protocols were used depending on whether the samples were primary
tumours or normal kidney, cell pellets from cell cultures or cell lines, peripheral blood, or wax
embedded tissue sections.
For primary tumours and normal kidney: tissues were homogenised in 2ml TNES (50mM Tris
pH7.5, 400mM sodium chloride, NaCl, lOOmM ethylenediaminetetra-acetic acid, EDTA, and 0.5%
sodium dodecyl sulphate, SDS) in a 2ml microcentrifuge tube and with a fitted hand held pestle. To
this solution 250pg Proteinase K was added and samples were incubated at 55 degrees centrigrade
(°C) overnight. Samples were then divided in to two microcentrifuge tubes, an equal volume of 2.6M
NaCl added to each, they were shaken vigorously for 15 minutes then centrifugcd at 13 OOOg for 5
minutes. Supernatant was removed to a clean tube and an equal volume of absolute ethanol added.
Samples were inverted to mix solutions and precipitate DNA, which was then spooled and
resuspended in 500jil distilled water (dH20). To calculate the DNA concentration a dilution was made
(such as 1 in 500) and the optical density measured using an ultra violet (UV) spectrophotometer set at
wavelength 260nm. The optical density reading x dilution factor (such as 500) x 50 = DNA
concentration in pg/ml. DNA was stored at 4°C.
For cell pellets: frozen cells were thawed at 37°C then immediately had 1ml lysis buffer
(lOOmM Tris pH8, 150mM NaCl, lOOmM EDTA and 0.5% SDS) added. To this 10|il ribonuclease A
(RNase A, lOmg/ml) was added and samples were incubated at 37°C for 1 hour, then 50|il Proteinase
K (5mg/ml) was added and samples were incubated at 37°C overnight. An equal volume of phenol
was added, mixed for 5 minutes then centrifuged at 3 OOOrpm (Sorvall RC-5B centrifuge, Du Pont) for
10 minutes. The upper (aqueous) phase was removed to a clean tube and an equal volume of 1:1
phenol-chloroform mixture was added. This was mixed and centrifuged as before. The upper phase
was removed to a clean tube and an equal volume of 24:1 chloroform-isoamyl alcohol mixture added.
This was mixed and centrifuged as before, then the upper phase removed to a clean tube and 0.5
volume 7.5M ammonium acetate and 2 volumes absolute ethanol added. This was inverted to mix
solutions and precipitate DNA. DNA was spooled if it precipitated. If no precipitation occurred, the
sample was incubated at —20°C for 30 minutes then centrifuged at 3 OOOrpm for 15 minutes to pellet
DNA. DNA was washed twice with approximately 5ml 70% ethanol then air dried and resuspended in
between 200|J.l and 500pl IX TE (lOmM Tris and lmM EDTA) at 4°C overnight. DNA concentration
was calculated and samples stored as described above.
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For peripheral blood a Nucleon I Kit (Scotlab) and the associated protocol was used as follows.
To between 0.5ml and 1.5ml blood, 3 volumes Reagent A was added. Samples were rotary mixed or
shaken for 5 minutes then centrifuged at 13 OOOg for 5 minutes. Supernatant was discarded and 340pl
Reagent B added and vortexed briefly. This solution was transferred to a 1.5ml microcentrifuge tube,
2.5pl RNase A (50pg/ml) was added and the sample incubated at 37°C for 30 minutes. To this lOOpl
Sodium Perchlorate Solution was added, rotary mixed or shaken at 37°C for 20 minutes then at 65°C
for 20 minutes. To this 580pl -20°C chloroform was added and rotary mixed or shaken at room
temperature for 20 minutes. The solution was transferred to a Nucleon Tube, ensuring that the
contents flowed through the insert and to the bottom of the tube. This was centrifuged at 13 OOOg for 1
minute, then 45pl Nucleon Silica suspension added and centrifuged at 13 OOOg for 4 minutes. Without
disturbing the brown layer, the upper phase was removed to a clean microcentrifuge tube and 880pl
absolute ethanol was added to precipitate DNA. This was centrifuged at 13 OOOg for 5 minutes, the
DNA pellet washed twice with approximately 500pl 70% ethanol then air dried. DNA was
resuspended in lOOp.1 dFLO. The DNA concentration was calculated and samples stored as described
above.
For wax embedded tissue sections the protocol described by Wright and Manos (1990) was
used as follows. Tissue sections were placed in a microcentrifuge tube, 1ml mixed xylene was added
and samples incubated at room temperature for 30 minutes, occassionally inverting to mix. Samples
were then centrifuged at 13 OOOg for 5 minutes and the supernatant discarded. This extraction was
repeated, then 500pl absolute ethanol was added to pelleted tissue, inverted to mix then centrifuged as
before. Supernatant was discarded, the absolute ethanol wash repeated and tissue dried under vacuum.
To this lOOpl digestion buffer (50mM Tris pH8.5, ImM EDTA and 0.5% Tween 20) and 4pl
Proteinase K (5mg/ml) was added and samples incubated at 55°C for 3 hours or 37°C overnight.
Samples were then centrifuged at 13 OOOg for 5 seconds then incubated at 95°C for 8 minutes.
Samples were stored at -20°C.
2.2.2 RNA extraction
Different total RNA extraction protocols were used depending on whether the samples were
primary tumours, cell pellets or peripheral blood. The Total RNA Isolation Reagent (Advanced
Biotechnologies Ltd.) described below is applicable to all samples but was only available towards the
latter part of this study. All solutions, glassware and plasticware were either pre-treated with 0.1%
diethyl pyrocarbonate (DEPC) and/or were steriled to minimise contamination from ribonucleases.
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For primary tumours a modified version of the protocol described by Promega (1991) was used
as follows. Tumour was homogenised in 10ml 4M GMT (4M guanidine thiocyanate, 42mM sodiun
citrate, 0.2mM 2-mercaptoethanol and 0.83% N-lauroyl sarcosine) then moved to a 30ml tube and 1ml
3M sodium acetate (NaOAc) was added and samples inverted to mix. To this 10ml phenol was added
and inverted, then 2ml 24:1 chloroform-isoamyl alcohol mixture added and mixed vigorously for 10
minutes. Samples were placed on ice for 15 minutes then centrifuged at 10 OOOrpm (Sorvall RC-5B
centrifuge), at 4°C for 20 minutes. The upper (aqueous) phase was removed to a clean tube and either
11ml isopropanol or 22ml absolute ethanol was added. Samples were incubated at -20°C for at least 1
hour then centrifuged as before. Supernatant was discarded, the pellet resuspended in 500pl 4M GMT
and then moved to a microcentrifuge tube. Two volumes absolute ethanol were added and samples
were incubated at -20°C for 1 hour then centrifuged at 13 OOOg for 10 minutes. Supernatant was
discarded, the RNA pellet washed twice with 70% ethanol then dried under vacuum. RNA was
resuspended in between 200ul and 500pl DEPC treated dH20 and the concentration calculated as
described for DNA in 2.2.1. RNA was aliquoted in between 20pl and 50pl volumes and stored at
-70°C.
For cell pellets a modified version of the protocol described by Chomczynski and Sacchi
(1987) was used as follows. Frozen cell pellets were thawed on ice and in 500pl (for 5xl06 cells) or
lml (for 5xl()7 cells) solution D (4M guanidinium thiocyanate, 25mM sodium citrate, 0.5% sarcosyl
and lOOmM 2-mercaptoethanol). Cells were disrupted by repeated and gentle passage through a 21g
needle, then 0.1 volume 2M NaOAc pH4, 1 volume phenol and 0.2 volume 24:1 chloroform-isoamyl
alcohol mixture (all volumes relative to original volume) were added, with the sample being inverted
after each addition to mix solutions. This was placed on ice for 15 minutes then centrifuged at
10 OOOrpm (Sorvall RC-5B centrifuge), at 4°C for 20 minutes. The upper (aqueous) phase was
removed to a clean tube, an equal volume of isopropanol added and samples incubated at —20°C for
between 1 hour and overnight. Samples were centrifuged at 10 OOOrpm. at 4°C for 15 minutes, the
supernatant discarded and RNA pellet resuspended by vortexing in 5ml solution D. An equal volume
of isopropanol was added and incubated at -20°C for 30 minutes. This was centrifuged as before and
the supernatant discarded. The RNA pellet was washed with approximately 3ml 70% ethanol, dried
for 10 minutes under vacuum then resuspended in 200p.l DEPC treated dH20. The RNA concentration
was calculated and samples aliquoted and stored as described above.
For all samples Total RNA Isolation Reagent (Advanced Biotechnologies Ltd.) and the
associated protocol was used as follows. Between lOmg and lOOmg tissue was homogenised in lml
Total RNA Isolation Reagent in a 2ml microcentrifuge tube and with a fitted hand held pestle. This
was incubated at 4°C for 5 minutes then 200pl chloroform added and mixed vigorously for 15 seconds.
Samples were placed on ice for 5 minutes then centrifuged at 13 OOOg, at 4°C for 15 minutes. The
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upper (aqueous) phase was removed to a clean microcentrifuge tube, an equal volume of isopropanol
added and sample incubated at 4°C for 10 minutes then centrifuged at 13 OOOg, at 4°C for 10 minutes.
The supernatant was discarded and the RNA pellet washed twice with approximately 1ml 70%
ethanol. Pellets were vortexed then centrifuged at 7 500g, at 4°C for 5 minutes after each wash. RNA
pellets were dried for 5 minutes under vacuum then resuspended in between 50pl and lOOpl DEPC
treated dH20 by vortexing for 1 minute. RNA concentration was calculated and samples aliquoted and
stored as described above.
2.3 cDNA synthesis
Total RNA was reverse transcribed in a first strand synthesis reaction as follows. RNA was
rapidly thawed and 20pg added to a microcentrifuge tube containing lpl RNase inhibitor (Boehringer
Mannheim) and lpl random hexamers (pd(N)6, I00pmol/|il) (Pharmacia). Sample volume was
increased to 13|il with DEPC treated dH20 and then incubated at 70°C for 5 minutes. Samples were
then placed on ice and 2jal 10X reverse transcriptase buffer (200mM Tris pH8.3, 30mM magnesium
chloride, MgCl2, 500mM potassium chloride, KC1 and lmg/ml bovine serum albumin), lp.1 lOmM
deoxyribonucleoside triphosphates (dNTP's, equimolar dATP, dCTP, dGTP and dTTP), lpl lOOmM
dithiothreitol (DTT), 2pl DEPC treated dH20 and lpl avian myeloblastosis virus (AMV) reverse
transcriptase (25U/|J.l) (Boehringer Mannheim) added. Samples were incubated at 42°C for 1 hour
then 75°C for 8 minutes. cDNA was stored at 4°C.
2.4 Polymerase chain reaction (PCR)
2.4.1 Design of oligonucleotides
Oligonucleotides were designed to comply with a number of criteria. Within a matched pair
(one sense and one antisense) oligonucleotides were of a similar length and were not shorter than 18bp
(18mer oligonucleotide) or longer than 26bp (26mer oligonucleotide). Sequences that were
complementary between a matched pair or that had the potential to form stem and loop structures were
avoided. Similarly, sequences that were known to be internally repeated in the proposed PCR product
were not incorporated. The theoretical annealing temperatures of oligonucleotides in a matched pair
differed by a maximum of 2°C and were in the range of between 58°C and 76°C. The formula TA =
[4(G+C) + 2(A+T)] -5°C, where TA is the theoretical annealing temperature, was used. The function
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within the brackets calculates the melting temperature (TM) of the oligonucleotide. Additional
oligonucleotides used in this study had been designed previously by M. Little or were extracted
directly from published research papers or via the Johns Hopkins University Genome Database
(GDB), which was accessed through the Human Genome Mapping Project Resource Centre (HGMP-
RC) computing facilities (Rysavy et al. 1992, not consulted).
2.4.2 Synthesis and purification of oligonucleotides
Oligonucleotides were synthesised on an Applied Biosystems 391 Synthesiser and prepared as
a concentrated stock in ammonium hydroxide solution (work of A. Gallacher). To purify the
oligonucleotides a precipitation protocol was used as follows. An aliquot of 300p.l of stock
oligonucleotide solution was transferred to a microcentrifuge tube and 30pl 3M NaOAc pH5.2 and
lml absolute ethanol added. Samples were then vortexed and incubated at -70°C for 15 minutes, then
centrifuged at 13 OOOg for 15 minutes. Supernatant was discarded and the oligonucleotide pellet
washed twice with approximately 500p.l 70% ethanol, then dried for 2 minutes under vacuum and
resuspended in 200pl dH20. Oligonucleotide concentrations were calculated as described in 2.2.1,
and samples were stored at -20°C.
2.4.3 PCR conditions
Standard, touchdown, multiplex, nested and biotinylated PCR's were used (additionally,
radiolabeled PCR's were used, they are described in 2.9.2). All reactions were overlaid with mineral
oil and placed in a Hybaid OmniGene thermal cycler for amplification. Different Taq DNA
polymerases, and hence buffers, were used during this study because scientific suitability and
manufacturers' obligations differed for each variant of the enzyme. The Taq DNA polymerases used
were AmpliTaq (Perkin Elmer), Pfu DNA Polymerase (Stratagene), Taq DNA Polymerase (Promega),
Thermostable DNA Polymerase (Advanced Biotechnologies Ltd.) and Vent DNA Polymerase (New
England Biolabs).
The standard PCR used comprised lp.1 genomic DNA (200ng/p.l) or cDNA (lpg/pl), 2.5pl each
of sense and antisense oligonucleotides (each 250ng/p.l), 5|J.l 10X Taq DNA polymerase buffer, 3pl
25mM MgCl2, lpl lOmM dNTPs, 0.2pl (5U/pl) Taq DNA polymerase and 34.8pl dH20. The
standard amplification programme used was lx(94°C for 1 minute, TA for 1 minute, 72°C for 1
minute), 30x(94°C for 30 seconds, TA for I minute, 72°C for 1 minute) then lx(94°C for 30 seconds,
Ta for 1 minute, 72°C for 10 minutes), where TA is the appropriate common annealing temperature for
68
the particular oligonucleotides used. If satisfactory specific amplification failed, PCR's were
optimised by altering the profile of the amplification programme and/or by adding dimethyl
sulphoxide (DMSO) to 10% or formamide to 1%.
Touchdown PCR's were used when no single annealing temperature produced satisfactory
specific amplification. These PCR's were comprised as above except that the profile of the
amplification programme incorporated multiple annealing temperatures. The initial annealing
temperature was decreased by 1°C consecutively throughout the amplification programme until, at
between approximately cycles 20 and 24, the lowest annealing temperature was reached and
maintained for the remaining cycles.
Multiplex PCR's were used to co-amplify a WT1 sequence and a pl6 sequence and therefore
differed from standard PCR's by containing two matched pairs of oligonucleotides. Different
concentrations of WT1 and pi6 oligonucleotides were used, 1250ng of the former and 500ng of the
latter, to alleviate observed differences in amplification kinetics.
For nested PCR's two matched pairs of oligonucleotides were used independently and a total of
60 cycles of amplification were performed. The first pair of oligonucleotides were used for the first 30
cycles and the second pair for the remaining 30 cycles. The second pair (or inner pair) were nested,
that is their sequence was internal for products specifically amplified by the first pair (the outer pair).
The first round of PCR comprised 20ul cDNA (a complete reverse transcription reaction, see
2.3), 2|il each of sense and antisense outer oligonucleotides (each 250ng/pl), 2)0.1 10X Taq DNA
polymerase buffer, 0.5|ol lOmM dNTP's, 0.16|ol (5U/|ol) Taq DNA polymerase and 13.34|ol dH20.
After 30 cycles of amplification, l|ol was removed and used as template for the second round of PCR,
which was a standard reaction incorporating the inner oligonucleotides.
Biotinylated PCR's were performed when specific amplification products were required for
automated sequencing (see 2.10.2). These PCR's differed from the above in one aspect only, the sense
or the antisense oligonucleotide was modified at the 5'-OH position by the addition of a biotin
molecule. Biotinylated oligonucleotides were supplied by Oswel DNA Service (University of
Edinburgh).
2.4.4 Sequences and annealing temperatures of oligonucleotides
The sequence of each olignucleotide used in this study, together with its genomic location,
laboratory code name, length, TM, orientation and origin is listed in Appendix B, Part I.
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The oligonucleotide annealing temperatures used in this study, together with the non-standard
amplification programme profiles used for some of the PCR's, and the lengths of the specific PCR
products are listed in Appendix B, Part II.
2.5 Purification of PCR products
2.5.1 Agarose gel electrophoresis
PCR's were electrophoresed through 2% agarose gels to resolve reaction products in the size
range of between approximately 150bp and lkb. The type of agarose used differed depending on
whether the products were to be recovered after electrophoresis. For PCR products that did not
require further experimental analysis, gels were prepared by diluting 5ml 20X TBE (1.8M Tris, 1.8M
boric acid and 40mM EDTA) with 95ml dH20, adding 2g standard agarose and dissolving with heat.
For PCR products that did require further experimental analysis, gels were prepared by diluting 20X
TAE (800nrM Tris, 400mM NaOAc and 20mM EDTA, adjusted to pH8.2 with glacial acetic acid)
with 95ml dFLO, adding 2g of low melting point (LMP) agarose (Gibco BRL) and dissoloving with
heat. Gels were cast with appropriately sized casting trays and well combs, solidified and submerged
horizontally in 0.5% TBE or 0.5% TAE (to match type used in gel preparation). PCR's had the
surface mineral oil removed and 5|il of loading buffer (200mM EDTA, 15% Ficoll and a few granules
of orange G pigment, adjust to pH8.1 with sodium hydroxide, NaOH) added before being loading and
electrophoresed, together with 500ng of cither a lkb DNA Ladder or a cpX174 RF DNAIHae III size
marker (Gibco BRL, for both), at 100 volts in standard agarose gels or 50 volts in LMP agarose gels.
Gels were submerged first in 0.5|ig/ml ethidium bromide stain for approximately 20 minutes then
dFLO for 10 minutes. DNA was visualised by placing gels on a UV transilluminator and
photographed using either a Mitsubishi video copy processor or a Polaroid MP-4 Land camera with
PLUS-X pan film (Kodak). PCR products required for further experimental analysis were recovered
by excision of a LMP agarose gel slice.
2.5.2 Commercial kits
Different commercial kits were used depending on the size of PCR product to be purified.
A Mermaid Kit (BIO 101) and a modified version of the associated protocol was used as
follows to purify PCR products of up to 200bp in length. LMP agarose gel slices were weighed and 3
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volumes Binding Solution and 10pl resuspended Glassfog resin added. Samples were incubated at
50°C for 5 minutes then at room temperature for 30 minutes, vortexing often to keep Glassfog in
suspension, then centrifuged at 13 OOOg for 5 seconds. Supernatant was discarded and 200jil Binding
Solution added. Samples were then vortexed for 1 minute and centrifuged as before. The supernatant
was discarded and the pellet washed with 300pl Wash Solution, then centrifuged as before, discarding
the supernatant. The wash and centrifugation steps were repeated and the supernatant discarded.
Pellets were dried for 30 seconds under vacuum, resuspended in 15pl dH20, incubated at room
temperature for 5 minutes and centrifuged as before. The supernatant was removed to a clean tube.
The pellet was resuspended in 10pl dfLO then incubated and centrifuged as before. The supernatant
was removed and pooled with the previous supernatant. This pooled solution contains the purified
PCR product. To estimate DNA concentration 2|il of purified PCR product solution was
electrophoresed through a 2% standard agarose gel together with 500ng lkb DNA Ladder. Purified
PCR product was stored at 4°C.
A Geneclean II Kit (BIO 101) and a modified version of the associated protocol was used as
follows to purify PCR products of 200bp in length or longer. LMP agarose gel slices were melted in a
microcentrifuge tube and 3 volumes Sodium Iodide Solution added. Samples were incubated at
between 45°C and 55°C for 5 minutes then placed on ice. To this 5|il resuspended Glassmilk resin was
added, vortexed then placed on ice for 5 minutes, vortexing often to keep Glassmilk in suspension.
Samples were centrifuged at 13 OOOg for 5 seconds and the supernatant removed and reserved. The
pellet was washed with 500pl NEW Wash, resuspended by pipetting then centrifuged as before. This
supernatant was discarded. The wash, resuspension and centrifugation steps were repeated twice, then
the pellet was resuspended in an equal volume of dH20 and incubated at between 45°C and 55°C for 5
minutes. This sample was centrifuged at 13 OOOg for 30 seconds and the supernatant removed to a
clean tube. The reserved supernatant was added to the pellet, vortexed and placed on ice for 5
minutes, vortexing often. This was centrifuged at 13 OOOg for 5 seconds and the supernatant
discarded. The pellet was washed, resuspended and centrifuged three times, then resuspended in
dH20, incubated and centrifuged as before. Supernatant was removed and pooled with supernatant
from the first round of purification. This pooled solution contains the purified PCR product. DNA
concentration was estimated and samples stored as described above.
A Magic PCR Preps Kit (Promega) and a modified version of the associated protocol was used
as follows to purify PCR products of 200bp in length or longer. LMP agarose gel slices were melted,
lml DNA Purification Resin added, and samples vortexed for 1 minute. Samples were then pipetted
into a 2ml syringe barrel with a Magic PCR Preps Mini-Column attached, the syringe plunger inserted
and the contents gently expelled through the Mini-Column. The Mini-Column was removed, 2ml
Column Wash were taken up into the syringe barrel, then the Mini-Column was reattached. The
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Column Wash was expelled and the Mini-Column removed and transferred to a microcentrifuge tube.
This was centrifuged at 13 OOOg for 20 seconds, then the Mini-Column was removed and left to air dry
for 15 minutes. The Mini-Column was then transferred to a clean microcentrifuge tube and 25pl dH20
added to the former. This was incubated at room temperature for 5 minutes then centrifuged as before
and the Mini-Column discarded. The elutant contains the purified PCR product. DNA concentration
was estimated and samples stored as described above.
2.5.3 Ultrafiltration
When required for automated sequencing PCR products were purified by ultrafiltration using
Centricon-100 centrifugal concentrators (Amicon) and the associated protocol as follows. PCR
products were added to a Sample Reservoir attached to a Filtrate Cup, and the sample volume
increased to 2ml with dH20. Samples were then centrifuged at 4 OOOrpm (Sorvall RC-5B centrifuge)
for 30 minutes. The Filtrate Cup and contents were discarded and a Retentate Cup placed on the
Sample Reservoir. This was inverted and centrifuged at 4 OOOrpm for 10 minutes. The volume of
DNA sample in the Retentate Cup was increased to 80pl with dH20. The DNA concentration was
estimated and samples stored as described in 2.5.2.
2.5.4 Enzymatic purification
The enzyme P-Agarase I (New England Biolabs), which purifies DNA by digesting agarose,
and the associated protocol was used as follows. LMP agarose gel slices were weighed and then
equilibrated by adding approximately 500|il IX p-Agarase I buffer and incubating at room
temperature for 30 minutes or at 4°C overnight. The buffer was discarded and the equilibration step
repeated if a 30 minute incubation was used. Agarose gel slices were then melted in a microcentrifuge
tube at 65°C for 10 minutes then cooled to 40°C by incubating at this temperature for 10 minutes. To
this 1.5p,l P-Agarase I was added for every 50pl 2% agarose to be digested, and samples were
incubated at 40°C for 1 hour. A repeat amount of p-Agarase I was added and incubated as before.
Samples then had 0.1 volume 3M NaOAc pH5.2 added and were placed on ice for 15 minutes and
centrifuged at 13 OOOg for 15 minutes. Supernatant was removed to a clean microcentrifuge tube and
3 volumes absolute ethanol were added. Samples were incubated at -70°C for 30 minutes then
centrifuged at 13 OOOg for 10 minutes. The supernatant was discarded and the PCR product pellet
washed twice with approximately 500pl 70% ethanol, then dried for 2 minutes under vacuum and
resuspended in 25pl dFFO. The DNA concentration was estimated and samples stored as described
2.5.2.
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2.6 Southern blotting and probing of PCR products
2.6.1 Blotting and prehybridisation of filter
PCR's were electrophoresed through 2% standard agarose gels as described in 2.5.1 then
Southern blotted as follows. Gels were washed in 0.4M NaOH for 2 minutes, Hybond N+ blotting
membrane (Amersham) was applied and blotting, unwicked and with sufficient absorbent paper on top
of Hybond N+ filter, was performed for between 6 hours and overnight. The filter was then removed,
rinsed in 2X SSC (300mM NaCl and 30mM tri-sodium citrate) and viewed on a UV transilluminator
to estimate the efficiency of DNA transfer. Filters were prehybridised in approximately 20mls Church
and Gilbert solution (7% SDS and 500mM sodium phosphate buffer pH7.2) for at least 1 hour and at a
temperature of 5°C below the TM of the oligonucleotide to be used as probe. All prehybridisations
were performed using a Hybaid mini hybridisation oven and glass bottles.
2.6.2 Radiolabelling probe
To prepare oligonucleotide as probe it was kinase end labelled at the 5'-OH position using
[Y-32P]ATP (Amersham) as follows. To lOng of oligonucleotide, 5|J.l 5X polynucleotide kinase (PNK)
buffer (350mM Tris pH7.6, 500mM MgCF and 25mM DTT) and 5pl [y-32P]ATP were added, the
volume was increased to 23pl with dH20 then 2p.l PNK (lOU/gl) (Boehringer Mannheim) was added.
Samples were incubated at 37°C for 30 minutes.
2.6.3 Hybridisation and washing of filter
Filters were hybridised and washed as follows. Radiolabeled oligonucleotide probe was added
directly to prehybridising filter in existing Church and Gilbert solution and hybridised overnight at the
prehybridisation temperature. After hybridisation the solution was discarded and the filter washed in
approximately 20mls 6X SSC containing 0.1% SDS, at the hybridisation temperature for 20 minutes.
Solution was discarded and wash repeated. Solution was discarded again and wash repeated but at the
Tm of the oligonucleotide probe and for 10 minutes. Filters were stored wrapped in cellophane.
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2.6.4 Signal detection
Hybridised probe was detected using autoradiography. Filters were exposed to X-OMAT AR
film (Kodak) for between 2 and 48 hours and the film was then developed using a Fiji RG II X-ray
film processer. Alternatively, filters were exposed to a Phosphor Screen (Molecular Dynamics) for
between 20 minutes and 6 hours, and the image processed and visualised using a Molecular Dynamics
Phosphorimager SP and the associated ImageQuant computer software.
2.7 The HOT technique of chemical modification and cleavage of mismatched
DNA
2.7.1 Formation of radiolabeled DNA heteroduplexes
Purified PCR product amplified, with specific oligonucleotides, from a known wild type
genomic DNA or cDNA template was the sole radiolabelled component in the chemical modification
and cleavage reactions performed in this study. For the radiolabelling reaction, lOOng of wild type
PCR product was kinase end labelled with [y-32P]ATP as described in 2.6.2. This was then
precipitated and used in a modified version of the protocols described by Cotton et al. (1988) and
Condie et al. (1993) as follows. For precipitation, 1.5pl mussel glycogen (lmg/ml), 25pl dH20, 5pl
3M NaOAc, lp.1 5mM EDTA and 150|il absolute ethanol were added and the sample incubated at
-70°C for 15 minutes, then centrifuged at 13 OOOg for 15 minutes and the supernatant discarded.
Pellets were washed twice with approximately 500|il 70% ethanol, then dried for 2 minutes under
vacuum and resuspended in lOpI IX TE. The wild type PCR product is now labelled and at a
concentration of lOng/pl. One pi of this was added to a microcentrifuge tube containing lOOng
purified PCR product amplified, with the same oligonucleotides as above, from a potential mutant
template. To this 2pl 5X Salts (0.5M Tris pH8 and 1.5M NaCl) were added and the sample volume
increased to lOpl with dH20. Samples were covered with mineral oil and incubated at 100°C for 5
minutes then 65°C overnight.
Mineral oil was removed, 50pl SE (0.3M NaOAc and 0.1 mM EDTA) and 50pl chloroform
added then sample vortexed and centrifuged at 13 OOOg for 2 minutes. The upper phase was removed
to a clean microcentrifuge tube. To the lower phase a further 50pl SE and 50pl chloroform was added,
and the sample vortexed and centrifuged as before. The upper phase was removed and pooled with the
previous. This extraction was repeated until the pooled upper phases reached a volume of 200pl. To
the pooled sample 1.5pl mussel glycogen (lOmg/ml) and 750pl absolute ethanol were added. Samples
were incubated at -70°C for 15 minutes then centrifuged at 13 OOOg for 15 minutes and the
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supernatant discarded. Pellets were washed twice with approximately 500pl 70% ethanol, dried for 2
minutes under vacuum then resuspended in 13pl IX TE. This is the labelled DNA heteroduplex
solution.
2.7.2 Modification of mismatched DNA
Hydroxylamine (HA) reaction: HA solution was prepared fresh by adding 3.36ml dH20 to
0.94g hydroxylamine hydrochloride (Aldrich), vortexing, then titrating to pH6 by adding 1.02ml
diethylamine (Aldrich) and inverting to mix. Seven pi labelled DNA heteroduplex solution was added
to 20pl of HA solution, vortexed to mix, incubated at 37°C for 1 hour (reactions performed during the
early stages of this study were incubated at 37°C for 2 hours) and then placed on ice.
Osmium tetroxide (0s04) reaction: Six pi labelled DNA heteroduplex solution was added to
2.5pl 10X Os04 buffer (lOOmM Tris pH7.7, lOmM EDTA and 15% pyridine). Then 15pl 0.8% 0s04
(freshly dilute 4% 0s04 [Aldrich] with dH20) was added, inverted to mix, incubated at 37°C for 5
minutes (reactions performed during the early stages of this study were incubated at 37°C for 10
minutes) and then placed on ice.
To completed HA and 0s04 reactions 200pl SE, 5pl dextran, molecular weight 2xl06
(lOmg/ml) and 750pl absolute ethanol were added. Samples were incubated in a methanol-dry ice
bath for 15 minutes, then centrifuged at 13 OOOg for 15 minutes and the supernatant discarded. Pellets
were washed twice with approximately 500pl 70% ethanol then dried for 2 minutes under vacuum.
2.7.3 Cleavage of modified mismatched DNA
To the dried pellets from the HA and Os04 reactions 50pl 1M piperidine (freshly dilute 10M
piperidine [Aldrich] with dH20) was added, vortexed for 1 minute then incubated at 90°C for 30
minutes. To this 200pl SE and 750pl absolute ethanol were added and the samples incubated in a
methanol-dry ice bath for 15 minutes. Samples were then centrifuged at 13 OOOg for 15 minutes and
the supernatant discarded. Pellets were washed twice with approximately 500pl 70% ethanol, dried
for 2 minutes under vacuum then resuspended in 5pl IX TE and 2pl stop mix (200mM EDTA, 95%
formamide, 0.05% bromophenol blue, 0.05% xylene cyanol FF).
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2.7.4 Resolution of reaction products
Reaction products were resolved by denaturing polyacrylamide gel electrophoresis (PAGE),
using 38.5cm x 20cm 6% acrylamide gels. To prepare casting plates the inner surface of a front glass
plate was treated with dimethyldichlorosilane then wiped with absolute ethanol, and the inner surface
of a back plate treated with a solution made by adding 30pl y-methacryloxypropyltrimethoxysilane to
10ml absolute ethanol, mixing and then adding 30pl glacial acetic acid diluted with 300pl dH20. This
solution was alllowed to evaporate then the surface of the plate was wiped with absolute ethanol.
Treated plates were assembled and then gel prepared by adding 180pl 1% ammonium persulphate and
50pl N,N,N',N'-tetramethyIethylenediamine (TEMED) to 30ml 6% acrylamide-7M urea sequencing
solution (Severn Biotech Ltd.). This solution was inverted to mix then poured immediately and a
sharks tooth comb inserted. When solidified, gels were assembled vertically with a heat dissipater
fitted and IX TBE as running buffer.
Reaction samples were incubated at 100°C for 2 minutes then loaded in gel, together with a
sequencing reaction as a size marker, and electrophoresed at a constant power of 30 Watts for either
lhour and 20 minutes (to resolve products of between approximately lbp and 250bp) or 4 hours (to
resolve products of between approximately 200bp and 450bp). The glass plates were then separated
and the acrylamide gel, adhered to the back plate, placed in fix solution (10% methanol and 10%
glacial acetic acid) for 30 minutes, then rinsed in dH20 and dried at 80°C for between lhour and 5
hours.
Radiolabeled reaction products were detected and visualised by autoradiography or
Phosphorimager analysis, as described in 2.6.4. Gels were exposed to film for between 12 hours and 1
week or to a Phosphor Screen for between 2 hours and 3 days.
2.8 Restriction enzyme digests
Different restriction enzymes and their accompanying buffers were used to digest purified or
precipitated PCR products in this study. PCR products to be digested were precipitated as follows.
Surface mineral oil was discarded and 50pl chloroform added. Samples were vortexed then
centrifuged at 13 OOOg for 5 minutes. The lower phase was removed to a clean tube and to this 5pl 3M
NaOAc pH5.2 and 2 volumes absolute ethanol were added. Samples were incubated at -70°C for 15
minutes then centrifuged at 13 OOOg for 15 minutes and the supernatant discarded. PCR product
pellets were washed twice with approximately 500pl 70% ethanol, dried for 2 minutes under vacuum
and resuspended in lOpl dH20. Eight pi were used for the digest reaction and the remaining 2pl for
the control reaction, lacking restriction enzyme.
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Restriction enzyme digest reactions were performed as follows. Between 200ng and 500ng of
purified, or 8pl of precipitated, PCR product was added to 2p.l 10X restriction enzyme reaction buffer
and 2p.l restriction enzyme (between 10U/pl and 20U/|il). Sample volume was increased to 20pl with
dH20 then incubated at the appropriate temperature for between 2 hours and overnight.
Reaction products were resolved by agarose gel electrophoresis, as described in 2.5.1.
Different types and concentrations of agarose were used to resolve digest reaction products of different
sizes. Two percent and 4% standard agarose gels were used to resolve products of between
approximately 150bp and lkb or approximately lOObp and 600bp, respectively. Four percent and 6%
NuSieve agarose (FMC BioProducts) gels were used to resolve products of between approximately
5()bp and 350bp. All gels were prepared and submerged in TBE as described in 2.5.1.
2.9 Allele loss studies
2.9.1 Restriction fragment length polymorphism (RFLP) analysis
RFLP analysis was performed using different restriction enzymes and purified or precipitated
PCR products. Restriction enzyme digest reactions were performed and the products resolved as
described in 2.8.
2.9.2 Microsatellite analysis
Microsatellite analysis was performed using PCR's with a proportion of either the sense or the
antisense oligonucleotide radiolabelled. For the radiolabelling reaction, 200ng of oligonucleotide was
kinase end labelled with [y-32P]ATP as described in 2.6.2. This reaction was then precipitated by
adding 2.5pl 3M NaOAc pH5.2 and 75pl absolute ethanol, and incubating at -70°C for 15 minutes.
Samples were then centrifuged at 13 OOOg for 15 minutes and the supernatant discarded. Pellets were
washed twice with approximately 500|Xl 70% ethanol then air dried and resuspended in 50pl dH20.
PCRs were set up as described in 2.4.3, except lp.1 dH20 was omitted and lpl radiolabelled
oligonucleotide (4ng/|J.l) added. PCRs were overlaid with mineral oil and amplified as described in
2.4.3. PCR products were resolved by denaturing PAGE using 38.5cm x 20cm 8% acylamide gels, as
described for 6% acylamide gels in 2.7.4.
Radiolabelled PCR products were detected and visualised by autoradiography or
Phosphorimager analysis, as described in 2.6.4. Gels were exposed to film for between 12 hours and 1
week or to a Phosphor Screen for between 2 hours and 3 days.
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2.10 Sequencing of PCR products
2.10.1 Direct sequencing
The Sequenase Version 2.0 Kit (USB Corporation) and a modified version of the protocol
described by Winship (1989) was used as follows for double stranded PCR product DNA sequencing.
Termination mixes were prepared by diluting 9 volumes of each of the four dGTP Termination
Nucleotide Mixtures (A, C, G and T) with 1 volume DMSO. Two pi of each termination mix was
added to a separate 0.5ml microcentrifuge tube and stored at 4°C. Template mix was prepared in a
0.5ml microcentrifuge tube by adding 300ng of purified PCR product to lpl oligonucleotide
sequencing primer (0.5pmol/|il) (oligonucleotide length in bp x 330 = g/mole), 2pl 5X Sequenase
Buffer and lpl DMSO. The volume was increased to 1 Ojul with dH20 and template mix placed on ice.
Labelling mix was prepared by adding 2pl diluted Labelling Nucleotide Mixture (diluted 1 in 15 with
dH20) to lpl 0.1M DTT and 0.5pl [35S]dATPaS (Amersham), then placed on ice. Enzyme was
prepared by adding lpl Sequenase T7 DNA Polymerase (13U/pl) to 5jlx1 Enzyme Dilution Buffer, then
placed on ice. The template mix was removed from ice and placed at room temperature for 1 minute,
then incubated at 99.9°C for 3 minutes. When this incubation had proceeded for 2 minutes the four
termination mixes were incubated at 37°C. At the end of the 3 minute incubation template mix was
placed into liquid nitrogen for a few seconds then 3.5pl labelling mix and 1.5pl enzyme added. To
thaw the frozen template mix it was agitated with the enzyme pipette tip. When thawed sufficiently to
allow pipetting the sample was incubated at room temperature for 50 seconds then 3pl were added
immediately to each of the four termination mixes, now at room temperature. Reactions were
incubated at 37°C for 5 minutes then 4pl stop mix was added. Reaction products were resolved by
denaturing PAGE using 38.5cm x 20cm 6% acrylamide gels, as described in 2.7.4. Samples were
electrophoresed for between lhour, 20 minutes and 4 hours.
Radiolabeled reaction products were detected and visualised by autoradiography, as described
in 2.6.4. Gels were exposed to film for between 12 hours and 1 week.
2.10.2 Automated sequencing
The PRISM Sequenase Terminator Single-Stranded DNA Sequencing Kit (Applied
Biosystems) and a modified version of the associated protocol (A. Brown, personal communication)
was used as follows. To 20pl Dynabeads (Dynal Ltd.) lOOpI wash solution (250mM Tris pH8 and
0.1% Tween 20) was added. Samples were vortexed then the Dynabeads pelleted with a magnet. The
supernatant was discarded, the wash repeated and the supernatant discarded again. Dynabeads were
resuspended in 40pl dH20, then 40pl ultrafiltration purified biotinylated PCR product (between
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12.5ng/(il and 25ng/p,I) and 40(0.1 6M lithium chloride (LiCl) were added. Samples were placed on a
rotary shaker at 14 OOOrpm (Ika Vibrax-VXR shaker, Scotlab) for 30 minutes. The Dynabead-DNA
complexes were then pelleted and washed as before. The supernatant was discarded, 100p.l dH20
added and the samples vortexed then pelleted as before., The supernatant was discarded and
Dynabead-DNA complexes resuspended in 20pl 0.1M NaOH (Analar grade) and incubated at room
temperature for 4 minutes. Samples were pelleted and washed as before, the supernatant discarded
and 1 OOjo.1 TE7.5 added. Samples were vortexed and pelleted as before, the supernatant discarded and
14(ol dH20 added. To this lpl oligonucleotide sequencing primer (0.8pM, of the opposite orientation
to that of the biotinylated oligonucleotide) and 5(0.1 5X SS buffer (equal volumes of MOPS Buffer and
Manganese-Isocitrate Solution) were added and the sample incubated at 65°C for 2 minutes then
cooled to room temperature for approximately 30 minutes. To this 4jol Sequenase Terminator Mix
was added and sample incubated at 37°C for 2 minutes, then lpl Sequenase T7 DNA Polymerase
(Version 2.0, 1.5U/(ol), was added, mixed and incubated at 37°C for 10 minutes. Dynabead-DNA
complexes were pelleted as before, the supernatant discarded and pellets washed as before. The
supernatant was discarded and pellets washed five times. Then 100)0.1 IX TE was added and the
sample vortexed and pelleted as before. The supernatant was discarded and Dynabead-DNA
complexes resuspended in 4jol automated sequencing stop mix (5 volumes deionised formamide and 1
volume 50mM EDTA containing 30mg/ml dextran blue).
Samples were incubated at 90°C for 2 minutes then loaded and electrophoresed in a 6%
acylamide gel in an Applied Biosystems 373A DNA Sequencer (work of A. Brown and A. Gallacher).
Sequence data was processed and visualised using the associated 373 DNA Sequencing System
computer software (Applied Biosystems).
2.11 Computer analysis of DNA sequences
The computer programmes and the database used were accessed through the HGMP-RC
computing facilities (Rysavy et al. 1992, not consulted). Restriction enzyme DNA recognition
sequences were identified using the Seqed, Map and Mapsort functions within the University of
Wisconsin's Genetics Computer Group (GCG) programme. Protein motifs were investigated by using




Searching for constitutional mutations in WT1 in individuals
with Wilms' tumour, renal abnormalities or testicular tumours.
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3.1 Mutation analysis techniques
3.1.1 Detection of gross mutations
Cytogenetic analysis techniques are capable of detecting many mutations, such as deletions and
insertions, that span approximately 3Mb or longer. With the increasing sophistication of these
techniques, incorporating methods such as chromatin extension and fluorescence in situ hybridisation
(FISH), the limits of resolution are continually improving. Mutations that are not of a suitable length
or arrangement to be detected by these techniques may be resolved with Southern blotting and
hybridisation analysis techniques, which can detect chromosomal abnormalities if they generate a
pattern of restriction fragments that alters from that normally observed. Early studies which applied
these techniques to WT rarely detected mutations at the WT1 locus. For example, Cowell et al.
(1991), Huff et al. (1991), Brown et al. (1992) and Tadokoro et al. (1992a), using Southern blotting
and a WT1 probe, detected mutations in a total of only 3 out of 170 (1.8%) WT. In accord with these
findings, many of the WT in this study were initially analysed in this way and no mutations were
detected (work of A. Seawright and K. Pritchard-Jones 1992, Ph.D. thesis). These results indicate that
the majority of WT1 mutations predicted to be present in this tumour type escape detection with these
techniques.
To gain resolution beyond the Mb and kb ranges, mutation detection methods involving PCR
analysis techniques are required. PCRs are designed to amplify sequences of between approximately
150bp and lkb. Mutations that span approximately 40bp or longer and similarly alter the length of a
specific PCR product can be distinguished from specific PCR products of wild type length after
appropriate gel electrophoresis. PCRs can also detect more discrete mutations, such as point
mutations, if they are present at one of two critical positions. Firstly, mutations that disrupt the
sequence where either one or both of the oligonucleotides anneal can be detected if they cause
amplification to be abolished or to be primed from inappropriate sequence. This feature is utilised by
multiplex PCR when used to detect deletions affecting one of the target sequences (Ballabio et al.
1990). Secondly, mutations that disrupt sequence at the exon-intron boundary can be detected if they
cause aberrant splicing, as this will generate specific PCR product of altered length when cDNA rather
than genomic DNA template is amplified. PCR techniques were used extensively for much of the
mutation analysis presented in this study.
3.1.2 Detection of point mutations
If the above techniques fail to detect mutations, point mutation analysis techniques are required.
These techniques are capable of detecting discrete mutations, including those that alter only a single
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base pair, and therefore provide maximum resolution for mutation analysis (reviewed by Prosser
1993). Sequencing techniques are increasingly being adapted for rapid point mutation analysis
however, even with the continuing advances in automated methods, this application is currently only
appropriate if a limited number of samples or relatively short lengths of sequence are to be scanned for
unknown point mutations, or if the presence of a specific, previously identified mutation is suspected.
Similarly, specific restriction enzyme digest assays can also be used to detect recurrent, previously
identified mutations which create or destroy restriction enzyme recognition sites. These two
techniques were used extensively for much of the WT1 point mutation analysis presented in this study.
When large numbers of samples or relatively long lengths of sequence are to be scanned for
unknown point mutations different techniques should be considered. Point mutations form sites of
mismatch when incorporated in to heteroduplexes (one wild type strand and one mutant strand) and
these sites can be enzymatically cleaved by RNase A (RNA-RNA or RNA-DNA
heteroduplexes)(Myers et al. 1985b) or E. coli mismatch repair enzymes such as MutY (DNA-DNA
heteroduplexes)(Lu and Hsu 1992). Heteroduplexes can also be distinguished from homoduplexes by
their altered mobility after non-denaturing PAGE (Keen et al. 1991, Perry and Carrell 1992). This
technique is called heteroduplex analysis and is very similar to the single strand conformation
polymorphism (SSCP) technique which, again after non-denaturing PAGE, detects the altered mobility
of wild type and mutant single strands (Orita et al. 1989). Furthermore, the altered mobility of
duplexes which contain at least one mutant strand may be detected with techniques, based on variant
forms of PAGE, termed denaturing gradient gel electrophoresis (DGGE) (Myers et al. 1985a),
temperature gradient gel electrophoresis (TGGE) (Wartell et al. 1990) and constant denaturant gel
electrophoresis (CDGE) (Hovig et al. 1991).
None of the above techniques were used in this study for a variety of reasons. For many, the
rate of mutation detection is less than 100% (RNase A cleavage, heteroduplex analysis and SSCP), the
optimal length of the PCR product to be scanned, between approximately 150bp and 400bp, is
relatively short (heteroduplex analysis, SSCP, DGGE, TGGE and CDGE) or the necessary materials
were unavailable during this study (E. coli mismatch repair enzymes, DGGE, TGGE and CDGE).
Additionally, although all of the above techniques based on PAGE can detect point mutations, they do
not indicate the location of these within the scanned sequence.
Two techniques have been described that provide a mutation detection rate of virtually 100%
and can scan for unknown point mutations in PCR products that, at up to 2kb, are relatively long.
Furthermore, as both techniques are based on chemical modification of bases at mismatched sites, the
location of any mutations detected is indicated. The first of these techniques is the carbodiimide (CDI)
technique, where mismatched bases in heteroduplexes are modified by this chemical, which then
blocks the procession of radiolabeled primer extension reactions (Ganguly and Prockop 1990). The
length of the truncated products of primer extension indicates the location of the blockage and
therefore that of the modified base within the heteroduplex. This technique was initially considered
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appropriate for this study however, after repeated attempts to establish it for detection of all possible
forms of single base pair mutation, it was found to be unworkable (in common with other groups) and
was therefore dismissed for point mutation analysis. The second technique, the HOT technique of
chemical modification and cleavage of mismatched DNA, had been established successfully (work of
J. Prosser) and was used extensively for much of the WT1 point mutation analysis presented in this
study.
3.1.3 The HOT technique of chemical modification and cleavage of mismatched DNA
The HOT technique was developed by Cotton et al. (1988) to permit detection of all forms of
naturally occurring single base pair mutations. Other point mutations, such as deletions and insertions,
can also be detected with this technique. The term HOT is an acronym derived from the two
modifying chemicals used, hydroxylamine (HA) and osmium tetroxide (0s04). Both chemicals
specifically modify bases located at sites of mismatch within heteroduplexes (RNA-DNA and DNA-
DNA) and both act by attacking the pyrimidine carbon double bond at C-5,C-6. HA modifies
mismatched C bases and 0s04 modifies mismatched T bases and, to a far lesser extent, mismatched C
bases also. Modification of purine bases is not involved or required by this technique as one or both
strands in a heteroduplex will always contain a mismatched pyrimidine. A GC base pair can be
mutated by transition to AT or by transversion to TA or CG. For each event the C on the wild type
strand, mismatched as AC, TC or CC, will be available for modification by HA. The remaining
possible single base pair mutation events comprise an AT base pair mutated by transition to GC or by
transversion to TA or CG. For each of these events the T on the wild type strand, mismatched as GT,
TT or CT, and will be available for modification by 0s04. Four of the mismatches, TC, CC, TT and
CT, will be available for modification by both HA and 0s04. When a mismatched pyrimidine base is
modified it causes the adjacent sugar-phosphate backbone to become sensitive to chemical cleavage by
piperidine. Base modification and strand cleavage therefore both occur at the location of the mutation.
PAGE can then be used to resolve cleaved and uncleaved strands, and these in turn can be visualised
by silver staining (Saleeba et al. 1992) or autoradiography (Figure 3.1.1). For all of the possible
modifications to be detectable by autoradiography, both strands of the heteroduplex have to have been
radiolabelled. In practice, it is most common for the radiolabel to be present on only one strand of the
heteroduplex, usually the wild type strand, as this does not significantly alter the mutation detection
rate of virtually 100%. Additionally, by radiolabelling strands of one type only they can be combined
with an excess number of unlabelled strands of the opposite type to promote formation of substrate
radiolabelled heteroduplexes and diminish formation of redundant radiolabelled homoduplexes.
The only mutations which are refractive to detection when using the HOT technique are those























































Figure 3.1.1 The HOT technique. The method that uses DNA-DNA heteroduplexes with
both types of strand radiolabelled is illustrated, and demonstrates the detection
of a GC—>TA transversion mutation.
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site (Forrest et al. 1991). However, with silver staining or appropriate strand labelling, this mutation
can still be detected as the reciprocal AC mismatch will be available for modification by HA. When a
mutation is detected its exact nature is determined by sequencing the identified region using specific
PCR product that has been independently amplified from the same template source. The location of
the mutated base and the nature of the mutation should be concordant when HOT technique and
sequencing results are compared. All of the HOT technique point mutation analysis presented in this
study was performed on DNA-DNA heteroduplexes that were radiolabeled on the wild type strand
only.
3.2 Individuals with WT and/or renal abnormalities
3.2.1 Possible involvement of constitutional WTI mutations
At the outset of this study mutations specifically affecting WTI had been detected in only three
cases of WT (Haber et al. 1990, Cowell et al. 1991, Huff et al. 1991) (see Table 1.3.1). These early
reports suggested that such mutations were infrequent in unilateral and bilateral WT and that, when
present, they destroyed the potential to encode four ZFs and therefore, presumably, the capacity for
sequence-specific DNA binding by WT1. Similar analysis of many more WT samples was required to
extend these initial findings and establish the frequency at which WT1 mutations contribute to WT, the
mutational mechanisms used and the functional significance predicted for any resulting protein
product. I chose to perform a WT1 mutation analysis study on unilateral, bilateral or familial WT
individuals considered candidates for containing constitutional mutations of this gene.
LCL derived from three individuals with unilateral WT, DAVAT, DYROG and KECUL, were
selected, as was normal kidney from a fourth individual with unilateral WT, 68.1. In accord with
Knudson's two hit model these individuals would be predicted to most likely contain only somatic
WTI mutations and therefore present as homozygous wild type for this gene at the constitutional level.
The study of these individuals was however appropriate as, in addition to WT, they had accompanying
abnormalities which also may have developed as a consequence of WTI mutations. DAVAT had
contralateral renal agenesis, DYROG had a duplex kidney and KECUL had a duplex collecting
system. As these are all defects of the renal system it is possible that constitutional WTI mutations
have had a pleiotropic effect at this site, resulting in the development of WT and renal abnormalities.
Individual 68.1 had a congenital heart defect and this may again have resulted from a pleiotropic effect
of constitutional WTI mutations, in this instance on the development of the kidney and the
pericardium. It is possible that, if such pleiotropic effects do occur, the exact nature of the WTI
mutation and/or the genetic background dictates which tissues are affected.
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Bilateral and familial WT are similar in that if they contain WT1 mutations these will, in
general, be present constitutionally at the heterozygous level, representing the first hit event. LCL
derived from two individuals with bilateral WT, MASOU and RUSSP, and two individuals with
familial WT, JEDOY and LISWI, were available and selected for study.
Two further LCL, derived from individuals ANBLA and KIRHO, were selected as both had
tumours that are possible but undiagnosed WT and accompanying features suggestive of constitutional
WT1 mutation. ANBLA had a retroperitoneal tumour, had fathered a child with hemihypertrophy and
also had a first cousin who had a paediatric kidney tumour (fatal). KIRHO, a possible Perlman
syndrome individual (see Table 1.2.1), had a renal mass and developmental delay.
Involvement of WT] mutations in development of renal abnormalities distinct from WT has not
been reported. As this gene is of critical importance in kidney development it is possible that in this
tissue a different class of WT1 mutations contributes to such abnormalities as compared to the ZF
altering mutations associated with tumorigenesis. This putative different class of WT1 mutations may
involve preferential mutation of exons 1 to 6, encoding the TD. I chose to investigate this possibility
by, again, analysing WT1 at the constitutional level in suitable individuals.
In addition to the three individuals with WT and renal abnormalities, DAVAT, DYROG and
KECUL, a number of LCL derived from individuals with renal abnormalities in the absence of WT
were studied. These individuals are CORMU, CRAST, DABEL, JOHON and RUFUL. The presence
of a contributing constitutional mutation in each of these individuals is suggested by the fact the they
all have family members with identical or similar renal abnormalities. CORMU (sex undetermined)
and the mother and maternal grandmother had/has branchio-oto-renal (BOR) syndrome, which
comprises abnormal branchial, auditory and renal development; the latter individual also had a child
with bilateral renal agenesis, CRAST and her mother have unilateral renal agenesis, the former also
had two children with bilateral renal agenesis, DABEL and his half sister had large, multicystic
kidneys, the latter also had a paediatric kidney tumour (fatal), JOHON has unilateral renal agenesis
and has two children with bilateral multicystic dysplasia and a first cousin once removed with
multicystic dysplasia, and RUFUL has bifid ureter and had a child with renal agenesis. Two further
LCL, derived from individuals FEWAR and REAKI, were selected. FEWAR had multicystic
dysplasia without a known familial predisposition and REAKI is unaffected but has two children, with
different fathers, with cystic kidneys.
PCR amplification of individual WT1 exons using intronic oligonucleotides CI55 and
945/E194 (exon 7), C323 and 796/G667 (exon 8), 798/G26 and 801/G25 (exon 9) and C911 and C912
(exon 10), and subsequent point mutation analysis using the HOT technique had been performed
previously for all the above samples except 68.1 and no mutations were detected (work of M. Little).
The same exons of WT1 from 68.1 were similarly analysed and, again, no mutations were detected
(work with M. Little). These exons were preferentially analysed as they encode the ZFs. The possible
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presence therefore of constitutional mutations affecting exons 1 to 6 in these samples was further
investigated.
3.2.2 PCR analysis of WT1
LCL DNA from the above individuals, or normal kidney DNA from 68.1, was analysed for
WT1 mutations by PCR amplification of individual exons using oligonucleotides C145/F518 and
C146/F519 (exon 1), C147 and C148 (exon 2), C149 and C150 (exon 3), C486 and C152 (exon 4),
C153 and C154 (exon 5) and C178 and C177 (exon 6). With the exception of C145/F518, all of the
oligonucleotides are intronic. Only specific PCR products of wild type length were generated (Table
3.2.1).
3.2.3 Point mutation analysis of WT1
As PCR analysis did not detect any mutations in the above samples, they were subjected to
WT1 point mutation analysis using the HOT technique. Exons 4, 5 and 6 were scanned against a
known wild type DNA, FATO, with HA and 0s04. No constitutional WT1 mutations were identified
in individuals with WT alone or WT and renal/other abnormalities (Table 3.2.2) or with renal
abnormalities alone (Table 3.2.3).
3.3 Individuals with testicular tumours
3.3.1 Possible involvement of constitutional WT1 mutations
Although WT1 mutations are known to contribute to development of gonadal abnormalities
such as cryptorchidism involvement of such mutations in gonadal tumours is less well defined. As
expression of WT1 in the mature gonad is confined to male-specific Sertoli cells and female-specific
granulosa cells, it is possible that mutations in this gene can contribute to the derived tumour types,
classified as sex cord-stromal tumours. The other major classification of gonadal tumours comprises
the germ cell tumours (Adkins and Jaffe 1988), which can present in males as seminomas, in females
as dysgerminomas and in both sexes as teratomas. Germ cells do not express WT1 and may therefore
be insensitive to mutations in this gene. It is however possible that, because of the numerous







DAVAT + u +/- 1,2,3,4,5,6 all wt
DYROG + u +/- 1,2,3,4,5,6 all wt
KECUL + u +/- 2,3,4,5,6 all wt
68.1 + u -1+ 2,3,4,5,6 all wt
MASOU + b 2,3,4,5,6 all wt
RUSSP + b 1,2,3,4,5,6 all wt
JEDOY + f 2,3,4,5,6 all wt
LISWI + f 1,2,3,4,5,6 all wt
ANBLA (rp) 1,2,3,4,5,6 all wt
KIRHO (rm) -/+ 2,3,4,5,6 all wt
CORMU +/- 2,3,4,5,6 all wt
CRAST +/- 2,3,4,5,6 all wt
DABEL +/- 1,2,3,4,5,6 all wt
FEWAR +/- 1,2,3,4,5,6 all wt
JOHON +/- 2,3,4,5,6 all wt
REAKI (+)/- 2,3,4,5,6 all wt
RUFUL +/- 2,3,4,5,6 all wt
Table 3.2.1 Constitutional mutation analysis of WT1 in individuals with WT and/or renal
abnormalities. Mutation analysis was performed using PCR amplification. The data
detailed in the 'results' column relates only to the length of the specific PCR products
generated. + - present; - - not present; (+) - present in offspring only; u - unilateral; b -
bilateral; f - familial; (rp) - retroperitoneal tumour, possible WT; (rm) - renal mass,













DAVAT + u + 4 wt wt
5 wt wt
6 wt wt
DYROG + u + 4 wt wt
5 wt wt
6 wt wt
KECUL + u + 4 wt wt
5 wt wt
6 wt wt
68.1 + u + he 4 wt wt
6 wt wt
MASOU + b 4 wt wt
5 wt wt
6 wt wt
RUSSP + b 4 wt nd
5 wt wt
6 wt wt
JEDOY + f + br 4 wt wt
5 wt wt
6 wt wt
LISWI + f 5 wt wt
6 wt wt
ANBLA + rp 4 wt wt
5 wt wt
6 wt wt
KIRHO + rm + dd 4 wt wt
5 wt wt
6 wt wt
Table 3.2.2 Constitutional point mutation analysis of WT1 in individuals with diagnosed or
possible WT. Mutation analysis was performed using the HOT technique. + - present;
u - unilateral; b - bilateral; f - familial; br - breast; rp - retroperitoneal, possible WT;
rm - renal mass, possible WT; he - heart; dd - developmental delay; wt - wild type and











CORMU + + 4 wt wt
5 wt wt
6 wt wt
CRAST + + 4 wt wt
5 wt wt
6 wt wt
DABEL + + 4 wt wt
5 wt wt
6 wt wt
FEWAR + 4 wt wt
5 wt wt
6 wt wt
JOHON + + 4 wt wt
5 wt wt
6 wt wt
REAKI + 4 wt wt
5 wt wt
6 wt wt
RUFUL + + 4 wt wt
5 wt wt
6 wt wt
Table 3.2.3 Constitutional point mutation analysis of WT1 in individuals from renal
abnormality families. Mutation analysis was performed using the HOT technique.
+ - present and wt - wild type.
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McGuinness and Griswold 1994) and between granulosa cells and oocytes (reviewed by Eppig 1991),
WT1 mutations expressed by the somatic cells of the gonad influence germ cell tumorigenesis.
Samples that permit investigation of the latter proposal were available and were analysed in a
preliminary study for constitutional mutations of WT1. These samples derived from 18 individuals,
male and female, from 6 testicular tumour families. Eleven of the males had germ cell tumours, and
six of these individuals additionally had cryptorchidism, a further indication that constitutional WT1
mutations may be present. The remaining individuals, all parents of the above, did not have gonadal
tumours however, because of possible inherited predisposition for this tumour type, these individuals
were also considered candidates for carrying constitutional WT1 mutations. Family 1 comprised a son
with teratoma and cryptorchidism, a son with teratoma and seminoma, father and mother; individuals
MARBE, MICBE, ALBBE and MILBE, respectively. Family 2 comprised a son with seminoma and
cryptorchidism, a son with teratoma, father and mother; individuals ALABO, ANTBO, JOHBO and
LOUBE, respectively. Family 3 comprised a son with teratoma, seminoma and cryptorchidism, and a
son with teratoma; individuals JOGRI and ANGRI, respectively. Family 4 comprised a son with
teratoma and cryptorchidism, a son with seminoma, father with bilateral sarcoma and hernia
(unspecified) and mother with breast carcinoma; individuals NIGUT, PEGUT, JAGUT and MHGUT,
respectively. Family 5 comprised a son with teratoma and cryptorchidism, a son with seminoma, and
mother; individuals JOPER, HEPER and NANMO, respectively. And lastly, Family 6 comprised a
son with teratoma and cryptorchidism; individual DARSFI.
3.3.2 PCR and point mutation analysis of WT1
Peripheral blood DNA from the above individuals was analysed for WT1 mutations by PCR
amplification of individual exons using intronic oligonucleotides C486 and C152 (exon 4), C153 and
C 154 (exon 5) and C178 and CI77 (exon 6). All of the samples amplified for each of these exons and
generated only specific PCR products of wild type length. Samples from all of the members of
families 1, 2, 3 and 5 were subsequently subjected to point mutation analysis using the HOT technique.
Exons 4 and 6 were scanned against a known wild type DNA, FATO, with HA and 0s04. No
constitutional WT1 mutations were detected. Upon completion of this analysis, further PCR and point
mutation analysis of WT1 in all of the testicular tumour family members was halted in anticipation of
receiving RNA/cDNA samples, which provide templates more convenient for such analysis.
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3.4 Discussion
The possible presence of constitutional WTl mutations in individuals with WT, renal
abnormalities or testicular tumours has been investigated. Firstly, DNA from 17 individuals with WT
and/or renal abnormalities; including unilateral, bilateral and familial WT, was analysed. Individual
WTl exons were PCR amplified and subjected to point mutation analysis using the HOT technique; no
mutations were detected in any of the samples. Mutations may however have escaped detection as
some exons were not amplified in all samples and some were not subjected to analysis using the HOT
technique. Furthermore, with the exception of exon-intron junction sequences, analysis of the non-
coding regions of WT1 was omitted.
The 5' region of WTl is very GC rich, making it refractive to PCR amplification. It is most
probably for this reason that exon 1 did not amplify in WT samples KECUL, 68.1, MASOU, JEDOY
and KIRHO, and renal abnormality samples CORMU, CRAST, JOHON, REAKI and RUFUL. The
first 362bp (44%) of exon 1 were excluded from analysis in all samples, however this is exclusively
untranslated sequence. Recently a new mutational mechanism has been identified in exon 1,
comprising discrete deletions and insertions at sites in close proximity to dinucleotide and
trinucleotide repeats (non-expanding) and the tetranucleotide 5'-CCTG-3' (Huff et al. 1995). These
types of sequence have been identified in other genes as hotspots for recombination (reviewed by
Steinmetz et al. 1987) and deletion (Krawczak and Cooper 1991). In the WTl study, 4 out of 80 (5%)
WT individuals, a relatively high proportion, contained this type of mutation either constitutionally or
somatically. These mutations all created a frameshift, predicted to cause termination of translation
within the TD. Gessler et al. (1994) have also reported an exon 1 frameshift deletion mutation in a
unilateral WT. Similarly, mutations in exons 2 and 3 have been detected by other researchers
subsequent to this study (see Table 1.3.1 and Figure 1.3.3). Three of these mutations are missense
mutations which may switch the TD from a repressor to an activator of transcription (Park et al.
1993a, Park et al. 1993c, Gessler et al. 1994), suggesting that even in the presence of correct
sequence-specific DNA binding, altered WTl can contribute to tumorigenesis. As point mutation
analysis was not performed on exons 1, 2 and 3 in this study, the possible presence of similar
mutations in the samples detailed here must not be overlooked.
Exons 4, 5 and 6 were preferentially selected for point mutation analysis as, second to those
encoding the ZFs, these three exons contain the most highly conserved sequence of W77. During this
study four mutations in this region of the gene were reported in WT; two frameshift deletion mutations
in exons 4 and 6 (Pelletier et al. 1991b) and two genomic deletions encompassing exon 6 (Huff et al.
1991, Tadokoro et al. 1992a). Mutations in exon 5 remain to be reported and therefore this exon is the
only coding region of W77 to always present as wild type, suggesting that preservation of this
sequence is an absolute requirement for cell viability. Similarly, mutations which affect exon 5
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alternative splicing are unknown. In this study, inclusion of the exon-intron junction sequences for
analysis indicates that exons 4, 5 and 6 should be correctly spliced, as should exons 7, 8, 9 and 10. In
support of this, PCR amplification of the TD encoding sequence from cDNA from RUSSP and LISWI
detected both the - 17aa and +17aa isoforms. There is no evidence therefore that the ratio of the four
mRNA isoforms is perturbed in any of the present samples.
In addition to the 17aa and KTS alternative splices involving exons 5 and 9, respectively,
splicing of exons 2, 4 and 8 will maintain the correct open reading frame of WT1. As exon 2 was not
subjected to HOT technique analysis it is possible that mutations causing its aberrant splicing are
present in many of the samples detailed here. Detection of this type of TD alteration in WT has been
reported (Haber et al. 1993). The significance of these findings is, however, unclear; firstly, in these
tumours the ratio of aberrant to wild type transcripts is low, and the presence of mutations could not be
demonstrated at the genomic level, and secondly, independent studies indicate that low levels of this
aberrant transcript are present in normal individuals (A. Seawright, personal communication).
As the majority of non-coding sequence was omitted from analysis, mutations that affect the
untranslated sequences of exons 1 and 10, or the promoter region will have escaped detection. This
aspect of mutation analysis was excluded from these studies as the consequences that such mutations
have on gene expression can frequently only be recognised with mRNA studies and for many of the
present samples only constitutional DNA was available. Interestingly, a recent report has indicated a
paucity of mutations within the promoter region of WT1 (Grubb et al. 1995). When present, however,
such mutations may have the potential to alter expression levels in some or all of the correct tissues or
to create an ectopic expression pattern. Additionally, a complete lack of mutations may still not
exclude such alterations of W77 expression as epigenetic features, such as hypermethylation of 5'
sequences, may also elicit these effects (reviewed by Counts and Goodman 1995). Reduced
expression as a result of hypermethylation has been reported for the von Hippel-Lindau (VHL) gene in
clear cell renal carcinoma (CCRC) (Herman et al. 1994), RBI in retinoblastoma (Greger et al. 1994)
and, as described in 1.5.8, pl6 in various tumour types (Merlo et al. 1995). Mutations abolishing
expression of one copy of WT1 are not predicted in these samples as these would cause WT1 haplo-
insufficiency and therefore a WAGR syndrome phenotype.
As only approximately 10% of unilateral and bilateral WT are predicted to contain WT1
mutations it is possible that the six individuals in this study with these forms of tumour contain
mutations in other critical genes, such as the putative WT2 gene at 1 lpl5.5. None of the WT from
these individuals are known to be anaplastic and therefore the presence of constitutional heterozygous
p53 mutations, constituting Li-Fraumeni syndrome, is not indicated. Individuals with this syndrome,
who are predisposed to development of many tumour types, only rarely develop WT (Hartley et al.
1993). Although unremarkable, the apparent lack of WT1 mutations in the unilateral WT individuals
in this study is perhaps surprising as each had an associated abnormality of the renal system or heart.
The similar lack of detectable mutations in the two familial WT individuals is, again, unremarkable,
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even though during this study Pelletier et al. (1991b) reported an inherited WT1 mutation (see Table
1.3.1). Furthermore, it is conceivable that the two possible WT samples, ANBLA and KIRHO, are
other types of renal tumour not associated with WT1 mutations.
In addition to the above results that provide no evidence to support the proposal that WT1
mutations may contribute to renal abnormalities, the results from the eight individuals with such
abnormalities in the absence of WT reinforces this. Interestingly, Kumer et al. (1992) have defined a
locus for BOR syndrome on chromosome 8q and it is possible that it is this and not W77 that is
mutated in CORMU. Additionally, it is feasible that REAKI, who is unaffected, may be a germline
mosaic, containing only wild type WT1 in her haematopoietic system, therefore making analysis of
LCL unsuitable.
Similarly to the study of individuals with WT and/or renal abnormalities, DNA from 18
individuals from 6 testicular tumour families was analysed to a more limited extent; no constitutional
WT1 mutations were detected. A number of more recent reports also detail WT1 mutation analysis
studies in a total of 119 gonadal tumour samples and, in agreement with this study, no mutations were
detected. Bruening et al. (1993) used SSCP point mutation analysis techniques to scan exons 1 to 10
of WT] in ovarian tumours, a tumour type previously identified as frequently containing deletions of
chromosome 11 p 13 and 11 p 15 (Viel et al. 1992). Similarly, Coppes et al. (1993b) scanned exons 6 to
10 in granulosa, Sertoli and Leydig cell sex cord-stromal tumours, and Looijenga et al. (1994) scanned
exons 2 and 6 to 10 in seminoma and non-seminoma male germ cell tumours, which, again, are tumour
types previously identified as frequently displaying LOH at chromosome 11 p 13 and 1 lpl5 (Lothe et
al, 1993). It was unfortunate that no sex cord-stromal tumours were available for analysis in this
study, however limited direct sequence analysis of cDNA from four ovarian carcinoma cell lines,
COV362, COV413, COV434 and COV446 (gift from T. Langerak, described by van den Berg-Bakker
et al. 1993) identified a possible mutation; the presence of only +KTS sequence in COV434, which,
interestingly, is the only cell line derived from a granulosa cell tumour. A further form of gonadal
tumour is gonadoblastoma and two individuals with such tumours (one of which was associated with a
granulosa cell tumour) have been found to contain W77 mutations. These tumours are however
remarkable as they developed in a DDS context (see Table 1.3.4) (Pelletier et al. 1991a).
Predisposition for gonadoblastoma rather than WT, in association with nephropathy and PGD,
comprises a syndrome distinct from DDS, the Frasier syndrome (Moorthy et al. 1987). Indeed, one of
the individuals described by Pelletier et al. (1991a) as having DDS may in fact have been
misdiagnosed and may actually have Frasier syndrome. In contrast however, an independent study
that analysed WT1 exons 8 and 9 in three diagnosed Frasier syndrome individuals detected no
mutations (Poulat et al. 1993), suggesting that, in common with the other forms of gonadal tumour,
involvement of WT1 mutations in tumorigenesis of this tissue is rare. Similarly, a tumour resected
from testis and believed to be germ cell in origin has been shown histologically to be a WT (Gillis et
al. 1994). However, analysis of WT1 in this tumour, by Southern blotting and SSCP analysis of exons
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2 and 6 to 10, did not detect any mutations. Furthermore, loci at lip 15.5 rather than 1 lpl3 are
implicated in this tumour as biallelic expression of H19 and IGF2 was detected.
Overall, this study has shown that, although no mutations in WT1 were detected, our findings
are in agreement with those subsequently reported for unilateral, bilateral and familial WT and for
gonadal tumours. Furthermore, the possible involvement of such mutations in renal abnormalities
distinct from WT remains unsupported. Finally, it is interesting to note that the current spectrum of
WT1 mutations forms a reciprocal pattern, that is that in general these mutations appear to contribute
to tumours but not abnormalities of the renal system, and conversely, to abnormalities but not tumours
of the gonadal system.
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Chapter 4
Analysis of first and second hit
WT1 mutations in WAGR syndrome
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4.1 Contribution of WT1 mutations to WAGR syndrome
The constitutional heterozygous 11 p 13 deletions invariant in WAGR syndrome render the WT1
and PAX6 genes hemizygous, thereby causing WT predisposition and aniridia, respectively. These
deletions may also disrupt flanking genes, a feature which was originally thought to elicit the
remaining two components of WAGR syndrome; GU abnormalities and mental retardation. The
former is now known to result from the pleiotropic effect of constitutional hemizygous WT1 on the
developing genital system, whereas the genetic basis of the latter remains undetermined.
As described in 1.2.4.2, development of WT, GU abnormalities and mental retardation is not
fully penetrant in this syndrome. With respect to WT1, the reason(s) why the hemizygous state elicits
GU abnormalities in only a proportion of WAGR syndrome individuals and with variable expressivity
is not fully understood. Certainly, genetic background is involved, as clearly demonstrated by the fact
that the developing genital system in males is more sensitive than that in females to WT1 mutations.
The GU abnormalities characteristic of this syndrome, most commonly hypospadias and
cryptorchidism, are relatively mild and, as described in 1.3.6, are thought to develop because of WT1
haploinsufficiency.
As mentioned, only a proportion of WAGR syndrome individuals develop WT. Tumorigenesis
is not fully penetrant as a requirement for a somatic second hit, in addition to the constitutional first hit
W77 deletion, is predicted. Again as described in 1.3.6, the most obvious form of second hit in this
syndrome is functional loss of the remaining copy of WT1. Homozygosity for the constitutional
deletion is rarely observed in WAGR syndrome as this is expected to be cell lethal (as they are such
large deletions). A second hit affecting the remaining copy of WT1 will, therefore, be more subtle, for
example intragenic deletion or insertion. At the outset of this study second hit WT] mutations had
been identified in only three WAGR-WT (Brown et al. 1992, Baird et al. 1992a) (Table 1.3.2). Each
of these mutations is intragenic and they create premature stop codons, which at the protein level are
predicted to produce WT1 with either no ZFs, one ZF or only a residual N-terminal peptide structure,
and therefore incapable of sequence-specific DNA binding.
4.2 Predicted involvement of second hit WT1 mutations in WAGR-WT from
two individuals
4.2.1 Phenotype of each WAGR syndrome individual
To investigate further the involvement of second hit WT1 mutations in this form of WT I chose
to perform a mutation analysis study of this gene in tumours from WAGR syndrome individuals.
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Samples from two such individuals, ALSTA and NAHAS were available for analysis. ALSTA has
partial spectrum WAGR syndrome, consisting of unilateral WT, aniridia and micropenis (not apparent
until late childhood). In contrast, NAHAS has full spectrum WAGR syndrome, consisting of
unilateral WT, aniridia, cryptorchidism (right testis), speech retardation and microcephaly. Both
individuals are XY males and contain 11 p 13 deletions that are sub-microscopic. The mother and
father of each individual are phenotypically normal.
4.2.2 PCR analysis of the remaining copy of WT1
Although previous analysis of ALSTA-WT and NAHAS-WT had detected expression of WT1,
these tumours had been temporarily thawed prior to the present study. Because of this the quality of
these tissues is poor and hence only low yields of RNA could be recovered from them. Standard PCR
techniques were inadequate for analysis of this material and therefore reverse transcription followed by
nested PCR (RT-nested PCR) was used. This PCR strategy offers increased sensitivity as it can
incorporate 60 cycles of amplification, in comparison to the standard 30 cycles. The TD encoding
sequence and the ZF encoding sequence were amplified from cDNA in two overlapping fragments,
5'TD and 3'ZF, respectively. The 5'TD fragment was amplified using outer oligonucleotides D609
(exon 1) and D610 (exon 6) and inner oligonucleotides B920 (exon 1) and B918 (exon 6), and the
3'ZF fragment amplified using outer oligonucleotides C582 (exon 5) and C583 (exon 10) and inner
oligonucleotides B919 (exon 6) and B917 (exon 10). Collectively, these two fragments cover all but
the first 256bp of coding sequence (Figure 4.2.1).
The 5'TD and 3'ZF regions amplified from ALSTA-WT and NAHAS-WT samples and only
specific PCR products of wild type length were generated. Similarly, amplification of the 5'TD region
detected both the -17aa and +17aa isoforms in each tumour sample.
4.2.3 Point mutation analysis of the remaining copy of WT1
As PCR analysis did not detect any mutations in the above samples, they were subjected to
point mutation analysis using direct sequencing. Additionally, similar analysis of individual exons
from NAHAS-WT DNA was performed when ambiguities were detected in the cDNA sequence. As a
result of this approach much of the coding sequence of WT1 in this tumour has been analysed
repeatedly. Specifically, sequencing of the 5'TD region was primed with oligonucleotides B920,
B918, 434/F25 (exons 1-2) and B700/E976 (exons 5-6), and similarly the 3'ZF region was primed with
oligonucleotides B919 and B917. Individual exons from NAHAS-WT DNA were PCR amplified
using oligonucleotides F516 and F517 (exon 1), C147 and C148 (exon 2), C153 and C154 (exon 5),
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C912 (exon 10). With the exception of F516, each of the latter oligonucleotides is intronic.
Individual exons were sequenced using one or both of the appropriate PCR oligonucleotides as primer.
Sequencing of the 3'ZF region with oligonucleotide B917 as primer identified two species of
specific PCR product, the -KTS and +KTS isoforms, in both ALSTA-WT and NAHAS-WT samples.
Additionally, in ALSTA-WT this analysis detected a 2bp deletion in exon 10. This frameshift
mutation, which alters the sequence starting at nucleotide 1696 from AGAG to AG, destroys the
normal stop codon and creates a new one at 201 bp downstream of the former (Figure 4.2.2a). It is
proposed that this deletion is a second hit as it was confirmed in ALSTA-WT DNA and, by analysis of
LCL cDNA, was found to be not present in the remaining copy of WT1 present constitutionally or in
the mother, MASTA or the father, FASTA. This latter analysis of WT1, in non-expressing cells, was
possible as RT-nested PCR permits, and was actually originally designed for, amplification of
illegitimate transcripts. These transcripts are those generated by breakthrough transcription, a process
which produces minute quantities of tissue-specific mRNA in non-expressing cells (it is estimated that
for each tissue-specific gene there may be as few as one mRNA per 100 to 1 000 such cells) (reviewed
by Kaplan et a I. 1992). As illegitimate transcripts have the same sequence as the corresponding ones
present in expressing cells, their use in mutation analysis is appropriate, and, indeed, often vital.
Despite repeated analysis, no second hit WT1 mutations were detected in NAHAS-WT.
Inclusion of the genomic amplification of exon 1 increased the 5' boundary of sequence analysis by
only 5bp, as oligonucleotides F516 and B920 are overlapping. Similarly, the genomic amplification of
exon 10 increased the 3' boundary by only 21 bp of untranslated sequence, as C912 and B917 are
overlapping. Definite wild type sequence was obtained for all but the first 15bp (excluding B920) of
the 5'TD region and for all but the last lbp (excluding B917) of the 3'ZF region.
4.3 Predicted consequence of the second hit WT1 mutation in ALSTA-WT
As the second hit WT1 mutation in ALSTA-WT causes a frameshift which increases the
potential coding sequence by 20lbp, it is predicted that translation of this sequence will produce
protein with an extended C-terminus (Figure 4.2.2b). This aberrant form of WT1 would lack the 10
residues that normally follow ZF4, RNMTKLQLAL, and these would be substituted by 77
inappropriate residues, KHDQTPAGALRGLPRGPFSVPGSTVCELLSSLTLHSSSLKRKLQLIFFI
QLPRQDTGASGNYQVCLEELVSALPTFS. No known protein motifs are present in the latter
residues. Nonetheless, it is possible that, given the terminal position of these residues, they cause
aberrancy by imparting an additional function to the protein, the TD and ZFs of which may retain the
correct conformation and permit sequence-specific DNA binding. Alternatively, aberrant WT1 that is
incapable of such DNA binding may be generated if these inappropriate residues interfere with protein
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Figure 4.2.2 Second hit WT1 mutation detected in ALSTA-WT. a) sequence analysis detected a
2bp (GA) deletion in exon 10. The resulting frameshift destroys the normal stop codon
and creates the potential to encode 77 inappropriate residues. The first H residue
illustrated, preceding the frameshift, is the most C-terminal zinc co-ordinating residue,
wt - wild type, b) schematic illustration of the predicted structure of WT1 in ALSTA-
WT, the protein is extended at the C terminus. Only the +17aa+KTS isoform is
illustrated, but the remaining three isoforms are also predicted to be present.
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Experiments to analyse the DNA binding properties of this predicted aberrant form of WT1
were initiated, however these could not be completed within the duration of this study. The mutant
coding sequence, in the +17aa-KTS and +17aa+KTS isoforms, has been unidirectionally cloned in to
the pET protein expression vector, but confirmation that PCR-generated mutations are not present and
subsequent protein expression and mobility shift assays remain to be performed.
4.4 Possible involvement of llp!5.5 loci in WAGR-WT
As described previously and demonstrated by ALSTA, the most obvious mutational mechanism
for development of WAGR-WT is a second hit causing functional loss of the remaining copy of WT1.
It is however possible that, although a second hit is present, a locus other than WT1 is affected.
Evidence for such a mechanism is presented by Henry et al. (1989) and Jeanpierre et al. (1990), who
describe a total of three WAGR-WT displaying somatic LOH at llpl5.5. As described in 1.2.6, a
putative gene for WT predisposition, WT2, maps to this region, and loci here frequently display LOH
(of the maternal homologue) in other forms of WT and are particularly implicated in development of
BWS-WT. It is possible therefore that constitutional deletion of WT1 followed by somatic LOH at the
more distal region 11 p 15.5 (affecting WT27) has caused development of these three WAGR-WT.
Unfortunately the status of the remaining copy of WT1 in these tumours has not been reported,
however for one it was demonstrated that the deletion and the LOH affected the maternally derived
homologue of 1 lp (Jeanpierre et al. 1990).
The apparent lack of a mutation in the remaining copy of WT1 in NAHAS-WT suggests that a
second hit affecting a different locus may be present in this tumour. To investigate the possible
involvement of a second hit affecting llpl5.5, I chose to analyse this region in NAHAS for LOH.
Three polymorphic marker sequences that map to 11 p 15.5 were selected, comprising the variable
number tandem repeat (VNTR) sequence 3' of the Ha-ras gene (Decorte et al. 1990) and the IGF2
RFLP sequences exon 4 Apa I (Tadokoro et al. 1991) and exon 9 Ava II (Gloudemans et al. 1993).
LCL and WT DNA from NAHAS was PCR amplified for these marker sequences using
oligonucleotides G517 and G518 (VNTR), G16 and G17 {Apa I) and G20 and G21 {Ava II). Specific
PCR products were generated for each of the marker sequences, and those of the RFLP markers were
subsequently digested with the appropriate restriction enzyme. Comparison of the final reaction
products from each marker sequence between LCL and WT identified heterozygosity but no
differences. This analysis therefore provides no evidence for the presence of 1 lp 15.5 LOH in
NAHAS-WT and, as with analysis of WTI, has not detected a second hit in this tumour.
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4.5 Does the mental retardation component of WAGR syndrome result from
imprinting at the WT1 locus?
4.5.1 Evidence for such a mechanism
Expression of WT1 in foetal brain, an ectoderm derived tissue, was first reported by Pritchard-
Jones et al. (1990), who describe the level of expression as very weak. More recently Jinno et al.
(1994) have also reported expression of this gene in foetal brain and, as mentioned in 1.3.2.3, provide
evidence for monoallelic expression, suggesting that WT1 may be imprinted in a subset of expressing
tissues. The specific temporal and spatial pattern of WT1 expression within the brain is not known,
although the latter mentioned study does report that, by using immunohistochemical techniques,
expression has been identified in the region in which the earliest stages of differentiation occur. In the
developing mouse, expression in the brain is detected for a period of only 24 hours and is localised to
the fourth ventricle (hindbrain) (Armstrong et al. 1992), whereas in rat brain expression persists
postnatally and is localised to the area postrema (Sharma et al. 1992). As the functions of these
regions of the brain are not known, in humans or rodents, suggested roles for WT1 in development of
this tissue are purely speculative.
Nonetheless, with the apparent identification of monoallelic expression of WT1 in this tissue,
albeit in only two samples, Jinno et al. (1994) have put forward an imprinting model implicating this
feature in the mental retardation component of WAGR syndrome. In their model the important factor
is not the size of the constitutional lip 13 deletion, but its parental origin. It is proposed that only the
maternally derived copy of WT1 is active in foetal brain and therefore constitutional deletions of
paternal origin should not disturb expression (as the remaining copy of W77 is maternally derived and
therefore active) whereas those of maternal origin should abolish expression (as the remaining copy of
WT1 is paternally derived and therefore inactive). Accordingly, it is suggested that the former
mutations will not elicit mental retardation and that the latter will. To support this model the authors
describe two WAGR syndrome individuals; both have paternally derived 11 p 13 constitutional
deletions and no evidence of mental retardation. This report by Jinno et al. (1994) remains the only
one to suggest that WT1 is imprinted and, consequently, the only one implicating this model as the
cause of mental retardation in WAGR syndrome.
4.5.2 Possible explanation for the phenotypic difference between ALSTA and NAHAS
Of the two WAGR individuals available for analysis in this study, ALSTA has not developed
mental retardation whereas NAHAS has. One reason for this phenotypic difference, evident from the
original model for mental retardation in this syndrome, is that a putative gene for mental retardation,
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flanking either WT1 or PAX6, is disrupted by the constitutional 11 p 13 deletion in NAHAS but left
intact by the similar deletion in ALSTA. Previous analysis to map the extent of these deletions has
been performed by FISH, using probes that included the marker sequences FSHB, ZF17, D11S1312,
D11S112, D11S914 (listed centromere distal to proximal, all distal of WTl), and YAC y23IC9,
D11S672, D11S1776 and D11S102 (also listed centromere distal to proximal, all proximal of WTl)
(work of J. Fantes). This analysis defined the proximal breakpoints of the deletions in both ALSTA
and NAHAS; the former lies within D11S672 and the latter within the more distal marker, y23IC9
(Fantes et al. 1995, see Appendix C). Similarly, the distal breakpoints were defined as lying between
ZF17 and the more proximal marker D11S112 for ALSTA, and proximal to D11S914 for NAHAS.
Marker sequences spanning the distal breakpoints were not identified. The extent of the 11 p 13
deletion in ALSTA was therefore found to exceed that of NAHAS both proximally and distally.
Additionally, similar analysis was performed on LCL samples from both sets of parents; two copies of
each marker sequence were identified in all of these individuals, indicating that the deletions in both
ALSTA and NAHAS arose de novo.
As the size of the constitutional deletion in' ALSTA has been found to exceed and wholly
encompass that of NAHAS, it is obvious that the mental retardation affecting the latter individual does
not result from deletion of an additional gene, as, if this were so, it is expected that ALSTA would be
similarly affected. The phenotypic difference between these two individuals must therefore be elicited
by a distinct mechanism and the imprinting model proposed by Jinno et al. (1994) was considered a
suitable candidate. Applying this model to the present study, it is possible that the larger deletion, that
of ALSTA, is of paternal origin, and the smaller deletion, that of NAHAS, is of maternal origin.
Consequently, the remaining copy of WTl in ALSTA would be maternally derived, therefore active
and not eliciting mental retardation, whereas in NAHAS the opposite pattern would exist, that is the
remaining copy of WTl would be paternally derived and therefore inactive, eliciting mental
retardation. It is important to note here that in this model the direction of WTl imprinting has not
actually been deduced for foetal brain but is presumed from similar analysis on placentae. Therefore,
for the present study the critical aspect is whether the deletions in ALSTA and NAHAS differ in
parental origin, which, respectively, could be paternal versus maternal (as described) or maternal
versus paternal.
4.5.3 Determining the parental origin of the constitutional llpl3 deletions in ALSTA and
NAHAS
To investigate the parental origin of the constitutional 11 p 13 deletions in ALSTA and NAHAS
I chose to analyse the status of polymorphic markers that map within the known deletion interval, that
is between the marker sequences ZF17 and y23IC9. Eleven polymorphic markers were selected,
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comprising microsatellite sequences D11S1312 (Gyapay et al. 1994), D11S995 (Browne et al. 1993),
PAX6 (GT)n (Martha et al. 1993) and WT1 (GT)n, and WT1 RFLP sequences exon 10 Hinf 1 (A)
(Hoban and Kelsey 1991), intron 9 Hha /, intron 7 Taq I (B) (Tadokoro et al. 1993), exon 7 Afl III
(Groves et al. 1992, Tadokoro et al. 1993), intron 5 Apa LI, intron 5 Taq I (A) and intron 3 Hinf I (B)
(Tadokoro et al. 1993).
LCL DNA from ALSTA, MASTA and FASTA, and from NAHAS, his mother, MAFIAS, and
father, FAHAS, was PCR amplified for each of these polymorphic markers using oligonucleotides
E460 and E461 (D11S1312), E221 and E222 (D11S995), G276 and F825 (PAX6 (GT)„), 716 and 718
(WT1 (GT)n), D157 and D158 (Hinf I -A), G192 and G193 (Hha /), G190 and G191 (Taq I -B), C155
and 945/E194 (Afl III), G188 and G189 (Apa LI and Taq I -A), and G186 and G187 (Hinf I -B).
Repeated attempts to amplify PAX6 (GT)n were unsuccessful and hence analysis of this microsatellite
sequence was not possible. Specific PCR products were generated for the remaining marker
sequences, and those of the RFLP markers were subsequently digested with the appropriate restriction
enzyme.
Heterozygosity for at least one of the polymorphic markers from D1 IS 1312, D11S995, WT1
(GT)n, Hinf I (A) and Hinf I (B) was identified in MASTA, FASTA and MAHAS, however only
D11S995 was informative for determining the parental origin of the 1 lp 13 deletions (Figure 4.5.1). In
ALSTA and NAHAS the maternally derived copy of the latter microsatellite sequence is present
whereas the paternally derived copy is absent. This demonstrates that in both of these individuals the
constitutional 1 1 p 13 deletion is present on the paternally derived homologue (Figure 4.5.2). This in
turn demonstrates that the imprinting model proposed by Jinno et al. (1994) to explain the cause of
mental retardation in WAGR syndrome can not be accurate, as paternally (or maternally) derived
deletions are not specific for either the absence or presence of this trait.
This analysis also confirms that both deletions arose de novo and has further defined the
location of the distal breakpoints, and hence size, of each deletion. For ALSTA, the distal breakpoint
was known to lie between the marker sequences ZF17 and D11S112 (M2 and M4 in Figure 4.5.2).
With the identification of heterozygosity for D1 IS 1312 (M3 in Figure 4.5.2), the region between this
marker and ZF17 must lie out with the deletion, locating the position of the distal breakpoint as
between D11S1312 and D11S112. This has been confirmed by FISH analysis with probe YAC
yF09162, which contains D11S1312 at the 3' end and crosses the breakpoint (work of J. Fantes,
Fantes et al. 1995, see Appendix C). The size of the 11 p 13 deletion in ALSTA is therefore now
estimated to be approximately 2.5Mb. For NAHAS, the distal breakpoint was known only to lie
proximal of DI1S9I4 (M5 in Figure 4.5.2), however with D11S995 (M6 in Figure 4.5.2) now
identified as lying within the deletion, the position of the distal breakpoint must be located between
these two marker sequences. This could be analysed further using yF09162, which extends from
D1 IS 1312 to this more proximal region. The size of the 11 p 13 deletion in NAHAS is therefore now
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Figure 4.5.1 Status of llpl3 polymorphic marker sequences in WAGR individuals ALSTA and
NAHAS, and their parents. Results from five of the eleven selected polymorphic
marker sequences are shown. Heterozygosity in at least one individual is demonstrated
for D11S1312, D11S995 (lane 4 is distorted), WT1 (GT)n and WT1 Hinfl (B). For all
marker sequences lane 1 - MASTA; lane 2 - FASTA; lane 3 - ALSTA; lane 4 -
MAHAS; lane 5 - FAHAS; lane 6 - NAHAS. a, b, c, d, 144 and 140 - allele designation
for appropriate marker sequence; 279bp - allele b of WT1 Afl 111 marker; 171bp and
152bp - alleles a and b, respectively, of WT1 Hinfl (B) marker; - - no restriction
enzyme; + - restriction enzyme; M3, M6, M8, M12 and M15 - marker sequence
numbers for reference to Figure 5.4.2.
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MASTA FASTA MAHAS FAHAS
M1 FSHB + + + + + + + + M1
M2 ZF17 + + + + + + + + M2
M3 D11S1312 a b b c + + + + M3
M4 D11S112 + + + + + + + + M4
M5 D11S914 + + + + + + + + M5
M6 D11S995 a b b b c "d" c c M6
M7 PAX6 (GT)n - - - - - - - _ M7
M8 WT1 (GT)n 144 140 144 144 144 144 144 144 M8
M9 Hinfl(A) a b a a a a a a M9
M10 Hhal a a a a a a a a M10
M11 Taql(B) b b b b b b b b M11
M12 Afllll a a a a a a a a M12
M13 ApaLI b b b b b b b b M13
M14 Taql(A) a a a a a a a a M14
M15 Hinfl(B) a b a a a a a a M15
M16 y23IC9 + + + + + + + + M16
M17 D11S672 + + + + + + + + M17
M18 D11S1776 + + + + + + + + M18
M19 D11S102 + + + + + + + + M19
ALSTA NAHAS
M1 + + + + M1
M2 + + + + M2
M3 a b + + M3
M4 + • + + M4
M5 + + + M5
M6 a "d" M6
M7 - - M7
M8 144 144 M8
M9 a a M9
M10 a a M10
M11 b b M11
M12 a a M12
M13 b b M13
M14 a a M14
M15 a a M15
M16 + + +/- M16
M17 + +/- + + M17
M18 + + + + M18
M19 + + + + M19
Figure 4.5.2 Parental origin and extent of the constitutional llpl3 deletions in WAGR
individuals ALSTA and NAHAS. Analysis of marker sequences in ALSTA and
NAHAS, and in their parents, demonstrates that the constitutional 1 lpl3 deletions in
both WAGR syndrome individuals are of paternal origin. ALSTA is deleted for M4
D11S112 to M16 y23IC9, and NAHAS for M6 D11S995 to M15 WT1 Hinfl (B) (all
inclusive). Ml to M19 - marker sequence numbers, these are listed centromere distal to
proximal; Ml to M5 map to the pl3p 14 boundary, M6 to M19 map to the distal end of
p 13. + - marker present, by FISH analysis (work of J. Fantes); +/— - marker crosses
breakpoint, by FISH analysis (work of J. Fantes); - - analysis not possible; a, b, c, d,
144, 140 - allele designation for polymorphic marker sequences analysed in this study.
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4.6 Discussion
The involvement of second hit WTI mutations in WAGR-WT has been investigated at the
mRNA level by PCR amplification and sequencing of cDNA. Two unilateral tumours of this type
were analysed and in one, ALSTA-WT, a second hit was detected; a 2bp deletion in exon 10. This
mutation is predicted to produce protein with an extended C-terminus. The additional, inappropriate
residues in this aberrant form of WT1 may destroy the capacity for sequence-specific DNA binding,
however it is also possible that such binding is retained as the deletion does not interrupt the coding
sequence for the TD and ZFs. This type of WTI mutation has not been reported previously in any
form of WT. If the TD and ZFs do adopt the correct conformation it would suggest that an alternative
pathway to loss of sequence-specific DNA binding, for example gain of function, exists for somatic
WTI mutations in WAGR-WT. Second hit WTI mutations have now been reported for eight WAGR-
WT (Table 1.3.2 and Figure 1.3.2) and all but one of these mutations are predicted to cause loss of
sequence-specific DNA binding. The exceptional mutation is a missense mutation in exon 3, which
encodes the change G201D (Park et al. 1993c). In in vitro transcription assays this TD mutation,
cloned in to the murine +17aa-KTS isoform, has been demonstrated to switch Wtl from a repressor to
an activator, however functional analysis of the DNA binding properties of the human equivalent have
not been reported. This latter form of analysis has been initiated for WTI in ALSTA-WT, where,
unfortunately, in situ protein analysis is not feasible (as this tumour has been temporarily thawed).
No second hit WTI mutations were detected in the one other WAGR-WT analysed, NAHAS-
WT. It is possible that such a mutation is present but has escaped detection as the first 290bp of
coding sequence and the majority of the untranslated sequence have not been analysed. The start of
the coding sequence was omitted from analysis because, as previously described, this region of WTI is
very GC rich and therefore refractory to PCR amplification and sequencing. Flowever, the recent
identification of mutations in this region, including somatic mutations, in a relatively high proportion
of WT individuals (Huff et al. 1995) suggests that attempts to analyse this remaining portion of coding
sequence in NAHAS-WT is appropriate. Mutations are not expected within the promoter region of
WTI, as expression has been detected previously, and the identification of both alternative splices
suggests that all four mRNA isoforms are present. With reference to the latter, it is important to note
that the 17aa and KTS alternative splices were identified independently. However, as this tumour
contains only one copy of WTI it is extremely unlikely that there is a cryptic mutation present which
can cause misrepresentation of the isoforms by affecting both alternative splices in a partial manner,
for example abolishing only the -17aa-KTS or +17aa+KTS isoform.
All of the eight WAGR-WT reported to contain second hit WTI mutations are unilateral
tumours, the most common form to develop in this syndrome. The apparent lack of a similar mutation
in NAHAS-WT is therefore remarkable, although there is one case of bilateral WAGR-WT reported
where second hit WTI mutations, predicted to be different in each tumour, were found to be not
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present (Baird et al. 1992a). Analysis of WT1 in these two tumours was performed exclusively at the
DNA level and involved SSCP analysis and sequencing of exons 1 to 10, including sequencing of the
last 60bp of the 5' untranslated sequence and of the exon-intron junction sequences. The latter analysis
indicates that alternative splicing is normal in these tumours and therefore all four mRNA isoforms
should be present. Mutations affecting the promoter region are not evident as expression of WT1 was
demonstrated, however this required 40 cycles of PCR as the quality of both WT is reported to be
poor.
The apparent lack of a somatic WT1 mutation in NAHAS-WT suggested the possible
involvement of a second hit affecting I 1 p 15.5 loci, including the putative gene WT2. LOH for
11 p 15.5 loci, analysed using three appropriate polymorphic markers, was however found to be not
present in this tumour. Similar analysis has been detailed for eight out of ten of the WAGR-WT
reported (Brown et al. 1989, Baird et al. 1992a, Gessler et al. 1993, Gessler et al. 1994), including the
bilateral tumours, and, concordant with NAHAS-WT, alteration was found to be confined to 1 lpl3.
Therefore, the only examples of known alteration at both 11 p 13 and 1 lpl5.5 in WAGR-WT are the
three unilateral tumours reported by Henry et al. (1989) and Jeanpierre et al. (1990), where
subsequent point mutation analysis of the remaining copy of VP77 in each tumour has not been
reported. Involvement of LOH at 1 lpl5.5 in this form of WT is therefore predicted to be infrequent,
although it has to be emphasised that the number of such tumours analysed is low. Detailed analysis of
this distal region should however be considered if all attempts to demonstrate functional loss of the
remaining copy of WT1 in WAGR-WT identifies only wild type sequence.
Previous analysis has demonstrated that the constitutional 11 p 13 deletion in NAHAS is smaller,
and completely internal, to that in ALSTA. This cytogenetic difference is particularly interesting
given that the smaller deletion elicits the more severe phenotype; NAHAS has full spectrum WAGR
syndrome whereas ALSTA has only a partial spectrum as he is not mentally retarded. Two models to
explain the genetic basis of this latter component of WAGR syndrome, the flanking gene model and
the imprinting model, have been tested in ALSTA and NAHAS. The flanking gene model proposes
disruption to a putative gene for mental retardation, mapping either proximal of WT1 or distal of
PAX6. The imprinting model, proposed recently by Jinno et al. (1994) and based on the apparent
monoallelic expression of WT1 in foetal brain, suggests development of mental retardation only when
the constitutional 1 lpl3 deletion is of maternal origin. With reference to the latter model, Huff (1994)
reviewed all reported cases of WAGR syndrome where the parental origin of the constitutional 11 p 13
deletion and the phenotype was known. A total of nine such cases are detailed, comprising three
maternally derived deletions with mental retardation, three paternally derived deletions with mental
retardation and three paternally derived deletions with no mental retardation (two of which were cited
by Jinno et al. (1994) to support the imprinting model). Additionally, for seven of these cases the
extent of the constitutional deletion was known and it is noted that the individuals carrying the smaller
deletions are those with no signs of mental retardation. On the basis of this data the author discounts
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the imprinting model and favours the flanking gene model. Analysis of the constitutional 11 p 13
deletions present in the two WAGR syndrome individuals in the present study clearly demonstrates
that neither of these models is correct. If the imprinting model were correct ALSTA and NAHAS
should differ in parental origin of the constitutional 11 p 13 deletion and, if the flanking gene model
were correct, ALSTA and not NAHAS should display mental retardation. The pattern observed in
these two WAGR individuals is in fact the opposite to the above. Firstly, the parental origin of the
constitutional 11 p 13 deletions in ALSTA and NAHAS does not differ, in both individuals the deletion
is present on the paternally derived homologue, hence discounting the imprinting model. The
predominance of paternally derived deletions in WAGR syndrome is actually not surprising as, in
general, the mutation rate in male gametes is much higher than that in female gametes (Redfield 1994).
Secondly, it is NAHAS and not ALSTA that displays mental retardation, hence discounting the
flanking gene model.
Although the flanking gone model cannot bo accurate, it is however possible that the size of
11 p 13 deletion is still the critical feature in development of mental retardation. For the latter, rather
than the actual size being the key factor there may be various but specific sizes that alter the gross
structure of the chromatin and hence affect gene expression, that is a periodicity may exist and it is the
disruption of this that is all important. Alternatively, and perhaps more likely given the complexity of
the trait, it may be the genetic background of the constitutional 11 p 13 deletion which dictates
development of mental retardation in WAGR syndrome.
Moreover, as a consequence of discounting the imprinting model as the cause of mental
retardation, this study has found no evidence to support the proposal of Jinno et al. (1994) that WT1 is
imprinted in a subset of expressing tissues. This proposal is not considered absolute for two main
reasons. Firstly, biallelic expression of WT1 was demonstrated in kidney (as expected) and placentae
matched for the foetal brain samples displaying monoallelic expression, however all of this analysis
was based on PCR amplifications and only the placentae were analysed with cDNA specific
oligonucleotides and also at the DNA level Secondly, the, identification of monoallelic. and biallelic
expression of WT1 in independent and apparently normal placentae, termed polymorphic imprinting by
the authors, is ambiguous; imprinting is generally understood to be a precisely controlled regulatory
mechanism and. in normal development, all tissues displaying monoallelic expression manifest this
pattern consistently.
In summary, this study has analysed the WT1 locus in two WAGR syndrome individuals; first
and second hits have been characterised in ALSTA whereas only the first hit has been characterised in
NAHAS. This analysis has identified a number of important features; a novel form of WT1 mutation
on ALSTA-WT, an apparent lack of a somatic mutation or involvement of previously implicated
11 p 15.5 loci in NAHAS-WT, and that the mental retardation component of WAGR syndrome is




mutations in Denys-Drash syndrome
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5.1 Contribution of WT1 mutations to DDS
Abnormal development of the renal and gonadal systems underlies DDS, manifesting, as
described in 1.2.4.3, as WT, DMS nephropathy and PGD. With the identification of WT1 expression
in these developing tissues, the possible involvement of this gene in DDS was recognised (Pritchard-
Jones et al. 1990). More specifically, expression of constitutional mutations of WT1 in the podocyte
cells of the glomerulus may influence the associated but non-expressing mesangial cells, which, in
turn, may function abnormally and effect DMS. Constitutional mutations of WT1 are also considered
sufficient to elicit PGD, which, similar to WAGR-GU abnormalities, display variable penetrance and
are more prominent in XY compared to XX individuals, again implicating the involvement of genetic
background in this phenotype. However, dissimilar to the GU abnormalities that develop in WAGR
syndrome, the penetrance of such abnormalities in DDS is very high and the severity of these dictates
that ambiguities between the genotypic and phenotypic sex of an individual are common.
Furthermore, the presence of rudimentary structures such as streak gonad in DDS indicates that WT1
plays a critical role during the earliest stages of gonadal development, perhaps preceding sex
determination (reviewed by Bogan and Page 1994). In DDS tumorigenesis may also be highly
penetrant and, as implicated in many cases of WT, a somatic second hit in addition to a constitutional
first hit WT1 mutation is predicted.
At the outset of this study Pelletier et al. (1991a) reported mutation analysis of WT1 in ten DDS
individuals; a constitutional missense mutation was detected in each. Nine of these mutations are
within exon 9 and, of these, seven are identical, encoding the change R394W. The two other exon 9
mutations both alter residue D396, and the remaining mutation, within exon 8, alters R366, the ZF2
equivalent of R394 (see Table 1.3.4). WT from three of these individuals was analysed and in each
tumour a second hit removing the wild type copy of WTJ, that is LOH, was identified. The
constitutional WT1 mutations associated with DDS therefore appeared to be of a specific type, altering
residues within the fingertip region of ZF3 and ZF2. This region of a ZF is known to confer sequence-
specificity for DNA binding and, in EGR1, it is known that the residues equivalent to WT1 R366 and
R394 are critical as they form hydrogen bonds with the G bases in the target sequence, 5'
GCGGGGGCG 3'. Similarly, the residue equivalent to D396 is also critical as it stabilises the
interactions between the R residue and G base (Pavletich and Pabo 1991). Pelletier et al. (1991a)
demonstrated by using mobility shift assays that, when cloned in to the murine -17aa-KTS isoform,
the DDS WT] exon 9 mutations prevent the ZFs binding to the EGR1 DNA target sequence. It was
therefore proposed that, rather than simply causing loss of sequence-specific DNA binding, these
mutations, when present constitutionally, may elicit the severe abnormalities associated with DDS by
acting in a dominant manner. For example, as the residues conferring DNA sequence-specificity are
altered, binding to inappropriate sequences may be present. An alternative mechanism, that DDS may
be elicited by the mutations acting in a dominant negative manner, was also stated.
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To investigate further the involvement of WT1 mutations in DDS, I chose to perform a mutation
analysis study of this gene in individuals with this syndrome. Analysis was focused at the
constitutional level and, when possible, was extended to DDS-WT.
5.2 Analysis of WT1 in seven individuals with diagnosed or suspected DDS
5.2.1 Phenotype of each individual
Although a rare syndrome, samples from seven individuals with diagnosed or suspected DDS
were available for analysis; DDS 1, DDS2, DDS3, DDS4, DDS5, DDS6 and DDS7. By ascertainment,
all of these individuals has (or had) nephropathy, and further, DDS3 and DDS7 had unilateral WT,
DDS2 and DDS4 bilateral WT, and DDS1, DDS5, and DDS6 are/was tumour-free (each underwent
bilateral nephrectomy). PGD has been described for the five individuals with a karyotype known to be
XY, one of whom, DDS1, is female (externally). For the remaining two individuals, DDS2 and
DDS3, an apparently normal female phenotype is observed, the karyotype of the former is known to be
XX. Interestingly, abnormalities affecting the brain and skull directly (cerebral atrophy, hypertensive
encephalopathy, craniosynostosis, prominent metopic suture and posterior scalp defect) and perhaps in
a less direct manner (pyschomotor retardation, gross motor delay, developmental delay and epilepsy)
are prominent in these individuals, as are respiratory illness and oedema. Furthermore, it is also
interesting to note that the bilateral WT in DDS7 developed within a horseshoe kidney. All of the
features described above for individuals DDS1 to DDS7 are detailed in Table 5.2.1. Two of these
individuals are known to have died; DDS3, at age 15 months, from end stage renal failure (ESRF), and
DDS5, at age 10 months, from respiratory infection.
5.2.2 PCR and point mutation analysis of WT1
5.2.2.1 Exon 9 studies
The indication that WT1 exon 9 is a hotspot for missense mutations in DDS suggests that this
exon should always be the first to be analysed in detail. Accordingly, DNA from individuals DDS 1 to
DDS6 was PCR amplified for exon 9 using intronic oligonucleotides 798/G26 and 801/G25, and
cDNA from DDS7-WT was PCR amplified for the 3'ZF fragment using oligonucleotides B919 (Exon
6) and B917 (exon 10) (see Figure 4.2.1). For each sample only specific PCR products of wild type
length were generated. Direct sequencing of these products, using as primer one or both of the
intronic oligonucleotides used for PCR or, for cDNA, oligonucleotides 792 (exon 7) or B451 (exon 8),
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detected mutations in three of the samples, DDS1, DDS2 and DDS6. Both DDS1 and DDS6 contain a
C to T transition mutation at nucleotide 1560, encoding the change R394W, whereas DDS2 contains a
G to A transition mutation at nucleotide 1566, encoding the change D396N. These missense
mutations present heterozygously at the constitutional level, and in DDS2-WT as mutant sequence
only (Figure 5.2.la).
The presence of either of these missense mutations destroys the single recognition site for the
restriction enzyme Rsr II, 5' CGGA/TCCG 3', which is present in WT1 exon 9. Consequently, exon 9
specific PCR product, normally digested by this enzyme in to two fragments of 182bp and 167bp, will
remain full length (349bp) if either missense mutation is present. This reaction can therefore be used
to screen for these mutations and was used to confirm their presence in DDS1 and DDS6. As
expected, digested and full length reaction products were generated from the heterozygous,
constitutional samples and only full length reaction products were generated from the WT sample
(Figure 5.2.1b, lanes 2, 6, 7 and 9). It is important to note that, as lack of digestion is the critical
feature, this type of screen should not be used exclusively for point mutation detection.
5.2.2.2 Exon 8 studies
For the DDS individuals found not to contain exon 9 mutations, DDS3, DDS4, DDS5 and
DDS7, exon 8 was selected for detailed analysis. DNA from the first three DDS individuals was PCR
amplified for this exon using intronic oligonucleotides C323 and 796/G667, and, as before, for each
sample only specific PCR products of wild type length were generated. DDS7-WT was analysed at
the cDNA level, as described in 5.2.2.1. Direct sequencing of these products, again using as primer
one or both of the intronic oligonucleotides used for PCR or oligonucleotide 792 (exon 7), detected
mutations in three of the samples, DDS3, DDS4 and DDS5. DDS3 contains a T to G transversion
mutation at nucleotide 1458, encoding the change C360G, DDS4 contains a C to T transition mutation
at nucleotide 1464, creating a stop codon at residue R362, and DDS5 contains a C to G transversion
mutation at nucleotide 1499, encoding the change H373Q. Therefore, two missense mutations and one
nonsense mutation have been detected in exon 8. These mutations present heterozygously at the
constitutional level in DDS3 and DDS5 (later also demonstrated for DDS4, work of K. Miyagawa),
and in tumour samples only mutant sequence is present in DDS4-WT, however, remarkably,
heterozygosity is retained in DDS3-WT (Figure 5.2.2a). This latter analysis suggests that an
independent mutation within WT1 may be present in DDS3-WT, causing compound heterozygosity.
To investigate this possibility DNA from this WT was PCR amplified using intronic oligonucleotides
C486 and C152 (exon 4), C178 and C177 (exon 6), C155 and 945/E194 (exon 7), and C911 and C912
(exon 10) and the specific PCR products, all of wild type length, were subsequently analysed using
direct sequencing and/or the HOT technique; no mutations were detected. Collectively therefore,
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Figure 5.2.1 WT1 exon 9 mutations detected in DDS. a) sequence analysis detected missense
mutations in DDS1, DDS2 and DDS6. The position of the nucleotide changes are
indicated by a circle for DDS1 and DDS6, and by a square for DDS2. The residue
changes are R394W and D396N, the inappropriate residues are drawn in bold, bl -
blood; NK,L - normal kidney, left; WT,R - Wilms' tumour, right; wt - wild type; the
recognition site for Rsr II is underlined, b) Rsr II digest patterns of exon 9 PCR product
from DDS1, DDS2, DDS6 and associated samples. Full length product (349bp)
indicates the presence of either of the above mutations, digested product (182bp and
167bp) indicates wild type sequence. Lane 1 - known wild type, positive control; lane
2 - DDS1; lane 3 - DDS1M; lane 4 - DDS IF; lane 5 - DDSlFe, lane 6 - DDS2, normal
kidney; lane 7 - DDS2-WT; lane 8 - DDS2M; lane 9 - DDS6. All samples are
constitutional unless stated. M - lkb size marker.
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Figure 5.2.2 WT1 exon 8 mutations detected in DDS. a) sequence analysis detected missense
mutations in DDS3 and DDS5, and a nonsense mutation in DDS4. The nucleotide
changes are indicated by a circle for DDS3, a square for DDS4 and a triangle for DDS5.
The residue changes are C360G, R362* and H373Q, the inappropriate residues or
change are drawn in bold, bl - blood; WT,L - Wilms' tumour, left; WT,R - Wilms'
tumour, right; wt - wild type; the recognition site for Hph I is underlined, b) Hph I
digest patterns of exon 8 PCR product from DDS3 and associated samples. The
mutation identified in DDS3 creates a second recognition site for Hph /, *H. Products
of 282bp indicate wild type sequence, those of 250bp and 32bp indicate mutant
sequence. A 70bp band is invariant. Lanes 1 - DDS3; lanes 2 - DDS3-WT; lanes 3 -
known wild type, positive control; lanes 4 - DDS3F; lanes 5 - DDS3M. All samples are
constitutional unless stated. The invariant 70bp band is too faint to be visible in lanes 3,
4 and 5. - - no Hph I; + - Hph /; M - tpA174 Hae III size marker.
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The missense mutation in DDS3 creates a second recognition site for the restriction enzyme
Hph /, 5' GGTGA(8/7) 3', in exon 8. Consequently, exon 8 specific PCR product, normally digested
by this enzyme in to two fragments of 282bp and 70bp, will be digested in to three fragments of
250bp, 70bp and 32bp if this mutation is present. This digest reaction was used to confirm the
presence of the missense mutation in DDS3 and, as wild type and mutant reaction products were
generated from the constitutional and tumour samples, further demonstrates that heterozygosity for this
mutation is retained in DDS3-WT (Figure 5.2.2b, lanes 1 and 2).
5.2.2.3 LOH studies
Comparison of the sequence and digest results obtained from constitutional and tumour samples
from DDS2 and DDS3 illustrates that, as described in 5.2.2.1 and 5.2.2.2, LOH for WT1 in WT is
restricted to the former individual. To analyse the possible presence of LOH in DDS4-WT,
constitutional DNA from three tissues and tumour DNA from the right and left WT was PCR
amplified for the Hinf I RFLP marker in WT] exon 10 (Hoban and Kelsey 1991) using exonic
oligonucleotides D157 and D158. Only specific PCR products of wild type length were generated and
subsequently digested. Heterozygosity is observed for this marker in each of the constitutional
samples, however only one copy is observed in the tumour (Figure 5.2.3), demonstrating that, similar
to DDS2-WT, LOH for WT1 is present in DDS4-WT. This result was confirmed by subsequent
sequence analysis of DDS4, as mentioned in 5.2.2.2 (work of K. Miyagawa).
5.2.2.4 Summary
A summary of all of the results relating to individuals DDSI to DDS7 is presented in Table
5.2.1; the apparent lack of mutations in DDS7-WT is discussed in 5.4. Furthermore, initial point
mutation analysis of DDS1 and DDS2, using the HOT technique, was performed by M. Little, and
much of the subsequent analysis of these individuals and of DDS3, DDS4 and DDS5, as described
above, was performed with M. Little.
5.2.3 Analysis of WT1 in parental samples
Eight parental samples, associated with DDSI, DDS2, DDS3 and DDS5, were available for
analysis. The DDS 1 parental samples were from both the mother and father, and, additionally, from
evacuated products of conception from the mother, samples DDS1M, DDS IF and DDSlFe,
respectively. DDS2 was conceived by in vitro fertilisation (IVF) involving an anonymous sperm
donor, and therefore only a sample from the mother, sample DDS2M, was appropriate and available
for analysis. For DDS3 and DDS5 samples from both sets of parents were available, samples DDS3M
and DDS3F, and DDS5M and DDS5F, respectively. All of the parental samples comprised normal,
non-gonadal material. To determine if any of the parental samples contained a mutation identical to
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Figure 5.2.3 Detection of LOH in DDS4-WT. The Hinfl polymorphism in WT1 exon 10 was used
to analyse heterozygosity in DDS4-WT. Two alleles, a and b, are present
constitutionally but only allele a is present in the tumour, demonstrating LOH at 11 pi3
in this tissue. Lanes 1 - fibroblast DNA; lanes 2 - blood DNA; lanes 3 - normal kidney
DNA; lanes 4 - left WT DNA; lanes 5 - right WT DNA, degraded; lanes 6 - no template
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the one previously identified in the associated DDS individual, DNA from each sample was analysed
as described in 5.2.2.1 and 5.2.2.2, that is it was PCR amplified for exon 8 or exon 9 and then either
digested with the appropriate restriction enzyme (DDS1M. DDS IF, DDSlFe, DDS2M, DDS3M and
DDS3F) or sequenced (DDS5M and DDS5F). All of the parental samples generated only wild type
results, some of which are shown in Figure 5.2.1b (lanes 3, 4, 5 and 8) and Figure 5.2.2b (lanes 4 and
5). This apparent lack of constitutional WT1 mutations in the parental samples suggests that the
mutations detected in this gene in DDS1, DDS2, DDS3 and DDS5 arose de novo. The presence of
germline mosaicism for the appropriate WT1 mutation in the parents does, of course, remain a
possibility. Finally, although samples were not available from the parents of DDS4 and DDS6, it is
presumed that the WT1 mutations detected in these two individuals also arose de novo.
5.3 Apparent lack of a WT1 mutation in DDS7
As a WT1 mutation was not detected in exons 8 and 9 in cDNA from DDS7-WT, analysis of the
remaining regions of coding sequence was appropriate. To accompany the previously amplified 3'ZF
fragment, the 5'TD fragment was PCR amplified using oligonucleotides B920 (exon 1) and B918
(exon 6) (see Figure 4.2.1). The 5'TD and 3'ZF fragments were also PCR amplified using
oligonucleotides M3897 (exon 1) and M3896 (exon 6), and M3895 (exon 6) and M3898 (exon 10), to
permit automated sequencing. Additionally, when ambiguities were detected in the cDNA sequence,
individual exons were PCR amplified from DNA using intronic oligonucleotides C147 and C148
(exon 2), C153 and C154 (exon 5), C178 and C177 (exon 6), C323 and 796/G667 (exon 8), 798/G26
and 801/G25 (exon 9), and C911 and C912 (exon 10). For each PCR, only specific products of wild
type length were generated and analysis of the 5'TD fragment detected both the -17aa and +17aa
isoforms. All specific PCR products were subsequently analysed by direct and/or automated
sequencing, using as primer one or both of the oligonucleotides used for PCR or, for automated
sequencing, oligonucleotides H193 (exon 1), 434/F25 (exon 1-2), B700/E976 (exon 5-6) or H195
(exon 6). Sequence analysis of the 3'ZF fragment, using oligonucleotide B917 as primer, detected
both the -KTS and +KTS isoforms. Definite sequence was obtained for all but the first 167bp
(excluding B920 and M3897) of the 5'TD region, that is from the start of exon 2, and for all of the
3'ZF region (excluding B917 and M3898); no mutations were detected.
Although analysis of cDNA has demonstrated that 17aa and KTS isoforms are present, it is
possible that the relative level of each splice form is aberrant because of a mutation in only one copy
of one of the splice sites. The sequence obtained from the DNA samples does, however, indicate that
such a mutation is not present; analysis of the exon-intron junction sequences of exons 5 detected only
wild type splice acceptor and donor sites, and similarly for exon 9 only wild type sequence was
120
detected for the splice acceptor site, KTS encoding sequence and the following splice donor site.
Collectively therefore, analysis of cDNA and DNA suggests that the relative level of each alternative
splice is normal. This analysis does not however eliminate the possibility that the overall level of the
17aa and KTS alternative splices may be aberrant, for example this level may be decreased because of
lack of expression from one copy of WT1. To analyse this possibility constitutional DNA, WT DNA
and WT cDNA from DDS7 was PCR amplified and digested for the Hinfl RFLP marker in WTI exon
10 (Hoban and Kelsey 1991), as described in 5.2.2.3. Heterozygosity for this marker sequence (alleles
a and b, as shown in Figure 5.2.3) was detected in each sample, demonstrating that in DDS7-WT two
copies of WT1 are retained and are expressed, and suggesting that the overall level of expression is not
aberrant. As cDNA specific oligonucleotides were not used for this analysis the possibility that
amplification from the tumour cDNA derived from contaminating DNA was considered, however
subsequent attempts to amplify from this cDNA sample using intronic oligonucleotides failed to
generate any PCR products, suggesting the purity of the sample is acceptable for this form of analysis.
Therefore, despite repeated and detailed analysis, this study has found no evidence for
intragenic mutations, aberrant splicing or an altered expression level of WT1 in individual DDS7.
5.4 Predicted consequences of the WT1 mutations identified in DDS1 to DDS6
The WT1 exon 9 mutations detected in DDS1, DDS2 and DDS6, encoding the change R394W
or D396N, are identical to eight of the mutations reported by Pelletier et a I. (1991a). As described in
5.1, in vitro experiments have indicated that these missense mutations, positioned within the fingertip
region, abolish binding of WT1 to the EGR1 DNA target sequence, an aberrancy mediated by the
inappropriate residues altering the DNA sequence-specificity of ZF3. Again as described previously,
this loss of sequence-specific DNA binding is compatible with either a dominant or dominant negative
mechanism. The WT1 exon 8 mutations detected in DDS3, DDS4 and DDS5, encoding the changes
C360G, R362stop and H373Q, respectively, differ from those of exon 9 as they do not directly affect
the residues at the fingertip region. Disruption to the ZFs is, however, still predicted. The C360G and
H373Q missense mutations each alter a residue critical for zinc co-ordination, hence destroying the
potential to form ZF2. The consequence of these mutations is therefore predicted to be either loss of
sequence-specific DNA binding, if the remaining three ZFs are not compromised, or, if they are
compromised, complete loss of DNA binding. The presence of the latter type of mutation in DDS is
indicated by the remaining mutation detected, R362stop. This nonsense mutation creates the potential
to encode only the TD and ZF1, and, if translated, is predicted to produce WT1 with no capacity to
bind DNA. The position of each of the residues predicted to be altered by the mutations in DDS1 to
DDS6 is shown in Figure 5.4.1, which similarly includes the mutations reported by Pelletier et al.
121
(1991a) and all subsequent reports (but one) of WT1 mutation in DDS (also detailed in Table 1.3.4 and
Figure 1.3.3).
The phenotype of DDS4, who carries the R362stop mutation, is not remarkable when compared
to that of other DDS individuals. This suggests that all of the constitutional missense mutations that
elicit DDS adopt the same mechanism as that indicated by the nonsense mutation, that is, they do not
result in binding to inappropriate DNA target sequences but instead cause complete loss of DNA
binding. In other forms of WT this consequence of constitutional WT1 mutation is also predicted and,
indeed, is clearly demonstrated by the constitutional heterozygous deletions of this gene in WAGR
syndrome. However, the fact that the abnormalities associated with the latter syndrome are relatively
mild suggests that complete loss of DNA binding does not elicit the severe abnormalities such as DMS
and extreme PGD that feature in DDS. The WT1 mutations that elicit DDS must therefore function by
a mechanism distinct from complete loss of or inappropriate DNA binding, indicating that it is a
dominant negative mechanism that is involved in this syndrome.
Dominant negative mutations involve the mutant form of a product disrupting the function of
the wild type form when both forms are present in the same cell. Such mutations were first described
by Muller (1932), who used the term antimorphs and, from analysis of the brown and ebony genes in
Drosophila, describes '..antagonistic mutant genes, having an effect actually contrary to that of the
gene from which they were derived by mutation..1 This type of mutation has subsequently been
described by Herskowitz (1987), who details models for the action of dominant negatives. Applying
one such model directly to this study, it is proposed that, at the constitutional, heterozygous level, a
dominant negative mutation in W77 will result in there being 50% mutant WT1 and 50% wild type
WT1. The level of functional wild type protein will however be less than 50% as a proportion of it
will be functionally inactivated because of interference from the mutant form. For WT1, interference
may comprise 'homodimerisation' between the wild type and mutant proteins, perhaps mediated
through the TD (as this domain contains the two putative leucine zipper like motifs and is, most likely,
the only one present in the mutant form of WT1 predicted for DDS4). It appears therefore that the
severity of the abnormalities associated with constitutional WT1 mutations may be determined by a
dosage effect, the critical aspect of which is the proportion of WT1 that can function normally. In
individuals with WAGR syndrome (and non-syndrome associated WT) the constitutional level of
functional wild type WT1 is 50%, eliciting only relatively mild abnormalities, whereas in DDS this
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Discussion
The possible presence of constitutional WT1 mutations in seven diagnosed or suspected DDS
individuals, DDS1 to DDS7, has been investigated. Each individual was ascertained as a DDS patient
as they displayed DMS and WT or PGD; two individuals developed the full spectrum of
abnormalities. For some of these individuals, for example DDS 1 and DDS6, a definite diagnosis of
DDS was considered dependent on the status of WT1. By PCR amplification and sequence analysis
six WT] mutations were detected; three exon 9 and two exon 8 missense mutations, and one exon 8
nonsense mutation. The three exon 9 missense mutations encode the changes R394W (in two cases)
and D396N, and, even with the many DDS WT1 mutations reported during this study, these mutations
still represent the two most commonly identified WT1 mutations in DDS, with 19 and 5 cases,
respectively, from a total of 42 reported (Pelletier et al. 1991a, Bruening et al. 1992, Baird et al.
1992b, Coppes et al. 1992b, Poulat et al. 1993, Sakai et al. 1993, Clarkson et al. 1993, Tsuda et al.
1993, Nordenskjold et al. 1994) (see Table 1.3.5). One of the R394W mutations in this study,
detected in DDS1, is included in the latter figures as it was also detected by Baird et al. (1992b).
These authors refer to DDS1 as individual GOS368, and it is by this code name that DDS1 was
originally reported by Jadresic et al. (1991). The remaining two missense mutations detected, in exon
8, encode the changes C360G and H373Q. These mutations differ from the other missense mutations
as, rather than altering fingertip residues that confer sequence-specific DNA binding, they each destroy
a critical zinc co-ordinating residue and hence formation of ZF2. Rather than causing inappropriate
DNA binding, the latter mutations may cause such major disruption to the ZFs that the aberrant forms
of WT1 produced display complete loss of DNA binding.
The concept that complete loss, as opposed to alteration, of DNA binding can elicit a DDS
phenotype is clearly demonstrated by the nonsense mutation identified, which encodes the change
R362stop. This mutation, which was subsequently confirmed by Clarkson et al. (1993), destroys the
potential to encode ZF2, 3 and 4, and is therefore predicted to produce WT1 consisting of only a TD
and, perhaps, ZF1. The generation of severe phenotypes from such a mutation indicated that, in
addition to not binding DNA, mutant WT1 in DDS acts in a dominant negative manner. During this
study an exon 6 nonsense mutation was reported by Baird et al. (1992b) and subsequently a third
example of this type of mutation, in exon 3, was reported by Bardeesy et al. (1994b). The first set of
authors did not however state that such mutations implicate a dominant negative mechanism in DDS.
The proposal that complete loss of DNA binding is a feature of DDS WT1 mutations has been
confirmed recently by Little et al. (1995). This study demonstrates that the presence of previously
reported missense and nonsense mutations in ZF2 and ZF3 prevents the mutant form of WT1 binding
to four different putative DNA target sequences, including that of EGR1. The involvement of
dominant negative mutations in DDS has been further implicated by a recent study by Reddy et al.
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(1995), who demonstrate that a peptide comprising only the first 182 residues of WT1 is sufficient to
disrupt wild type WT1 function. This N-terminus region of WT1 is encoded by exons 1 and 2 only
and, although not containing either of the putative leucine zipper like motifs, binds to wild type WT1
and inhibits the activation properties of the latter. It is thought that sequence-specific DNA binding is
not compromised for the mutant-wild type WT1 dimers. Interestingly, all of the intragenic DDS WT1
mutations reported do not affect exons 1 and 2 (see Figure 1.3.3) and therefore all have the potential to
encode the minimum region required for dominant negative action. Furthermore, it is perhaps
significant that the only DDS WT1 mutation predicted to actually truncate the TD, an exon 3 nonsense
mutation encoding Y221stop, elicits a relatively mild and incomplete DDS phenotype (Bardeesy et al.
1994b). This suggests that, although 182 residues are sufficient, the dominant negative mutants that
contain a full length TD may be more effective, hence their prominence in the more complete forms of
DDS.
This dominant negative model cannot however explain all cases of DDS. It is predicted that
perturbation of the isoform ratio is the critical feature in three cases displaying an intron 9 splicing
mutation, as the potential to encode the +KTS isoforms is abolished. Additionally, two individuals
with DDS in combination with WAGR syndrome have been reported (Jadresic et al. 1991, Baird et al.
1992b, Henry et al. 1993). Both of these individuals carry constitutional 11 p 13 deletions that render
WT1 hemizygous, therefore implicating the additional involvement of other factors, such as genetic
background, in these unusual cases of DDS.
In the present study a WT1 mutation was not detected in individual DDS7. It is possible that
such a mutation is present as the first 439bp of coding sequence, that of exon 1, and the untranslated
sequence has not been analysed in detail. As the 5'TD fragment amplified from DDS7-WT appears
wild type in length, deletions or insertions spanning approximately 40bp or longer are not predicted
for exon 1. However, to investigate the possible presence of more subtle mutations, analysis of this
exon, although technically difficult, should be pursued. It is important to note, with respect to
dominant negative mutations, that even if an exon 1 mutation creates a frameshift, the potential to
encode 182 wild type residues will be destroyed. Furthermore, the presence of a WT1 mutation in
DDS7 is indicated by the fact that in the associated WT and the contralateral kidney heterotopic
muscle has developed. WT1 is thought to inhibit myogenesis and therefore development of
heterotopic muscle suggests that this inhibitory function of WT1 has been lost, perhaps as a result of
direct mutation. Evidence for this proposal derives from analysis of a number of WT, including
DDS4-WT; heterotopic muscle is present in this bilateral tumour only in the regions that display LOH
for the constitutional WT1 mutation detected in the present study, R362stop (work of K. Miyagawa).
It is also possible that a WT1 mutation affecting the isoform ratio is present but undetected in DDS7.
This possibility exists as, although the presence, and the relative and overall levels of expression of the
17aa and KTS alternative splices was analysed and identified no mutations, the presence of all four
isoforms has not been demonstrated by using a single PCR. It is possible therefore that there is a lack
125
of any one of the isoforms or of both the -17aa-KTS and +17aa+KTS isoforms or both the -17aa
+KTS and +17aa-KTS isoforms.
Collectively therefore, the analysis of DDS7 suggests that, if a WT1 mutation is present, the
DDS phenotype may have resulted from a mechanism distinct from the dominant negative and altered
isoform ratio mechanisms. Perhaps similar to DDS7, an apparent lack of WT1 mutation was identified
in one of the DDS individuals, GOS374, reported by Baird et al. (1992b). The analysis of WT1 in this
study was performed exclusively on constitutional DNA and involved SSCP analysis and sequencing
of exons 1 to 10 and the exon-intron junction sequences. GOS374 did not develop WT but did display
additional features, comprising cleft palate, nystagmus and mental retardation, which, interestingly,
have been previously reported in part for two individuals known to have WT1 mutations, one had
unilateral WT (possibly as part of a mild BWS phenotype) (Park et al. 1993a) and one WAGR
syndrome (Santos et al. 1993) (see Table 1.3.1 and Table 1.3.2). Cytogenetically visible deletion is
not present in GOS374 and, unfortunately, as constitutional heterozygosity and cDNA analysis was not
performed, the presence and expression of two copies of WT1 in this individual can not be confirmed
and the presence of all four isoforms is indicated by DNA sequence only.
The possibility that DDS7 is a non-W77 DDS individual is, although novel, a valid
consideration. This individual does contain a constitutional, cytogenetic X chromosome abnormality,
Xpl l.2>pl 1.22. Loci mapping in the proximity of this region include one for mental retardation and
cerebral atrophy, at p 11 -q21, one for gonadotropin deficiency and cryptorchidism, at p21, and the
androgen receptor gene, at Xcen-q22 (HGM 1995). It is possible that disruption to one or more of
these loci contributes to the phenotype of DDS7. Furthermore, in DDS7-WT an additional
chromosome abnormality, del9q22, is observed. This chromosomal region has not been previously
implicated in development of WT but may, however, be significant in this tumour. It is not known if a
similar abnormality is present in the ILNR within the contralateral kidney.
Analysis of parental samples has indicated that the constitutional WT1 mutations detected in
individuals DDS1 to DDS6 arose de novo. This finding is in agreement with similar analysis detailed
in many of the other DDS cases reported. Moreover, LOH for WT1 has been observed for all of the
reported DDS-WT tested and similarly, LOH was identified in DDS4-WT and DDS7-WT. The
remaining tumour in this study, DDS3-WT, is however remarkable as heterozygosity for the
constitutional exon 8 mutation (encoding the change C360G) is retained. It is possible that as W77
exons 1, 2, 3 and 5 have not been analysed, this WT may display compound heterozygosity. This form
of independent first and second hits has been identified previously in a unilateral WT (Varanasi et al.
1994). Alternatively, DDS3-WT may contain a second hit at a locus other than WT1, this has not been
analysed.
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Finally, our understanding of the complex genetic mechanisms that contribute to DDS may be
aided by the recent establishment of a mouse model for this syndrome. Chimaeric mice, generated
with embryonic stem cells containing a WT1 exon 9 frameshift mutation, can develop segmental
mesangial sclerosis and, in one case, WT, and mice heterozygous for this mutation develop DMS
(Patek et al. submitted). With respect to the genetic basis of an additional feature, the mental
retardation frequently observed in DDS has been proposed to involve WT1 imprinting (Jinno et al.
1994), however results from previous analysis (see Chapter 4) has indicated that this proposal is in fact
not relevant to DDS and therefore this feature was not investigated in the present study.
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Chapter 6
Searching for WT1 mutations
in malignant mesothelioma
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6.1 Possible involvement of WTI mutations in MM
As described in 1.6, expression of WTI in the mesothelium (Pritchard-Jones et al. 1990) and
detection of WTI point mutations in mesothelial abnormalities (Park et al. 1993b, Devriendt et al.
1995) indicates that alteration of this gene may contribute to tumorigenesis of this tissue. Further
molecular evidence for such involvement of WTI is provided by reports of overexpression in MM of
IGF2 (reviewed by Macauley 1992) and PDGF-A (Gerwin et al. 1987, Versnel et al. 1988), both
putative target genes for WTI transcriptional repression. However, as mentioned in 1.4.4.4, the
frequent gain of chromosome 7p in this tumour type may contribute significantly to overexpression of
the latter gene. Similarly, gain of chromosome 11, a less frequent event but observed by three
independent studies (Tiainen et al. 1988, Tiainen et al. 1989, Hansteen et al. 1993), may influence
expression levels of WTI and IGF2. Rearrangements confined to lip are however only rarely
observed (Gibas et al. 1986, Hagemeijer et al. 1990), suggesting that if WTI mutations do contribute
to MM they are infrequent and/or they present as more subtle alterations. To investigate the possible
involvement of WTI mutations in this tumour type I chose to perform a mutation analysis study of this
gene on cell lines derived from pleural and peritoneal MM.
6.2 Analysis of WTI in MM
6.2.1 MM analysed
Eight human MM cell lines were available for analysis, Mero-14, Mero-25, Mero-48b, Mero-
48c, Mero-83, Mero-84, Mero-96 and Mero-123. Five of these were derived from pleurae; Mero-14, -
25, -83, -84 and -96, two from peritoneum (from the same individual); Mero-48b and -48c, and one
was of unspecified origin; Mero-123.
6.2.2 WTI expression in normal and malignant mesothelial cell lines
RNA from a mesothelial cell line, Met5a, and four mesothelioma cell lines, JU77, L068, N036
and ONE58, had been available for previous analysis by northern blotting; expression of WTI was
detected in each cell line (work of K. Miyagawa).
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6.2.3 PCR analysis of WT1
For all of the above Mero cell lines only low yields of RNA were available for analysis and
therefore RT-nested PCR was used to amplify the TD encoding sequence, 5'TD, and the ZF encoding
sequence, 3'ZF. As described in 4.2.2, the 5'TD region was amplified from cDNA using outer
oligonucleotides D609 (exon 1) and D610 (exon 6) and inner oligonucleotides B920 (exon 1) and
B918 (exon 6), and the 3'ZF region similarly amplified using outer oligonucleotides C582 (exon 5)
and C583 (exon 10) and inner oligonucleotides B919 (exon 6) and B917 (exon 10). For both the 5'TD
and 3'ZF regions only specific PCR products of wild type length were generated. The 5'TD region
failed to amplify from Mero-25 and -96, however in the remaining six cell lines both the -17aa and
+ 17aa isoforms were detected.
6.2.4 Point mutation analysis of WT1
As PCR analysis did not detect any mutations in the above samples, they were subjected to
point mutation analysis using the HOT technique. Purified +17aa 5'TD products and 3'ZF products
were scanned against a known wild type cDNA, EMBK, with HA and 0s04. Strand cleavage
subsequent to HA modification was detected for the 5'TD products from Mero-48b, -48c and -123,
indicating mismatch at a wild type C nucleotide (Table 6.2.1 and Figure 6.2.1a). For each of these
samples, the radiolabelled cleaved fragment was 134bp in length. Direct sequence analysis of cDNA,
using oligonucleotide B920 as primer, detected an identical base change in all three samples; an exon
1 C to T transition at nucleotide 768 (Figure 6.2.1b). This is a novel transition and converts codon
130 from AAC to AAT, both of which encode a N residue. This transition is therefore considered a
silent base change and is not thought to be functionally significant.
6.3 Exon 1 base change studies
If a silent base change presents at a frequency > 5% it constitutes a polymorphism. To
determine if the C to T transition at nucleotide 768 is polymorphic 77 control DNA samples, 54 of
which were from parents from 36 CEPH families (families 17, 23, 28, 35, 37, 45, 66, 102, 104, 884,
1331, 1332, 1333, 1334, 1341, 1344, 1345, 1346, 1347, 1349, 1350, 1362, 1375, 1377, 1408, 1413,
1416, 1418, 1420, 1421, 1423, 1424, 13291, 13292, 13293 and 13294) were selected for analysis.
For each of these samples exon 1 was PCR amplified using oligonucleotides C145/F518 and
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MM site of WT1 cDNA HA 0s04
cell line tumour region scanned result result
Mero-14 Pi 5'TD wt wt
3'ZF wt wt
Mero-25 Pi 3'ZF wt wt
Mero-48b pt(o) 5'TD mut wt
3'ZF wt wt
Mero-48c Pt(l) 5'TD mut wt
3'ZF wt wt
Mero-83 Pi 5'TD wt wt
3'ZF wt wt
Mero-84 pl 5'TD wt wt
3'ZF wt wt
Mero-96 Pi 3'ZF wt wt
Mero-123 nd 5'TD mut wt
3'ZF wt wt
Table 6.2.1 Point mutation analysis of WT1 in MM cell lines. Mutation analysis was performed
using the HOT technique, pi - pleurae, pt(o) - peritoneum (omentum), pt(l) - peritoneum
(liver), nd - not determined, 5'TD - exons encoding transregulatory domain , 3'ZF -
exons encoding ZF DNA binding domain, wt - wild type and mut - mutant.
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Figure 6.2.1 Detection of a base change in WT1 exon 1. a) detection of a cleaved fragment, 134bp
in length, using the HOT technique. This fragment was specific for HA modification
reactions and was detected in MM cell lines Mero-48b, -48c and-123. + - positive
controls, these were 3'ZF products and comprised radiolabelled WT33 scanned against
EMBK (•) and radiolabelled EMBK scanned against WT33 (»); M - size marker b)
direct sequence analysis of cDNA from these three cell lines detected a C to T transition
at an identical location in each (only Mero-48b is shown); nucleotide 768, within exon
1. wt - wild type; mut - mutant.
132
C146/F519 or F516 and F517, which generate only specific PCR products. The DNA recognition
sequence of the restriction enzyme Tha /, 5' CGCG 3', is present in these products and one such site is
destroyed if nucleotide 768 is T (5' TGCG 3'). Digestion of these products with this enzyme was
therefore used to determine the frequency of transition. Eight out of 77 (10.4%) samples were either
C/T or T/T, however further analysis to establish Mendelian inheritance of this apparent
polymorphism (using CEPH families 28, 35 and 1362) generated ambiguous results; it appears that the
sequence context of this CG or TA base pair can make it refractive to Tha I digestion. For this reason
the exon 1 C to T transition could not be confirmed as polymorphic; extensive sequence analysis
would be required and this was not performed. In contrast, Tadokoro et al. (1993) have reported this
transition and calculated a frequency of observed heterozygosity of 40% (in normal Japanese).
6.4 Discussion
The possible involvement of WT1 mutations in MM has been investigated. Eight MM cell
lines, derived from pleurae and peritoneum, were analysed for point mutations in this gene using PCR
amplification and the HOT technique. Virtually the entire coding sequence was analysed at the cDNA
level; no mutations considered functionally significant were detected. One alteration, a silent base
change in exon 1 comprising a C to T transition at nucleotide 768, was detected. As the first 256bp of
coding sequence were omitted from this study, as they are refractory to PCR amplification, it is
possible that mutations are present in this region and have escaped detection. Similarly, mutations
affecting the untranslated sequences or the promoter region may be present, perhaps causing the
observed levels of mRNA to be aberrant and/or affecting translation of WT1.
The analysis of these MM cell lines was performed as part of a collaborative study with T.
Langerak and colleagues (Rotterdam). By Southern and northern blotting experiments these
researchers also identified a lack of alteration at the WT1 locus and confirmed expression of this gene
in mesothelial cell lines and in the Mero cell lines detailed. Furthermore, in the latter samples the four
mRNA isoforms were detected and the level of expression of WT1 was found to not correlate with cell
morphology (mesenchymal or epithelial) or with the level of expression of IGF2 or PDGF-A. This
study therefore provides no evidence for contribution of WT1 mutations to MM. Expression of this
gene in human MM cell lines has also been reported by Walker et al. (1994) and Amin et al. (1995).
Additionally, the latter study detected expression of WT1 in primary MM and demonstrated that, in
both this form of tumour sample and in the cell lines, WT1 is present. Preliminary studies involving
Southern blotting and sequence analysis of WT1 in three of the MM cell lines found mutations to be
not present. These results are, therefore, consistent with the finding of the present study, as are those
reported by Park et al. (1993b), where SSCP analysis of WT1 exons 2 to 10 found mutations to be not
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present in a total of 32 MM samples. In addition, the present study provides no evidence for a role for
WT1 in mesenchymal to epithelial cell type transitions or for IGF2 or PDGF-A being true in vivo
targets for WT1.
It is however possible that the lack of detectable WT1 mutations stems from experimental bias,
as only one type of MM are known to have been analysed: the asbestos status of the samples reported
by Amin et al. (1995) is not detailed, however all of the present samples and those reported by Park et
al. (1993b) are derived from asbestos induced tumours. This bias suggests that it is perhaps only the
asbestos-independent form of MM that is sensitive to WT1 mutations. As asbestos-independent MM
are rare it would be difficult to perform parallel studies on a comparable number of samples, however
analysis of such tumours is vital. Interestingly, in the study by Park et al. (1993b) one mesothelial
lesion was analysed in concert with the 32 MM. The lesion was the only sample to have developed in
an asbestos-independent manner and was the only one in which a WT1 mutation was detected; an exon
6 missense mutation encoding the change S273G. This mutation, demonstrated in in vitro
transcription assays to switch WT1 from a repressor to an activator, was not present constitutionally
and was homozygous within the lesion. More specifically, the lesion was a multicystic peritoneal
(omentum) mesothelioma which, as a developmental abnormality of borderline malignancy, is distinct
from MM. Subsequent to this present study the research group I am part of obtained a portion of an
asbestos-independent MM which had developed in the peritoneum of a teenage male. Preliminary
analysis has demonstrated WT1 expression in this tumour (work of A. Seawright). I believe that this
tumour, DC, is an excellent candidate for containing a WT1 mutation and, if this proposal were
confirmed, would represent the first direct evidence for involvement of such mutations in MM.
Finally, it is conceivable that in the mesothelium the effects of WT1 mutations are similar to
those observed in gonadal tissue, that is these mutations may contribute to abnormalities but not to
tumorigenesis of these tissues.
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Investigatingpi6 as a putative
Wilms' tumour predisposition gene
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7.1 Possible involvement ofpl6 mutations in WT
As described in 1.6.3, the lack of WTJ mutations in the majority of WT, primarily those that are
not syndrome-associated, implicates the involvement of other genes in this form of tumorigenesis. The
location and hence the identity of many of these putative WT predisposition genes is indicated by the
non-random chromosomal rearrangements that are observed in this tumour type, such as the repeated
alterations at 11 p 15.5 highlighting the IGF2 and H19 genes. Rearrangements affecting chromosome
9p are not a common feature of WT (reviewed by Slater and Mannens 1992) and therefore for this
tumour type the possible involvement of specific genes mapping to this region has not been a principal
area of research. However, with the recent identification of pl6, the central role of this gene in cell
cycle regulation and its frequent mutation in many different types of tumour cell line, the potential
importance of loci at 9p21 in all forms of tumorigenesis has been highlighted (Kamb et al. 1994a,
Nobori et al. 1994). The involvement of pi6 in WT has not been reported. To investigate the
possibility that this gene is a WT predisposition gene I chose to perform a pl6 mutation analysis study
on different forms of WT.
7.2 Analysis ofpi6 in WT
7.2.1 WT analysed
A total of 30 tumours were selected, comprising 21 unilateral WT; AmWh, ANDMA, BeMa,
BeOc, CAROL, DAMBA, DANLE, DARCA, GaWa, JAHUM, JOMEE, KABEL, KEARK, KEDEV,
MIWAT, MORGAN, PACUR, RUTPA, ZAGRE, 68.1 and 8RS, 1 bilateral WT; NP58, 2 WAGR-
WT; NAHAS and ALSTA, 4 DDS-WT; DDS2, DDS3, DDS4 and DDS7, and 2 BWS-WT; CRASI
and ANRIA. In addition to these primary tumours, primary cell cultures derived from DAMBA-,
JOMEE-, NAHAS- and CRASI-WT, and a cell line derived from NAHAS-WT were available and
selected.
7.2.2 Mutational mechanisms ofp16
The initial studies of pl6 indicated that virtually all rearrangements affecting this locus
comprise homozygous deletions and only a minority present as point mutations (see 1.5.8). For this
reason I chose to analyse only the former mutational mechanism in this study. Furthermore, the initial
studies also indicated that when homozygous deletions are present they most often eliminate the entire
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gene. This feature suggested that, for this study, analysis limited to exon 2 would be appropriate, as
this is the central exon and contains the majority of the coding sequence. This region of pl6 was
therefore selected to analyse the possible presence of homozygous deletions at this locus in the tumour
samples detailed.
7.2.3 PCR analysis ofpl6
Intronic oligonucleotides G386 and G387 were used to PCR amplify pl6 exon 2. One species
of PCR product only was generated and this was shown to be specific by restriction enzyme digests;
digestion with Ava /, Bgl /, Hind III or Xma I generated restriction fragments of the expected length
(252bp/170bp/87bp, 334bp/175bp, 420bp/89bp and 257bp/252bp, respectively). As these
oligonucleotides were to be used in PCRs investigating possible homozygous deletions, inclusion of a
positive control for amplification was imperative. I chose to use multiplex PCR, enabling
simultaneous amplification of both pi6 and a positive control, thereby ensuring that if pi 6 alone failed
to amplify it was a feature of the template and not a PCR artefact. WT1 was selected as a suitable
internal positive control and intronic oligonucleotides C323 and 796/G667 (exon 8) were found to be
compatible for co-amplification with oligonucleotides G386 and G387. This multiplex PCR was used
to analyse DNA from the WT samples detailed; only specific products of wild type length were
generated and both pi6 exon 2 and the internal positive control amplified in all samples. Results from
some of the samples are shown in Figure 7.2.1. This analysis demonstrates that homozygous deletions
ofpl6 exon 2 are not present.
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Figure 7.2.1 Multiplex PCR analysis ofpl6 in WT. pl6 exon 2 was co-amplified with an internal
positive control, WT1 exon 8, from WT samples. Specific PCR products were generated
from all of the samples, demonstrating a lack of homozygous deletions. Lanes 1 and 2 -
CRASI; lanes 3 and 4 - DAMBA; lanes 5 and 6 - JOMEE; lanes 7 to 9 - NAHAS; lane
10 - no template, negative control; lane 11 - MORGAN; lane 12 - JAHUM; lane 13 -
RUTPA; lane 14 - KEARK; lane 15 - KEDEV; lane 16 - KABEL; lane 17 - MIWAT;
lane 18 - DANLE; lane 19 - no template, negative control; lane 20 - known wild type,




The possible involvement of homozygous deletions of pl6 in primary WT has been
investigated. DNA from 30 unilateral, bilateral and syndrome-associated WT was analysed by
multiplex PCR amplification; no homozygous deletions were present. In primary tumours in general
the frequency of this type of mutation is low as compared to that observed in tumour cell lines, and
therefore the lack of such mutations in primary WT is unremarkable. Analysis of a comparable
number of WT derived cell lines was not possible as such samples are difficult to establish and hence
are limited in number. However, four primary cell cultures and one cell line, all derived from matched
WT, were available for analysis and, concordant with the results from primary WT, no homozygous
deletions were present. These results suggest that pl6 homozygous deletion is not a feature of WT
cells either in vivo or in vitro. Five of the selected WT, ZAGRE, ALSTA, DDS2, DDS3 and DDS4,
were known to contain W77 mutations (Little et al. 1992b, Chapters 4 and 5). Additionally, 11 out of
11 LCL DNA from WT individuals (ANRIA, CAROL, DAMBA, DANLE, JAHUM, JOMEE,
KEARK, KEDEV, MIWAT, MORGAN, RUTPA) amplified by multiplex PCR also failed to show
pi6 homozygous deletion, as did 11 out of 13 similar samples (ALSTA, DAVAT, DYROG, JELON,
KECUL, KIRHO, LISWI, and NAHAS, and renal abnormality individuals CORMU, DABEL and
REAKI) amplified by standard PCR. The LCL included one derived from a familial WT individual
(LISWI), suggesting that, as with the above samples, rearrangements at this locus do not contribute to
this form of tumour.
It is possible that in all of the WT samples and LCL analysed deletions of p!6 are present but
have escaped detection. These deletions would include those that affect only the flanking exons, exons
1 and 3, or that cause hemizygosity. This last feature would be missed in this study as the PCRs used
were not quantitative. Similarly point mutations, together with mutations and alterations of the
promoter sequence, such as the 5' hypermethylation pattern detected for pl6 in various tumour types
by Merlo et al. (1995), may be present.
In summary, although the full spectrum of genes involved in development of WT remains to be
determined, this study has found no evidence for inclusion of p!6 as one such gene.
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surrounding loci in malignant mesothelioma
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8.1 Possible involvement of 9p21 loci in MM
Six studies have reported loss of 9p sequences in MM, including loss involving the region
9p21-22 (Tiainen et al. 1988, Tiainen et al. 1989, Center et al. 1993, Cheng et al. 1993, Hansteen et
al. 1993, Taguchi et al. 1993), but only one further study has focused on the pl6 locus within this
region (Cheng et al. 1994). Therefore, although pi6 has been implicated from analysis of tumour cell
lines as an important tumour suppressor gene, little is known of its potential involvement in MM. The
report by Cheng et al. (1994), as described in 1.5.7, detected 1 intronic pl6 point mutation and 39
homozygous deletions encompassing this locus, from a total of 63 MM samples. Approximately two
thirds of the samples analysed were cell lines and these were found to contain 88% of the mutations
detected. This study therefore suggests that, similar to analyses of other tumour types reported,
homozygous deletion does appear to be the preferred mutational mechanism of pi6 in MM.
Furthermore, this study resolved the extent of the smallest homozygous deletions to 1Mb, indicating
that, in addition to pi6, many genes at 9p21 may be affected in these tumour samples. To investigate
the possibility that it is the pi6 locus that is of critical importance in 9p21 deletions in MM, I chose to
perform a more detailed homozygous deletion analysis study of this region, focused on the pl6 locus,
in MM cell lines and primary MM.
8.2 Homozygous deletion analysis ofpi6 in MM cell lines
8.2.1 Cell lines analysed
Fifteen human MM cell lines were available for analysis, Mero-14, Mero-25, Mero-41, Mero-
48a, Mero-48b, Mero-48c, Mero-72, Mero-82, Mero-83, Mero-84, Mero-95, Mero-96, Mero-123,
TM2 and JU77. Eleven of these were derived from pleurae; Mero-14, -25, -41, -48a, -72, -82, -83, -
84, -95, -96 and JU77, two were derived from peritoneum; Mero-48b and -48c (from the same
individual), one was of unspecified origin; Mero-123, and one, not a true MM, derived from
spontaneous transformation of a mesothelial cell line; TM2. Two human mesothelial cell lines, NM7
and Met5a, were also available for analysis. NM7 is the source of TM2, whereas Met5a is
independent of all of the MM cell lines detailed. Additionally, three glioblastoma cell lines were
available, U87, U373 and A172.
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8.2.2 PCR analysis ofpl6
As described in 7.2.2 and 7.2.3, analysis of pl6 exon 2 was considered appropriate to
investigate the possible presence of homozygous deletions at this locus and comprised PCR
amplification using intronic oligonucleotides G386 and G387 multiplexed with those of an internal
positive control, C323 and 796/G667 (VV77 exon 8). This multiplex PCR was used to analyse DNA
from all of the cell lines detailed; for each sample specific PCR product of wild type length was
generated for the internal positive control, but specific PCR product for pl6 exon 2 was generated
from only the mesothelial cell lines, NM7 and Met5a, and not from any of the MM cell lines. (Figure
8.2.1). This multiplex PCR strategy therefore indicates that pi6 exon 2 is homozygously deleted in all
of the MM cell lines; Mero-14, -25, -41, -48a, -48b, -48c, -72, -82, -83, -84, -95, -96 and -123, and
TM2 and JU77. Similarly, homozygous deletion of pl6 exon 2 was demonstrated in the glioblastoma
cell lines.
8.3 Mapping the extent of 9p21 deletions in MM cell lines
8.3.1 Selection of marker sequences mapping proximal and distal ofpl6 exon 2
To analyse the extent of the pl6 homozygous deletions identified in each of the MM cell lines,
fifteen marker sequences mapping centromere distal or proximal of exon 2 of this gene were selected.
Thirteen of these marker sequences map to the distal region of 9p21, that is p21.3, and comprise
1063.7, cl8.b (Kamb et al. 1994a), p!6 exon 3 and c5.1 (Kamb et al. 1994a) (listed centromere distal
to proximal, all distal of pl6 exon 2), and pl6 exon 1, c5.3, R2.3, R2.7 (Kamb et al. 1994a), pi5 exon
2, cl.b (Kamb et al. 1994a), D9S171 (Cheng et al. 1993), D9S126 (Fountain et al. 1993) and, close to
the boundary with p21.2, D9S169 (Cheng et al. 1993) (also listed centromere distal to proximal, all
proximal of pi6 exon 2). The two additional marker sequences comprise the most distal one selected,
TYRP-1, originally named TRP1 (Abbott et al. 1991), at 9p23, and IFN A (Abbott and Povey 1991) at
the p21-p22 boundary.
Collectively, therefore, the marker sequences selected extend from the distal region of 9p23,
across p22 and p21.3, to the boundary with p21.2, and are present at the greatest density at the most
distal region of 9p21, where pi6 maps. The genetic distance from the most distal (TYRP-1) to the
most proximal (D9S169) selected marker sequence is estimated to be 20cM. The physical distance of
this interval has not been determined, however IFN A and D11S171 are known to be separated by at
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Figure 8.2.1 Homozygous deletion ofpl6 in MM cell lines. Multiplex PCR analysis was used to
amplify p!6 exon 2 and an internal positive control, WT1 exon 8. All of the MM cell
lines are homozygously deleted for pi6. Lane 1 - Mero-14; lane 2 - Mero-25; lane 3 -
Mero-41; lane 4 - Mero-48a; lane 5 - Mero-48b; lane 6 - Mero-48c; lane 7 - Mero-72;
lane 8 - Mero-82; lane 9 - Mero-83; lane 10 - Mero-84; lane 11 - Mero-95; lane 12 -
Mero-96; lane 13 - Mero-123; lane 14 - TM2; lane 15 - JU77; lane 16 - NM2; lane 17 -
Met5a; lanes 18 and 19 - DC; lane 20- no template, negative control; lane 21 - known
wild type, positive control. MMcl - MM cell lines; NMcl - normal mesothelial cell
lines; bl - blood; T - MM tumour; M - lkb size marker.
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8.3.2 PCR analysis of marker sequences
DNA from all of the MM cell lines (and from the three glioblastoma cell lines) was PCR
amplified for each of the selected 9p marker sequences using oligonucleotides TYRP1F and TYRP1R
(TYRP!), IFNAF and IFNAR (IFNA), G591 and G592 (1063.7), G593 and G594 (cl8.b), G857 and
G858 (p!6 exon 3), G595 and G596 (c5.1), G599 and G600 (pl6 exon 1), G601 and G602 (c5.3),
G603 and G604 (R2.3), G605 and G606 (R2.7), G607 and G608 (pi5 exon 2), G609 and G610 (cl.b),
G787 and G788 (D9S171), G729 and G730 (D9S126), G789 and G790 (D9S169). All of these
marker sequences were amplified by standard PCR. Additionally, multiplex PCR was used to amplify
marker sequences 1063.7 and R2.3, with oligonucleotides C323 and 796/G667 (W77 exon 8) as
positive control, and R2.7 and cl.b, with oligonucleotides 798/G26 and 801/G26 (WT1 exon 9) as
positive control. Multiplex PCRs could not be successfully established for the remaining marker
sequences.
The standard and multiplex PCR amplification patterns generated from each cell line for
marker sequences 1063.7, R2.3, R2.7 and cl.b were concordant, indicating that false negative results
are not present. Results from some of these PCRs are shown in Figure 8.3.1. False negative results
can be generated if a combination of standard and multiplex PCR is not used, as reaction failure in the
former and amplification kinetics favouring the positive control in the latter can generate homozygous
deletion results from samples that are in fact wild type for the target locus. A lack of false results is
further indicated by the amplification patterns generated from each cell line for the remaining marker
sequences; these patterns were consistent with those above. Collectively, therefore, this approach
indicates that any cell line failing to amplify one or more of the selected marker sequences does so
because it is homozygously deleted for that sequence.
All of the MM cell lines (and the glioblastoma cell lines) generated specific PCR products for
the most distal and proximal marker sequences, TYRP1 and D9S169, respectively. For all of the
intervening marker sequences, specific PCR products were not generated from each cell line, with the
exact pattern of those showing homozygous deletion varying depending on the marker sequence. This
indicates that the extent of 9p21 deletion differs between the cell lines.
8.3.3 Conformation that background amplification is non-specific
In many of the PCRs, particularly those that did not generate obvious specific products, a smear
of background amplification was observed. It is proposed that this form of amplification is non¬
specific and is favoured only when oligonucleotides cannot anneal to their true target sequences and,
consequently, are available to anneal and amplify inappropriate sequences. The presence of non¬
specific PCR products may therefore be a further indicator that target sequences are homozygously









Figure 8.3.1 Comparison of standard and multiplex PCR amplification of 9p21 marker
sequences, a) marker sequence 1063.7 with (top) or without (bottom) an internal
positive control, WT1 exon 8. b) marker sequence R2.7 with (top) or without (bottom)
an internal positive control, WT1 exon 9. For both marker sequences the results between
standard and multiplex PCR are concordant. The multiplex PCR negative controls are
slightly contaminated with WT1 products, however the levels of amplification are lower
than those observed in the other samples. Lane 1 - Mero-14; lane 2 - Mero-25; lane 3 -
Mero-41; lane 4 - Mero-48a; lane 5 - Mero-48b; lane 6 - Mero-48c; lane 7 - Mero-72;
lane 8 - Mero-82; lane 9 - Mero-83; lane 10 - no template, negative control; lane 11 -
Mero-84; lane 12 - Mero-95; lane 13 - Mero-96; lane 14 - Mero-123; lane 15 - JU77;
lane 16 - TM2; lane 17 - U87; lane 18 - U373; lane 19 - A172; lane 20- no template,
negative control; lane 21 - known wild type, positive control. MMcl - MM cell lines;
GBcl - glioblastoma cell lines; M - lkb size marker.
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of this marker sequence had indicated that it is homozygously deleted in all of the cell lines, and from
these PCRs a relatively high level of background amplification was observed. Southern blotting
transfer was performed for the PCR products generated with the oligonucleotides for pi 6 exon 1,
G599 and G600, from DNA from all of the cell lines, Mero-14, -25, -41, -48a, -48b, -48c, -72, -82, -
83, -84, -95, -96, -123, JU77 and TM2, and U87, U373 and A172, and a known wild type, C2. As
predicted, the smear of background amplification associated with the latter, positive control sample
was weaker in comparison to the smears associated with the cell lines. The transferred products were
hybridised with the probe oligonucleotide G840, which is specific for pl6 exon 1 as its sequence is
complementary to only the internal sequence of this exon. Signal was detected from the positive
control sample only, demonstrating that, as previously indicated, pl6 exon 1 PCR products have not
been generated from any of the cell lines and that homozygous deletions favour background
amplification (Figure 8.3.2). This analysis therefore confirms that the smears of background
amplification associated with this marker sequence are comprised solely of non-specific PCR products
and suggests that the smears similarly observed in many of the other PCRs are also non-specific.
8.3.4 Formation of a deletion map for 9p21-p23
All of the results from the standard and multiplex PCRs described in 8.3.2 were assembled to
form a deletion map of 9p21-p23 for the fifteen MM cell lines and the three glioblastoma cell lines
(Table 8.3.1). As described previously, only TYRP-1 and D9S169 generated specific PCR products
from all of the cell lines, and these marker sequences therefore represent the distal and proximal
anchor points of the deletion map. The largest deletions present in Mero-41, -48a, -48b, -48c, -83 and
-84. For the first four of these cell lines the deletions extend from TYRP-1 to D9S126, and for the last
cell line from TYRP-1 (IFN A not determined) to D9S169. It is not surprising that the deletions
present in Mero-48a, -48b and -48c are identical as these three cell lines derive from one individual.
The smallest deletions present in Mero-82, -95 and TM2 and extend from 1063.7 to cl.b, which,
estimated from the maps detailed by Kamb et al. (1994a), is a distance of at least 90kb. The deletions
present in Mero-123 and JU77, which extend from p!6 exon 3 to D9S171, and from IFN A to R2.7,
respectively, may be of a comparable distance, however this can not be confirmed as the distance
between cl.b and D9S171, and between IFN A and 1063.7, is not known. The extent of each of the
above deletions is not inclusive of the appropriate marker sequences named.
In addition to delineating the extent of each deletion, this map reveals a smallest region of
overlap (SRO), a distance of approximately 24kb. The distal and proximal boundaries of the SRO are
established by , respectively, Mero-123, the only cell line to retain pl6 exon 3, and JU77, the only cell
line to retain R2.7. The SRO is therefore virtually limited to the pl6 locus and hence highlights this
gene as the critical sequence in each of the 9p21 deletions in the MM cell lines (and glioblastoma cell
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Figure 8.3.2 Non-specific nature of PCR background amplification, a) total products from PCR
amplification of pi 6 exon 1. b) Southern blotting and hybridisation of these products
with a pl6 exon 1 specific probe detects product in the positive control sample only,
demonstrating that all of the other amplification products are non-specific. Lane 1 -
Mero-14; lane 2 - Mero-25; lane 3 - Mero-41; lane 4 - Mero-48a; lane 5 - Mero-48b;
lane 6 - Mero-48c; lane 7 - Mero-72; lane 8 - Mero-82; lane 9 - Mero-83; lane 10 - no
template, negative control; lane 11 - Mero-84; lane 12 - Mero-95; lane 13 - Mero-96;
lane 14 - Mero-123; lane 15 - TM2; lane 16 - JU77; lane 17 - U87; lane 18 - U373; lane
19 - A172; lane 20- no template, negative control; lane 21 - known wild type, positive
control. MMcl - MM cell lines; GBcl - glioblastoma cell lines; M - lkb size marker.
147







































































































































































































































































































Table8.3.1Deletionmapof9p21-p23inMMcelllin s.R sultsfr mPCRamplif c tionft ark rseq ences( llu trated gth )h MMcelllin sstudied.Thpositionsftmarkerequenceanotdr wcal .istancfrom1063.75x2iapp oximately68kb, andfrompi5exon2tcl.btle st2kb( stimatedKa l1994a).Resu shglioblastomae linU87,373A1 2 areincluded.+-pres nt;-b ,homozygousde eti?notetermin d. 148
extends past pi5 exon 2. Therefore in 14 out of 15 of the MM cell lines and in all three of the
glioblastoma cell lines the two genes known to map to this region are both deleted.
Furthermore, although all oligonucleotides used in PCRs are designed to amplify only specific
products, this map further demonstrates that PCR cross-amplification between the analogous exons of
pl6 and pi5, which share large tracts of identical or near-identical sequence, has not occurred. For
exon 1, specificity is indicated by JU77, which is homozygously deleted for this sequence in pi6 but is
presumed to retain it in pi5 (as it is proximal of R2.7). For exon 2, although the length of the specific
PCR products differ for pl6 and pi5 (509bp and approximately 540bp, respectively), JU77 confirms
that these PCRs are completely distinct; in this cell line this sequence is, similar to exon 1,
homozygously deleted in pl6 but retained in pl5. Finally, for exon 3, specificity is indicated by
Mero-123 and JU77. The former cell line is presumed to be homozygously deleted for this sequence
in pi5 but retains it in pl6, and the latter cell line displays the opposite pattern, that is this sequence is
homozygously deleted in pi6 but presumed to be retained in pi5 (again, as it is proximal of R2.7).
8.4 Homozygous deletion analysis ofpl6 and pl5 in primary MM
As the deletion map of 9p21-p23 highlights pl6 as the critical sequence deleted in all fifteen of
the MM cell lines analysed, the possible involvement of homozygous deletions of this gene in primary
tumours was considered. Furthermore, the co-deletion of pi5 in all but one of the cell lines indicated
that analysis of this gene in primary tumours was also appropriate. Eleven human primary MM
samples were available for analysis; 2125, 3775-1, 3775-11, 6517, 6517-11, 10563, 12894, 20348,
22754, 23046 and DC. With the exception of the latter, all of the primary MM samples were in the
form of wax embedded pleural tissue sections. The DC primary MM was available as an excised
portion of peritoneal tumour.
DNA from DC primary MM (and DC blood) was amplified by multiplex PCR as described in
8.2.2, that is for pl6 exon 2 and WT1 exon 8. DNA from each of the tissue section samples was PCR
amplified for pl6, pi5 and WT1 using oligonucleotides G386 and G387 (pl6 exon 2), G607 and G608
(p]5 exon 2), C323 and 796/G667 (WT1 exon 8) and C911 and C912 (WT1 exon 10). Multiplex
PCRs could not be established for these samples as both the quality and quantity of DNA that can be
recovered from them is low (it is for this reason also that two positive controls were included).
One or both of the WT1 exons selected as positive controls failed to amplify from samples
23046 and 22574, however specific PCR products for pl6 exon 2 were generated from each sample
and, additionally, for pi5 exon 2 from each of the tissue section samples (Figure 8.2.1 lanes 18 and 19,
Figure 8.4.1a) For sample 22574 the intensity of pi5 exon 2 products was extremely low (Figure
8.4.1a lanes 8), suggesting that the template may have derived solely from normal cells and actually be
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homozygously deleted in the tumour cells. A mixture of normal and malignant pleural cells is a
feature of this type of tissue section. This aspect of possible homozygous deletion of pi5 exon 2 was
analysed further in sample 22574 and in three other samples, two displaying a low level of pi5 exon 2
products, 3775-11 and 23046, and one displaying approximately equal amounts of pl6 and p!5
products, 2125. To eliminate the possible contribution of DNA from normal cells, microdissections to
remove all such cells and leave only tumour cells were performed on these four tissue section samples
(work of S. Fleming). DNA from the resulting tumour-specific samples, 22574md, 2775-IImd,
23046md and 2125md, was PCR amplified as before for pi6 exon 2, pi5 exon 2, and WT1 exons 8
and 10. Similarly to the previous analysis, W77 exon 10 failed to amplify from 22574md, however
specific PCR products for pl6 exon 2, pl5 exon 2 and WT1 exon 8 were generated from all four of
these tumour-specific samples (Figure 8.4.1b). This analysis demonstrates that, even when the levels
of specific PCR products are low, amplification does not derive solely from normal cells and therefore
the tumour cells can not be homozygously deleted for either of the pl6 and pl5 sequences tested.
Consequently, this analysis indicates that 9p21 homozygous deletions are not present in any of the
primary MM samples, including DC and those that were not microdissected.
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Figure 8.4.1 Homozygous deletion analysis ofp!6 andpl5 primary MM. Standard PCR was
used to amplify pl6 exon 2, p!5 exon 2 and two positive controls, WT1 exons 8 and 10.
Specific PCR products for pl6 exon 2 and pl5 exon 2 were generated from all of the
primary MM [including that in b) lanes 3, very faint], demonstrating a lack of
homozygous deletions. For each sample pi6 exon2, WT1 exon 8 and WT1 exon 10 were
loaded in one lane and pl5 exon 2 in the following lane, a) lanes 1 - 10563; lanes 2 -
6517-11; lanes 3 - 6517; lanes 4 - 2125; lanes 5 - 3775-1; lanes 6 - 3775-11; lanes 7 -
23046; lanes 8 - 22574; lanes 9 - 20348; lanes 10 - 12894; lanes 11 - no template,
negative control; lanes 12 - known wild type - positive control, b) microdissected
samples, lanes 1 - 2125md; lanes 2 - 3775-IImd; lanes 3 - 23046md; lanes 4 - 22574md;
lanes 5 - no template, negative control; lanes 6 - known wild type - positive control.
M - 1 kb size marker.
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8.5 Discussion
The possible involvement of pl6 homozygous deletions in MM has been investigated by a
combination of multiplex and standard PCR analysis of this gene in two sample types, cell lines and
primary tumours. Fifteen MM cell lines, 13 of which are Mero cell lines, were analysed for
homozygous deletion of pl6 exon 2; such a deletion was identified in each cell line. This feature is
remarkable as, although similar analysis has been reported for many panels of tumour cell lines,
including 40 MM cell lines reported by Cheng et al. (1994), the present cell lines represent the only
panel known to display an incidence of pl6 homozygous deletion of 100%. This suggests that in the
present cell lines pl6 may be the critical locus that is disrupted. To investigate this possibility the
extent of each of the identified deletions was determined by high resolution mapping of 9p23-p21.2.
This analysis involved homozygous deletion analysis of fifteen marker sequences that map to this
region, including the remaining two exons of pl6. Nine of these marker sequences map within
approximately 40kb distal or proximal of pl6 exon 2, providing a high density of marker sequences in
the putative critical region. By amassing of all of the results from the marker sequences a detailed
deletion map of this region in the MM cell lines was created, identifying the extent of the largest and
smallest deletions, at least 2Mb and at least 90kb, respectively. This deletion map also highlights a
SRO of approximately 24kb and positioned directly at the pl6 locus, again indicating the this gene is
the critical sequence deleted in the MM cell lines.
Of further interest, the deletion map also indicates that pi5 is co-deleted in all but one of the
MM cell lines. This observation suggests that in these cell lines there is a requirement for loss of both
pl6 and pi5. As the proteins encoded by both of these genes are virtually identical in structure and
known function, both inhibit CDK4 and CDK6, it is possible that a loss of function of only one will be
compensated for by the normal functioning of the other, that is, pl6 and p 15 may be functionally
redundant with respect to each other. If there is a requirement for functional inactivation of both of
these proteins this may be achieved, perhaps most easily, by a single mutational event disrupting both
genes simultaneously, hence explaining the predominance of homozygous deletion as compared to
intragenic mutation of this sequence. Evidence for such a mechanism is indicated by three studies of
pl5 reported recently; in two of these studies mutations solely affecting pi5 were found to be not
present in a total of 58 tumour cell lines and 131 primary tumours (Otsuki et al. 1995, Stone et al.
1995), and similarly, in the other study only 3 out of 25 (12%) primary tumours were found to contain
such mutations (Okamoto et al. 1995). The latter figure is comparable to the observed frequency of
intragenic pl6 mutations detected in tumour cell lines and primary tumours (with the exception of
melanoma cell lines and oesophageal carcinoma) (see 1.5.8), a similarity that is, perhaps, not
surprising if both genes are indeed virtually equivalent, as described.
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As analysis of pl6 and p!5 in each of the MM cell lines indicates that these genes are the
critical sequences deleted, the potential involvement of homozygous deletion of these genes in primary
MM was highlighted. Eleven primary MM tissue sections and four derived tumour cell-specific
samples were analysed for homozygous deletions of pl6 exon 2 and p!5 exon 2; for each sample no
such deletions were present. This analysis indicates that the pattern of p!6 homozygous deletion in
MM is similar to that observed in the majority of other tumour types tested, that is, that although
frequent in tumour cell lines, there is a paucity of such deletions in primary tumours. The reasons for
this bias are not understood, but it is possible that in vivo homozygous deletion of p!6 and pi5 is less
evident as an additional level of functional redundancy may exist, and this may prevent such deletions
conferring a growth advantage to the cell. Alternatively, the generation of such deletions in vivo may
be cell lethal unless a specific genetic background is present.
The primary MM in this study were not associated with any of the MM cell lines analysed as,
unfortunately, matched tumour and cell line samples were not available. Detailed cytogenetic analysis
of the primary tumours that the Mero cell lines derived from is however reported (Hagemeijer et al.
1990). This report states that, 'Loss of the short arm of 9 was the most consistent feature of the
hypodiploid and hypotetraploid karyotypes: only one case (Me-19) of 24 showed no alteration of
chromosome 9, and three cases (Me-41, Me-83, and Me-96) even had apparent nullisomy for 9p.' The
stemline karyotype of each of the ten primary tumours associated with all but one (Mero-123) of the
thirteen Mero cell lines in the present study show that abnormalities of 9p were present in eight of the
tumours and, of these, four had specific deletions of 9p21. The latter four primary tumours derived the
cell lines Mero-14, -25, -41 and -96. This analysis therefore suggests that in a proportion of MM
homozygous loss of pl6 (and pi5) may not result simply from in vitro culture, but may be of critical
importance in tumorigenesis, and hence pl6 may indeed be a true tumour suppressor gene for this
tumour type.
In addition to the MM cell lines, three glioblastoma ceil lines were similarly analysed for all of
the selected 9p marker sequences; in each sample homozygous deletions were identified and each of
these extends across both pi6 and pi5. A lack of homozygous deletion in other tumour cell lines has,
however, also been observed; four ovarian carcinoma cell lines, COV362, COV413, COV434 and
COV446 (gift from T. Langerak, described by van den Berg-Bakker et al. 1993), analysed by
multiplex PCR for pi6 exon 2 only, did not display such deletions, in common with one WT cell line
(see Chapter 7). In contrast to this perhaps, similar analysis of independent ovarian carcinoma cell
lines has identified pi6 homozygous deletions in 2 out of 10 (20%) samples (Chenevix-Trench et al.
1994). This difference between two panels of similar tumour cell lines may however simply reflect the
small sample size. Moreover, it is of course possible that more subtle p!6 mutations such as intragenic
point mutations, or aberrant expression levels, are present in the COV and WT cell lines, and the
primary MM analysed. This aspect of pl6 mutations was omitted from this study because, as
previously described, these types of mutation are predicted to be infrequent. It is however important
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to note that expression of pl6 has been detected in 6 out of 6 normal mesothelial cell lines (J-B Prins,
personal communication).
Finally, with the exception of DC, all of the primary MM analysed, and all of the tumours that
the MM cell lines derived from, are known to be asbestos induced tumours. Therefore, similar to the
findings of Cheng et al. (1994), this study provides no evidence for a correlation between 9p21





9.1 Summary of the tumour types and genes studied
Two tumour types, Wilms' tumour and malignant mesothelioma, and two genes, WT1 and pl6,
were selected for analysis in this study. The first tumour type mentioned, WT, is a common paediatric
malignancy of the kidney. The survival rate for this tumour is, in general, good as surgical resection
and post-operative treatments are highly effective. WT can present in association with GU
abnormalities and,, as an extension of this, as a component of WAGR syndrome or DDS.
Abnormalities of the short arm of chromosome 11, particularly the region 11 p 13, are frequently
observed in WT individuals. In contrast, the other tumour type analysed in this study, MM, is a rare
but increasingly prevalent adult tumour of the pleurae, pericardium and peritoneum. The survival rate
for this tumour is poor as surgical resection and post-operative treatments are merely palliative. The
majority of cases of MM develop as a result of asbestos exposure and there are no apparent
associations with any developmental abnormalities or clinical syndromes. Abnormalities of the short
arm of chromosome 9, particularly the region 9p21, have been reported for this tumour.
The first gene mentioned, WT1, is expressed in a tissue-specific pattern and is known to
contribute to normal development of the urogenital system and the mesothelium. This gene, which
maps to 11 p 13, was cloned in 1990 and the limited amount of WT1 mutation analysis (in WT) reported
at the outset of this study indicated that it is a tumour suppressor gene. Many subsequent reports have
confirmed the status of WT1 as a member of this class of genes. The product of this gene is a nuclear
protein, WT1, which functions as a ZF transcription factor. The DNA and protein sequence targets of
WT1 are not known. The other gene analysed in this study, pi6, is expressed in an apparently
ubiquitous pattern and is known to contribute to regulation of the cell cycle. This gene, which maps to
9p21, was cloned in 1994 and hence is not as well characterised as WT1. Initial reports identified pl6
homozygous deletions in many tumour types and as a result this gene was classified as a tumour
suppressor gene. At the outset of this study the bias of pl6 mutations towards in vitro samples had not
been realised, however subsequent reports of this feature have questioned the initial classification of
pl6. The product of this gene is a nuclear protein, pl6, which functions as a CDK inhibitor. CDK4
and CDK6 are known protein targets of pi6.
The tumour types WT and MM were selected for analysis as, although distinct in many
features, genetic links between the tissues that these tumours derive from are being identified, links
which are perhaps a consequence of the developmental pathway these tissues share. It is predicted that
the presence of such links may be reflected at the tumorigenic level by the involvement of mutations in
commonly expressed genes, two of which, as described, are WT1 and pl6. As these latter genes have
been classified as tumour suppressor genes and mutations affecting them are reported for either WT or
MM, each was considered appropriate for selection as a candidate gene for involvement in both
tumour types.
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9.2 Summary of results
This study set out to investigate the possible involvement of WTI and p!6 in both WT and
MM. Analysis of WTI did not detect constitutional mutations in individuals with unilateral, bilateral
or familial WT, but did detect constitutional and somatic mutations in individuals with WAGR
syndrome or DDS. This pattern of results is consistent with the findings reported for many similar
studies, that is there is a predominance of WTI mutations in individuals with WAGR syndrome or
DDS and a paucity of such mutations in individuals with other forms of WT. Considering somatic
mutations alone, when WT from individuals with WAGR syndrome or DDS were analysed second hits
functionally inactivating the remaining wild type copy of WTI were detected. These somatic
mutations comprise intragenic deletion in WAGR-WT and LOH in DDS-WT, again a pattern of
results consistent with previous reports and confirming that WTI is a tumour suppressor gene. This
analysis also revealed some unusual features. In one WAGR-WT and one DDS-WT somatic
mutations were not detected, and, perhaps more remarkable, in one DDS individual a constitutional
mutation was not detected. Although WTI was analysed extensively in the latter three samples, it is
still possible that mutations in this gene are present but have escaped detection. It is interesting to note
however that an apparent lack of WT1 mutation at the somatic or constitutional level in, respectively,
WAGR-WT and DDS has been reported previously (Baird et al. 1992a, Baird et al. 1992b). In
contrast to the above results, analysis of W77 in MM cell lines did not detect any mutations considered
functionally significant. Additionally, constitutional mutations affecting this gene were similarly
found to be not present in individuals from testicular tumour families, although this analysis was more
limited than that for WT and MM.
Collectively, the analysis of WTI in these tumour types has detected 7 mutations, of which 3 are
novel, and demonstrates the involvement of such mutations in tumorigenesis of the kidney, but not in
tumorigenesis of the mesothelium or the gonads. Many independent studies have reported similar
findings. Furthermore, it is interesting to note that when abnormalities distinct from tumours are
considered a pattern opposite to that above is observed, as WTI mutations appear to contribute to
mesothelial and genital abnormalities but not to renal abnormalities.
Analysis of pl6 in WT and matched cell cultures or cell lines did not detect any mutations.
Similar analysis of primary MM and independent MM cell lines did detect mutations but only in the
latter type of sample. The incidence of pi6 mutation in the cell lines was 100%, a feature which has
not been reported previously for any type of tumour cell line. Additionally, analysis of a limited
number of samples detected pi6 mutations in glioblastoma cell lines but not in ovarian carcinoma cell
lines and mutations were found to be specific for tumour as compared to normal cell lines. A bias for
mutations in tumour cell lines rather than primary tumours is a consistent feature of pl6 and has been
reported for many different tumour types. Moreover, this difference between in vitro and in vivo cells
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has raised doubts about the actual importance of pl6 in tumorigenesis. However, the few reports
detailing analysis of pl6 in both constitutional and primary tumour samples do demonstrate a mutation
pattern consistent with the two hit model for tumorigenesis, suggesting that the initial classification of
this gene as a tumour suppressor gene is correct (Hussussian et al. 1994, Kamb et al. 1994b, Ohta et
al. 1994) Nonetheless, for the majority of tumour types analysed, the frequency with which pl6
appears to function as this type of gene in primary samples remains low (Cairns et al. 1995).
Collectively, analysis of pl6 in these tumour types has detected 15 mutations and demonstrates
the involvement of such mutations in MM cell lines but not in primary MM or in any form of WT. As
mutations were not detected in the primary samples, this study provides no evidence to support the
classification of pl6 as a tumour suppressor gene. However, a report detailing 9p21 deletions in a
proportion of the primary tumours that the MM cell lines derived from (Hagemeijer et al. 1990) and an
intragenic pl6 mutation detected in a single primary MM (Cheng et al. 1994) indicate that pl6 may
indeed be involved in tumorigenesis of the mesothelium.
This study has therefore detected a contrasting pattern of mutations in WT and MM; WT1
mutations were detected only in the former tumour type and pl6 mutations only in the latter tumour
type. Nine WT and 6 MM cell lines were each analysed for mutations in both genes, and, although it
has been reported that mutations affecting pl6 and RB are mutually exclusive (Li et al. 1994, Otterson
et al. 1994, Aagaard et al. 1995), the number of samples in this study are considered inadequate to
propose a similar pattern for pl6 and WTJ. A further contrast is the type of mutational mechanism
associated with each of these genes; analysis of WT1 indicates a predominance of subtle, intragenic
mutations, whereas analysis of pl6 indicates that more gross mutations are favoured. For WT1, the
small deletion detected somatically in the WAGR-WT is interesting as the predicted protein product
may retain sequence-specific DNA binding properties, a feature reported for only one other somatic
WTI mutation in this form of WT (Park et al. 1993c). The W77 mutations detected in DDS are of a
specific type, predicted to alter critical residues of ZF2 and ZF3, and introduced the proposal that all
DDS WTI mutations have a dominant negative mode of action. The pattern of mutations detected is
consistent with the findings of virtually all reports of WTI mutation in this syndrome, and all of these
mutation appear compatible with the dominant negative model proposed. Homozygous deletion of
WTI was not detected. From previous reports it is known that deletion of the entire WTI gene can
occur as a constitutional, heterozygous event, most obviously in WAGR syndrome, but only rarely is
the remaining wild type copy of the gene predicted to suffer a similar type of mutation, and
homozygosity is never observed for deletions that extend to adjacent known genes. In contrast, it is
exactly this type of mutation that is revealed for pl6 in the MM cell lines. In these cell lines the extent
of homozygous deletion differs but a SRO highlights the p!6 locus as the critical deleted region. All
of the homozygous deletions extend for at least 90kb and all but one extend to the adjacent and related
gene, pi5. This mutational pattern is consistent with the findings reported for numerous other studies,
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and suggests that in many tumour samples loss of both pl6 and pI5 is a requirement for growth
advantage. This in turn suggests that pi6 and pi5 may be functionally redundant.
The consequence of constitutional heterozygous mutation is also different for WT1 and p!6.
For WT1, deletions and intragenic mutations at this level can, in addition to causing predisposition for
tumorigenesis, elicit developmental abnormalities. This feature is clearly evident in individuals with
WAGR syndrome or DDS. In contrast, this level of pl6 mutation does not appear to elicit any
abnormalities and may simply predispose to tumorigenesis, a feature which is perhaps a reflection of
the more widespread expression of this gene in comparison to WT1.
This study has therefore identified mutations in WT1 and pl6, and has highlighted the fact that
functional loss of these genes is associated with different tumour types and different mutational
mechanisms. Mutation of either of these genes in both WT and MM has not been demonstrated,
providing no evidence for a genetic link between the kidney and the mesothelium in tumorigenesis. It
is however possible that such a link does exist and this may become apparent if further analysis,
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Known cDNA sequence of each gene studied
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GTTCAAGGCA GCGCCCACAC CCGGGGGCTC TCCGCAACCC GACCGCCTGT
CCGCTCCCCC ACTTCCCGCC CTCCCTCCCA CCTACTCATT CACCCACCCA
CCCACCCAGA GCCGGGACGG CAGCCCAGGC GCCCGGGCCC CGCCGTCTCC
TCGCCGCGAT CCTGGACTTC CTCTTGCTGC AGGACCCGGC TTCCACGTGT
GTCCCGGAGC CGGCGTCTCA GCACACGCTC CGCTCCGGGC CTGGGTGCCT
ACAGCAGCCA GAGCAGCAGG GAGTCCGGGA CCCGGGCGGC ATCTGGGCCA
AGTTAGGCGC CGCCGAGGCC AGCGCTGAAC GTCTCCAGGG CCGGAGGAGC
CGCGGGGCGT CCGGGTCTGA GCCTCAGCAA ATGGGCTCCG ACGTGCGGGA
CCTGAACGCG CTGCTGCCCG CCGTCCCCTC CCTGGGTGGC GGCGGCGGCT
GTGCCCTGCC TGTGAGCGGC GCGGCGCAGT GGGCGCCGGT GCTGGACTTT
GCGCCCCCGG GCGCTTCGGC TTACGGGTCG TTGGGCGGCC CCGCGCCGCC
ACCGGCTCCG CCGCCACCCC CGCCGCCGCC GCCTCACTCC TTCATCAAAC
AGGAGCCGAG CTGGGGCGGC GCGGAGCCGC ACGAGGAGCA GTGCCTGAGC
GCCTTCACTG TCCACTTTTC CGGCCAGTTC ACTGGCACAG CCGGAGCCTG
TCGCTACGGG CCCTTCGGTC CTCCTCCGCC CAGCCAGGCG TCATCCGGCC
AGGCCAGGAT GTTTCCTAAC GCGCCCTACC TGCCCAGCTG CCTCGAGAGC
CAGCCCGCTA TTCGCAATCA GG^GTTACAGC ACGGTCACCT TCGACGGGAC
GCCCAGCTAC GGTCACACGC CCTCGCACCA TGCGGCGCAG TTCCCCAACC
ACTCATTCAA GCATGAGGAT CCCATGGGCC AGCAGGGCTC GCTGGiGTGAG
CAGCAGTACT CGGTGCCGCC CCCGGTCTAT GGCTGCCACA CCCCCACCGA
CAGCTGCACC GGCAGCCAGG CTTTGCTGCT GAGGACGCCC TACAGCAGiTG
ACAATTTATA CCAAATGACA TCCCAGCTTG AATGCATGAC CTGGAATCAG
ATGAACTTAG GAGCCACCTT AAAGGG^AGTT GCTGCTGGGA GCTCCAGCTC
AGTGAAATGG ACAGAAGGGC AGAGCAAiCCA CAGCACAGGG TACGAGAGCG
ATAACCACAC AACGCCCATC CTCTGCGGAG CCCAATACAG AATACACACG
CACGGTGTCT TCAGAGGCAT TCAG^GATGTG CGACGTGTGC CTGGAGTAGC
CCCGACTCTT GTACGGTCGG CATCTGAGAC CAGTGAGAAA CGCCCCTTCA
TGTGTGCTTA CCCAGGCTGC AATAAGAGAT ATTTTAAGCT GTCCCACTTA
CAGATGCACA GCAGGAAGCA CACTGiGTGAG AAACCATACC AGTGTGACTT
CAAGGACTGT GAACGAAGGT TTTCTCGTTC AGACCAGCTC AAAAGACACC
AAAGGAGACA TACAG^GTGTG AAACCATTCC AGTGTAAAAC TTGTCAGCGA
AAGTTCTCCC GGTCCGACCA CCTGAAGACC CACACCAGGA CTCATACAGG


























































Nucleotides underlined and in bold - initiation and stop codons
Nucleotides underlined only - alternative splice I (5 lbp) and alternative splice II (9bp)
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Part II - p!6
190
1 CGGAGAGGGG GAGAACAGAC AACGGGCGGC GGGGAGCAGC ATGGAGCCGG
51 CGGCGGGGAG CAGCATGGAG CCTTCGGCTG ACTGGCTGGC CACGGCCGCG
101 GCCCGGGGTC GGGTAGAGGA GGTGCGGGCG CTGCTGGAGG CGGGGGCGCT
151 GCCCAACGCA CCGAATAGTT ACGGTCGGAG GCCGATCCAG J'GTCATGATGA
201 TGGGCAGCGC CCGAGTGGCG GAGCTGCTGC TGCTCCACGG CGCGGAGCCC
251 AACTGCGCCG ACCCCGCCAC TCTCACCCGA CCCGTGCACG ACGCTGCCCG
301 GGAGGGCTTC CTGGACACGC TGGTGGTGCT GCACCGGGCC GGGGCGCGGC
351 TGGACGTGCG CGATGCCTGG GGCCGTCTGC CCGTGGACCT GGCTGAGGAG
401 CTGGGCCATC GCGATGTCGC ACGGTACCTG CGCGCGGCTG CGGGGGGCAC
451 CAGAGGCAGT AACCATGCCC GCATAGATGC CGCGGAAGGT CCCTCAGJ'ACA
501 TCCCCGATTG AAAGAACCAG AGAGGCTCTG AGAAACCTCG GGAAACTTAG
551 ATCATCAGTC ACCGAAGGTC CTACAGGGCC ACAACTGCCC CCGCCACAAC
601 CCACCCCGCT TTCGTAGTTT TCATTTAGAA AATAGAGCTT TTAAAAATGT
651 CCTGCCTTTT AACGTAGATA TAAGCCTTCC CCCACTACCG TAAATGTCCA
701 TTTATATCAT TTTTTATATA TTCTTATAAA AATGTAAAAA AGAAAAACAC
751 CGCTTCTGCC TTTTCACTGT GTTGGAGTTT TCTGGAGTGA GCACTCACGC
801 CCTAAGCGCA CATTCATGTG GGCATTTCTT GCGAGCCTCG CAGCCTCCGG
851 AAGCTGTCGA CTTCATGACA AGCATTTTGT GAACTAGGGA AGCTCAGGGG
9 01 GGTTACTGGC TTCTCTTGAG TCACACTGCT AGCAAATGGC AGAACCAAAG




Nucleotides underlined and in bold - initiation and stop codons
The initiation codon highlighted corresponds to Serrano et al. (1993). This has been revised by
Hannon and Beach (1994), who have extended the N terminus of pl6 by eight residues (no DNA
sequence reported). The 40bp of sequence now available 5' to the highlighted ATG do not contain an




1 GAGGACTCCG CGACGGTCCG CACCCTGCGG CCAGAGCGGC TTTGAGCTCG
51 GCTGCTTCCG CGCTAGGCGC TTTTTCCCAG AAGCAATCCA GGCGCGCCCG
101 CTGGTTCTTG AGCGCCAGGA AAAGCCCGGA GCTAACGACC GGCCGCTCGG
151 CACTGCACGG GGCCCCAAGC CGCAGAAGAA GGACGACGGG AGGGTAATGA
201 AGCTGAGCCC AGGTCTCCTA GGAAGGAGAG AGTGCGCCGG AGCAGCGTGG
251 GAAAGAAGGG AAGAGTGTCG TTAAGTTTAC GGCCAACGGT GGATTATCCG
301 GGCCGCTGCG CGTCTGGGGG CTGCGGAATG CGCGAGGAGA ACAAGGGCAT
351 GCCCAGTGGG GGCGGCAGCG ATGAGGGTCT GGCCACGCCG GCGCGGGGAC
401 TAGTGGAGAA GGTGCGACAC TCCTGGGAAG CCGGCGCGGA TCCCAACGGA
451 GTCAACCGTT TCGGGAGGCG CGCGATCCAG iGTCATGATGA TGGGCAGCGC
501 CCGCGTGGCG GAGCTGCTGC TGCTCCACGG CGCGGAGCCC AACTGCGCAG
551 ACCCTGCCAC TCTCACCCGA CCGGTGCATG ATGCTGCCCG GGAGGGCTTC
601 CTGGACACGC TGGTGGTGCT GCACCGGGCC GGGGCGCGGC TGGACGTGCG
651 CGATGCCTGG GGTCGTCTGC CCGTGGACTT GGCCGAGGAG CGGGGCCACC
701 GCGACGTTGC AGGGTACCTG CGCACAGCCA CGGGGGACTG ACGCCAGGTT
751 CCCCAGCCGC CCACAACGAC TTTATTTTCT TACCCAAiTTT CCCACCCCCA
801 CCCACCTAAT TCGATGAAGG CTGCCAACGG GGAGCGG
^
- exon junctions
Nucleotides underlined and in bold - initiation and stop codons
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Appendix B
Oligonucleotides used in this study
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C145 GGG TCT GAG CCT CAG CAA ATG
F518 repeat of C145
C146 GGG CGC TCC CCG GCC TAC
F519 repeat of C146
F516 CGA GGA GCA GTG CCT GAG CG













exon 2 intron 1 C147 AAG CTT GCG AGA GCA CCG CTG 21iner 68 S
intron 2 C148 TAA TTT GCT GTG GGT TAG GAA
TTC 24mer 66 AS
KW
KW




GGC TCA GGA TCT CGT GTC TC







exon 4 intron 3 C486 AAA CAG TTG TGT ATT ATT TTG
TGG 24mer 62 S
intron 4 C152 ACT TTC TTC ATA AGT TCT AAG
CAC 24mer 64 AS
ML
KW




CAG ATC CAT GCA TGC TCC ATT C







exon 6 intron 5 CI78 AAG CTT CAC TGA CCC TTT TTC
CCT TC 26mer 76 S
intron 6 C177 GAA TTC CAA AGA GTC CAT CAG









exon 9 intron 8
intron 9
exon 10 intron 9
exon 10
CI55 GAC CTA CGT GAA TGA TCA CAT G 22mer 64
945 ACA ACA CCT GGA TCA AGA CCT 21 mer 62
El94 repeat of 945
C323 CCT TTA ATG AGA TCC CCT TTT CC 23mer 66
796 GGG GAA ATG TGG GGT GTT TCC 21 mer 66
G667 repeat of 796
798 TGC AGA CAT TGC AGG CAT GGC
AGG 24mer 76
G26 repeat of 798
801 GCA CTA TTC CTT CTC TCA ACT
GAG 24mer 70
G25 repeat of 801
C911 ACT TCA CTC GGG CCT TGA TAG 21 mer 64






























name sequence (5' to 3')
D609 CAA ACA GGA GCC GAG CTG G
D610 GCA CAT CCT GAA TGC CTC TG
B920
B918
AGC AGT GCC TGA GCG CCT T



































AAA TGG ACA GAA GGG CAG AGC 21 mer 64
TTG GAA GTT GGA TGA AGA AGA TC 23 mer 64
GAG AGC GAT AAC CAC ACA AC




















for location name sequence (5' to 3') length. Tm orient.





















G186 CAC TCG CTC AGC TGT CTT CGG
G187 CAA GGA CCC AGA CGC AGA G
GI88 GTT GTC CTT TTC AGC ATT GC
G189 GCA GGG TTT CAT CCT CGG
G190 CTC ACA CTG CTA AGG ACC C
G191 CTC CTG ACC TTG GGT GAT C
G192 ACA ATA TTT CGA TCC TTA AAG
CCC
G193 GTC CCC GAG GGA GAC CCC
716 AAT GAG ACT TAC TGG GTG AGG
718 TTA CAC AGT AAT TTC AAG CAA
CGG
D157 GCC TGG AAG AGT TGG TCT CT













































HI93 CTG TCC ACT TTT CCG GCC AG
434 CAA TCA GGG TTA CAG CAC




B700 GTA CCC TGT OCT GTG GTT GCT C 22mer 70
E976 repeat of B700
H195 CAT CCT CTG CGG AGC CCA
792 GCT GTC CCA CTT ACA GAT GC



















Oligonucleotides for other lip sequences
for location name seauence (5' to 3') length, TV., orient. origin
VNTR Ha-ras G517 GAG CTA GCA GGG CAT GCC GC 20mer 68 S PP
G518 AGC ACG GTG TGG AAG GAG CC 20mer 66 AS PP
Apa I IGF2 G16 CTT GGA CTT TGA GTC AAA TTG G 21mer 62 S PP
RFLP G17 CCT CCT TTG GTC TTA CTG GG 20mer 62 AS pp
Avail 1GF2 G20 AGC ACA GCA GCA TCT TCA AAC 21 mer 62 S PP
RFLP G21 TTG TTG CTA TTT TCG GAT GGC 21mer 60 AS PP
D11S1312 E460 CTC CTG GAG GTA GGG AGT 18 mer 58 S WB
micros. E461 ACA ACA CCG TTT TTG CTA A 19 mer 52 AS WB
D11S995 E221 GAT TTT CCC ACA TCT ATA ATT
micros. ATA 24mer 60 S PP
E222 CTC TCA GAG AAA CTG AAC CAA 21 mer 60 AS PP
(GT)„ PAX6 G276 ATG CCA CAT CTT CAG TAC I8mer 44 S PP
micros. F825 TTG GAA TGG CAT TCA GTG AC 20mer 58 AS AB
Oligonucleotides forpl6
for location name seauence (5' to 3') length i TM orient. origin
exon 1 exon 1 G599 GAA GAA AGA GGA GGG GCT G 19mer 60 S PP
exon 1 G600 GCG CTA CCT GAT TCC AAT TC 20mer 60 AS PP
exon 2 intron 2 G386 GGA AAT TGG AAA CTG GAA GC 20mer 58 S PP
intron 2 G387 TCT GAG CTT TGG AAG CTC T 19mer 56 AS PP
exon 3 exon 3 G857 CGC TTT CGT AGT TTT CAT TTA G 22mer 60 S KW
exon 3 G858 CCA TTT GCT AGC AGT GTG AC 20mer 60 AS KW
exon 1 G840 GCT GCC CAA CGC ACC GAA TAG 21 mer 68 S KW
Oligonucleotides for other 9p sequences
for location name seauence 15' to 3') length, Tu orient. origin
TYRP-l TRRP1F GGA TAG TGT GAA GAT CTT TGG
CAT G 25mer 72 s PP
TYRP1R ACA GTG GCA AAC ACA GGC AAT
ATCC 25mer 74 AS PP
1FN-A IFNAF GGA TTG AAA ACT GGT TCA ACA
TGG C 25 mer 72 S PP
IFNAR TAC TAG TGC CTG CAC AGG TAT
ACAC 25 mer 74 AS PP
1063.7 G591 CCG TTT CAG CTT CTC ATC AC 20mer 60 S PP
G592 CCG ACT GTC CCA TTG TGA TT 20mer 60 AS pp
198
for location name seauence (5' to 3') length, Tm orient. origin
cl8.b G593 CAA AGA CTT TAT GGA TGG GG 20mer 58 s PP
G594 TCC ATT TCT CTG CTT GCT C I9mer 56 AS PP
c5.1 G595 GAA GTC TTG GTC CTG ATG TC 20mer 60 S PP
G596 CTC TTC TGC ACA ACT CAA CT 20mer 58 AS PP
c5.3 G601 GTG GTA GAA CTA GGA CAG GG 20mer 62 S PP
G602 CTG TGT TAA GCC TTC ATA GA 20mer 56 AS PP
R2.3 G603 GAA AAT GAA ACT GTA CCC ATT G 22mer 60 S PP
G604 GGG ACA CAC ATT AAA TAC ACT 21mer 58 AS PP
R2.7 G605 GAG AAC AGG TTT TGG GCA G 19mer 58 S PP
G606 AAC TAG ACC TAG GGA TAA GG 20mer 58 AS PP
pl5 intron 1 G607 TGA GTT TAA CCT GAA GGT GG 20mer 58 S PP
intron 2 G608 GGG TGG GAA ATT GGG TAA G 19mer 58 AS PP
cl .b G609 AAG CTT TCC CAC AAA CTG GC 20mer 60 S PP
G610 AAT GCC TTG GCA TAA GGG AC 20mer 60 AS PP
D9S126 G729 ATT GAA ACT CTG CTG AAT TTT
CTG 24mer 64 S PP
G730 CAA CTC CTC TTG GGA ACT GC 20mer 62 AS PP
D9S171 G787 AGC TAA GTG AAC CTC ATC TCT
GTC T 25mer 72 S PP
G788 ACC CTA GCA CTG ATG GTA TAG
TCT 24mer 70 AS PP
D9S169 G789 AGA GAC AGA TCC AGA TCC CA 20mer 60 S PP
G790 TAA CAA CTC ACT GAT TAT TTA
AGG C 25mer 66 AS PP
All Tm are in °C; orient. - orientation; S - sense; AS - antisense. Origin KW - self; ML - M. Little; WB
- W. Bickmore; AB - A. Brown; PP - published paper, the appropriate paper for each oligonucleotide
is detailed within the main body of text (except for B920, B918, B919 and B917, which are from
Brown et al. 1992).
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Part II - Annealing temperatures, PCR
programme profiles and lengths of specific PCR products
200
Oligonucleotides for WT1
Oligonucleotide pair Ta PCR programme profile specific I'CR product length
C145/F518
C146/F519 60 standard + formamide 482
F516
F517 69 standard + formamide 249
C147
CI 48 60 standard + formamide 260
CI 49
C150 59 standard 268
C486
C152 57 standard 244
C153
CI 54 60 standard 176
CI78
CI 77 58 standard 230
C155
945/E194 57 standard 350
C323
796/G667 58 standard 352
798/G26
801/G25 63 standard 349
C911
C912 57 standard 260
D609
D610 54 10 cycles 1' ext., 10 cycles 1* 30"ext., 10 cycles 2' ext. 686
B920
B918 54 10 cycles 1' ext., 10 cycles 1* 30"ext., 10 cycles 2' ext
+ DMSO 568/619
M3897
M3896 as B920 and B918
C582
C583 62-57 touchdown and 10 cycles 1' ext., 10 cycles 1' 30"ext.,
10 cycles 2'ext 702
B919
B917 51 10 cycles 1'ext., 10 cycles 1'30"ext„ 10 cycles 2'ext. 590/599
M3895
M3898 as B919 and B917
G186
G187 62 standard 171
G188
G189 59 standard 405
G190
G191 60 standard 520
G192
G193 55 standard 340
201
Oligonucleotide pair Ta l'CR programme profile specific PCR product length
716
718 57 standard 138 - 146 (microsatellite)
D157
D158 58 standard 952
Oligonucleotides for other lip sequences
Oligonucleotide pair Ta PCR programme profile specific PCR product length
G517
G518 61 3 minute ext. + DMSO 860 - 2600 (VNTR)
G16
G17 55 standard 236
G20
G21 49 standard 485
E221
E222 65-50 touchdown 123 - 139 (microsatellite)
G276 47 standard and also
F825 55-50 touchdown and also
47-42 touchdown 180 (no amplification)
Oligonucleotides for pl6
Oligonucleotide pair Ta PCR programme profile specific PCR product length
G599
G600 55 standard + DMSO -350
G386
G387 51 standard + DMSO 509
G857
G858 55 standard -330
202
Oligonucleotides for other 9p sequences
Oligonucleotide pair Ta PCR programme profile specific PCR product length
TYRP1F
TYRP1R 55-50 touchdown 439
IFNAF
1FNAR 50 standard 178
G591
G592 55-50 touchdown -200
G593
G594 55-50 touchdown -180
G595
G596 55-50 touchdown -140
G601
G602 55-50 touchdown -160
G603
G604 55-50 touchdown -300
G605
G606 55-50 touchdown -160
G607
G608 51 standard + DMSO -540
G609
G6I0 55-50 touchdown -140
G729
G730 55 standard -250 (microsatellite)
G787
G788 65 standard -160 (microsatellite)
G789
G790 55 standard -180 (microsatellite)
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Multiplex PCRs
Oligonucleotide pair Ta PCR programme profile specific PCR product length
G386 - G387 with 10 cycles 1'ext., 10 cycles 1' 30"ext., 10 cycles
C323 - 796/G667 51 2'ext + DMSO 509 with 352
G591 - G592 with
C323 - 796/G667 55-50 touchdown -200 with 352
G603 - G604 with
C323 - 796/G667 55-50 touchdown -300 with 352
G605 - G606 with
798/G26 - 801/G25 64-56 touchdown -160 with 349
G609 - G610 with
798/G26 - 801/G25 68-60 touchdown -140 with 349
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We describe a detailed physical map of human chro¬
mosome 11, extending from the distal part of pl3
through the entirety of pl4 to proximal pl5.1. The pri¬
mary level of mapping is based on chromosome
breakpoints that divide the region into 20 intervals.
At higher resolution YACs cover approximately 12 Mb
of the region, and in many places overlapping cosmids
are ordered in contiguous arrays. The map incorpo¬
rates 18 known genes, including precise localization
of the GTF2H1 gene encoding the 62-kDa subunit of
TFIIH. We have also localized four expressed se¬
quences of unknown function. The physical map incor¬
porates genetic markers that allow relationships be¬
tween physical and genetic distance to be examined,
and similarly includes markers from a radiation hy¬
brid map of 11. The cytogenetic location of cosmids
has been examined on high-resolution banded chromo¬
somes by fluorescence in situ hybridization, and
FLpter values have been determined. The map there¬
fore fully integrates physical, genie, genetic, and cyto¬
genetic information and should provide a robust
framework for the rapid and accurate assignment of
new markers at a high level of resolution in this region
of lip. © 1995 Academic Press, Inc.
INTRODUCTION
The short arm of human chromosome 11 is well stud¬
ied and mapped, due to its involvement in the Wilms
tumor, aniridia, genitourinary anomalies, mental re-
1 To whom correspondence should be addressed at MRC Human
Genetics Unit, Western General Hospital, Crewe Road, Edinburgh
EH4 2XU, Scotland. Telephone: (44) 31-3322471. Fax: (44) 31-
3432620.
tardation (WAGR) syndrome and Beckwith-Weide-
mann syndrome (BWS). Several physical maps of
llpl3 and llpl5 have been published (Compton et al.,
1988; Gessler and Bruns, 1989; Rose et al., 1990; Rede-
ker et al., 1994). There are also good genetic maps and
a radiation hybrid map of chromosome 11 (Gyapay et
al., 1994; Litt et al., 1993; James et al., 1994). A prob¬
lem in comparing information from these maps has
been that they use different sets of DNA markers and
landmarks in their construction and the information is
expressed in different formats (for example, in kb, cM,
or cR). This means that it is difficult to relate informa¬
tion from one source with that from another and to
integrate a marker mapped in one particular way, such
as by genetic mapping, into a map derived in a different
form, such as an FLpter map (Evans, 1993).
We have tackled this problem by constructing a de¬
tailed and integrated map of the distal region of llpl3,
extending in a telomeric direction to reach the proximal
part of llpl5.1. This region encompasses the G band
lip 14, an example of a cytogenetic region that is not
often well studied and whose DNA content remains
somewhat of a mystery. The map is integrated at the
physical, genetic, and cytogenetic levels. To do this we
have used, as our primary mapping landmarks, a set
of lymphoblastoid cell lines carrying mainly WAGR-
derived chromosome breakpoints. These breakpoints
divide the region into 20 intervals, and in several cases
the intervals can be subdivided by further breakpoints.
The breakpoints chosen to define interval boundaries
are those where the aberrant chromosome 11 has been
segregated from the normal homologue in somatic cell
hybrids so that mapping can be by both PCR and FISH.
Within this framework we have ordered anonymous
DNA markers, cosmids, YACs, microsatellite markers,
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genes, and other expressed sequences, generated both
in our own laboratory and in the laboratories of many
other groups (Compton et al., 1988; Gessler and Bruns,
1989; Tanigami et al., 1992; Litt et al., 1993; Smith
et al., 1993; Gyapay et al., 1994; James et al., 1994).
Mapping has been primarily by PCR on hybrid DNAs
and YACs and by fluorescence in situ hybridization
(FISH) to metaphase chromosomes from breakpoint
cell lines. Markers in the same interval were ordered
either by physical mapping on cloned and genomic
DNAs or by interphase FISH. Genetic markers were
mapped by PCR on hybrid DNAs and YACS and the
PCR primers were also used to derive cosmids by hy¬
bridization, allowing them to be mapped by FISH. In
some instances, cosmids were derived from YACs, both
by library construction from YAC DNA and by hybrid¬
ization of isolated YAC DNA to cosmid libraries. Arrays
of overlapping cosmids were identified by fingerprint¬
ing (Heding et al., 1992). The FLpter value for a repre¬
sentative cosmid from each interval, when available,
was also ascertained (Lichter et al., 1990).
The map is estimated to extend over 15 Mb of geno¬
mic DNA and includes 237 cosmids, 220 of which are
arrayed in 31 contigs, each of which contains up to 32
members. Approximately 12 Mb of the region is cloned
in YACs. The map covers 13% of the physical meta¬
phase length of chromosome 11 and contains 18 known
genes, 4 expressed sequence-tagged sites (ESTs), and
at least 15 CpG islands. These are unevenly distributed
across the region in a manner consistent with other
studies that have indicated that genes cluster in the R
band regions of the genome (Gessler and Bruns, 1989;
Craig and Bickmore, 1994). There are >50 STSs in the
map including 16 microsatellite markers covering at
least 15 cM of genetic distance (Couillin et al., 1994).
The map also covers 375 cR (one-third of the entire p
arm) of the radiation hybrid map of chromosome 11,
established by James et al. (1994) using an X-ray dose
of 9000 rads. Finally, the map spans a region where
the conserved region of synteny with the mouse genome
changes from chromosome 2 to chromosome 7.
The many layers of this map are internally consistent
and therefore rapidly highlight any discrepancies and
errors in the placement of new markers. The integra¬
tion of genetic and physical data has pinpointed the
physical location of genes that might play a role in Type
I Usher syndrome and familial hyperinsulinism (Keats
et al., 1994; Glaser et al., 1994).
MATERIALS AND METHODS
Cell lines and hybrids. Cell lines, and the corresponding hybrids
where available, the phenotype and karyotype of the individuals from
which they were established, and the estimated physical extent of
deletions are all summarized in Table 1.
Pulsed-field gel electrophoresis. High-molecular-weight mamma¬
lian DNAs were prepared, digested, and resolved, as previously de¬
scribed (Bickmore et al., 1993). YAC plugs were processed as de¬
scribed by Fantes et al. (1995).
PCR. Most primers and cycling conditions have been described
elsewhere (Miwa et al., 1993; Smith et al., 1993; Gyapay et al., 1994;
James et al., 1994; Sellar et al., 1994a) or are available in GDB. In
addition, primers C809 (5'-GCAAGCAGTATTCAATTTCTG-3') and
C810 (5'-CTCGCACAGTACAATCAGTGC-3') were from introns 1
and 2, respectively, of the FSHB gene (Watkins et al., 1987) and give
a 300-bp product. B960 (5 '-CTATCTTCCCCTTTTAATGGTC-3') and
C908 (5'-AAGGACGCAGACTTGTACACG-3') were designed from
BDNF sequence published by Maisonpierre et al. (1991) and generate
a 500-bp product. These reactions were carried out in the presence
of 1 mM Mg2+ and cycled at 94°C, 1 min, 55°C, 1 min, and 72°C, 1
min for 30 cycles. Last, G78 (5'-GTGGCCATGATGCTTACAGG) and
G77 (5'-AGTCTCCAATGTGCAAGTAC) were designed from the 3'
untranslated region of the GTF2H1 gene (GenBank Accession No.
M95809). These primers amplify a 165-bp human product in the
presence of 2.5 mM Mg2"".
Microsatellite analysis of WAGR deletions. The extent of chromo¬
some 11 deletions was examined by PCR with microsatellite markers
on DNAs from the deleted individual and their unaffected parents.
Primers were fluoresceinated and the PCR products analyzed on an
ALF automated sequencer (Pharmacia) with a 6% hydrolink (Long
Ranger, AT Biochem), 7 M urea gel made up and run in 0.6% TBE.
Alternatively, primers were labeled with [y-32P]ATP and T4 poly¬
nucleotide kinase and the products examined on a manual sequenc¬
ing gel. Deletions manifested as regions of apparent homozygosity/
hemizygosity (Bruford et al., manuscript in preparation).
Cosmid and YAC isolation and overlap analysis. Random-prime
labeled plasmid-derived probes were hybridized to gridded chromo¬
some 11 cosmid library 107 supplied by the ICRF RLDB (Zehetner
and Lehrach, 1994). The names of these cosmids have the prefix
cICRFcl07-, but this is usually omitted, especially in figures. Oligo¬
nucleotides were end-labeled and hybridized to filters at 50°C. YAC-
derived probes were obtained by PCR amplification of catch-linked
gel-purified YAC DNA, in the presence of [<*-32P]dCTP. Probes con¬
taining repeated DNA sequences were preannealed in the presence
of 2.5 pg human CotI DNA (Gibco) before adding to the hybridization
mix.
To generate cosmid libraries from YAC DNA itself, spheroplasts
were lysed in NDS (10 mMTris-HCl, 0.5 M EDTA, 1% lauryl sarcos-
ine, pH 9.5) and incubated at 55°C for 4 h with 0.5 mg/ml proteinase
K. After extraction and ethanol precipitation, the DNA was resus-
pended in TE, RNased, reextracted, and dialyzed at 4°C against TE.
It was then digested partially with serial dilutions of Sau3AI. DNA
cut to the optimal size range was dephosphorylated and ligated to
Lawrist 4 cosmid arms, at the BamKl site. Cosmids containing hu¬
man DNA were selected by hybridization to total human DNA. All
cosmids were subject to fingerprint analysis to identify overlapping
clones (Heding et al., 1992).
YACs were obtained from CEPH or were isolated by screening the
ICI (Anand et al., 1990) and ICRF YAC libraries 900 and 901 by
PCR analysis or hybridization to gridded filters. All YAC clones are
denoted by the prefix y.
FISH. Cosmid DNAs were nick-translated with biotin-16- or di-
goxigenin-ll-dUTP (Langer-Safer et al., 1982). Isolated YAC DNAs
were labeled with biotin after isolation from pulsed-field gels and
ligation to catch-link oligonucleotides (Fantes et al., 1995). Single-
color FISH of biotin-labeled probes to metaphase chromosomes from
lip breakpoint cell lines was as described in Fantes et al. (1992).
FLpter values (Lichter et al., 1990) were obtained for a representa¬
tive cosmid in each map interval, where available. Digital images were
obtained with the MRC BioRad confocal microscope from at least 20
chromosomes with a length between 8 and 12 pm. Fractional length
measurements were made with BioRad software, and mean FLpter
values and 95% confidence intervals were calculated (Table 2).
Cosmids were localized on prometaphase chromosomes produced
by early S phase synchronization with methotrexate (10'7 M) ofPHA-
stimulated peripheral blood cultures followed by release with 5 X
10~3 M bromodeoxyuridine (BrdU). Hybridization signals were de¬
tected by successive layers of avidin-Texas red, biotinylated anti-
avidin, and avidin-Texas red. A final incubation with FITC-conju-
gated anti-BrdU antibody gave a replication G-banding pattern
(Craig and Bickmore, 1994). The Texas red cosmid signal and the
FITC banding pattern were visualized simultaneously through a
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Chroma Pinkel No. 1 filter set fitted to a Zeiss Axioplan microscope,
with a Photometries CCD camera and Digital Scientific software.
The order of cosmids within a map interval was determined by
multicolor FISH to interphase nuclei from G1 serum-depleted fibro¬
blasts (Trask et al., 1991). Two cosmids, labeled with either biotin
or digoxigenin, were hybridized simultaneously with a reference cos-
mid, labeled with both biotin and digoxigenin. Wherever possible the
analysis was repeated using reference cosmids from adjacent map
intervals both telomeric and centromeric of the region under study.
Hybridization signals were detected with successive layers of FITC-
conjugated sheep anti-digoxigenin, FITC-conjugated anti-sheep anti¬
body plus avidin-Texas red, biotinylated anti-avidin, and avidin-
Texas red. The Pinkel No. 1 filter set was used to visualize the three
cosmids simultaneously as red, green, and orange hybridization sig¬
nals, respectively, and their order was determined in ~50 nuclei.
The cosmids used were chosen to be equidistant from each other and
neither too far apart nor too close to each other. Only signals that
were lying approximately in a straight line to each other were scored.
YACs were labeled with biotin and used as FISH probes as de¬
scribed by Fantes et al. (1995).
RESULTS
The region under study is divided up into 20 inter¬
vals defined by chromosome breakpoints. The most cen¬
tromere-proximal interval is interval I, and the most
telomeric is interval XX. The detailed mapping of each
interval is described in detail below.
Interval I
This interval is defined at the centromeric end by the
T-ALL translocation (Boehm et al., 1991) and at the
telomeric end by the deletion breakpoint of ANNA and
is approximately 300 kb in size. The T-ALL breakpoint
is 5' of the RBTNL1 gene, transcribed from the most
centromere-proximal CpG island ofFig. 1. Distal to this
is a 550-kb Notl fragment that is bissected by the
ANNA breakpoint (Bickmore et al., 1989). Located on
this fragment, in interval I, are the D11S48 and
D11S102 loci (contained on the same 120-kb BssHII
fragment), the D11S184 and D11S1301 loci, and the
gene(s) encoding the CD59/MIC11 antigens (Bickmore
et al., 1993). Although the relative order of CD59/
MICH, D11S48, D11S102, and D11S1301 has not been
established here, James et al. (1994) have placed
D11S1301 distal of RBTNL1 and CD59. c65-6/6
(D11S102) has an FLpter value of 0.256 (Table 2).
Interval II
The boundaries of this interval, of approximately 400
kb in size, are the deletion breakpoint of ANNA and
the POR translocation (Fig. 1). D11S376 is on the 550-
kb Notl fragment but distal of the ANNA breakpoint
(van Heyningen and Jones, 1993). PCR analysis also
places the microsatellite D11S1776 (James et al., 1994)
and D11S672 (Miwa et al., 1993) in this interval. FISH
analysis with D11S672 (FLpter value of 0.251) shows
that this locus is proximal of the submicroscopic dele¬
tion in the WAGR patient NAHAS. Similarly, in AL-
STA, a submicroscopic deletion associated with Wilms
tumor and aniridia alone (Table 1), there is FISH sig¬
nal on both chromosomes 11, but one of the signals is
consistently weaker than the other, suggesting that
D11S672 spans the ALSTA proximal breakpoint.
Hence, the ALSTA deletion extends more proximally
than that of NAHAS (Fig. 1). Both ALSTA and NAHAS
are heterozygous, and hence not deleted, for D11S1776.
We do not know whether the POR breakpoint is within
the small Notl fragment immediately distal to the 550-
kb fragment or on the next one, since the breakpoint
is a minimum of 350 kb and a maximum of 600 kb
proximal to D11S294 (Bickmore et al., 1989) (Fig. 1).
Interval III
This small (200—300 kb) interval is defined by the
POR translocation and the TRAKE deletion break¬
points (Fig. 1). D11S307 and D11S311 loci (van Hey¬
ningen and Jones, 1993) are both located on a 300-
kb Notl fragment (Gessler and Bruns, 1989), but only
D11S307 is present on y23IC9 (see Interval IV). The
distal end of this Notl fragment has been cloned
(LFC5), but we do not know whether it is deleted in
TRAKE (Gessler et al., 1990). The EST D11S1938E
(Adams et al., 1993; James et al., 1994) maps to this
interval by PCR analysis on hybrid DNAs and, like
D11S311, appears to be proximal to y23IC9.
Interval IV
This is a 350-kb interval defined by the proximal
deletion breakpoints of TRAKE and PAZO, at the cen¬
tromeric end of which is a 160-kb Notl fragment har¬
boring D11S299 (Gessler and Bruns, 1989; van Hey¬
ningen and Jones, 1993). Distal to this a 500-kb Notl
fragment is disrupted by the PAZO breakpoint (van
Heyningen et al., 1990). The centromeric end of this
fragment has been isolated as a Notl end clone
(D11S2133), which is probably equivalent to LFC1
(Gessler et al., 1990). D11S294 and D11S303 map to
the same 90-kb BssHII fragment as D11S2133 (Bick¬
more et al., 1989; Gessler and Bruns, 1989), and the
distal end of this BssHII fragment (D11S305) has also
been cloned (Gessler et al., 1990). D11S417 and
D11S321 are <200 kb distal to these probes (Compton
et al., 1990; Gessler and Bruns, 1989). Cosmid ICRFc-
107G1135 at the D11S417 locus has an FLpter value
of 0.239 (Table 2) and is present on both chromosomes
11 in PAZO but absent from the previously uncharac-
terized deletion chromosomes of PKPA, NAHAS, and
ALSTA (Table 1, Fig. 1). PKPA has a proximal deletion
end point centromeric of D11S102 (interval I). The
most distal interval IV marker is HD42, a BssHII jump¬
ing clone 250 kb centromeric of WT1 (Royer Pokora et
al., 1991), equivalent to LFT1 (Gessler et al., 1990).
Primers for D11S2133 were used to isolate y23IC9
(375 kb), which also contains D11S294 and D11S307.
This YAC therefore spans the proximal TRAKE
breakpoint (Fig. 1). D11S311 did not hybridize to
y23IC9, and restriction mapping suggests that y23IC9
ends within the 300-kb genomic Notl fragment con¬
taining D11S307 and D11S311 (Fig. 1). Neither D11S-
1776 nor HD42 are contained on y23IC9. FISH con-
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FIG. 1. Integrated map of the distal region of lip 13 (intervals I to VI). The positions of chromosome breakpoints that define map
intervals are shown relative to the physical map of the chromosome determined by genomic and YAC PFGE analysis (scale bar = 100 kb).
The orientation of the map relative to the centromere is shown. Vertical arrows indicate translocation breakpoints. Horizontal arrows
pointing right or left mark the proximal and distal extent of deletions, respectively. The positions of known genes and markers are shown,
as are ordered cosmids at these loci. The prefix is omitted from the names of cosmids from the ICRF RLDB due to space constraints. The
extent of YAC clones covering the region is shown. Markers in common with the map described by James et al. (1994) are shown together
with their separation on the radiation hybrid map (cR). Finally, the FLpter values for representative cosmids of each interval are indicated
(Table 2). Some restriction enzyme sites on the genomic map, principally those indicating the presence of CpG islands, are included: A,
AscI; B, BssHII; E, EagI; N, Notl; S, SacII.
firmed that this YAC is nonchimeric. Some signal was
present on the NAHAS deletion chromosome, but there
was no detectable hybridization to the TRAKE or AL¬
STA deletion chromosomes (Figs. 2a and 2b).
Interval V
The most proximal marker in this 450-kb interval,
bounded by the PAZO and DAR deletion breakpoints,
is D11S87 (Lewis et al., 1988). This is 87 kb from the
WT1 gene, which lies on a 375-kb Notl fragment and is
represented by cB2.1 (Fantes et al., 1992). The FLpter
value of cB2.1 (0.247) suggests a more centromeric loca¬
tion than D11S417 (interval IV) and serves to illustrate
the unreliability of determining order by FISH on
metaphase chromosomes for markers so close together
(~250 kb apart).
WTl-specific primers were used to isolate YACs
ylIE5 (450 kb), y23HD9 (275 kb), and y32BH5 (250
kb). ylIE5 is nonchimeric by FISH and contains
D11S87 and HD42. Hence, it must cross the PAZO
breakpoint, although no FISH signal was detectable on
these chromosomes. Restriction mapping of the WT1
YACs indicates that they all include the CpG island
100 kb distal of the 5' end of WT1 (Fig. 1).
Interval VI
This interval is 400 kb in size and bounded by the
distal DAR breakpoint and the proximal breakpoint in
the deletional translocation of DG85 (Compton et al.,
1988). D11S377 is on the same 375-kb Notl fragment
as WT1, and the distal end of this fragment is present
in clone HD27 (Royer Pokora et al., 1991). None of the
WT1 YACs contain D11S377, although FISH signal
from yIE5 is visible in DAR. The next most distal Notl
fragment (325 kb) contains D11S324 and D11S323
(Compton et al., 1988). The interval is subdivided by
the proximal deletion breakpoint of KAZHM, which
must be contained within the set of overlapping cos¬
mids covering the D11S377 and D11S2134 loci (Fig.
1), since FISH shows that c20/18/DllS377 (FLpter =
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TABLE 1




cell line Hybrid Karyotype (11)
of deletion
(Mb) Phenotype Reference
ALSTA del pl3 (s) 2.5 A, W
ANNA ANX6.14 del pl2 pl4.1 4.0 A Seawright et al. (1988)
BAN BAN68 del pl2pl4 -15 A, G, R, W Couillin et al. (1989)
BID BID7 del pl2pl4.3 A, G + cardiomyopathy Couillin et al. (1989)
GM4613 POR4/POR11 t(2;ll)(pll;pl3) G, P Seawright et al. (1988)
DAR DAR15.14 del pl2pl3 -10 G, W Couillin et al. (1989)
DG85 DGR7/DG R30 t(ll;22)(pl3;ql2.2)del pl3 (s) A Compton et al. (1988)
GOTY GOX 1.5 del pl2 pl4 -12 A, R, W Seawright et al. (1988)
KAZHM del pl3pl4.1 (s) 2.3 A
LEV LEV14.13.6/LEV 22.1 t ins (14;ll)(ql3;pl2pl4) Retinopathy Couillin et al. (1989)
MARGA MAX 13 del pl3 7 A, W Seawright et al. (1988)
NAHAS del pl3 (s) 1.8 A, G, R, W
NYMI NYX3.1 del pl2pl5.1 >20 A, R Seawright et al. (1988)
PAZO PAX 1 del pl3 (s) 1.1 A, G van Heyningen et al. (1990)
PKPA del pl3pl4.1 Pt Hanson et al. (1994a)
RIWAR RIX 1 del pl2pl4.3 -17 A, R Seawright et al. (1988)
SATO SAX 3.10 del pl2pl3 7 A, R, W Seawright et al. (1988)
SGL inv pl3 (s) A Fukushima et al. (1993)
SIMO SMXB1/SMX B2 t(4; Il)(q22;pl3) A Seawright et al. (1988)
SOA SOA54 del pl3pl4 12 A, R, W Couillin et al. (1989)
T-ALL 8511-36/8511-7 t(ll; 14)(pl3;qll) T-ALL Boehm et al. (1991)
TRAKE TRX del pl3pl4.2 8 A, G, R van Heyningen and Jones (1993)
Note. The table shows the relationship between cell lines and corresponding somatic cell hybrids where the abnormal chromosome 11
has been segregated from the normal homologue. The karyotype of the chromosome 11 abnormality, defined in molecular terms, is indicated
together with an estimate of the physical size of deletions, (s) indicates submicroscopic deletion, defined solely by molecular analysis. The
phenotype of the individual from which the line was derived is described. A, aniridia. G, genitourinary anomalies such as cryptorchidism,
hypospadias. P, Potters facies, urethral and ureteral atresia, and cryptorchidism. Pt, Peter's anomaly. R, Mental retardation. W, Wilms
tumor.
0.233) is on both KAZHM chromosomes 11, whereas
ICRFcl07H11148/DllS2134 (FLpter = 0.236), 55 kb
more distal, is deleted. ylOHD6 (230 kb) hybridizes
to D11S377 and HD27 but not to probes for WT1 or
D11S324. The 32 cosmids shown in Fig. 1, which consti¬
tute the largest cosmid contig on our map, were isolated
with ylOHD6 and probes therein.
Interval VII
This 100-kb interval, defined by the DG85 and SATO
breakpoints (Fig. 3), has been intensively studied since
it is the location of the aniridia gene PAX6 (Ton et
al., 1991) contained on cFAT5 (FLpter = 0.244) and
cFATIO (Fantes et al., 1992). Cosmids ICRFcl07G-
11117, A1280, and A11151 hybridize to the 3' untrans¬
lated region of PAX6. y589 (310 kb), y591 (260 kb), and
y593 (420 kb) were isolated with PAX6-specific primers
(Fantes et al., 1995). y593 and y589 extend both centro-
meric and telomeric of PAX6 and extend past D11S323
and D11S324. Restriction analysis and FISH suggest
that D11S324 is more proximal than D11S323. y591
does not contain the full 5' end of PAX6 and extends
3' of the gene. A cosmid library made from this YAC
and screening of a chromosome 11 library with y591
produced a series of overlapping cosmids covering over
150 kb of DNA from intervals VI, VII, and VIII (Fig.
3). ICRFcl07C1170 (D11S2135) and 591/21 show FISH
signal only on a proportion of SATO deletion chromo¬
somes and at reduced intensity, suggesting that these
cosmids cross the distal SATO breakpoint.
Interval VIII
This interval lies between the SATO deletion
breakpoint and the translocation breakpoint in SIMO
(Table 1). This interval also contains the distal inver¬
sion breakpoint of SGL. All of the PAX6-derived YACs
cross the SATO breakpoint, and y591 and y593, but
not y589, cross over the SIMO translocation. This is
thought to be 100-200 kb from the Notl site at the
proximal end of the 1400-kb fragment harboring PAX6
and is marked by the D11S310 locus (Gessler et al.,
1989a; Fantes et al., 1995). FISH showed that the most
distal members of the overlapping cosmids extending
from PAX6 to ICRFcl07F02121 (DllS2136/FLpter =
0.241) and c591/8 are still proximal to the SIMO
breakpoint.
Interval IX
This interval (of approximately 200 kb) is bounded
by the SIMO translocation and by the distal deletion
breakpoints of PAZO and NAHAS. Some of the cosmids
isolated with y591 are in this interval (Fig. 3). One of
them, c591/l (FLpter = 0.242), distal to the endpoints
of y589 and y593, was used to identify a polymorphic
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I C65-6/6 D11S102 0.256 0.247-0.264
II N/A
III cl-11-458 D11S672 pl3 0.251 0.241-0.260
IV clCRFcl07G1135 D11S417 pl3 0.239 0.230-0.248
V cB2.1 WT1 pl3 0.247 0.243-0.251
VI C20/18 D11S377 0.233 0.226-0.239
clCRFcl07H11148 D11S2134 pl3 0.236 0.228-0.244
cp60 D11S324 0.241 0.233-0.248
VII FAT5 PAX6 pl3 0.244 0.237-0.250
VIII clCRFcl07F02121 D11S2136 pl3 0.241 0.232-0.250
IX 591/1 D11S995 pl3 0.242 0.235-0.249
X clCRFcl07E08153 D11S112 pl3/pl4 0.236 0.231-0.242
XI ZF17 D11S781 pl3/pl4 0.232 0.225-0.239
XII clCRFcl07E0499 FSHB pl3/pl4 0.219 0.214-0.225
clCRFcl07C08160 D11S151 pl4.1 0.223 0.219-0.228
clCRFcl07G09161 KCNA4 pl4.1 0.222 0.210-0.234
XIII clCRFcl07D1029 BDNF pl4.1 0.199 0.189-0.209
XIV N/A
XV cl-11-585 D11S739 0.187 0.176-0.198
clCRFcl07F1238 HVBS1 pl4.2 0.194 0.185-0.203
clCRFcl07G0122 D11S904 0.193 0.185-0.200
XVI N/A
XVII cl-11-536 D11S713 0.178 0.171-0.185
XVIII N/A
XIX cSRL-7d7 D11S865 pl4.3 0.172 0.167-0.177
clCRFcl07C0720 D11S1359 0.158 0.152-0.165
clCRFcl07BO798 D11S2137 pl5.1 0.152 0.145-0.158
clCRFcl07E0873 D11S1308 0.135 0.129-0.140
cl-11-514 D11S592 pl5.1 0.151 0.146-0.156
cl-11-443 D11S664 0.149 0.144-0.154
clCRFcl07H0229 D11S21 pl5.1 0.147 0.142-0.152
XX cl-11-242 D11S455 0.135 0.130-0.140
cl-11-564 D11S729 0.125 0.119-0.130
cHSAA SAA pl5.1 0.141 0.133-0.149
clCRFcl07E048 TPH 0.125 0.119-0.132
Note. For each interval of the map, the mean FLpter measurement and 95% confidence limits (Lichter et aL, 1990) of at least one
representative cosmid are shown. N/A, none available.
CA„ repeat D11S995 that maps 3 cM proximal to
D11S929 (interval XV), but 2 cM distal of D11S914, a
marker that physically is in interval X (Browne et al.,
1993). Hence there is a discrepancy between the physi¬
cal and the genetic mapping data. The position of
D11S995 on the radiation hybrid map (James et al.,
1994) confirms its physical location proximal of
D11S914.
Interval X
This interval is defined by the distal deletion
breakpoints of PAZO/NAHAS and DG85/ALSTA, an
FIG. 2. FISH analyses. Biotinylated y23Ic9 DNA, detected with avidin-FITC (green) on propidium iodide-stained chromosomes (red)
from ALSTA (a) and NAHAS (b). Chromosomes 11 are indicated by the arrows. Note the complete absence of FISH signal on one of the
ALSTA homologues and the reduced FISH signal detectable on the deletion chromosome from NAHAS. (c) Interphase FISH with interval
X cosmids cICRFcl07A04160/DHS317 (green) and cICRFcl07E08153/DHS112 (red), together with the more distal interval XI ZF17/
D11S781 (orange). G1 nuclei were counterstained with DAPI. Seventy-eight percent of the nuclei produce the preferred order cen-DHS317-
D11S112-D11S781. In 12% of cases the order of D11S317 and D11S112 was inverted, and D11S781 and D11S112 were inverted in 9% of
nuclei, (d) FISH with biotinylated (red) cICRFcl07E08153 (D11S112) from interval X on long DAPI-stained metaphase chromosomes with
a late replication (G) banding pattern detected with anti-BrdU-FITC (green). The signal lies at the distal boundary of llpl3, with no
visible overlap into llpl4.1, which would appear as yellow signal, (e) FISH with cICRFcl07D1029 (BDNF) from interval XIII. Detection
was as in (d), but the FISH signal appears orange/yellow as it overlaps the late-replicating (green) band llpl4.1. (f) FISH with
cICRFcl07F1238 (HVBS1) from interval XV. Two chromosome 11 homologues are shown, and in each case signal is in the middle of llpl4
in the small subband llpl4.2. (g) FISH with cSRL7d7 (D11S865) from interval XIX. Signal (orange/yellow) is in distal llpl4 in subband
pl4.3. (h) FISH with ICRFcl07B0798 (D11S2137) from interval XIX, but distal of D11S865 (Fig. 5). Signal is in llpl5.1 between the late-
replicating pl4.3 and pl5.2 subbands. Note that the red color of the signal indicates that this cosmid is in an early-replicating compartment.




estimated distance of 500 kb. Genetically, the order
of microsatellite markers in this interval is cen—
D11S914-1 cM-D11S1322/D11S1312 (Gyapay et
al., 1994). The radiation hybrid map suggests the
order cen-DllS1322-DHS914, with D11S1322
close to D11S995 (James et al., 1994). In addition,
this interval contains D11S317, linked to D11S914
h
by overlapping cosmids (Fig. 3) and D11S112.
Multicolor interphase FISH, with reference cosmids
both centromeric and telomeric of this group, con¬
firms the physical order cen-FAT5 —D11S317 —
DllS112-ZF17-tel (Fig. 2c). Analysis of these
markers in YACs that encompass the region (Fig.
3) confirms this order. yICRFy900F09162 (850 kb),
 






























































































































FIG. 3. Integrated map of Ilpl3-pl4 boundary (intervals VII to XII). As in Fig. 1. The position of chromosome breakpoints, cosmids,
and YACs are shown relative to the physical map of the chromosome (scale bar = 100 kb). The double-headed arrow of SGL denotes an
inversion breakpoint. In addition to the radiation hybrid distances (cR), the relationship of the physical map to genetic distances (cM) is
also shown. Note the inversion of D11S914 and D11S1322 in the genetic map vs the physical and radiation hybrid maps.
isolated with D11S112, is nonchimeric and contains
all of the interval X markers. The proximal end of
this YAC extends approximately 250 kb into the
400-kb SacII fragment containing PAX6, since it hy¬
bridizes to cF02121, but it does not extend as far as
the PAX6 gene (Fig. 3). Distally it includes
D11S1312 from interval XI, and FISH suggests that
a small part of yF09162 crosses the ALSTA
breakpoint, implying that this breakpoint is approx¬
imately half way through the 1000-kb SacII frag¬
ment (Fig. 3). Two apparently nonchimeric YACs
isolated with D11S1322 were analyzed in detail.
y890dll (1000 kb) contains PAX6 and D11S1312.
y891a7 (1500 kb) also includes the PAX6 gene; how¬
ever, its maximal distal extent is D11S914. Of the
DllS914-containing YACs, y938a8 (1400 kb) ex¬
tends from cF02121 (interval VIII) to D11S16 in in¬
terval XI, but not as far as FSHB. y940hll (1600 kb)
has a similar distal extent but also includes PAX6.
y953a4 (>1600 kb) extends from PAX6 up to inter¬
val XII to include the KCNA4 gene (Gessler et al.,
1992) (Fig. 3). FISH on high-resolution banded chro¬
mosomes places D11S112 at the distal extent of, but
still within, llpl3, although on some chromosomes
hybridization was to the pl3/pl4 boundary (Fig. 2d).
Interval XI
The DG85/ALSTA and MARGA breakpoints flank
this interval (approximately 500 kb in size). At the
proximal end it contains the microsatellite D11S1312.
More distally it contains the contiguous D11S16 and
D11S781 (FLpter = 0.232) loci (Heding et al., 1992)
that are present on YAC yD49H10 (650 kb). D11S315
(Gessler and Bruns, 1989) is located between the DG85
breakpoint and D11S16. yD49H10 contains the geno¬
mic CpG island immediately distal of D11S16 and ex¬
tends 420 kb past this to include the FSHB gene, but
not the more telomeric locus D11S47. These latter
markers are on a 3100-kb genomic Notl fragment
whose large size and apparent dearth of CpG islands
is indicative of G band DNA (Gessler and Bruns, 1989;
Craig and Bickmore, 1994). This, together with the cy¬
togenetic location of D11S112 (Fig. 2d), suggests that
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the interval X-XI region spans the transition from
llpl3 to pl4.1.
Interval XII
This interval is flanked by the distal deletion
breakpoints of MARGA and ANNA/KAZHM. Toward
its proximal end is the FSHB gene (FLpter = 0.219),
~400 kb distal of the telomeric NotI site of Fig. 3.
ylOCBlO (100 kb) and y25GH6 (300 kb) contain both
FSHB and D11S47. y25GH6 was shown to be nonchim-
eric by FISH. D11S151 maps distal to D11S47 and out¬
side the extent ofy25GH6. The potassium channel gene
KCNA4 has also been mapped 200-600 kb distal of
FSHB (Gessler et al., 1992). Cosmids were isolated
from the FSHB and KCNA4 genes, D11S47, D11S151,
and y25GH6 (Fig. 3). D11S151 and KCNA4 cosmids
have FLpter values of 0.223 and 0.222, respectively
(Table 2), and appear to map to llpl4.1. Interphase
FISH gives the order cen-DHSl51-KCNA4-tel and
suggests that D11S151 and KCNA4 are closely ap¬
posed. Although FISH with the KCNA4 cosmid cICRF-
cl07GO9161 shows signal in the appropriate place on
the lip, there is also signal on llq. While Gessler et
al. (1992) place KCNA4 in lip 14, Philipson et al. (1993)
have mapped it to Ilql3-ql4, and Wymore et al.
(1994) also detect some FISH signal in this location.
These results suggest that there may be two related
copies of this gene, one on each arm of chromosome 11.
FSHB, D11S47, D11S151, and KCNA4, but not mark¬
ers from interval XIII, are all contained on the large
YAC y953a4 (Fig. 3).
Interval XIII
This interval is bounded by the ANNA/KAZHM and
GOTY deletion breakpoints and is further subdivided
by the PKPA deletion and the LEV insertional translo¬
cation. The only microsatellite in this interval is
D11S1324 (Couillin et al., 1994). James et al. (1994)
place D11S1324 proximal to KCNA4, but our map indi¬
cates that it is more distal. D11S1324 containing YACs
y815d9 (1000 kb) and y934e5 (1100 kb) both include
D11S1031 (Smith et al., 1993), but the relative order of
these loci is not known. y934e5 (1100 kb) also contains
KCNA4, and since KCNA4 is maximally 1000 kb distal
of the NotI site centromeric of FSHB (Gessler and
Bruns, 1989; Gessler et al., 1992), D11S1324 and
D11S1031 must also be on that 3100-kb NotI fragment.
y934e5 is nonchimeric and shows some FISH signal on
KAZHM and ANNA deletion chromosomes as expected
from the markers that it contains. No signal could be
seen on the PKPA deletion. In LEV, all of the signal
was on the part of 11 translocated to chromosome 14
(Fig. 4).
The only interval XIII marker on the telomeric side
of PKPA/LEV is the BDNF gene (Hanson et al., 1992).
A cosmid containing BDNF (cICRFcl07D1029) has a
mean FLpter value of 0.199 (Table 2) and an llpl4.1
location on high-resolution banded chromosomes (Fig.
2e). y886hl2 (800 kb) and y739e5 (1300 kb) contain
BDNF as well as markers from more distal intervals.
Neither of these YACs contains the more proximal in¬
terval XIII markers; thus, there is a gap in our physical
map at this point. y886hl2 is nonchimeric by FISH and
apparently absent from the GOTY deletion chromo¬
some, even though HSPCAL3 is present on the YAC.
Also, despite the fact that y886hl2 contains the BDNF
gene itself, only a small amount of FISH signal was
apparent on the LEV deletion chromosome, most of the
signal being at the insertion point on chromosome 14.
Interval XIV
The boundaries of this interval are the breakpoints
of GOTY and SOA, and the only marker within it is
HSPCAL3 (an HSP90a gene). The location of
HSPCAL3 here is consistent with that described by
James et al. (1994), distal of BDNF. If there really is
a functional HSP90a gene here (Ozawa et al., 1992),
its location in the mouse genome will be of interest
since, at present, BDNF is the most distal human gene
in this region that is in a conserved synteny group with
mouse chromosome 2 (Hanson et al., 1992). The next
known human genes telomeric of BDNF are LDHA/C,
in llpl5.1 (interval XX) and in a conserved synteny
group with mouse chromosome 7 (Sellar et al., 1994b).
HSPCAL3 is present on y886hl2 (800 kb) and y739e5
(1300 kb) and hence within 800 kb of BDNF.
Interval XV
This interval is defined by the SOA and TRAKE
breakpoints. y739e5, y691b6, y694hl0, y822h6, and
y959a6 all contain both of the microsatellites (D11S904
and D11S1750) found in this interval. But only
D11S1750 is on y938h8 (1100 kb), a YAC that extends
into interval XVI, suggesting that D11S1750 is distal
of D11S904 (Fig. 4). HVBS1 (van Heyningen and Jones,
1993) is also in this interval, and FISH with an HVBS1
cosmid (FLpter value of 0.194) places it in the middle
of llpl4, in subband pl4.2 (Fig. 2f). D11S904 cosmids
were isolated (FLpter = 0.193) and shown to be distal,
but close to, HVBS1 by interphase FISH. This is consis¬
tent with the order described by Glaser et al. (1994),
which places HVBS1 and D11S904 below and above,
respectively, the breakpoint in the WAGR deletion MJ.
FISH analysis puts D11S739 (Tanagami et al., 1992)
between HVBS1 and BDNF but distal of the GOTY
deletion. However, the FLpter value of 0.187 suggests
a localization distal of HVBS1 (there is also a minor
signal component from this cosmid at a more centro¬
meric location).
Interval XVI
This interval is defined by the distal deletion
breakpoints in TRAKE and J1-23/BAN68. Its physical
size must be <2400 kb since HVBS1 and D11S17, from
the flanking intervals, have been physically mapped to
a common genomic BssHII fragment of this size and a
3500-kb Mlul fragment (Gessler and Bruns, 1989). The
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FIG. 4. Integrated map of Ilpl4.1-pl4.2 (intervals XIII to XVII). As in Figs. 1 and 2, comparisons among the cytogenetic, physical,
genetic, and radiation hybrid maps are shown. Note that here the scale bar = 200 kb. The slash lines on the physical map indicate region
of unknown size that are not bridged either by the genomic PFGE map or by YACs or cosmids. In this region of the genome the physical
map is not well established, and the only restriction sites indicated are the BssHII sites (B) detected by Gessler and Bruns (1989).
interval contains the microsatellites D11S930 and
D11S929. D11S930 is the more proximal of the two
genetically (Gyapay et al., 1994) and physically since
it is present on y739e5 (Fig. 4). D11S992 is distal of
these two microsatellites since it is absent from
y938h8.
Interval XVII
This interval is bounded by the distal breakpoints of
J1-23/BAN68 and Jl-24 and corresponds to interval H
ofTanagami et al. (1992). It contains only two markers,
D11S17 and D11S713. D11S17 is in the distal 300 kb
of the 2400-kb BssHII fragment described by Gessler
and Bruns (1989) that also carries HVBS1. The FLpter
value ofcl-11-536 (D11S713) is 0.178, close to the value
for D11S865, from interval XIX, but its position on the
genomic long-range restriction map is not known.
Interval XVIII
This interval between the Jl-24 and RIWAR/BID7
breakpoints contains only one marker, the microsatel-
lite D11S915. While y773d6 (850 kb) and y859a2 link
D11S915 with more distal markers, there are no YACs
that bridge the gap between D11S992 and D11S915
(Figs. 4 and 5).
Interval XIX
Bounded on the proximal side by the RIWAR/BID7
breaks and on the distal side by the NYMI breakpoint,
this appears to be a very large interval physically since
the spread of FLpter values for markers mapping here
is 0.172-0.147, i.e., 2.5% of the total chromosome
length, and the genetic distance encompassed is 4 cM.
The most proximal group of markers in the interval
is D11S865, D11S1359, and D11S1106, since they are
retained on the DllS915-containing YACs y773d6 and
y859a2 (Fig. 5). D11S865 (FLpter value of 0.172) is
cytogenetically in llpl4.3 (Fig. 2g) and telomeric of,
but close to, D11S1359 by interphase FISH. This group
of markers is probably tightly linked since they cose-
gregate in four other YACs—y950c6, y964f4, y922b3,
and y956c8 (1000 kb). These last two clones also con¬
tain the more distal marker D11S947E. If this EST
represents a functional gene it will be the most centro¬
mere-proximal known gene in the Ilpl4.3-pl5.1 re¬
gion, and it will be interesting to establish whether it
is in a conserved synteny group with mouse chromo¬
some 7 (Sellar et al., 1994b).
The next microsatellite in this interval is D11S928,
2 cM distal of D1 IS 1359. There are no YACs that
bridge the gap between D11S947E and D11S928 (Fig.
5), suggesting that there is quite a large gap in the
physical map here. D11S928 is physically linked to the
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FIG. 5. Map of Ilpl4.3-pl5.1 (intervals XVIII-XX). As in Fig. 4, only limited restriction mapping data are available in this region of
the genome, and physical scale is determined mainly by the sizes of YAC clones.
next most distal genetic marker (D1 IS 1308) by y910h9.
Two other YACs (y730c8 and y855bl) closely link
D11S1308 with D11S1034. y910h9 also contains the
D11S592/DUS 1062 loci and the EST D11S1944E. Two
cosmids from this region produce FLpter values of
0.152 (ICRFcl07BO798/DllS2137) and 0.151 (cl-11-
514/D11S592). D11S2137 is centromeric of D11S1308
by FISH and has an apparent llpl5.1 localization on
banded chromosomes (Fig. 2h). Hence the transition
from llpl4.3 to pl5.1 lies in the gap of interval XIX
between D11S865 and D11S2137. D11S592 is telo-
meric of D11S2137 by interphase FISH.
In radiation hybrids (James et al., 1994) D11S1944E
cosegregates with D1 IS 1308 and the more distal
D11S899. However, none of the YACs analyzed here
included D11S899. Other interval XIX markers not
present on the YACs described here are D11S664 and
D11S21. D11S21 maps toward the distal end of the
interval by metaphase FISH (FLpter = 0.147) and in¬
terphase FISH versus D11S865, D11S2137, and
D11S592. D11S664 produces an FLpter value of 0.149,
suggesting a location just centromeric of D11S21.
D11S1075, D11S1019, and D11S1043 also map within
this interval by PCR analysis but could not be ordered
with respect to the other markers. It is possible that
they map to the gap between D11S865 and D11S928/
D11S2137 where there are no YACs and few cosmids
with appropriate FLpter values (0.172—0.152). Addi¬
tionally, the radiation hybrid map (James et al., 1994)
suggests that D11S1755 and D11S1759 map between
D11S1359 and D11S928.
Interval XX
This interval is defined at its centromeric end by the
NYMI deletion breakpoint and distally by Jl-8.
D11S455 maps proximal of the SAA cluster genetically
(Sellar et al., 1994a) and by radiation hybrid mapping
(James et al., 1994); however, it produces an FLpter
value (0.135) that may indicate a more distal localiza¬
tion, since the FLpter value for a cosmid at the SAA
locus is 0.141 (Sellar et al., 1994a). However, within
this interval FLpter values seemed to be a poor guide
to physical order. On the radiation hybrid map markers
located between D11S455 and the SAA genes include
D11S1310, D11S921, D11S1890, and D11S729. Both
D11S921 and D11S1890 lie outside the extent of the
most centromeric YAC (y22AD12) at the LDH-
MYOD1 cluster (Fig. 5). However, D11S1310 is present
on yl4FH12 and y25ED3, suggesting that it is close
to D11S18. The orientation and order of genes and
markers around the SAA cluster, cen—LDHA/C-SAA1,
-2, -4, -3-TPH-DllS18-KCNCl-MYODl-tel, ascer¬
tained by YAC analysis and interphase FISH (Sellar
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et al., 1994b), is at odds with that established by James
et al. (1994), who place MYOD1 proximal to both
LDHA/C and SAA. An EST D11S955E is close to, but
proximal of, the LDH genes since it is absent from
y22AD12.
The gene GTF2H1, encoding the 62-kDa subunit of
TFIIH, has been mapped to Ilpl4-pl5.1 by FISH
(Heng et al., 1994). PCR analysis on hybrid DNAs and
YACs places this gene in interval XX between the
LDHA/C and the SAA genes, since it is retained only
on YAC y22AD12 (Fig. 5). Furthermore, restriction
mapping of y22AD12 places GTF2H1 within 50 kb of
LDHA.
Distal but close to SAA3 is the TPH gene, separated
from the KCNC1 and MYOD1 genes by D11S18. The
close physical linkage of KCNC1 and MYOD1 is consis¬
tent with their tight genetic and physical linkage (Wy-
more et al., 1994; Sellar et al., 1994b) on mouse chromo¬
some 7. D11S1888 maps close to MYOD1 on y25ED3
and y20FB3 and is absent from Jl-8, as is the microsa-
tellite D11S902, which James et al. (1994) map with
KCNC1, SAA, and D11S1888. However, D11S902 is
more distal since it is not contained on the YACs
analyzed here. On the radiation hybrid map, the
next group of markers is D11S419, D11S1901, and
D11S574, but these are all distal of Jl-8. Between
NYMI and Jl-8 there are two other markers, D1 IS 1032
and D11S1059, that are not present on any of the YACs
of this interval and so have not been precisely ordered.
Recently Keats et al. (1994) demonstrated tight link¬
age of Usher syndrome type I to the region of llpl5.1
between D11S899 and the microsatellite D11S861 (Litt
et al., 1993), that is just distal of D11S902. In addition,
linkage disequilibrium was observed in the D11S921-
D11S419 region. Hence, this well mapped and gene-
rich region of llpl5.1 is also the location of the gene(s)
for type I Usher syndrome. Some of the genes already
mapped to this critical region (Fig. 5) might be consid¬
ered candidate genes for this disorder. Familial hyper-
insulinism similarly shows linkage to D11S921, with
linkage disequilibrium to specific D11S921/D11S491
haplotypes in some families (Glaser et al., 1994).
DISCUSSION
Complete maps of regions of the genome are im¬
portant for a variety of studies. As well as being essen¬
tial for localizing genes, particularly those associated
with inherited disorders, they allow the functional and
structural organization of the genome to be studied.
This map of Ilpl3-pl5.1 illustrates some of these fea¬
tures. First, it highlights the unequal distribution of
genes between different chromosomal regions. In the
most proximal 3.5 Mb of the map (intervals I through
X) that defines the distal part of llpl3, there are 4
known genes, 2 of which are involved in the WAGR
syndrome, 1 EST, and many as-yet uncharacterized
CpG islands. There are also 4 known genes and 1 EST
(D11S947E) but very few CpG islands in the region of
at least 9 Mb that extends from intervals XI into XIX
and covers llpl4. Of these, only the EST is in the part
of pl4 considered to be the most extreme G band-like
DNA (Francke, 1994). Finally, in the proximal 3-4 Mb
part of lip 15.1 that is included in this map (the distal
part of interval XIX through interval XX), there are
10 known genes and 2 ESTs, and limited restriction
mapping in the LDH-MYOD1 region indicates the re¬
appearance of closely spaced CpG islands (Sellar et al.,
1994b). This region is probably the location of the
gene(s) involved in type I Usher syndrome (Keats et
al., 1994) and familial hyperinsulinism (Glaser et al.,
1994). The uneven disposition ofCpG islands and genes
between R and G band regions is consistent with other
studies and parallels changes in replication timing and
chromosome structure (Craig and Bickmore, 1994). The
nature of the DNA that constitutes the small R band
llpl4.2, which includes the DNA around the HVBS1
locus (Fig. 2D, is not apparent.
Second, the map spans the region where there has
been a break in the conserved synteny relationship
with the mouse genome—from chromosome 2 to 7. The
most distally located human gene mapped here and
known to be on mouse chromosome 2 is BDNF. The
most centromere proximal genes on the map in a con¬
served synteny group with mouse chromosome 7 are
LDHA/C. The intervening region corresponds to the
most gene-barren region of our map. In this regard,
the map location of the HSP90a gene and the genes
corresponding to ESTs D11S947E, D11S1944E, and
D11S955E in the mouse genome will be interesting to
establish. From the map position of GTF2H1 (Fig. 5),
we predict that this gene will be located on mouse chro¬
mosome 7.
The primary level of the map has utilized chromo¬
some breakpoints, principally from individuals with
full or partial WAGR syndrome. These breakpoints
have been remarkably unambiguous at dividing up the
region and provide absolute mapping landmarks since
they have definitive ends (at the single basepair level),
whereas most other map objects have length that may
be imprecisely defined. We have found no evidence for
complex rearrangements accompanying chromosome
deletions. Because of the interest in the biology of the
WT1 and PAX6 genes, there is a concentration of
breakpoints flanking these genes. Aside from this,
there is no evidence for clustering ofbreakpoints, which
might indicate regions especially susceptible to break¬
age. Of the WAGR-associated breakpoints analyzed
here and by Gessler et al. (1989b), none has been found
with a more distal extent than that of NYMI, sug¬
gesting that haplosufficiency for a gene(s) distal of this
point may not be viable. Table 2 indicates the estimated
size of the deletions and the corresponding clinical phe-
notype of the individual from whom the cell line was
derived. There is no simple relationship between the
size of deletion and the degree of mental retardation
reported. NAHAS, whose deletion ends just telomeric
of the PAX6 gene, has quite severe mental retardation,
while ALSTA, who has a deletion similar in extent, but
larger, than that of NAHAS, has little or no retarda-
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tion. In general, mental retardation is seen in individu¬
als with deletions that extend more distally up the
chromosome. There is either none or mild mental retar¬
dation reported in MARGA, ANNA, PKPA, and
KAZHM. Telomeric of these breakpoints, GOTY, SOA,
TRAKE, BAN, RIWAR, and NYMI all exhibit more se¬
vere retardation. Thus, a gene(s) predisposing to men¬
tal retardation may reside within, or telomeric to, inter¬
val XIII the location of the BDNF gene.
Our integration of microsatellite markers into the
physical map has allowed us to analyze the relation¬
ship between physical and genetic distance. As well as
mapping these STSs to intervals and YACs, we have
used the primers to isolate cosmids by hybridization to
gridded filters. In general, the cosmids isolated have
mapped into the predicted physical position by FISH.
However, in a few cases the cosmids mapped to a differ¬
ent location from the corresponding microsatellite; for
example, cICRFcl07B0798/T)llS2137 (interval XIX)
was isolated by hybridization to oligonucleotides used
to amplify the D11S929 locus (interval XV). In these
cases, the cosmid DNA failed to amplify with the appro¬
priate PCR primers, and we assume that there has
been fortuitous hybridization of one of the two oligonu¬
cleotides to a sequence contained in these cosmids. An
added bonus of integrating the microsatellite markers
into the physical map is that it provides a rapid method
for analyzing the extent of new uncharacterized chro¬
mosome deletions. Markers contained within the de¬
leted region will demark a region of apparent homozy¬
gosity (in fact hemizygosity) in the haplotype and pin¬
point regions where FISH analysis will be most useful
for refining the deletion endpoints.
There are a few discrepancies between the physical
and the genetic maps. For example, on the genetic map
D11S914 is reported as being 1 cM proximal of
D11S1322 (Gyapay et al., 1994). The physical map de¬
scribed here and the radiation map (James et al., 1994)
place D11S914 more distally between D11S1322 and
D11S1312. There is also some variation in the relation¬
ship between genetic and physical distances across the
map, from the 1 cM per Mb of DNA rule of thumb.
For example, 1 cM separates D11S1324 from D11S930,
markers that we estimate are >2 Mb apart (Fig. 4),
and no recombination appears to separate D11S921
and D11S902, which physically (Fig. 5) seem far apart.
By contrast, 3 cM separates D11S915 and D11S1359,
markers that are both contained within a YAC
(y773d6) of only 850 kb in size (Fig. 5), although we
cannot exclude the possibility that there is an internal
deletion within this YAC. Overall, the entire llpl4
region, as defined here by high-resolution FISH at
metaphase (Fig. 2), spans 10 cM of recombination.
These genetic distances represent the sex-averaged
map. Throughout the region there appears to be more
recombination on the female than on the male map.
For example, between D11S929 and D11S861 there are
24.9 cM of female recombination but only 14.5 cM of
male recombination (Litt et al., 1993). The biological
significance of these differences is not understood.
There is remarkably good agreement between the
map described here and that based on radiation hybrid
mapping (James et al., 1994). There are a few excep¬
tions; for example, the order of KCNA4 and D11S1324
reported by James et al. (1994) is inverted relative to
that presented here. The more proximal location of
KCNA4 is supported by both our placement of it in
interval XII through breakpoint analysis and its inclu¬
sion within y953a4 (Fig. 3). D11S1324 is in the more
distal interval XIII, but <1100 kb from KCNA4 (the
size ofy934e5). Similarly, we have mapped D11S947E
distal of D11S865 and D11S1359 (Fig. 5). The largest
discrepancy is in the placing of MYOD1, which James
et al. (1994) map proximal of the LDH genes and
D11S921. Both the mapping of MYOD1 on y20FB3 and
y25ED3 and the order of genes on mouse chromosome
7 (Sellar et al., 1994b) support a localization of MYOD1
telomeric to KCNC1 (Fig. 5). The distance separating
markers on the radiation hybrid map of chromosome
11 (James et al., 1994) is expressed as centiRays (cR)
at an X-ray dose of 9000 rads. Over the extent of the
map here, 1 cR corresponds to a mean separation of 41
kb. If this relationship is relatively constant over the
entire chromosome arm, it would extrapolate to a
length of 50 Mb for the short arm of chromosome 11.
Most of the YAC clones that we have examined by
FISH, from the ICI, ICRF, and CEPH libraries, have
been nonchimeric. However, this is not a fair represen¬
tation of the proportion of chimeric clones in these li¬
braries. We isolated and mapped markers in many
more clones than is shown on this map. Any clones that
contained only one marker from the map, or whose
pattern of marker retention seemed aberrant, were
eliminated from further study. Hence, the YACs finally
analyzed on metaphase chromosomes were a selected
group.
Finally, we have measured the FLpter values for cos¬
mids from each interval where available (Table 2). The
spread of these values (0.256-0.125) shows that our
map covers 13% of the chromosome length. Cosmids
located in lip 13 produce measurements down to values
of 0.23. Ilpl4.1 ranges from 0.22 to 0.20, cosmids in
the small subband 14.2 produce FLpter values of ap¬
proximately 0.20—0.19, and llpl4.3 probably extends
from values of 0.18 to 0.17. Cosmids located in llpl5.1
produce values of <0.155. There are two large gaps in
the FLpter values. We have no cosmids that produce
measurements between 0.187 and 0.178 (in llpl4.3)
or between 0.158 and 0.152 (at the Ilpl4.3-pl5.1
boundary). No YACs bridge these gaps either. In gen¬
eral, FLpter values are a guide to regional localization,
but they are not dependable for ascertaining order of
closely apposed markers. Interphase FISH with care¬
fully chosen reference cosmids above and below the
region of interest has been a reliable technique for this
purpose.
We hope that this map, particularly the breakpoints
and YACs, will continue to be used as a framework to
map any new markers and genes in this part of lip
rapidly and with a high level of resolution and confi-
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dence. The pinpointing of the position of the GTF2H1
gene and the region implicated in both type I Usher
syndrome (Keats et al., 1994) and familial hyperinsu-
linism (Glaser et al., 1994) on this map illustrates this
well. The cloned DNA resources are available to other
groups who have an interest in this region of human
chromosome 11.
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Expression of the Wilms* Tumor Gene WTI in Human
Malignant Mesothelioma Cell Lines and Relationship to
Platelet-Derived Growth Factor A and Insulin-Like Growth
Factor 2 Expression
Anthonie W. Langerak, Kathleen A. Williamson, Kiyoshi Miyagawa, Anne Hagemeijer, Marjan A. Versnel, and
Nicholas D. Hastie
Departments of Immunology (A.W.L., M.A.V.) and Cell Biology and Genetics (A.H.), Erasmus University, Rotterdam, The
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Mutations in the WTI tumor suppressor gene are known to contribute to the development of Wilms' tumor (WT) and
associated gonadal abnormalities. WTI is expressed principally in the fetal kidney, developing gonads, and spleen and also in the
mesothelium, which lines the coelomic cavities. These tissues develop from mesenchymal components that have subsequently
become epithelialized, and it has therefore been proposed that WTI may play a role in this transition of cell types. To test the
possible involvement of this gene in malignant mesothelioma, we have first studied its expression in a panel of human normal
and malignant mesothelial cell lines. WTI mRNA expression levels varied greatly between the cell lines and no specific
chromosomal aberration on lip, which could be related to the variation in WTI expression in these cell lines, was observed.
Furthermore, no gross deletions, rearrangements, or functionally inactivating point mutations in the WTI coding region were
identified. All four WTI splice variants were observed at similar levels in these cell lines. The WTI gene encodes a zinc-finger
transcription factor and the four protein isoforms are each believed to act as transcriptional repressors of certain growth factor
genes. Lack of WTI expression is thus predicted to result in growth stimulation of tumor cells. Binding of one particular WTI
isoform construct to the insulin-like growth factor 2 (IGF2) and platelet-derived growth factor A (PDGFA) gene promoters has
been demonstrated to result in repression of these genes in transient transfection studies. Analysis of IGF2 and PDGFA mRNA
expression levels compared with WTI mRNA expression levels failed to demonstrate an inverse correlation in the mesothelial
cell lines, which endogenously express these genes. Finally, the putative role of WTI in the transition of cell types was
investigated. No obvious correlation between WTI expression levels and cell morphology of the malignant mesothelial cell lines
was evident from this study. Moreover, no change in WTI expression was observed in normal mesothelial cells which were,
by alteration of culture conditions, manipulated to switch from the mesenchymal to epithelial morphology. Genes Chromosom
Cancer 12:87-96 (1995). © 1995 Wiley-Liss, Inc.
INTRODUCTION
Human malignant mesothelioma is a mesoder-
mallv derived tumor, which is most often found in
the pleura. Its incidence is strongly associated with
exposure to asbestos fibers (Wagner et ah, 1960).
Malignant mesothelioma is thought to develop
from mesothelial cells, which form a specialized
epithelium lining the coelomic cavities. Malignant
mesothelioma was mentioned as one of the so-
called second risk tumors in a few patients who had
recovered from the pediatric kidney malignancy
Wilms' tumor (WT) (Austin et ah, 1986). This sug¬
gests the possible involvement of a common un¬
derlying genetic event in both malignancies.
The WTI locus on 11 p 13 has been identified as
one of the chromosomal loci contributing to WT
development (Call et ah, 1990; Gessler et ah,
1990). WTI encodes a protein with DNA-binding
capacity, elicited by four zinc-fingers at the C-ter-
minal part, which bind to DNA sequences with the
core consensus element 5'-GCGGGGGCG-3'
(Rauscher et ah, 1990). T he WTI protein addi¬
tionally possesses transcriptional regulatory activity
exerted through the N-terminal glutamine- and
proline-rich regions of the protein (Madden et ah,
1991). Alternative splicing of the WTI gene at two
independent splice sites has been shown to result
in the formation of four WTI splice variants. In
tumor tissue and fetal kidney there appears to be
little variation in the ratios of these four isoforms
(Haber et ah, 1991; Brenner et ah, 1992).
In transient transfection studies insulin-like
growth factor 2 (IGF2), platelet-derived growth
factor A (PDGFA), and IGF/R have recently been
identified as potential target genes for transcrip¬
tional repression by WTI (Drummond et ah, 1992;
Gashler et ah, 1992; Wang et ah, 1992; Werner et
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al., 1993). These and other results have led to the
hypothesis that the WT1 protein functions as a
tumor suppressor gene product and that reduction
or absence of WTl expression that is seen in a pro¬
portion ofWTs results in an increased expression
of certain growth factor genes. However, transac-
tivation by WTl was also seen, depending on the
presence of wild-type TP53 protein, the number of
WTl binding sites in the promoter of the target
gene, or the presence of specific missense muta¬
tions within the transregulatory domain (Ma¬
heswaran et al., 1993; Park et al., 1993a; Wang et
al., 1993).
Despite these results on repression or activation
of certain target genes by WTl in transient assays,
not much is known about the physiological role of
WTl. It has been suggested that WTl may play a
role in mediating the shift from a mesenchymal to
an epithelial phenotype, as it is expressed in the
nephrogenic epithelia, in epithelial cells of the go¬
nads, and in the mesothelium (Pritchard-Jones et
al., 1990; Pelletier et al., 1991; Armstrong et al.,
1992). These are all cells of mesodermal origin that
have undergone the transition to the epithelial
morphology. However, other cell types undergoing
this transition do not express the WTl gene,
whereas in embryonic mice distinct regions in the
spinal cord and brain that are of ectodermal origin
display 1177 expression, arguing that there should
be other tissue-specific roles for WTl in develop¬
ment (Armstrong et al., 1992). Recently, a crucial
role for 11*77 in early urogenital development was
established in a model system by gene targeting in
murine embryonic stem cells (Kreidberg et al.,
1993). In these W77 knockout mice a failure in
kidney development was observed. This was sug¬
gested to be caused by inhibition of inductive
events leading to the formation of the metanephric
kidney. In addition, abnormal development of the
gonads, the heart, and the mesothelium was seen
as well. Abnormalities in the phenotypes of these
tissues support the idea of a role for WTl in the
mesenchymal to epithelial cell transition.
As WTl expression was observed in the human
and mouse developing and mature mesothelium
(Pritchard-Jones et al., 1990; Armstrong et al.,
1992; Park et al., 1993b), we were interested to
determine whether WTl was also expressed in its
malignant counterpart as this might indicate a pos¬
sible involvement of WTl in the pathogenesis of
malignant mesothelioma. In this respect, it is
worth noting that cytogenetic analysis of 40 con¬
firmed mesothelioma patients revealed karyotypic
abnormalities in several chromosomes, but only in
a few cases were rearrangements in lip seen
(Hagemeijer et al., 1990). We have studied expres¬
sion of the WTl gene in a panel of human normal
and malignant mesothelial cell lines. Expression
levels were related to the morphology (epithelial or
mesenchymal) of the mesothelioma cells in vitro in
order to clarify putative WTl involvement in cell
type transition. We also investigated whether gross
alterations or point mutations could be detected at
the H/77 locus, whether the four different alterna¬
tively spliced mRNAs were present in the various
normal and malignant mesothelial cell lines, and
whether the 1E77 mRNA expression level in these
cell lines could be correlated to their PDGFA and
IGF2 mRNA levels.
MATERIALS AND METHODS
Cell Lines, Growth Conditions, Characterization,
and Cytogenetics
Experiments were performed using the human
pleural malignant mesothelioma cell lines Mero-
14, -25, -41, -48b, -48c, -72, -82, -83, -84, -95, -96,
and -123 (Versnel et al., 1988, 1989) and the nor¬
mal mesothelial cell lines NM-1, -4, -5, -9, and -12
(Versnel et al., 1991, 1993; Langerak et al., in
preparation). All mesothelioma cell lines were de¬
rived from mesothelioma patients whose diagnosis
was based on routine cytology, which was histolog¬
ically or ultrastructuraily confirmed. Cell lines were
routinely cultured as described earlier (Versnel et
al., 1988, 1989). Cytogenetic analysis was per¬
formed as described earlier (Versnel et al., 1988).
Northern and Southern Blot Analyses and Probes
Northern blotting and Southern blotting were
performed as described in Langerak et al. (1992).
For hybridization of Northern and Southern blots
a 1.8 kb EtwRI WTl fragment derived from the
WT33 cDNA was used (Call et al., 1990). North¬
ern blots were rehybridized with the 1.3 kb AVoRl
PDGFA fragment (Betsholtz et al., 1986), the 1.4
kb Xba\-Fco\lA IGF2 fragment from pIGF-II (Jan-
sen et al., 1985), and the 0.7 kb EcoR\-Pst\ glyc-
eraldehvde-3-phosphate dehydrogenase (GAPDH)
fragment (Benham et al., 1984). Rehvbridizatjon of
Southern blots was performed with a 1.3 kb Pstl
1GF2 fragment from pKT218 (Jansen et al., 1985).
Reverse Transcription (RT) Polymerase Chain
Reaction (PCR) Analysis
RT of RNA, isolated from the normal and ma¬
lignant mesothelial cell lines, and subsequent PCR
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analysis were performed as described previously
(Langerak et al., 1992). For amplification of the
alternative splice variants the sense primers B297
(5'-TTG GTC GAC ATG ACC TGG AAT
CAG/C ATG-3'; located in WTI exon 4) or B439
(5'-CTT GTA CGG TCG GCA TCT-3'; located
in WTI exon 7) were used in combination with
antisense primer B298 (5'-TGC AAG CTT GAG
CTG AAG GGT/C TTC/T TC-3'; located in WTI
exon 10) (Little et ah, 1992). Thirty-five cycles of
1 min at 94°C, 1 min at 50°C, and 2 min at 72°C
were performed. PCR products were analyzed on
10% polyacrylamide gels using PstI digested
lambda DNA as a marker.
Point Mutation Analysis
Chemical cleavage mismatch analysis using hy-
droxylamine and osmium tetroxide (HOT analysis)
was performed as described (Cotton et ah, 1988;
Rrosser et al., 1990). Templates were generated by
RT-nested PCR (Hanson et al., 1993), a strategy
required due to low yields of available RNA. The
WTI region encoding the transregulatory domain
was amplified with outer primers D609 sense (5'-
CAA ACA GGA GCC GAG CTG G-3') and D610
antisense (5'-GCA CAT CCT GAA TGC CTC
TG-3') followed by inner primers 1 and 3 (Brown
et ah, 1992). The DNA-binding domain was sim¬
ilarly amplified with primers C582 sense (5'-AAA
TGG ACA GAA GGG CAG AGC-3') and C583
antisense (5'-TTG GAA GTT GGA TGA AGA
AGA TC-3') followed by primers 2 and 4 (Brown et
ah, 1992). PCR conditions for D609/D610 are step
1, 1 minat94°C; step 2, 30 cycles of 30 sec at 94°C,
1 min at 54°C, and 1-2 min at 72°C; step 3, 10 min
at 72°C. Touchdown PCR conditions for C582/
C583 are step 1, 1 min at 94°C; step 2, 30 cycles of
30 sec at 92°C, 1 min at 62-57°C and 2 min at
72°C; step 3, 10 min at 72°C. Samples generating
cleaved fragments after HO T analysis were sub¬
jected to a second round of RT-nested PCR. Then
the products were purified by (3-Agarase 1 (New
England Biolabs, Beverly, MA) and subsequently
sequenced directly as described (Winship, 1989).
RESULTS
WTI mRNA Expression in Mesothelial Cell Lines
Expression of the 1F77 gene was studied on
Northern blots, containing total RNA from normal
and malignant mesothelial cell lines of human ori¬
gin. WTI mRNA was found to be consistently ex¬
pressed in the normal mesothelial cell lines, al¬
though some variation in the levels was observed
(Fig. 1). The WI'J expression level was highly vari¬
able in the investigated panel of malignant me¬
sothelioma cell lines, ranging from very high
(Mero-25) to nearly or totally undetectable (Mero-
41, -72, -82, -83, -95) (Fig. 1). WTI mRNA expres¬
sion levels were normalized over GAPDH mRNA
levels after quantification by densitometric analysis
(see Table 1).
Based on their histology, malignant mesothelio¬
mas can be classified as epithelial, mesenchymal,
or biphasic. The morphology of the cultured me¬
sothelioma cells in monolayer can differ from the
primary tumor-tissue morphology (see Table 1). In
an attempt to clarify the possible role of the IF77
gene product in the transition of certain cell types
from a mesenchymal toward an epithelial morphol¬
ogy, WTI mRNA expression levels in the cultured
mesothelioma cells were therefore related to the
epithelial or fibrous/mesenchymal morphology of
these cell lines. Although the highest WTI mRNA
level was observed in Mero-25, which has the
clearest epithelial phenotype, IF77 expression was
not completely confined to cell lines showing an
epithelial or biphasic morphology. WTI mRNA was
undetectable in several cell lines with a fibrous
morphology like Mero-41 and -72, but other fi¬
brous cell lines did express WTI (Mero-83, -96, and
-123). In cell lines that were predominantly either
fibrous or epithelial, expression was observed oc¬
casionally (Mero-48b, -48c, and -84), and in others
not at all (Mero-82 and -95).
The putative involvement of IF77 in the mesen¬
chymal to epithelial shift was further studied using
a second approach. It has been described that cul¬
tured normal mesothelial cells can adopt a mesen¬
chymal (fibrous) or epithelial cell shape depending
on the presence or absence of epidermal growth
factor (EGF) in the culture medium, respectively
(Connell and Rheinwald, 1983). Therefore, the
WTI mRNA level was determined in two normal
mesothelial cell lines under these conditions. The
two cell lines showed a more epithelial morphology
upon removal of EGF [and hydrocortisone (HC)]
for 3 days from the standard culture medium. How¬
ever, analysis of RNA isolated from the mesothelial
cells cultured for 72 hr in the absence of EGF and
HG did not result in a significantly altered level of
IF77 mRNA (data not shown).
Alternative Splicing Pattern of WTI
The WTI gene is capable of producing four dif¬
ferent mRNAs by alternative splicing, which can
lead to the insertion of an extra 51 bp (exon 5)
upstream of the zinc-fingers and/or 9 bp (giving rise




Figure I. Northern blot analysis with 25 p.g total RNA from normal (NM) and malignant (Mero)
mesothelial cell lines. RNA was hybridized to WTI and GAPDH probes.
TABLE I. Summary of Cytogenetics, Tumor Cell Line Morphology, and WTI Expression in Normal (NM) and Malignant (Mero)
Mesothelial Cell Lines
Modal No' of copies of chromosome (arm) WTI gene WTI
Tumor chromo- WTI structure WTI mRNA
cell line some Normal Rearranged Total mRNA (Southern gene (alternative









































































I xinv (I I )(p I I q 14)
I x mar (t(9p; I I p))
I x mar (t(9p; I I p))
I x mar (t(9p; I I p))
2 x add I I p 15
t(6p + ; I lp~),
+ der(l I )t(l I ;22)
2X 6q — (6p::I Ip)
2 0.81 NDb ND 4 isoforms
2 0.28 ND ND ND
2 O.I 2 ND ND ND
2 0.26 Normal ND ND
2 0.08 ND ND ND
3(4) 0.04 Normal Not found 4 isoforms
4(5) 9.59 Normal Not found 4 isoforms
4 0 Normal ND NAC
4 ND Normal Not found ND
4 0.43 Normal Neutral ND
transition
4 0.12 Normal Neutral 4 isoforms
transition
2 0 Normal ND NA
2 0 Normal ND NA
4 0.04 Normal Not found 4 isoforms
2 0.14 Normal Not found 4 isoforms
3 0 Normal ND NA ■
4(5) 0.26 Normal Not found 4 isoforms
3 0.91 ND Neutral 4 isoforms
aShown over GAPDH expression levels as determined by densitometry.
bND, not determined.
CNA, not applicable.
dln parentheses: minority of the cells.
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Figure 2. RT PCR analysis with RNA from malignant mesothelioma
cell lines Mero-14 and -25 and normal mesothelial cell line NM-1. WT33
cDNA was used as a positive control ( + ). In the left lane Pstl digested
lambda DNA was loaded as a size marker.
to the KTS amino acid sequence) between zinc-
fingers 3 and 4 (Haber et al., 1991; Brenner et al.,
1992). In this study the occurrence of these distinct
WTI mRNA forms was examined in clonal cell
lines. For this purpose cDNA derived from total
RNA of several of the WTI expressing malignant
mesothelioma cell lines (see Table 1) was used in a
PCR reaction with primers B297 and B298. Four
distinct DNA fragments of 499 bp ( — 51 bp,
— KTS), 508 bp ( — 51 bp, +KTS), 550 bp ( + 51
bp, —KTS), and 559 bp ( + 51 bp, +KTS), result¬
ing from two independent alternative splicing
events, were observed (see Table 1). All four splice
variants were detected in normal mesothelial cell
line NM-1 as well. In Figure 2 these results are
shown for the cell lines NM-1 and Mero-14 and
-25. Using primers B439 and B298 in all cell lines
studied, two distinct fragments of 320 and 329 bp
were seen, which result from the 9 bp alternative
splicing event (data not shown). In our 11"/'/
mRNA expressing mesothelial cell lines, little vari¬
ation was observed in the ratios of the four iso-
forms.
Cytogenetic and Genomic Data Concerning WTI
The variation in WTI mRNA expression that we
observed in the malignant mesothelioma cell lines
could be due to differences in the whole or partial
copy number of chromosome arm lip. Further¬
more, rearrangements of the WTI gene or gene
amplification may also be involved. To see if any of
these possibilities may explain the variation in WTI
mRNA level in the mesothelioma cell lines, cyto¬
genetic analysis and Southern blotting were em¬
ployed.
Cytogenetic data from the mesothelioma cell
lines were obtained by studying metaphase cells.
Analysis of chromosome arm lip in the mesothe¬
lioma cell lines did not point toward any specific
chromosomal aberration that could be correlated to
their WTI mRNA expression level (see Table 1).
The aneuploidy of chromosome arm lip and the
WTI mRNA level in the various cell lines did not
correlate either (Table 1).
To see if gene rearrangements had occurred in
those cell lines showing very low or undetectable
amounts of WTI mRNA, the IF/7 gene was stud¬
ied by Southern blot analysis. No differences were
found in the EcoWl and /////dill digestion pattern
of DNA from any of the malignant mesothelioma
cell lines studied compared to the pattern of nor¬
mal mesothelial cell line NM-9 (Fig. 3; also data
not shown). This indicated that gross rearrange¬
ments in the IF/'/ gene had not occurred in the
malignant mesothelial cell lines and thus were not
likely to be the cause of undetectable WTI mRNA
expression in Mero-41, -72, -82, and -95.
By Southern blot analysis we did detect small
differences in the intensity of the bands for the
various cell lines, which could in principle be
caused by variation in the number of WTI gene
copies. However, rehybridization of the filter con¬
taining HindUl digested DNA with a probe for the
IGF2 gene, which is also located on the short arm
of chromosome 11 at 11 p 15, showed similar differ¬
ences in intensity (data not shown). This meant
that the WTI gene was not differentially amplified
in any of the cell lines. Variation in the number of
copies of 1 lp may exist but in general the number
of chromosome arm lip largely balanced the total
chromosome number, which suggests that the
small differences in intensity are most probably
due to small variations in loading of the gels.
WTI Point Mutation Analysis
The HOT technique of chemical cleavage mis¬
match analysis was used to scan virtually the entire
coding sequence of WTI for point mutations. Only
the first 256 bp in exon 1 were omitted from this
analysis, as the high GC content of this region ren¬
ders it refractory to PGR amplification. The malig-
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Figure 3. Southern blot analysis of the WTI gene. EcoRI-digested genomic DNA from a normal (NM-9)
and several malignant (Mero) mesothelial cell lines was hybridized to a 32P-labeled WTI probe.
nant mesothelioma cell lines Mero-14, -48b, -48c,
-83, -84, and -123 were scanned for point mutations
in exons 1-6, encoding the transregulatorv do¬
main, and Mero-14, -25, -48b, -48c, -83, -84, -96,
and -123 were scanned for point mutations in exons
6-10, encoding the DNA-binding domain. The
only base change detected was a novel C to T
transition at nucleotide 768 (numbered according
to Gessler et ah, 1990). This exon 1 transition is a
third base change and does not cause amino acid
substitution (AAC/T encodes an Asn residue). It is
present in the homo/hemizygous state in Mero-
48b, -48c, and -123 (data not shown). No function¬
ally inactivating nonsense or missense mutations
were detected (see Table 1).
WT/ mRNA Expression in Relation to PDGFA and
IGF2 mRNA Expression
In transient transfection assays WTI was re¬
ported to repress the expression of PDGFA and
IGF2 promoter constructs. In order to see if the
described variation in WTI mRNA expression in
our mesothelial cell lines could be related to dif¬
ferent levels of PDGFA and IGF2 mRNA, blots
were rehybridized with probes for these two genes
and analyzed by densitometry. The results from a
representative experiment are presented as arbi¬
trary units over GAPDH signals in Table 2.
TABLE 2. mRNA Expression Levels of WTI, PDGFA,
and IGF2 (6.0 and 4.8 kb) in Normal (NM) and
Malignant (Mero) Mesothelial Cell Lines, Expressed as
Relative Densitometric Units Over GAPDH
Expression Levels
IGF2
Cell line3 WTI PDGFAb 6.0 kb 4.8 kb
NM-1 0.81 0.65 0 0.53
NM-4 0.28 0.78 0.19 0.66
NM-9 0.26 NDC 0 0.23
NM-5 0.12 0.62 0.12 0.48
NM-1 2 0.08 ND 0.23 0.48
Mero-25 9.59 1.42 0 0.73
Mero-123 0.91 2.22 0 0.68
Mero-48b 0.43 1.41 0.28 1.02
Mero-96 0.26 3.74 1.72 6.55
Mero-84 0.14 1.55 0.02 0.23
Mero-48c 0.12 0.50 0.29 0.43
Mero-14 0.04 0.04 0 0.16
Mero-83 0.04 1.18 0.01 0.18
Mero-82 0 1.02 0 0.21
Mero-72 0 2.59 2.37 . 2.62
Mero-95 0 2.62 0.07 0.44
Mero-41 0 7.54 0.24 1.27
aCell lines are arranged in descending order of WTI expression
levels.
bTotaled levels of 2.8, 2.3, and 1.9 kb PDGhA transcripts.
CND, not determined.
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Figure 4. Relative densitometric units of the mRNA expression lev¬
els of WTI, PDCFA (2.8, 2.3, and 1.9 kb totaled) and IGF2 (6.0 kb) in
normal (NM) and malignant (Mero) mesothelial cell lines. The data are
presented on a log scale. See Table 2 for the exact densitometric units.
Cell lines are arranged in descending order of WTI expression levels.
Expression levels that were not determined are indicated by an asterisk.
The densitometric data of the three PDGFA
transcripts (2.8, 2.3, and 1.9 kb) were totaled, as
expression of these three messengers is under con¬
trol of a single promoter region that contains con¬
sensus WTI binding sequences. Our mesothe¬
lioma cell lines demonstrated variation in PDGFA
mRNA expression, but in general the expression
level was higher than in normal mesothelial cell
lines. In a few cell lines lacking WTI mRNA, a
relatively high PDGFA expression was seen (Mero-
41, -72, and -95), but other cell lines which did
show WTI mRNA expression, i.e., Mero-96 and
-123, displayed a similar PDGFA mRNA level. Cell
line Mero-25, in which a very high 1177 mRNA
level was seen, showed an intermediate level of
PDGFA expression. This intermediate PDGFA
level, however, was also seen in cell lines with a
lower WTI mRNA content than Mero-25. So, as is
also illustrated in Figure 4, no clear correlation was
observed between WTI and PDGFA expression in
our mesothelial cell lines.
The 6.0 kb IGF2 transcript is the product of the
fetal P3 promoter, which contains WTI consensus
binding sequences, whereas the 4.8 kb transcript is
expressed from a different fetal promoter (P4), also
containing consensus WTI binding sequences.
Relatively high WTI mRNA levels were found in
cell lines which do not express the 6.0 kb IGF2
transcript (NM-1 and Mero-25 and -123), but other
cell lines which demonstrated very low or no 6.0 kb
IGF2 mRNA expression, like NM-9 and Mero-14,
-82, -83, -84, and -95, showed a low or intermedi¬
ate 11-77 mRNA level. In the panel of normal and
mesothelial cell lines no clear relationship, recip¬
rocal or otherwise, was observed between the 6.0
kb IGF2 and 1177 mRNA level (see also Fig. 4).
The same holds true for the expression level of the
4.8 kb IGF2 transcript.
DISCUSSION
The WT gene IF/7 on 11 p 13 acquired its name,
as it was originally mapped by deletion analysis of
individuals with the WAGR (WT, aniridia, geni¬
tourinary abnormalities, and mental retardation)
syndrome (Riccardi et ah, 1978; van Hevningen et
ah, 1985). The demonstration of constitutional and
somatic intragenic deletions in the WTI gene in a
proportion of WT patients has confirmed that it is
a WT predisposition gene (Haber et ah, 1990;
Cowelletah, 1991; Huff et ah, 1991; Brown et ah,
1992; Tadokoro et ah, 1992). In expression studies
in human and mouse embryos the WTI gene was
reported to be involved in normal genitourinary
development (Pritchard-Jones et ah, 1990; Arm¬
strong et ah, 1992). Because of this limited spatial
expression, WTI was suggested to be important in
tissues which are of mesodermal origin and which
undergo a mesenchymal to epithelial transition, al¬
though expression was also observed in the spinal
cord and developing brain. In situ hybridization
studies showed high IF/7 expression in the devel¬
oping Sertoli cells of the testis and granulosa cells
of the ovary (Pelletier et ah, 1991; Armstrong et
ah, 1992).
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As the studies by Pritchard-Jones et al. (1990)
and Armstrong et al. (1992) had revealed the ex¬
pression of WTl in the mesothelium, a specialized
epithelium lining the coelomic cavities, an obvious
question was if expression of the 1177 gene could
be detected in mesothelioma as well. This
prompted us to study WTl expression in a panel of
normal and malignant human mesothelial cell
lines. Northern blot analysis revealed the consis¬
tent presence of 1F77 mRNA in cultured normal
mesothelial cells, whereas in cultured malignant
mesothelioma cells a variation in the expression
level, ranging from very high to undetectable, was
seen. We also found that the apparent lack of WT1
mRNA expression in several of these cell lines
probably was not due to deletions or rearrange¬
ments in the 1177 gene. Furthermore, differences
in the WTl mRNA expression level between dif¬
ferent cell lines could not be accounted for by gene
amplification or a specific chromosomal aberration
on lip. Differences in transcription initiation or
RNA degradation thus most probably account for
the variation in 11 77 mRNA expression between
the malignant mesothelioma cell lines.
When the 1177-expressing malignant mesothe¬
lioma cell lines were analyzed for more subtle al¬
terations within the coding sequence, no nonsense
or missense mutations were found. Three lines
contained an identical C to T transition in the se¬
quence encoding the transregulatorv domain.
However, this mutation is predicted to be silent at
the protein level and therefore most likely patho¬
logically insignificant. Recently a homozygous
WT1 missense mutation that alters a Ser residue in
the transregulatory domain has been reported for a
single case of human peritoneal mesothelioma
(Park et al., 1993b). This case is unusual in that the
mesothelioma was not asbestos-related and was not
actually a malignant tumor but rather a develop¬
mental abnormality. In addition, Park et al.
(1993b) found no 1177 mutations in 32 specimens
of asbestos-related mesothelioma. For our samples
it is possible that there are undetected 1177 muta¬
tions in the 5'-most coding region of exon 1 or in
the untranslated or intronic sequences of the gene.
The cell lines that fail to show 1177 mRNA expres¬
sion may additionally have mutations in the pro¬
moter/control regions of the gene. Differences in
the occurrence of the four alternative splicing prod¬
ucts, which may result in altered specificity for
DNA binding sites (Bickmore et al., 1992), were
not observed in our panel of WTl expressing me¬
sothelial cell lines. All four variants were identified
earlier in WT tissue and in fetal kidney (Haber et
al., 1991; Brenner et al., 1992). In these tissues the
transcripts with the 9 bp alternative splice were
suggested to be slightly predominant, whereas in
our mesothelial cell lines we did not observe this,
but a more quantitative assay has to be performed
to unravel this putative discrepancy.
Taken together, the results obtained in our
panel of malignant mesothelioma cell lines thus
suggest that the WTl gene may play a role as a
tumor suppressor gene in a minority of human me¬
sotheliomas. To test this in vivo, we started to
study primary tumor material from mesothelioma
patients. WTl mRNA expression could be ob¬
served in cells from pleural effusions of four ma¬
lignant mesothelioma patients (data not shown).
These pleural fluids, however, contain tumor cells
in combination with several other cell types, which
means that this expression cannot be simply attrib¬
uted to tumor cells, even though pleural fluids
with a high percentage of mesothelioma cells were
analyzed. Immunofluorescence staining with WT1
antibodies and/or RNA in situ hybridization would
be more informative in this respect.
As the ovarian surface epithelium is considered
to be a specialized mesothelium (Papadaki and
Beilbv, 1971) and several ovarian carcinoma cell
lines demonstrated a comparable PDGFA and
PDGFB mRNA expression to malignant mesothe¬
lioma cell lines (V'ersnel et ah, 1994), we also an¬
alyzed several ovarian carcinoma cell lines for 11 77
mRNA expression. Comparable to the expression
in malignant mesothelioma cell lines, in three of
six serous ovarian carcinoma cell lines studied,
IF77 expression was observed on Northern blots,
while in the other three no 117/ transcripts were
detected (data not shown). Furthermore, we re¬
cently observed a very high WTl mRNA level in
cell line COV-434, which is derived from a granu¬
losa tumor of the ovary and thus is not of mesothe¬
lial origin (data not shown). This expression is in
agreement with the observed WTl expression in
ovarian granulosa cells (Armstrong et al., 1992).
Malignant mesotheliomas are classified as epi¬
thelial, fibrous/mesenchvmal, or biphasic. We
therefore tried to correlate the morphology of the
various malignant mesothelioma cell lines with
their WTl mRNA expression level. Although the
highest expression was found in cell line Mero-25,
which has the most obvious epithelial morphology,
no clear correlation could be observed between
1177 mRNA expression and morphology. More¬
over, normal mesothelial cells which can switch in
morphology depending on the addition or removal
of EGF from the culture medium, showed similar
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WTI expression levels independent of the pheno-
type of the cells. So in these mesothelial cell lines
no evidence could be found for a WTI role in the
mesenchymal to epithelial transition of cells. How¬
ever, this may be different in vivo. Therefore, me¬
sothelioma tissue from patients with a biphasic
(i.e., with mesenchymal and epithelial elements)
malignant mesothelioma should be studied with
WTI antibodies or by RNA in situ hybridization to
investigate the putative correlation between WTI
expression and morphology in vivo.
It has been shown in transient transfection assays
that WTI represses PDGFA (Gashler et al., 1992;
Wang et ah, 1992) and IGF2 mRNA expression
(Drummond et ah, 1992). Our panel of normal and
malignant mesothelial cell lines showing variation
in WTI mRNA expression was analyzed for PDGFA
and IGF2 mRNA levels as well. No clear relation¬
ship, reciprocal or otherwise, between WTI and
PDGFA or IGF2 expression was found in our cell
lines. The fact that no clear correlation could be
found in cells endogenously expressing these
genes is in contrast with the repression seen in the
forementioned studies. However, these data were
obtained in cells upon transfection of 1177 expres¬
sion constructs together with PDGFA and IGF2 re¬
porter constructs, whereas we looked at endoge¬
nous expression levels in a panel of cell lines. It
may also be that in our mesothelial cell lines other
factors are also involved in regulating PDGFA and
IGF2 mRNA expression, thereby masking regula¬
tion by WTI. Alternatively, mutations in the WTI
binding sequences in the promoters of these genes
may prohibit WTI regulation. It remains to be de¬
termined, whether WTI can regulate expression of
these genes in a physiological context. Evidence
for this may come from stable transfection of the
WTI gene in Mero cell lines lacking 1177 or knock¬
ing out the endogenous 1177 gene expression in
WTI expressing cell lines.
In summary, we have shown that 1177 mRNA is
consistently expressed in normal mesothelial cell
lines and that there is no expression in a minority of
malignant mesothelioma cell lines. No indications
were found for chromosomal aberrations, dele¬
tions, rearrangements, functionally inactivating
missense or nonsense mutations, or an aberrant al¬
ternative splicing pattern in these cell lines. The
1T77 expression level does not seem to correlate
with the mesenchymal or epithelial morphology of
the various cell lines in vitro. No inverse correla¬
tion between 1177 and PDGFA or IGF2 mRNA
expression was seen in our panel of mesothelial cell
lines, which endogenously express these genes.
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ABSTRACT
The triad of nephropathy, partial gonadal dysgenesis and
Wilms' tumour (WT) is known as Denys — Drash syndrome
(DDS). The WT predisposition gene WT1, which plays a vital
role in both genital and renal development, is known to be
mutated in DDS patients. The WT1 mutations in these
patients are constitutional point mutations clustered in the
zinc finger (ZF) encoding exons, particularly the exons
encoding ZF2 and ZF3. The predicted functional alteration
in WT1 is thought to underlie DDS aetiology either by
abolishing binding of the WT1 ZF domain to its normal target
DNA binding site(s), perhaps blocking the binding of the wild
type WT1 present (dominant negative mutation), and/or by
conferring the ability to recognise novel but inappropriate
DNA binding sites (dominant mutation). We report here on
the analysis of WT1 in a further five cases of DDS. In each
case a constitutional point mutation was detected in either
ZF2 or ZF3. Three of these mutations are novel, with two
affecting the conserved histidine and cysteine residues crucial
for ZF tertiary structure. The protein product of the third
is predicted to lack ZF2, 3 and 4 as a result of a chain
termination mutation, and is presumably incapable of binding
DNA. However since the DDS phenotype is only elicited by
mutations which lead to loss or alteration of ZF function
(presumably DNA binding) while the N-terminal upstream
portion of the gene remains intact, we suggest that a dominant
negative mechanism is at work here.
INTRODUCTION
Denys-Drash syndrome (DDS) comprises the triad of partial
gonadal dysgenesis, congenital or infantile nephropathy and
Wilms' tumour (WT) (1,2). Patients usually present within the
first three years of life (3) with renal failure or nephrotic
syndrome, often accompanied by hypertension. The unifying
feature of DDS is the nephropathy. This always results from
glomerular abnormalities, usually focal or diffuse mesangial
sclerosis, with such abnormalities histologically visible in the
podocyte layer of glomerular cells (4). When possible, renal
function is restored by renal transplantation at an early age,
however patients with a slower onset of renal failure or those
possessing original renal tissue show a high incidence of WT.
Even after nephrectomy patients are still at risk for gonado-
blastoma.
An association between these anomalies was first made in an
individual with XX/XY mosaicism (1), and subsequently in two
XY individuals with ambiguous external genitalia (2). XY patients
can also present with apparently normal female genitalia, but
ambiguous or dysplastic internal genitalia, sometimes including
persistent Mullerian duct derivatives (uterus, fallopian tubes). XX
patients are usually phenotypically normal females; however, in
common with the XY patients, the internal genitalia are often
found to be dysplastic. Indeed, it is now appreciated that XX
individuals with normal external genitalia presenting with this
form of nephropathy are at risk for WT and should be considered
DDS patients (5). In general, the term DDS has been expanded
to include patients with this form of nephropathy together with
either gonadal dysgenesis, WT or both (3).
Genital anomalies are also present in association with WT in
>50% of boys with WAGR syndrome (WT, aniridia,
genitourinary abnormalities and mental retardation) (6, 7). These
patients carry a constitutional heterozygous deletion of the short
arm of chromosome 11, involving band llpl3. The WT
predisposition gene WT1 was isolated from this region by
positional cloning (8,9). WT1 is thought to act as a transcriptional
regulator, a function consistent with the presence of four zinc
finger (ZF) motifs at the C-terminus and an N-terminal proline-
glutamine-rich transregulatory domain (8, 9). Intragenic
microdeletions (10, 11, 12, 13) and point mutations (14) within
WT1 have been found in both sporadic and hereditary WT. The
predicted pleiotropic effect of constitutional WT1 mutation on
genital development (15, 16) is now strongly supported by
observations of WT1 mutations in two WT patients with
cryptorchidism and hypospadias (12). It has recently been shown
that DDS patients carry constitutional point mutations within the
ZF region of one copy of the WT1 gene (17, 18, 19), with 20
such cases reported to date. The two central ZFs, ZF2 and ZF3,
are the most commonly affected. Point mutations were reported
in patients with WT and/or gonadoblastoma, and also in patients
* To whom correspondence should be addressed
+ Present address: Centre for Molecular Biology and Biotechnology, University of Queensland, St Lucia, 4072 Brisbane, Australia
260 Human Molecular Genetics, Vol. 2, No. 3
with nephropathy and gonadal dysgenesis but no tumour. In every
case where tumour material was examined, generation of
homozygosity for the constitutional mutation was observed. Thus
it seems that a constitutional missense mutation within the ZF
region of one copy of WT1 is sufficient to produce gonadal
dysgenesis, glomerulopathy and predisposition to WT or
gonadoblastoma, whereas the total deletion of one copy of WT1,
as is the case in WAGR, (lip del) (16) or a more N-terminal
mutation (11,12) often produces much milder genital anomalies
(usually cryptorchidism and/or hypospadias) and no overt kidney
disease. It was therefore proposed that the WT1 mutations present
in DDS patients produce a mutant protein with altered function
which overrides the normal activity of the remaining wild type
WT1 allele. With rare exception (see later) all of the reported
mutations in DDS affect amino acids predicted to play a critical
role in ZF DNA-binding (20).
In this study we have investigated a further five DDS patients
for WT1 mutations. While all patients showed the characteristic
renal pathology, the severity of the genital anomalies and presence
of a tumour varied. All patients were found to have constitutional
WT1 point mutations. However, the observation of a chain
termination mutation in ZF2 in one case, as well as a case
reported by Baird et al (19), suggests that the DDS phenotype
can arise from loss as well as alteration of specific WT1 DNA




The clinical features of the 5 patients investigated in this study
are summarised in Table 1A. The severity of the DDS phenotype
is variable within this series. Patient 4 exhibited a number of
other anomalies not generally associated with DDS but not
uncommon in other WT patients. Horseshoe kidney has
previously been reported in association with sporadic WT (21)
and in Beckwith—Wiedemann syndrome (BWS) patients (22).
Craniostenosis and prominent metopic suture have also been
observed in BWS patients (22). The respiratory distress and
hypertension seen in patients 3 and 5 has been observed in other
DDS patients (2, 3). While two of the patients did not present
with WT, this may have been due to the early advent of death
Table 1A. Summary of the clinical features of the patients described in this paper.
PATIENT 1 2 3 4 5











WILMS TUMOR NIL BILATERAL UNILATERAL BILATERAL NIL
'DRASH*
NEPHROPATHY

























LOCATION ZF3 ZF3 ZF2 ZF2 ZF2
POINT
MUTATION
C to T G to A T to G C to T C to G
AMINO ACID
CHANGE
394R toW 396D toN 360C to G 362R to STOP 373H to Q
CONSTITUTIONAL
MUTATION
HETEROZYGOUS HETEROZYGOUS HETEROZYGOUS HETEROZYGOUS HETEROZYGOUS
TUMOUR
MUTATION N/A HOMOZYGOUS HETEROZYGOUS HOMOZYGOUS N/A
Shaded boxes represent previously undescribed mutations or phenomena. The mutation in patient 1 was independently detected by Baird et al (19).
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or transplantation. Tumour material was analysed from all three
patients who developed WT.
Diagnostic chorionic villus sampling (CVS) was requested,
primarily because of advanced maternal age, in a subsequent
pregnancy from the parents of patient 1. At the time this
individual went for CVS the pregnancy was found to be non
viable, and an evacuation of the products of conception was
performed. These were used for karyotyping and WT1 mutation
analysis.
WT1 mutation analysis
Chemical mismatch cleavage (Fig. 1) or direct sequence analysis
(Figs. 2 and 3) of PCR products from these DDS patients
identified the presence of WTl point mutations in ZF2 or ZF3
in all individuals (Table IB). These mutations were
constitutionally heterozygous (that in patient 4 was also verified
by Mark Patterson, Cambridge, personal communication).
Homozygosity for the mutant WTl allele was seen in the tumours
from patients 2 and 4. The tumour from patient 3 retained both
alleles (Fig. 3B). The mutations seen in patients 1 and 2 (Figs.
1 and 2) have previously been reported in other DDS patients
(17, 18, 19) however the other three patients show novel DDS
point mutations. Analysis of constitutional DNA from the only
available parents, those of patients 1,3, and 5, revealed no WTl
mutations (Figs. 2B, 3A and B), establishing that the mutations
in these DDS patients arose de novo.
Predicted consequence of detected mutations
The close similarity in the amino acid sequence of EGR1 and
WTl led to the suggestion, and in vitro demonstration (23, 24),
that they bind similar DNA targets. NMR and X-ray
crystallography analysis of EGR1 DNA-binding (20) has revealed
the key amino acids which confer binding specificity. The ZF3
mutations of 394arginine (R) to tryptophan (W) in patient 1, and
of 396aspartic acid (D) to asparagine (N) in patient 2 (Fig. 2A)
both affect DNA-binding by disrupting hydrogen bonding with
a critical guanine residue in the target site. Such mutations may
be expected, in principle, to act in a dominant or dominant
negative fashion.
The mutations found in patients 3 and 5 affect either a
conserved cysteine (C) or histidine (H) residue (Fig. 3A) both
of which are zinc chelating amino acids crucial to the tertiary
structure of this class of zinc finger proteins (C2.H2 zinc finger
motif). Therefore, as the mutant ZF2 in these patients will not
fold into a finger structure, DNA-binding will be compromised
and may be prevented. Even if such conformational changes do
not de-stabilise the surrounding ZFs, the specificity and affinity
of WT1-DNA binding is likely to be affected.
The point mutation in patient 4 converts ZF2 362R into a
termination codon (Fig. 3A) which will completely eliminate
binding of mutant WTl protein to DNA by truncating the last
three ZFs. This patient provides strong evidence that the DDS
mutations do not act in a dominant fashion as this effectively
fingerless form of WTl is extremely unlikely to have a novel
DNA binding specificity.
Screening for common DDS mutations using restriction
enzymes
As the number of DDS patients analysed for WTl mutations
increases, certain mutations appear to predominate. The most
common WTl mutation, representing 12 of the 20 mutations now
detected (17, 18, 19), is a C to T transition in ZF3 resulting in
an R to W amino acid change. A number of other mutations have
also been reported more than once. We therefore set out to
establish rapid restriction-based assays for these prevalent DDS
WTl mutations, eliminating the need for more labour intensive
methods of mutational analysis in such cases.
The two most common DDS mutations, 394R to W (60%) and
396D to N (15%), abolish an RsrII site in ZF3 (Fig. 2A),
preventing the digestion of a 349bp PCR fragment (primers
798/801) into 167bp and 182bp fragments (Fig. 2B). As the
presence of a mutation in this case prevents digestion, patient












Figure 1. Chemical mismatch cleavage patterns of ZF3 PCR product for patients
1 and 2. Modification was performed with both hydroxylamine (Ha) and osmium
tetroxide (Os04). Patient 1: lane 1, negative control; lane 2, constitutional DNA.
Patient 2: lane 1, negative control; lane 2, left tumour DNA; lane 3, right tumour
DNA; lane 4, constitutional DNA; lane 5, parental constitutional DNA. The nature
of the mutation in patient 1 (C to T) results in cleavage of Ha modified fragments,
whereas the nature of the mutation in patient 2 (G to A) results in cleavage of
both Ha and Os04 modified fragments.
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ft] PATIENT 2
Ay NK, L T, R
TGCATGCA
PATIENT 1
PB Mo. Fa. Fe.
PATIENT 2
1018 NK T
Figure 2.A. Sequencing of ZF3 for patients 1 and 2, showing point mutations.
PB = peripheral blood; NK,L = normal kidney, left; T,R = tumour, right.
The recognition sequence of Rsrll is shaded. B. RsrII restriction digest patterns
for patients 1 and 2. Mo. = mother; Fa. = father; Fe. = foetus; M = molecular
weight markers.
The third reported DDS mutation in this portion of ZF3 , 396D
to glycine (G), creates a Haelll site resulting in a pattern of
4 bands (21bp, 60bp, 81bp and 182bp) rather than 3 bands (21bp,
60bp and 263bp).
Tfie PCR product for ZF2 (primers C323/796) contains a single
HphI site, which cleaves the 352bp fragment into a 70bp and
a 282bp fragment. Chemical mismatch cleavage analysis of
patient 3 revealed a 360C to G mutation in ZF2. This T to G
mutation creates a new HphI site (Fig. 3A) within the 282bp HphI
fragment resulting in 32bp and 250bp bands (Fig. 3B). This
provides another restriction-based screen for a DDS mutation,
but as this mutation has only been described once it may be of
less use than the other two digests.
Prenatal screening
From what is now known of the nature of WT1 mutations in
DDS patients, the likelihood of siblings presenting with DDS is
highly unlikely, as it would require either germline mosaicism
for such a mutation in a parent or two distinct de novo DDS WT1
mutations occurring in the same family. There has however been
one report of nephrotic syndrome and WT in siblings (25). During
this study, we were asked to examine tissue from the nonviable
foetal sibling of patient 1 to ascertain whether it carried a WT1
mutation. As the likelihood of two de novo DDS mutations was
minute, we first identified the point mutation present in the
affected child, patient 1, and then used PCR and restriction digest
screening to look for the 394R to W mutation in the foetal
sample. The foetal sample was normal at this base (Fig. 2B) and
for all other mutations detectable by restriction digest screening.
Cytogenetic analysis of foetal tissue revealed that the foetus was
47,XY,+21, which may have been a contributing factor to the
cause of death in utero.
DISCUSSION
Mutations within the 1 lpl3 Wilms' tumour gene have now been
described in WT patients both with and without any associated
congenital anomalies. However, the proportion of WT patients
with identified WT1 mutations is still small, except for the
subgroup of WT patients displaying the Denys-Drash syndrome
of nephropathy and gonadal dysgenesis. Almost all DDS patients
analysed have a single constitutional WT1 point mutation and
these predominantly result in an amino acid change within a ZF.
As these mutations appeared to act in a dominant fashion, it was
possible that the mutant WT 1 protein bound to and regulated a
novel and inappropriate DNA target (dominant) or that it was
able to interfere with or inhibit the normal activity of the wild
type protein (dominant-negative).
It may be envisaged that in DNA-binding proteins, the
substitution of critical amino acid residues in the DNA-binding
domain may alter the specificity of the DNA-binding. This has
been described for the steroid hormone receptors which belong
to a family of ZF genes where four C residues complex one zinc
molecule. Alteration of a single amino acid in the ZF region of
the glucocorticoid receptor alters the DNA binding specificity
such that the receptor can now bind both the glucocorticoid and
oestrogen responsive elements (26). The first DDS point
mutations described (17) are predicted to disrupt WT1 binding
in a similar manner (20). However, a case was recently reported
with a mutation of a ZF1 zinc chelating C (18) . In this study
we have found two further cases of DDS with mutation in zinc
chelating C and H residues in ZF2 (patients 3 and 5, Table IB).
Such mutations are unlikely to confer a unique new binding
specificity. It is probable that they will result in a de-stabilisation
of ZF tertiary structure and compromise DNA binding.
The concept that loss, as opposed to alteration, of DNA-binding
can lead to the severe DDS phenotype is clearly shown by the
chain termination mutation in ZF2 of patient 4. An even more
clear-cut loss-of-binding is seen in the exon 6 chain termination
mutation which results in complete absence of all four zinc fingers
in DDS patient GOS389, described by Baird et al (19). Such
truncation mutations indicate that DDS mutations may act to
effectively destroy WT1-DNA binding without altering the rest
of the protein. As only one WT1 allele is mutated, this appears
to confer onto the mutant protein a dominant effect over the wild
type molecule. There are many examples of DNA-binding
transcription factors whose activity is modulated or facilitated
by protein-protein interactions, such as homo-multimerisation.
The steroid hormone receptors contain a dimerisation domain
which consists of a series of discontinuous hydrophobic heptad
repeats, not dissimilar to a leucine (L)-zipper motif (27). Although
there is no evidence to date that WT1 binds as a dimer, exon
4 of the WT1 gene does encode a pseudo-L-zipper motif similar
to that in the steroid hormone receptors. This motif consists of
three continuous hydrophobic heptad repeats together with three
other possible discontinuous heptads. These heptads are perfectly
conserved in the mouse WT1 gene. It has been shown in some
L-zipper proteins that the introduction of mutants containing the
dimerisation component but no functional domain cause the
accumulation of inactive mutant-wild type protein oligomers (28).
Given that DDS can arise from truncation mutations, we
hypothesise that the DDS phenotype may result from the
formation of inactive mutant-wild type WT1 protein dimers.
While this has yet to be formally tested, we have isolated clones
to which WT1 specifically binds and these contain both
continuous and inverted repeat sequences, suggesting a double
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Figure 3.A. Sequencing of ZF2 for patients 3, 4 and 5, showing point mutations. B = blood; T = tumour (R, right or L, left); LCL = lymphoblastoid cell line;
Mo. = mother; Fa. = father. The recognition sequence of HphI is shaded. B. HphI restriction digest patterns for patient 3. Co. = control; M = molecular weight
markers; Fa. = father; Mo. = mother; + = HphI; - = no Hphl. The HphI site created by the T to G point mutation (*H) cuts the 282bp fragment into a 250bp
and a 32bp fragment, the latter migrating too fast to be detected on the gel.
binding site (24). In addition, studies currently in progress
characterising WT1 binding to a candidate target promoter have
revealed a double WT1 footprint, suggesting that two adjacent
molecules of WT1 protein bind to the promoter (Andrew Ward,
Oxford, personal communication). Whether WT1 dimerises
remains to be tested formally. If it does, then the mutant form
of the protein in DDS patients is likely to be acting in a dominant-
negative fashion by complexing with the wild type protein, and
preventing DNA-binding of this complex.
All previous studies have demonstrated LOCH wherever
tumour tissue was available from DDS patients (17, 18, 19) or
from other constitutional WT1 mutation patients (11,12). This
suggests that while DDS mutations appear to have a dominant
effect over normal glomerular and genital development,
tumorigenesis requires mutation of both WT1 alleles. However,
we have previously described two non-DDS WT patients in which
only one WT1 allele was found to be mutated in the tumours
(14, 29) and proposed that while mutation of both WT1 alleles
is one pathway to tumour formation, this is sufficient but not
essential. It now appears that DDS is no exception to this
observation as we describe in this study a tumour from patient
3 which retains both constitutional WT1 alleles. In this patient,
it is possible that there has been a second mutation in either WT1
exons 1, 2, 3 or 5 (not yet analysed) or alternatively that a second
mutation has occurred at another WT locus other than WT1.
1 lp 15 specific allele loss has been reported in WT and this may
represent the second mutation in this tumour. This has not been
previously observed in a DDS tumour.
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Figure 4. Diagram of ZF2 and 3 indicating the conserved cysteine and histidine
residues and the mutations found in this series of DDS patients. Also indicated
is a ZF3 R to STOP mutation which we have previously reported in a bilateral
WT patient with no evidence for genital anomalies.
In summary, we have identified and characterised WT1
mutations in five more DDS patients, further supporting a role
for WT1 in both renal and genital development. Our observation
of a ZF2 truncation mutation indicates that DDS WT1 mutations
can most likely lead to abolition of DNA-binding. Consequently
we have hypothesised that WT1 binds as a dimer and that it is
the formation of wild type/mutant heterodimers which interferes
with normal WT1 activity. We feel that this is evidence that DDS
mutants act in a dominant-negative fashion resulting from loss
or reduction in normal WT1 DNA-binding.
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MATERIALS AND METHODS
DNA extraction and PCR
DNA was prepared from lymphoblastoid cell lines (LCL) or peripheral blood
samples from 5 DDS patients as previously described (29). Tumour sample DNA
was extracted from 3 of these patients. When available, DNA was also prepared
from parental peripheral blood or LCLs. The oligonucleotide primers used for
amplification of WT1 exons 4, 6, 7 (ZF1), 8 (ZF2), and 9 (ZF3) lay in the
preceding and following intronic sequences. For exon 10 (ZF4), only the ZF
region of the exon was examined. Many of these oligonucleotides have been
previously described (14). The primers used were as follows.
Exon 4: C486 (5' AAA CAG TTG TGT ATT ATT TTG TGG
3') and C152 (5' ACT TTC TTC ATA AGT TCT AAG
CAC 3'); 225bp
Exon 6: C178 (5' AAG CTT CAC TGA CCC TTT TTC CCT
TC 3') and CI77 (5' GAA TTC CAA AGA GTC CAT
CAG TAAGG 3');230bp
Exon 7 (ZF1): C155 (5' GAC CTA CGT GAA TGA TCA CAT G 3')
and 945 (14); 348bp
Exon 8 (ZF2): C323 (5' CCT TTA ATG AGA TCC CCT TTT CC 3')
and 796 (14); 352bp
Exon 9 (ZF3): 798 and 801 (14); 349bp
Exon 10 (ZF4): 802 and 447 (14); 354bp or C911 (5' ACT TCA CTC
GGG CCT TGA TAG 3') and C912 (5' GTG GAG A-
GT CAG ACT TGA AAG 3'); 275bp
PCR reactions were 50^1 total volume containing 200ng of genomic DNA, 200^M
nucleotides, IjiM of each primer, 1 xPromega PCR buffer and 1U of Promega
Taq Polymerase. Reactions were denatured at 92C for 45s, annealed at the
appropriate temperature for 1 min and elongated at 72C for 1 — 1.5 min for 30
cycles (Hybaid Thermal Cycler; tube control). All PCR fragments were purified
from low-melting temperature agarose (SeaPlaque) using Mermaid (BiolOl).
Chemical mismatch cleavage analysis and direct sequencing
Chemical mismatch cleavage analysis was performed as previously described
(14,30) using both hydroxylamine and osmium tetroxide. One lane of a PCR
fragment sequencing reaction was run as a size marker. When a mismatch was
detected, independently amplified fragments were directly sequenced as previously
described (14,31) using either the same primers as were used for the PCR reaction
or internal primers. This enabled the characterisation of any specific base changes
and determined whether the sample was homo- or heterozygous for that mutation.
Restriction analysis
After amplification excess paraffin oil was removed and the PCR reactions were
chloroform extracted, precipitated with ethanol, washed two times in 70% ethanol,
vacuum dried and resuspended in PCR-quality H20. Restriction digests were
performed in 1 x restriction digestion buffer of appropriate salt composition and
concentration for the restriction enzyme (Boehringer Mannheim or New England
Biolabs) used. Digests were performed overnight and the results run out on either
a 2% agarose gel (RsrII digests) or a 6% Nusieve gel (HphI digests) adjacent
to a <pX 174 Haein size marker.
Cytogenetics
Phytohaemagglutinin-stimulated peripheral blood lymphocyte cultures from patient
1 were set up to provide mitotic chromosomes for cytogenetic analysis (32). Foetal
tissues from the missed abortion in the mother of patient 1 were also cultured
for karyotypic analysis (33).
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Do children with diffuse mesangial sclerosis in association with mutations of the Wilms' tumour
suppressor gene (WT1) require bilateral nephrectomy?
Key words: Diffuse mesangia! sclerosis - Wilms" tumour
suppressor gene - Nephrectomy
Sirs.
Denys-Drash syndrome (DDS). characterised by the asso¬
ciation of an early-onset nephropathy [commonly diffuse
mesangial sclerosis (DMS)], pseudohermaphroditism in
males and a high risk for developing Wilms' tumour (WT)
was first described in 1967 [1], More recent publications
have proposed extending the concept of the syndrome to
those with only two features of the disease, including the
nephropathy [2]. The development of WT in DDS has been
linked to germline mutations of the WT1 gene (chromo¬
somal position 11p 13). which encodes a zinc finger protein
thought to have transcriptional regulatory function. These
mutations almost always occur de novo and the majority
are clustered within exon 9 of the WT1 gene. It has been
suggested that as DMS is intimately associated with DDS.
all phenotypic females presenting with DMS should have
chromosome studies performed to detect unexpected XY
karyotypes and all children undergo ultrasonography to
exclude WT [3],
We present a 17-month-old boy with DDS in whom
intensive investigation and intervention led to the preven¬
tion of WT. He presented with hypertensive encephalopa¬
thy and oedema, and was found to have renal failure
(sodium 136 mmol/1, potassium 7.6 mmol/1, urea
25.7 mmol/1. creatinine 311 p.mol/1) with nephrotic syn¬
drome [urine protein/creatinine ratio 3,875 mg/mmol
(normal 0-25), serum albumin 15 g/1]. Physical examina¬
tion revealed hypospadias with bilaterally descended testes
and scars from previous bilateral hernia repairs. His initial
treatment consisted of positive pressure ventilation, in¬
travenous labetalol and peritoneal dialysis (PD). Im¬
munological causes for renal failure were excluded and his
renal tract was structurally normal on ultrasound.
Renal biopsy showed one of nine glomeruli to be
globally sclerosed: the remainder all showed diffuse me¬
sangial hypercellularity with expansion of mesangial ma¬
trix and sclerosis. There was focal tubular atrophy with
interstitial fibrosis and the vessels showed marked medial
hypertrophy. The findings were consistent with a diagnosis
of DMS. His karyotype was 46 XY. DNA analysis [4] re¬
vealed a mutation in exon 9 (encoding zinc finger 3) of one
copy of the WT1 gene, a CGG codon (encoding arginine)
having mutated to TGG (encoding tryptophan). Neither
parent carried this mutation.
A diagnosis of DDS was made. He was discharged on
PD 36 days after admission, clinically well with his hy¬
pertension controlled with captopril. Despite improvement
in the intrinsic renal function, we elected to proceed to
bilateral nephrectomy because of the considerable risk for
the development of WT. As part of the pre-operative work¬
up. an abdominal computed tomographic scan was per¬
formed which was entirely normal. At surgery, a small
nodular area. 1.4 cm in diameter, was noted close to the left
renal hilum. Histological examination revealed a cyst lined
with cuboida! ciliated epithelium and surrounded by groups
of immature tubules, primitive ducts with a collar of 11-
bromuscular tissue, mesenchyme, bundles of smooth mus¬
cle and islands of fat. Blastemal cells were not prominent,
but the appearances were compatible with a cystic in-
tralobar nephrogenic rest, blending imperceptibly into the
renal parenchyma. There was no evidence of malignancy.
The remaining renal tissue showed most of the glomeruli to
be globally sclerosed with severe tubular atrophy and a
heavy interstitial inflammatory infiltrate, consistent with
end-stage kidney in DMS. There were no peri-operative
complications, and he is currently well on PD.
Whilst the natural history of nephrogenic rests in those
without WT1 mutations is somewhat variable, a small
proportion develop into WT. In those with WT1 mutations
in association with DDS, WT occurs in over 909c [5 ]. Two
of the three children with DDS on our end-stage renal
failure (ESRF) programme presented with bilateral WT. Bv
electing for bilateral nephrectomy in this child, we have
removed the risk of WT and its treatment-associated mor¬
bidity, including prolongation of time to consideration for
transplantation. It can be aruged that early bilateral ne¬
phrectomy is preferable to serial radiological examinations
in this population. This is not a problem in those with ne¬
phropathy, as the time-course from presentation to ESRF is
short, although the role of bilateral nephrectomy in those
who have not yet developed nephropathy is more deba¬
table.
We recommend that all children with early-onset pro¬
teinuria, especially where DMS is present on biopsy, re¬
quire DNA analysis to exclude mutations of the WT1 gene
and that bilateral nephrectomy is considered early in those
children with DDS, WTI mutation and overt nephropathy.
We would be most interested to hear the opinions from
other centres.
N. J. A. Webb1. M. A. Lewis1, K. Williamson4, V. van Heyningcn4.
J. Bruce2, M. Lendon2, and R. J. Postlethwaite1
Departments of 1 Nephrology, 2 Surgery, and 2 Pathology
Royal Manchester Children's Hospital
Pendlebury
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Renal anomalies in Down syndrome
Key words: Renal anomalies - Down syndrome
Sirs.
We read with interest the comments by Ehrich [1] and by
Robson and Leung [2] in this journal about renal replace¬
ment therapy and renal abnormalities, respectively, in
children with Down syndrome. Since there are only a few
reports, we reviewed the outpatient charts of all children
with Down syndrome who were seen in the Pediatric
Cardiology Clinic at James H. Quillen College of Medicine
and East Tennessee State University, Johnson City. Ten¬
nessee. This report describes our findings and a review of
:he literature.
Fifty-four children (34 males. 20 females) aged 2 months
:o 24 years (median 4.5 years) with Down syndrome were
;een in our clinic over the last 8 years. Clinical history and
aboratory data were reviewed for any possible renal dis¬
order. Follow-up data were obtained from the primary
ohysician either by questionnaires or by'phone, or by both.
Df the 54 patients. 40 had congenital heart disease. All had
lormal urinalysis. Serum creatinine and blood urea nitro-
ten were measured in 28 children and were normal. Thir-
een children had flat plate of the abdomen immediately
lfter cardiac catheterization to visualize the kidney, ureter,
ind bladder; these were normal in all.
Six children had symptoms related to their urinary tract;
i of these, all females, had recurrent urinary tract infec-
ions. Further investigations with one or more of the (bl¬
owing tests: voiding cystourethrography, abdominal ul-
rasound. intravenous pyelography, and blood urea nitrogen
nd serum creatinine were performed in these 3 patients,
ut all were within normal limits. One male child had ur-
thral stricture that required repeated dilatations following
urgical correction. This child had a normal functioning
idney as indicated by a normal blood urea nitrogen and
erum creatinine. No further details are available about this
hild. Of the 6 patients. 2 developed acute renal failure
blowing angiotensin converting enzyme (ACE) inhibitor
lerapy for cardiac failure and died. One of them had
ormal kidneys by gross and microscopic examination at
utopsy; the other patient did not have an autopsy.
From our limited retrospective clinical data, the in-
dence of renal anomalies in children with Down syn-
rome does not appear to be higher than in the normal
npulation. It should be noted that our series did not in-
ude fetuses, still-borns. or infants with Down syndrome
ho may have died in the nursery with renal disease,
itherto. three autopsy studies have reported renal
anomalies in children with Down syndrome. In 1960. Bera
et al. [3] reported 4 patients with renal agenesis or hypo¬
plasia and I with horseshoe kidney of 141 autopsies (2.81)
of patients with Down syndrome. In 1973, Egli and Stalder
[4] reported renal anomalies in 7 of 103 autopsies (6.7%) of
children with Down syndrome (cysts 2, hydronephrosis 1.
hydroureter 3, ureteral stenosis 2. megacystitis 3). In 1991.
Ariel et al. [5] reported renal anomalies, such as renal hy¬
poplasia, cysts, and obstructive uropathy (d% in infants and
children, 15% in still-borns and fetuses), in 124 autopsy
cases of Down syndrome.
Besides these and other reports (6. 7] of congenital renal
anomalies, there are few isolated reports of acquired renal
disorders in children with Down syndrome, such as chronic
glomerulonephritis [2], mesangiocapiilary glomerulone¬
phritis [8], and immunolactoid glomerulopathy [9]. Non¬
structural renal disorders, such as hyperuricemia and a
decrease in the clearance of uric acid and creatinine, are
also reported in children with Down syndrome [10],
Although 6 patients in our series had signs and symp¬
toms of renal disease, none had renal pathology except for
1 child who had urethral stricture. Two children (a 5-year-
old male and a 5-month-oId female) with heart failure and
Down syndrome developed renal failure after ACE inhib¬
itor therapy and died before renal replacement therapy. An
association between ACE inhibitor therapy and acute renal
dysfunction has been noted in patients with bilateral renal
diseases such as polycystic kidney [11], bilateral renal ar¬
tery stenosis, and scleroderma [12]. Neither of our 2 patients
had any preexisting renal disease. Both had normal uri¬
nalysis and normal blood levels of urea and creatinine prior
to ACE inhibitor therapy. One also had a normal gross and
microscopic examination of both kidneys at autopsy.
Nevertheless, several minor renal abnormalities, such as
immature glomeruli [7], renal hypoplasia or relatively
small kidney [13], maturation delay of nephrogenic zone of
cortex, and persistent fetal lobulation, are reported in
children with Down syndrome [13. 14], These abnormal¬
ities may predispose to a high risk for renal failure when
exposed to ACE inhibitors.
From our data and those of others [3-5], the incidence
of clinically significant renal anomalies does not appear to
be higher in children with Down syndrome than in the
general population. VVc, however, recommend that caution
should be exercised when using ACE inhibitors in children
with Down syndrome and congestive heart failure. A larger
clinical study of a similar cohort may further delineate this
issue.
Int. J. Exp. Path. (1994), 75, 147-155
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Towards an understanding of Wilms' tumour
KATHLEEN A. WILLIAMSON AND VERONICA VAN HEYNINGEN
MRC Human Genetics Unit, Western General Hospital, Edinburgh, Scotland
Wilms' tumour: histopathology and statistics
Wilms' tumour (WT) or nephroblastoma is a paediatric
renal malignancy first described by Max Wilms in 1899. It
affects approximately 1 in 10000 children, making it the
most common solid tumour of childhood. Diagnosis is
normally made between 2 and 4 years of age (Breslow et
al. 1988), with the overall survival rate at present
exceeding 80% (Mehta et al. 1991).
The histology of WT most clearly demonstrates the
embryonal nature of this malignancy, with the consti¬
tuent elements of the tumour recapitulating the early
stages of nephrogenesis. Post pronephric and meso-
nephric renal development begins with the condensation
of metanephric mesenchyme, by a reciprocal inductive
interaction with the ureteric bud, to form the metanephric
blastema (Figure 1). This in turn becomes epithelialized
and progresses through the multiple stages of nephroge¬
nesis to form the permanent mammalian kidney, the
metanephros. WT is thought to arise from aberrant
development of the metanephric blastema, with the cells
being held at the early, embryonal stage. The transient
immature epithelial structures characteristic of this
stage, such as renal vesicles, comma, S-shaped and
glomeruloid bodies, persist in the tumour, whereas the
development of mature renal structures, such as fully
formed glomeruli and proximal and distal tubules, is
blocked. In addition to the blastemal and epithelial
elements WT also contain stroma which, together with
the epithelium, is thought to derive from the blastema
(Pritchard-Jones & Fleming 1991). The majority of WT
contain approximately equal proportions of these three
elements and are therefore said to display triphasic or
classic histology. Cell types not normally found in the
Correspondence: Kathleen A. Williamson, MRC Human Gene¬
tics Unit, Western General Hospital, Crewe Road, Edinburgh
EH4 2XU, Scotland.
kidney are present in a minority of WT. Such heterotopic
elements include mesodermally derived striated and
smooth muscle cells, chondrocytes, adipocytes, and also
neuroblasts and ganglion cells (Sotelo-Avila 1990). This
histological picture suggests than an early pluripotential
stem cell, involved in kidney development and perhaps
in other mesodermal pathways too, is immortalized in
WT. In normal development such cells are committed to
their correct fates but in WT development aberrant
differentiation into progeny cell types is found in the
disorganized tumour tissue.
Abnormally persistent islands of nephrogenic cells,
present beyond the cessation of nephrogenesis but with
little potential for metastasis, are called nephrogenic
rests (NR), of which there are two main categories:
intralobar nephrogenic rests (ILNR) and perilobar neph¬
rogenic rests (PLNR). Each has a distinct histology and is
not categorized solely on lobar position (Beckwith et al.
1990). In association with other blastemal derivatives
NRs form benign nephroblastomatous lesions, which are
thought to be precursors of WT, intermediate between
normal nephrogenesis and renal malignancy. Infant
autopsies suggest that these lesions (PLNR type) are
present in approximately 1% of the general population
(Beckwith et ai. 1990). Statistically, only about 1 in 100
such individuals goes on to develop WT; therefore,
presumably, in the majority of cases nephroblastomato-
sis does not progress to the tumorigenic state.
Almost 8% of WT cases present in association with
other developmental abnormalities, in particular spora¬
dic aniridia (iris hypoplasia, 0.8%), genitourinary (GU)
abnormalities (3%) (most commonly hypospadias and
cryptorchidism (75% of GU abnormalities)) and hemihy-
pertrophy (3%) (Breslow et al. 1988). These abnormali¬
ties are also often part of syndromes such as the WAGR
syndrome (WT, aniridia, GU abnormalities and mental
retardation), Denys-Drash syndrome, DDS (nephro¬
pathy, partial gonadal dysgenesis and WT) and Beck-
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(d) elongation 1 (e) elongation 2 (f) maturation
Figure 1. Development of the
metanephros. a, Induction: U-ureteric
bud, M-metanephric mesenchyme; b,
condensation: B-metanephric blastema;
c, vesiculation: RV-renal vesicle; d,
elongation 1: C/S-comma-/S-shaped
body, P-podocytes; e, elongation 2:




with-Wiedemann syndrome, BWS (foetal overgrowth,
hemihypertrophy and embryonal tumours). The proposal
that there may be pathogenetic heterogeneity for WT with
respect to the above abnormalities is based on the
finding that WT presenting with aniridia and DDS are
associated with ILNRs whereas those presenting with
hemihypertrophy and BWS are associated with PLNRs
(Beckwith et at. 1990). Unlike ILNR-WT, PLNR-WT are
predominantly blastemal/epithelial, contain structures
from the later stages of nephrogenesis, and rarely
develop heterotopic elements, that is, the blastema in the
latter appears to be more committed than in the former.
A further variability observed with WT relates to the
age of onset. The majority of WT patients present as
sporadic unilateral cases, with a median age at diagno¬
sis of 3 years (Breslow et at. 1988). Bilateral and familial
patients, together often referred to as hereditary WT
(Knudson 1985), constitute only 7% and 1% of cases,
respectively. Although less frequent than unilateral WT,
the bilateral cases have a lower median age at diagnosis
of 2 years. In both cases females tend to present at a
slightly later age. WT associated with aniridia and/or GU
abnormalities also show a younger age distribution than
those associated with hemihypertrophy, highlighting a
further difference between ILNR-WT and PLNR-WT
(Beckwith et at. 1990), and most probably reflecting the
earlier onset of the blastemal defect in ILNR-WT.
The earlier presentation of bilateral tumours is consis¬
tent with the two-hit model for tumorigenesis proposed
by Knudson in 1971. This model has been applied to WT
(Knudson & Strong 1972) and developed further to
suggest that both functional copies of a tumour suppres¬
sor gene, or anti-oncogene, have to be mutated to permit
tumour formation (Knudson 1985). Bilateral cases have
one germline (constitutional) mutation which represents
the first hit, and then require only one subsequent
somatic hit at the same locus to disrupt the remaining
copy of the gene. Unilateral cases are however expected
to develop sporadically from two somatic hits at the same
locus and in the same cell. The number of target cells for
the second mutational event are obviously far fewer in
comparison with germline cases and hence unilateral
tumours tend to develop later in childhood.
As described, WT age of onset patterns are consistent
with Knudson's model for tumour suppressor genes.
However, the lower frequency of bilateral tumours
compared with unilateral tumours and the paucity of
familial cases suggest that constitutional mutations
leading to WT development are genetically deleterious
(van Heyningen et at. 1990).
Evidence for genetic heterogeneity in WT
The fact that WT can present in association with other
developmental abnormalities was critical in defining a
chromosomal location for a WT gene. Sporadic aniridia
patients, a high proportion of whom develop WT, often
have cytogenetically detectable deletions involving the
short arm of chromosome 11, at band p 13 (Francke et al.
1979). Many of these deletion patients have the more
complex WAGR phenotype (also including GU abnor¬
malities and mental retardation), which is representative
of a contiguous gene syndrome. A key patient with a
large 11 p13 deletion and partial WAGR, WT but no
aniridia, defined aniridia as a separate locus (Davis etal.
1988; Gessler et al. 1989; van Heyningen et al. 1990) and
helped to refine the position of a putative WT gene at this
region.
The majority of WT patients do not, however, have
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confined to 11p15
Figure 2. Mechanisms for functional loss of both copies of a
tumour suppressor gene in WT development. 1-locus at
11 p13, 2-locus at 11p15, the maternal allele is primed.
"Hit; LOCH, loss of constitutional heterozygosity.
cytogenetically detectable alterations at 11 pi3. Knud-
son's two-hit model predicts functional loss of both
copies of a tumour suppressor gene in WT development
(Knudson 1985). The second hit can be achieved in
several different ways (Figure 2). Most easily, homo¬
zygosity for the first hit can be achieved by mitotic
recombination or loss and reduplication. Alternatively,
the second allele can be disrupted by a separate
mutation or deletion of part or whole of the relevant
chromosomal region. Except when there is an indepen¬
dent second mutation, these events will result in allele
loss or loss of constitutional heterozygosity (LOCH) at
the target gene and usually at neighbouring loci also.
Thirty to forty per cent of WT show LOCH and, surpris¬
ingly, it is almost exclusively the maternal allele that is
lost (Schroeder etai. 1987; Williams etai. 1989; Pal etai.
1990). A further surprise is that in many cases the allele
loss is not observed at 11 p13 but is confined to the more
telomeric position 11 p15 (Mannens et al. 1988; Reeve et
at. 1989; Henry ef al. 1989; Koufos etai. 1989; Wadey et al.
1990). This suggests the possibility that there is a second
WT gene, with duplication (if the remaining homologue
has not been hit and is then duplicated) or loss of both
copies of this 11 p15 gene contributing to tumour develop¬
ment. Alternatively, 11 p13 and 11 p15 loci could act
cumulatively, with a single hit at each locus initiating WT
development. Further evidence for the existence of an
11 p15 WT gene comes from chromosome translocations
and paternal duplications of this region which have been
observed in, and implicated in the aetiology of, BWS
(Henry et al. 1991). As previously mentioned, BWS
patients are at a high risk for developing embryonal
tumours, the most frequent of which is WT.
Familial WT does not appear to involve genes on
chromosome 11. Cytogenetic and linkage studies have
produced conflicting reports regarding linkage of a third
WT gene to chromosome 16q, where LOCH in WT has
been detected (Maw etai. 1992; Huff ef al. 1992; Coppes et
al. 1992a). Alterations of chromosome 1, including tri¬
somy 1 q, have also been reported for WT (Douglass etai.
1985; McDowell et al. 1989; Kaneko etai. 1983; Golden et
al. 1992); however, further analysis is required as the
location of the familial locus/loci remains undetermined
at this date.
The apparent involvement of multiple loci and the
potential for synergistic interactions between them may
be one of the reasons, together with genetic background,
for the incomplete penetrance and variable expression
observed in WT. Individuals carrying the same chromo¬
somal alterations, whether at the relatively crude cytoge¬
netic level or more highly resolving molecular level (see
later), can display differing degrees of severity regard¬
ing WT development and associated abnormalities. It is
also found that males are more frequently affected than
females with GU abnormalities, with the development of
hypospadias and/or cryptorchidism being particularly
variable.
Isolation of WT1: a WT predisposition gene
Molecular analysis of overlapping 11 pi3 WAGR dele¬
tions, such as the previously mentioned partial WAGR
case (Davis et al. 1988), defined the chromosomal
location of a putative WT gene. The position and extent of
the critical deleted region was confirmed by the dis¬
covery of a small homozygous 11 p13 deletion in a
sporadic WT (Lewis et al. 1988). This deletion covers
approximately 345 kb of DNA (Rose et al. 1990), a region
that would encompass at least part if not all of a putative
WT gene and which was small enough in which to search
for candidate gene sequences. This positional cloning
approach led to the identification in 1990 of a gene from
this region (Call et al. 1990), the WT1 gene, which has
subsequently been confirmed both at the biological and
the genetic level as a WT predisposition gene.
Biological analysis of WT1: expression studies
Candidate genes should display expression patterns
consistent with their proposed function and associated
phenotype. Expression of WT1 is detected in metaneph-
ric blastema, renal vesicles and, most strongly, in the
podocyte cells of glomeruloid bodies (see Figure 1)
(Pritchard-Jones et al. 1990), in keeping with a role in
renal development. As mentioned above, these struc¬
tures are present only during active nephrogenesis and
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WT1 renal expression is accordingly restricted to the
foetal kidney (Pritchard-Jones et at. 1990). In WT the
persistence of these structures correlates with continued
WT1 expression, at levels comparable to those in foetal
kidney (Call et al. 1990; Pritchard-Jones et at. 1990). It
would therefore appear that in normal development WT 1
expression is required during the initial stages of
nephrogenesis, but expression must then be turned off to
allow nephron maturation. The continued expression of
WT1 in tumours suggests that mutations affecting this
gene may contribute towards alteration of the balance
between proliferation and differentiation. These ex¬
pression studies also show that it is the epithelial and not
the differentiated mesenchymal derivatives of blastema
that express WT1 (Pritchard-Jones etal. 1990; Pritchard-
Jones & Fleming 1991). This explains why stromal
predominant WT have far lower levels of WT1 mRNA
compared with epithelial predominant and triphasic WT
(Pritchard-Jones et al. 1990; Miwa et al. 1992a; Gerald et
al. 1992; Yeger etal. 1992).
WT1 expression is also detected in some non-renal
tissues. Human studies have shown that the developing
genital ridge and the Sertoli and granulosa cells of the
mature gonad express WT1, as do mesothelial cells
(Pritchard-Jones et al. 1990), spleen and some haemato¬
poietic cells (Call et al. 1990; Miwa et al. 1992b). A
functional role for WT1 in these cell types is more clearly
demonstrated by newly published results from WT1
knock-out mice (which completely lack functional WT1)
(Kreidberg et al. 1993). These non-viable mice display
renal and gonadal agenesis and developmental defects
of the mesothelium. The gonadal and mesothelial cells
share a common differentiation pathway with the renal
system in that all three tissues initially develop from
mesenchyme that subsequently becomes epithelialized.
The only other cells that show this developmentally
regulated conversion are the endothelial cells lining
blood vessels and the trophectoderm in pre implantation
embryos (Ekblom 1989). The transition of mesenchyme
to epithelium appears therefore to be a rare event and it
is possible that WT1 is either directly or indirectly
involved in this switch in cell types.
The gonadal expression of WT1 is however most
interesting in relation to the GU abnormalities so fre¬
quently seen with WT (Breslow et al. 1988). WT patients
have an approximately threefold increased risk for
developing such abnormalities, and in WAGR and DDS
XY individuals the risk frequency is >80%. It was initially
proposed that a gene contributing to gonadal develop¬
ment was distinct from but closely linked to a WT gene
and hence alteration of one would similarly disrupt the
other. With the renal and gonadal systems originating







Figure 3. Schematic diagram of the WT1 protein, indicating
the position of functional domains and alternative splices.
from the same mesodermal components early in de¬
velopment (for a general review of this topic see Browder
etal. 1991), the finding that WT1 expression was common
to both supported the proposal that this single gene may
be acting pleiotropically, playing a crucial role early in
the development of both systems (van Heyningen et al.
1990; Pritchard-Jones et al. 1990). Constitutional altera¬
tions of WT1 that contribute to aberrant renal develop¬
ment could therefore also contribute to aberrant gonadal
development, explaining the high incidence of GU abnor¬
malities in WT patients and also perhaps suggesting a
reduced reproductive capacity, helping to explain the
low frequency of familial WT.
Genetic analysis of WT1: function studies
The WT1 gene maps close to the aniridia gene (AN2,
PAX6) and comprises ten exons spanning approximately
50 kb of DNA (Call etal. 1990; Haber ef al. 1991; Gessler et
al. 1992). The 3.2 kb mRNA encodes a 49-52 kDa protein
that localizes to the nucleus (Morris etal. 1991; Telerman
et al. 1992). WT1 protein contains several classic motifs
(Figure 3) (Call et al. 1990); exons 1-6 encode a domain
rich in proline (P) and glutamine (G) residues which
appears to act as a transregulatory domain (these
domains influence the transcription of target genes,
probably by attracting and binding other factors required
by the transcription complex) and exons 7-10 each
encode a C2H2-type zinc finger (ZF) motif, conferring
sequence-specific DNA binding properties (Rauscher et
al. 1990; Bickmore etal. 1992). In addition exons 2-4 have
the potential to encode a protein dimerization domain
similar to the leucine zipper motif (Madden et al. 1993).
The expression pattern, cellular localization and motifs
of WT1 suggest that it functions as a tissue-specific
transcription factor.
Two independent alternative splices within the coding
region of WT1 give rise to four proposed protein isoforms
(see Figure 3) (Haber et al. 1991). Alternative splice I
comprises exon 5, which encodes 17 amino acids.
Inclusion of this splice introduces six additional serine
(S) or threonine (T) residues into the transregulatory
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domain. The phosphorylation of S and T residues is a
common regulatory mechanism used by many proteins,
including transcription factors; however, WT1 does not
appear to exhibit significant levels of phosphorylation
(Morris et al. 1991) and splice I may therefore be
important for other aspects of WT1 activity. No functional
differences between the + and — 17 amino acid
isoforms have been described. The second alternative
splice utilizes two splice donor sites at the end of exon 9,
which encodes the third ZF. If the downstream splice
donor site is used an extra three amino acids (lysine,
threonine and serine KTS) are added, increasing the
linker region between ZF3 and ZF4. The four different
splice forms have been designated A (— 17aa — KTS) B
(+ 17aa — KTS) C (-17aa + KTS) and D ( + 17aa+KTS)
and are present in normal kidney at a ratio of approxi¬
mately 1A:2.5B:4C:8D (Haber et al. 1991). In all but a
single WT (see later) and in expressing murine tissues
this ratio is generally conserved (Haber et al. 1991;
Brenner et al. 1992), suggesting that perturbation of it
may be deleterious to development.
WT 1 ZF2,3 and 4 display > 60% homology to the three
ZFs of EGR1, a member of the early growth response
gene family (Sukhatme et al. 1988). EGR1 is a transcrip¬
tion factor that activates the expression of target genes
(Lemaire et al. 1990) via the consensus DNA binding
sequences 5'GCG GGG GCG 3' (Christy & Nathans 1989).
X-ray crystallography studies have identified conserved
residues within the EGR1 ZF motifs that are critical for
binding this target sequence (Pavletich & Pabo 1991). In-
vitro studies have shown that — KTS WT 1 (the ZF isoform
most similar to the EGR1 ZFs) can also bind this
sequence (Rauscher et al. 1990) and a distinct set of
sequences to which + KTS WT1 binds (Bickmore et al.
1992). The fact that + and — KTSWT1 can have different
DNA binding sites, and can therefore potentially regulate
different genes, strengthens the proposal that the main¬
tenance of the isoform ratio is crucial for normal
development.
In-vivo studies to find the true target genes for WT1 are
lacking but a number of putative targets have been
studied using transient transfection assays where WT1
can be overexpressed. The insulin-like growth factor II
(IGF-II), insulin-like growth factor I receptor (IGF-IR) and
platelet derived growth factor A chain (PDGF-A) genes
are often overexpressed in WT (interestingly, IGF-IR and
PDGF-A have also been implicated in the malignant
transformation of mesothelial cells (Lee etal. 1993)). The
overexpression of IGF-II may simply be a reflection of the
embryonal nature of WT or resultfrom other mechanisms
thought to participate in WT development (see later);
however, IGF-II, and IGF-IR and PDGF-A, do have the
ability to aid tumorigenesis through autocrine growth
stimulation. The increased expression levels may there¬
fore represent a direct deregulation from WT1 and all
three genes do contain EGR1 consensus binding
sequences within their promoters. When these pro¬
moters or the EGR1 promoter are each linked to reporter
genes and coexpressed with WT1 ZF constructs, ex¬
pression from the reporter gene is repressed (Drum-
mond et al. 1992; Werner et al. 1993; Gashler et al. 1992;
Wang etal. 1992; Madden eta/. 1991). Similarly, finger
swap experiments where the transregulatory domain of
WT1 is joined to the ZF domain of EGR1 converts the
latter from transcriptional activator to repressor (Mad¬
den et al. 1991). One model proposed from these studies
suggests that EGR1 activates expression of growth
promoting genes, perhaps allowing proliferation of the
metanephric blastema, and then WT1 is required to
repress their expression and so allow differentiation to
proceed, that is EGR1 and WT1 may act antagonistically.
This model cannot however explain the action of the
+ KTS WT1 isoforms, which do not bind the EGR1
consensus sequence (Bickmore et al. 1992).
Genetic analysis of WT1: mutation studies
The most fundamental way to confirm that a candidate
gene is involved in a particular phenotype is to search for
mutations in that gene in affected individuals. As pre¬
viously mentioned, the majority of WT patients do not
have cytogenetically detectable alterations at 11 p13;
however, by using more sensitive molecular detection
methods WT1 mutations have been found in 10-15% of
tumours tested. These submicroscopic mutations
include intragenic deletions, insertions, duplications and
single base changes and they have been detected in
sporadic unilateral, bilateral, familial WT and DDS
patients, and as second hits in WAGR tumours.
With one exception (Little et al. 1992a), the reported
WT1 mutations found in sporadic unilateral WT all result
in transcripts that can no longer code for at least one of
the ZF motifs, causing disruption of the DNA binding
domain (Haberefa/. 1990;Cowell etal. 1991; Tadokoro ef
al. 1992; Coppes et al. 1993). These mutations are
predicted to produce WT1 protein that has lost all DNA
binding capacity. Binding experiments using one of
these WT1 mutants, which lacks ZF3, has demonstrated
almost complete loss of binding to the EGR1 consensus
sequence (Rauscher et al. 1990). A similar result is also
suggested by the WT1 mutation where the coding
potential for all of the ZF motifs is destroyed (Tadokoro et
al. 1992). This would produce a fingerless protein which
seems unlikely to have retained any capacity to bind DNA
directly.
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Mutations predicted to produce fingerless WT1 protein
are also detected in bilateral (again there is one excep¬
tion (Little et al. 1992a)) (Huff et at. 1991; Pelletier et a/.
1991a) and WAGR tumours (Brown etal. 1992; Baird etal.
1992a; Gessler et al. 1993) and in one of the two familial
cases known to involve inheritance of WT1 mutations
(see later) (Pelletier et al. 1991a). The last category is
predicted to be extremely rare as the vast majority of
heritable tumours involving WT1 derive from de-novo
germline mutation, which, as stated earlier, is perhaps
because individuals with constitutional WT1 mutations
have a reduced reproductive capacity.
In WAGR individuals the above type of mutation is of
course the second hit, required only for tumorigenesis.
The hypospadias and cryptorchidism that develops in
WAGR individuals appears to result from WT1 protein
haplo-insufficiency (having only 50% of wild type levels,
as one allele is constitutionally deleted). GU abnormali¬
ties developing in bilateral WT individuals may also
result from a 50% constitutional loss of functional WT1
protein, suggesting that these mutations are functionally
analogous to the WAGR situation. The possible presence
of an expressed N-terminal region of WT1 does not
appear to induce a novel phenotype; however, the effect
of these mutations has not been analysed at the protein
level.
In all but four tumours, whenever LOCH has been
analysed homozygosity for WT1 mutations has been
observed. These four exceptions (Haber et al. 1990; Little
etal. 1992a; Littleefa/. 1993) introduce the possibility that
the loss of only one copy of WT1 can, under some
circumstances, lead to tumour formation. This could
occur either through involvement of a second locus,
possibly at 11 p15, or through the action of a dominant-
negative mutation in WT1. This type of mutation causes
interference of the wild type function by the mutant
protein, perhaps through heterodimer formation (Hers-
kowitz 1987). There is evidence that the WT1 mutant
lacking ZF3 functions as a dominant-negative (Haber et
al. 1992).
More clear-cut evidence for dominant-negative
mutation is presented in DDS cases. The majority (29 out
of 31) of these patients have constitutional WT1 point
mutations, most of which are missense mutations within
ZF2 or ZF3 (Pelletier et al. 1991b; Bruening et al. 1992;
Baird et al. 1992b; Coppes et al. 1992b; Little et al. 1993).
Sixty-one per cent of DDS mutations show alteration at
one of two specific, conserved residues in ZF3, which
correspond to critical binding residues identified in the
EGR1 X-ray crystallography studies (Pavletich & Pabo
1991). In comparison to the WAGR phenotype, DDS is
more severe, comprising nephropathy as well as partial
or complete gonadal dysgenesis in virtually 100% of XY
patients. This suggests that DDS constitutionally hetero¬
zygous WT1 mutations act in a dominant or dominant-
negative manner. Dominant mutations imply a gain of
function, such as novel and inappropriate target binding.
The finding of three DDS-associated nonsense mutations
(Baird et al. 1992b; Ogawa et al. 1993a; Little et al. 1993)
which truncate the ZF domain suggests that the mechan¬
ism is more likely to be dominant-negative (Little et al.
1993). This is not the sole mechanism implicated in this
phenotype, however, as the only WT1 mutation de¬
scribed which perturbs the isoform ratio was also found
in a DDS individual (Bruening et al. 1992).
The above studies provide us with a general pattern of
the types of WT1 mutation associated with particular
subtypes of WT. No strict correlations can be inferred,
however, again because of the incomplete penetrance
and variable expressivity of the WT mutant phenotype.
On this theme, there are currently four examples of
individuals displaying very different phenotypes but
having identical WT1 mutations. Two of these examples
involve inherited WT1 mutations, where the carrier
parent does not have the GU abnormalities (Pelletier et
al. 1991a) or DDS phenotype (Coppes et al. 1992b) that
develops in the child. Also, an XY DDS individual has the
same constitutional WT1 nonsense mutation (Little et al.
1993) as a female who has only sporadic unilateral WT
(Coppes et al. 1993). Finally, an identical 11 p13 deletion
has been found in two related children, a boy having the
extremely severe phenotype of WAGR together with DDS
and a girl having only aniridia (Henry etal. 1993). The last
two examples again show that XY individuals are more
sensitive to WT1 mutations than XX individuals.
Evidence for an imprinting effect in WT
Genomic imprinting refers to the monoallelic expression
of genes in a parental-specific pattern. Murine studies
have identified four genes controlled in this way, includ¬
ing the Igf2 and Igf2 receptor (Igf2r) genes (DeChiara et
al. 1991; Barlow et al. 1991) which are expressed from
only the paternally and only the maternally inherited
alleles, respectively. Recent experiments have shown
that human IGF-II is imprinted in the same direction as its
mouse homologue (Ohlsson et al. 1993; Giannoukakis et
al. 1993). IGF-II maps to 11 p15, where, as previously
mentioned, LOCH is observed in some WT. The preferen¬
tial loss of the maternal 11 p in WT together with
duplication of the corresponding paternal region has the
potential therefore to produce a double dose of any
exclusively paternally expressed gene located here,
such as IGF-II (see Figure 2). Such paternal disomy for
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11 p15 is observed in BWS (Henry et al. 1991), and
overexpression of a growth factor is concordant with the
overgrowth or hemihypertrophy characteristic of this
syndrome. Many WT overexpress IGF-II (Reeve et al.
1985; Scott et al. 1985) even with approximately 60% not
displaying 11 p LOCH. Statistically, it is likely that 3 out of
4 of these WT will still have a double dose of IGF-II as
imprinting is relaxed at the normally silent maternal
allele, resulting in biallelic IGF-II expression (Rainier et
al. 1993; Ogawa et al. 1993b).
Loss, as opposed to relaxation of imprinting, of
maternal 11 p15 in WT may additionally result in loss of an
exclusively maternally expressed tumour suppressor
gene (a possible candidate gene is H19 (Zhang & Tycko
1992)). WT1, which remains the only WT predisposition
gene currently cloned, is not imprinted in foetal kidney or
WT (Little et al. 1992b; Zhang & Tycko 1992).
Summary
Many areas of research are contributing to our under¬
standing of WT and the role of WT1 in development of the
renal and genitourinary systems. Characterization of
putative target genes and the control of their expression
continues. The importance of isoform ratios and imprint¬
ing effects are also under active investigation, often
using animal models. The accumulating mutation data,
together with evolutionary studies, illuminate WT1 struc¬
ture-function relationships, highlighting the regions
critical in normal development and tumorigenesis. And
last, but by no means least, the hunt for the WT2 and WT3
genes continues.
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